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This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic
Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA).  The
original guidelines were published in the Federal Register on April 17, 1987.  Each profile will be revised 
and republished as necessary.
The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects 
information for these toxic substances described therein.  Each peer-reviewed profile identifies and 
reviews the key literature that describes a substance's toxicologic properties.  Other pertinent literature is
also presented, but is described in less detail than the key studies. The profile is not intended to be an
exhaustive document; however, more comprehensive sources of specialty information are referenced.
The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile
begins with a public health statement that describes, in nontechnical language, a substance's relevant
toxicological properties.  Following the public health statement is information concerning levels of
significant human exposure and, where known, significant health effects.  The adequacy of information to 
determine a substance's health effects is described in a health effects summary.  Data needs that are of
significance to the protection of public health are identified by ATSDR.
Each profile includes the following:
(A) The examination, summary, and interpretation of available toxicologic information and 
epidemiologic evaluations on a toxic substance to ascertain the levels of significant human 
exposure for the substance and the associated acute, subacute, and chronic health effects;
(B) A determination of whether adequate information on the health effects of each substance 
is available or in the process of development to determine levels of exposure that present a 
significant risk to human health of acute, subacute, and chronic health effects; and
(C) Where appropriate, identification of toxicologic testing needed to identify the types or
levels of exposure that may present significant risk of adverse health effects in humans.
The principal audiences for the toxicological profiles are health professionals at the Federal, State, and
local levels; interested private sector organizations and groups; and members of the public.  
This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been
peer-reviewed.  Staffs of the Centers for Disease Control and Prevention and other Federal scientists have 
also reviewed the profile.  In addition, this profile has been peer-reviewed by a nongovernmental panel
and was made available for public review.  Final responsibility for the contents and views expressed in
this toxicological profile resides with ATSDR.
Patrick N. Breysse, Ph.D., CIH
 
Director, National Center for Environmental Health and
 
Agency for Toxic Substances and Disease Registry
 















     
     










The toxicological profiles are developed under the Comprehensive Environmental Response, 
Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund).  CERCLA section 
104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related
authorities” of the statute.  This includes the preparation of toxicological profiles for hazardous
substances most commonly found at facilities on the CERCLA National Priorities List and that pose the
most significant potential threat to human health, as determined by ATSDR and the EPA. Section 
104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile
for each substance on the list.  In addition, ATSDR has the authority to prepare toxicological profiles for
substances not found at sites on the National Priorities List, in an effort to “…establish and maintain 
inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA
Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise













    
   
  






     
   
     
  
 
    
  
 
    
    
 
    
     





   
     
   
    
 
 
   









   
  
   
 
DEET vii
QUICK REFERENCE FOR HEALTH CARE PROVIDERS
Toxicological Profiles are a unique compilation of toxicological information on a given hazardous
substance.  Each profile reflects a comprehensive and extensive evaluation, summary, and interpretation
of available toxicologic and epidemiologic information on a substance.  Health care providers treating
patients potentially exposed to hazardous substances may find the following information helpful for fast
answers to often-asked questions.
Primary Chapters/Sections of Interest
Chapter 1: Public Health Statement: The Public Health Statement can be a useful tool for educating
patients about possible exposure to a hazardous substance.  It explains a substance’s relevant
toxicologic properties in a nontechnical, question-and-answer format, and it includes a review of
the general health effects observed following exposure.
Chapter 2:  Relevance to Public Health: The Relevance to Public Health Section evaluates, interprets,
and assesses the significance of toxicity data to human health.
Chapter 3:  Health Effects: Specific health effects of a given hazardous compound are reported by type
of health effect (e.g., death, systemic, immunologic, reproductive), by route of exposure, and by
length of exposure (acute, intermediate, and chronic).  In addition, both human and animal studies
are reported in this section.
NOTE: Not all health effects reported in this section are necessarily observed in the clinical
setting.  Please refer to the Public Health Statement to identify general health effects observed
following exposure.
Pediatrics:  Four new sections have been added to each Toxicological Profile to address child health 
issues:
Chapter 1 How Can (Chemical X) Affect Children?
 
Chapter 1 How Can Families Reduce the Risk of Exposure to (Chemical X)?
 
Section 3.7 Children’s Susceptibility
 
Section 6.6 Exposures of Children
 
Other Sections of Interest:
Section 3.8 Biomarkers of Exposure and Effect
Section 3.11 Methods for Reducing Toxic Effects
ATSDR Information Center
Phone: 1-800-CDC-INFO (800-232-4636) or 1-888-232-6348 (TTY)
Internet:  http://www.atsdr.cdc.gov
The following additional materials are available online:
Case Studies in Environmental Medicine are self-instructional publications designed to increase primary
health care providers’ knowledge of a hazardous substance in the environment and to aid in the














   
  










    
 
   
 
 
   
   
   

















    
   
 
   
 
 
     
   
DEET viii
Managing Hazardous Materials Incidents is a three-volume set of recommendations for on-scene 
(prehospital) and hospital medical management of patients exposed during a hazardous materials 
incident (see https://www.atsdr.cdc.gov/MHMI/index.asp).  Volumes I and II are planning guides
to assist first responders and hospital emergency department personnel in planning for incidents
that involve hazardous materials.  Volume III—Medical Management Guidelines for Acute
Chemical Exposures—is a guide for health care professionals treating patients exposed to 
hazardous materials.
Fact Sheets (ToxFAQs™) provide answers to frequently asked questions about toxic substances (see 
https://www.atsdr.cdc.gov/toxfaqs/Index.asp).
Other Agencies and Organizations
The National Center for Environmental Health (NCEH) focuses on preventing or controlling disease, 
injury, and disability related to the interactions between people and their environment outside the
workplace.  Contact:  NCEH, Mailstop F-29, 4770 Buford Highway, NE, Atlanta, GA
30341-3724 • Phone:  770-488-7000 • FAX:  770-488-7015 • Web Page:
https://www.cdc.gov/nceh/.
The National Institute for Occupational Safety and Health (NIOSH) conducts research on occupational
diseases and injuries, responds to requests for assistance by investigating problems of health and
safety in the workplace, recommends standards to the Occupational Safety and Health
Administration (OSHA) and the Mine Safety and Health Administration (MSHA), and trains
professionals in occupational safety and health.  Contact: NIOSH, 395 E Street, S.W., Suite 9200, 
Patriots Plaza Building, Washington, DC 20201 • Phone:  202-245-0625 or 1-800-CDC-INFO 
(800-232-4636) • Web Page: https://www.cdc.gov/niosh/.
The National Institute of Environmental Health Sciences (NIEHS) is the principal federal agency for
biomedical research on the effects of chemical, physical, and biologic environmental agents on
human health and well-being.  Contact:  NIEHS, PO Box 12233, 104 T.W. Alexander Drive, 
Research Triangle Park, NC 27709 • Phone:  919-541-3212 • Web Page:
https://www.niehs.nih.gov/.
Clinical Resources (Publicly Available Information)
The Association of Occupational and Environmental Clinics (AOEC) has developed a network of clinics 
in the United States to provide expertise in occupational and environmental issues.  Contact:
AOEC, 1010 Vermont Avenue, NW, #513, Washington, DC 20005 • Phone:  202-347-4976 
• FAX:  202-347-4950 • e-mail: AOEC@AOEC.ORG • Web Page:  http://www.aoec.org/.
The American College of Occupational and Environmental Medicine (ACOEM) is an association of
physicians and other health care providers specializing in the field of occupational and 
environmental medicine.  Contact:  ACOEM, 25 Northwest Point Boulevard, Suite 700, Elk
Grove Village, IL 60007-1030 • Phone:  847-818-1800 • FAX:  847-818-9266 • Web Page:
http://www.acoem.org/.
The American College of Medical Toxicology (ACMT) is a nonprofit association of physicians with











    
 
 
   
 
      
   
 
   
   




Suite 200-111, Phoenix AZ 85028 • Phone: 844-226-8333 • FAX:  844-226-8333 • Web Page:
http://www.acmt.net.
The Pediatric Environmental Health Specialty Units (PEHSUs) is an interconnected system of specialists 
who respond to questions from public health professionals, clinicians, policy makers, and the
public about the impact of environmental factors on the health of children and reproductive-aged
adults.  Contact information for regional centers can be found at http://pehsu.net/findhelp.html.
The American Association of Poison Control Centers (AAPCC) provide support on the prevention and 
treatment of poison exposures.  Contact:  AAPCC, 515 King Street, Suite 510, Alexandria VA

















































   




   
   
 
     
   
 












Robert Williams, CDR, Ph.D.
 








SRC, Inc., North Syracuse, NY
 
THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:
1.	 Health Effects Review. The Health Effects Review Committee examines the health effects 
chapter of each profile for consistency and accuracy in interpreting health effects and classifying
end points.
2.	 Minimal Risk Level Review.  The Minimal Risk Level Workgroup considers issues relevant to
substance-specific Minimal Risk Levels (MRLs), reviews the health effects database of each
profile, and makes recommendations for derivation of MRLs.
3.	 Data Needs Review. The Environmental Toxicology Branch reviews data needs sections to
assure consistency across profiles and adherence to instructions in the Guidance.





























      
 






   
 
  
   
   
   
 
 
   
    
  
   
 
  




A peer review panel was assembled for DEET.  The panel consisted of the following members:
1.	 Dr. Mohamed B. Abou-Donia, Professor of Pharmacology and Cancer Biology and of
Neurobiology, Duke University Medical Center, Durham, North Carolina;
2.	 Dr. Thomas G. Osimitz, Diplomat, American Board of Toxicology, European Registered 
Toxicologist, Science Strategies, LLC, Charlottesville, Virginia; and
3.	 Dr. Andrey I. Nikiforov, President, Principal, Charlottesville, Virginia.
These experts collectively have knowledge of DEET’s physical and chemical properties, toxicokinetics,
key health end points, mechanisms of action, human and animal exposure, and quantification of risk to
humans.  All reviewers were selected in conformity with the conditions for peer review specified in
Section 104(I)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as
amended.
Scientists from the Agency for Toxic Substances and Disease Registry (ATSDR) have reviewed the peer
reviewers' comments and determined which comments will be included in the profile.  A listing of the
peer reviewers' comments not incorporated in the profile, with a brief explanation of the rationale for their 
exclusion, exists as part of the administrative record for this compound.  
The citation of the peer review panel should not be understood to imply its approval of the profile's final
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1. PUBLIC HEALTH STATEMENT FOR DEET
 
This Public Health Statement summarizes the Agency for Toxic Substances and Disease Registry’s 
(ATSDR) findings on DEET, including chemical characteristics, exposure risks, possible health effects 
from exposure, and ways to limit exposure.
The U.S. Environmental Protection Agency (EPA) identifies the most serious hazardous waste sites in the 
nation.  These sites make up the National Priorities List (NPL) and are targeted for long-term federal
clean-up activities.  U.S. EPA has found DEET in at least 2 of the 1,832 current or former NPL sites.
The total number of NPL sites evaluated for DEET is not known.  But the possibility remains that as more
sites are evaluated, the sites at which DEET is found may increase. This information is important because 
these future sites may be sources of exposure, and exposure to DEET may be harmful.
If you are exposed to DEET, many factors determine whether you’ll be harmed.  These include how much 
you are exposed to (dose), how long you are exposed (duration), how often you are exposed (frequency), 
and how you are exposed (route of exposure).  You must also consider the other chemicals you are
exposed to and your age, sex, diet, family traits, lifestyle, and state of health.
WHAT IS DEET?
DEET is the chemical N,N-diethyl-meta-toluamide.  Technical DEET is a nearly colorless liquid with a
faint characteristic odor.  DEET is the active ingredient in some common repellents widely used to repel
biting pests such as mosquitos and ticks. A significant benefit of DEET is protection against mosquito or
tick borne illnesses. Examples of tick-borne illnesses include Lyme disease and Rocky Mountain Spotted
Fever.  Mosquito-borne illnesses may include those caused by West Nile Virus and Zika Virus.
DEET is the common name for an insect and acarid repellent used to repel, but not kill, biting insects,
mites, and ticks.  DEET formulations are typically used as sprays or mists, lotions and wipes.  DEET
formulations can be applied directly onto human skin or onto clothing.  DEET has been formulated with 
sunscreen lotions for direct application to skin.  DEET has also been infused into various products such as
wrist bands, intended to be worn by the consumer while outdoors.
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1.  PUBLIC HEALTH STATEMENT
DEET has been previously and is currently sold as an ingredient in several common repellent products, 
including Skeeter Skat®, as well as various Off!®, Repel®, and Old Time Woodsman® brand products and 
various Cutter brand products, such as Cutter All Family®, Cutter Dry®, and Cutter Backwoods®.
WHAT HAPPENS TO DEET WHEN IT ENTERS THE ENVIRONMENT?
DEET can enter the air during spray applications.  Approximately 9.6% of the DEET applied to human 
skin evaporates in 1 hour. DEET has occasionally been detected in air samples at low concentrations. If
released to the atmosphere, DEET will exist solely as a vapor.  Half of the amount of DEET in air will
disappear in approximately 5 hours.  DEET is not expected to persist or be transported long distances in 
the environment.
DEET can be released from common showering and laundering practices and eventually may enter waste
water treatment facilities. DEET can also enter surface water from recreational activities such as 
swimming.  DEET has been detected at low levels in streams, surface water, and groundwater systems, 
and sewage treatment plant effluents throughout the United States. If released to water, bioaccumulation 
of DEET in aquatic organisms is not expected. Volatilization from water surfaces is not expected. DEET
may be biodegraded in water or undergo direct photolysis in sunlit waters; therefore, persistence in water
systems is not expected.
Although DEET is registered by the EPA Office of Pesticides, it only acts as a repellent, not a pesticide.  
Therefore, applications to crops or agricultural products do not typically occur.  DEET may enter soils as 
the result of overspray, disposal in landfills, or irrigation of soils with reclaimed water containing DEET.  
No data were located on the environmental concentrations of DEET in sediment or soil.  If released to 
soils, volatilization is not expected and DEET will have moderate mobility.  Data suggest that DEET
would be biodegradable in soils under aerobic conditions and would biodegrade slowly under anaerobic
conditions.
HOW MIGHT I BE EXPOSED TO DEET?
The most important route of exposure to the general population is through dermal contact from intentional
application to human skin and clothing of consumer products containing DEET.  It might also get into
your eyes if sprayed improperly.  DEET can be released into the air, water, and soil at places where it is 
produced or used.  DEET is most often released into surface waters following its incomplete removal at
waste water treatment facilities, and to a lesser extent released into the air when applying DEET-
   
 








      





    
      
    
     




   
 
 
     
  
 
   
 
        
    
 
    
 
    
     
    
     
 




1.  PUBLIC HEALTH STATEMENT
containing repellents.  You will be exposed to DEET if you use water containing DEET for drinking or
bathing.  However, the levels of DEET detected in water and air are generally low. 
HOW CAN DEET ENTER AND LEAVE MY BODY?
Scientists have not yet studied whether DEET in the air can be absorbed into your lungs after inhalation.  
It is absorbed through the skin and digestive tract, so it is likely that DEET can also be absorbed through 
the lungs and into the blood.  DEET in the lungs can be coughed up and swallowed, if it is not absorbed 
first.  DEET in water or food can be absorbed from the digestive tract; studies in animals suggest that 
most of the ingested DEET will be absorbed.  Small quantities of DEET (less than 10–20% of the applied 
DEET) can be absorbed through your skin.  In addition, if your skin contacts water with DEET in it, you
may absorb some DEET through your skin.  
Although rarely found in soil, if you accidentally eat soil contaminated with DEET, some of the DEET
will enter your body through the digestive tract.  In addition, if you touch soil contaminated with DEET, 
some of the DEET may enter your body through the skin.
In your body, most of the DEET is broken down into other substances (metabolites) in the liver, and both 
DEET and the metabolites distribute widely throughout your body.  Studies have detected DEET or its 
metabolites in many organs of exposed animals, including the brain, liver, kidneys, lungs, spleen, fat, 
tears, and inside the nose.  DEET does not appear to accumulate in any particular organ in the body.
Most of the DEET that is absorbed into your body is excreted quickly through your urine either
unchanged or as a metabolite.  A small proportion of the DEET that is taken in is excreted in the feces.
HOW CAN DEET AFFECT MY HEALTH?
The health effects of DEET depend on several factors including how much of this substance you are
exposed, the route and length of that exposure, and how often you are exposed.  Environmental
monitoring data suggest that any DEET levels that the public might encounter in the environment are 
much lower than levels causing effects in animal studies, and at much lower levels than people are
exposed to when using insect or acarid repellents.  Considering the intentional extensive consumer use of
products containing DEET on the skin, the risk of health effects due to exposure to DEET appears to be 
quite low. 
   
 








     
   
 
 
    
    
  
 
    
    
    
   
   
  
     
 
      
   
  
       
   
 














1.  PUBLIC HEALTH STATEMENT
There have been sporadic reports over the last several decades of an association between excessive use of
repellents containing DEET and adverse neurological effects including seizures, uncoordinated
movements, agitation, aggressive behavior, low blood pressure, and skin irritation.
In a study of more than 9,000 exposures to DEET-containing repellents reported to Poison Control
Centers between 1985 and 1989, most exposures (88%) did not produce symptoms that required treatment
in a health care facility.  In a similar study of more than 20,764 exposures to DEET-containing repellents
reported to Poison Control Centers between 1993 and 1997, nearly 89% of the occurrences were managed 
at the exposure site; 11% of the cases were evaluated in a health care facility (80% of these subjects were 
treated and released).  About half of the subjects were reported or judged to suffer no ill effects due to 
DEET exposure.  A similar percentage was reported or judged to have a minor effect that were not
bothersome, did not last long, and did not require treatment.  Some of these included drowsiness, skin 
irritation, or temporary cough.  Four percent experienced a moderate or greater effect or a potentially
toxic exposure such as corneal abrasion, high fever, disorientation, or isolated brief seizures, and required 
treatment.  In both reports, nearly 50% of cases were a result of DEET ingestion.
Workers at a national park who used insect repellents or lotions containing DEET repeatedly during the
summer season complained more often of chest pain or wheezing, muscle cramping, skin rashes and
blisters, dizziness, disorientation, and difficulty concentrating than workers who used the products less
often or did not use them at all.  Because exposure was inferred only from survey responses, these
findings should be interpreted with caution.
A study of workers in Sweden found that those who used insect repellents for 115 days or longer had an 
increased risk of developing testicular cancer.  However, because of deficiencies in the study, the results 
were not conclusive.
Long-term studies in which dogs, rats, and mice were given DEET orally or in which liquid DEET was 
applied to the skin of mice and rabbits did not find an increase in tumors in the animals.
The U.S. Department of Health and Human Services (DHHS) has not classified DEET as to its
carcinogenicity.  The U.S. EPA’s Office of Pesticide Programs (OPP) has classified DEET as a Group D
chemical, not classifiable as a human carcinogen.  The International Agency for Research on Cancer
(IARC) has not classified DEET as to its carcinogenicity.
See Chapters 2 and 3 for more information on health effects of DEET.
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1.  PUBLIC HEALTH STATEMENT
HOW CAN DEET AFFECT CHILDREN?
This section discusses potential health effects of DEET exposure in humans from when they’re first
conceived to 18 years of age.
Some children exposed to insect repellents or lotions containing DEET have experienced the same type of
neurological effects observed in adults (i.e., agitation, hypertonia, seizures, ataxia, restlessness, and
uncontrolled limb movements).  In the specific case of seizures, it should be noted that because a
relatively high percentage (23–29%) of children are exposed to DEET in the United States and because 
seizure disorders occur in approximately 3–5% of children from any cause, it might be possible, just by
chance alone, to erroneously find an association.
A study of more than 9,000 human exposures involving insect repellents containing DEET reported to 
Poison Control Centers did not find evidence that children are more likely to develop adverse health 
effects than adults if exposed to DEET.  As mentioned earlier, considering the extensive use of products
containing DEET and limited reports of significant health effects, the risk of serious health effects from
exposure to DEET may be quite low.
Two studies of women who used insect repellents containing DEET during pregnancy did not find 
abnormalities in the babies at birth that were attributable to exposure to DEET.
Studies in rats and rabbits administered DEET in their food during pregnancy did not find birth defects or
other abnormalities in the offspring.
HOW CAN FAMILIES REDUCE THE RISK OF EXPOSURE TO DEET?
If your doctor finds that you have been exposed to significant amounts of DEET, ask whether your
children might also be exposed.  Your doctor might need to ask your state health department to 
investigate.  You may also contact the state or local health department with health concerns.
It is possible to transfer DEET from your hands onto food.  Encourage good hygiene practices (e.g., hand-
washing) to minimize this possible route of exposure and be careful not to overspray and contaminate
foods, utensils, etc. when applying DEET-containing products from aerosol dispensers. The American
Association of Pediatrics (AAP) recommends that products containing DEET should not be applied to 
   
 








        





   
  
  
    
     
  
 
    
   
  
     
  
   
  




















1.  PUBLIC HEALTH STATEMENT
young children’s hands or around the mouth, or to infants below the age of 2 months. The Centers for
Disease Control and Prevention (CDC) supports these restrictions. Children under 10 years of age should 
not apply DEET by themselves.  Do not re-use DEET product containers, especially for storing food and 
water.
Many consumer repellents contain DEET as an active ingredient.  Check the label of these products and 
follow the instructions listed below regarding the proper use, disposal, and application of DEET.  In 
general, do not apply DEET near your mouth or eyes and do not apply over cuts or irritated skin.  Do not
apply it under clothing, and wash clothing that has been sprayed with DEET before wearing it again.  
When applying DEET to the facial area, first apply to your hands, then rub the product onto your face, 
and then wash your hands.  Avoid direct spraying to the face as this could cause the product to get into
your eyes, mouth, or lungs.  To avoid overexposure, be sure to remove DEET containing products from
your body before going to bed (shower or use a wash cloth to remove from skin).
The U.S. EPA requires the following statements on all DEET product labels:
1. Read and follow all directions and precautions on this product label.
2. Do not apply over cuts, wounds, or irritated skin.
3. Do not apply near eyes and mouth. Apply sparingly around ears.
4. Do not apply to children’s hands.
5. Do not allow children to handle this product.
6. When using on children, apply to your own hands and then put it on the child.
7. Use just enough repellent to cover exposed skin and/or clothing.
8. Do not use under clothing.
9. Avoid over-application of this product.
10. 	After returning indoors, wash treated skin with soap and water.
11. 	Wash treated clothing before wearing it again.
12.	  Use of this product may cause skin reactions in rare cases.
13. 	If you suspect a reaction to this product, discontinue use, wash treated skin, and call your
local poison control center.
14. 	If you go to a doctor, take this product with you. 
15.	  ACTIVE INGREDIENTS: DEET…….XX.XX%
16.	  A toll-free telephone number for consumers to call for additional product information and to 
report incidents.
The EPA does not require an expiration date on the label of DEET products manufactured in the United 
States.
Animal research indicates that drinking less alcohol might reduce how much DEET passes into the body
through the skin. 
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ARE THERE MEDICAL TESTS TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO
DEET?
DEET and its breakdown products (metabolites) can be measured in blood and urine.  However, the
detection of DEET or its metabolites cannot predict whether or not health effects might develop from that
exposure.  Because DEET and its metabolites leave the body fairly rapidly, such tests need to be
conducted within hours after exposure.
For more information on the different substances formed by DEET breakdown and on tests to detect these 
substances in the body, see Chapters 3 and 7.
WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT
HUMAN HEALTH?
The federal government develops regulations and recommendations to protect public health.  Regulations
can be enforced by law.  Federal agencies that develop regulations for toxic substances include the
Environmental Protection Agency (EPA), the Occupational Safety and Health Administration (OSHA),
and the Food and Drug Administration (FDA).  Recommendations provide valuable guidelines to protect
public health but are not enforceable by law.  Federal organizations that develop recommendations for
toxic substances include the Agency for Toxic Substances and Disease Registry (ATSDR) and the 
National Institute for Occupational Safety and Health (NIOSH).
Regulations and recommendations can be expressed as “not-to-exceed” levels; that is, levels of a toxic 
substance in air, water, soil, or food that do not exceed a critical value usually based on levels that affect
animals; levels are then adjusted to help protect humans.  Sometimes these not-to-exceed levels differ
among federal organizations.  Different organizations use different exposure times (e.g., an 8-hour
workday or a 24-hour day), different animal studies, or emphasize some factors over others, depending on 
their mission.
Recommendations and regulations are also updated periodically as more information becomes available.
For the most current information, check with the federal agency or organization that issued the regulation
or recommendation.
In order to protect against vector-borne illnesses such as Lyme Disease or those caused, for example, by 
West Nile Virus or Zika Virus, the Centers for Disease Control and Prevention (CDC), the EPA, and the
World Health Organization (WHO) all recommend and/or endorse the use of DEET-containing products. 
   
 









         
      
  
 
   




   
  


















1.  PUBLIC HEALTH STATEMENT
CDC specifically recommends using products with at least 20% DEET on exposed skin to reduce biting
by ticks or mosquitos that may spread disease. The concentration of DEET in a product can be selected to
meet the type and duration of protection. The manufacturer’s directions on the label should be followed 
for applying and reapplying the product; excessive reapplication is not useful and should be avoided. 
The EPA has not recommended drinking water guidelines for DEET.  OSHA has not set a legal limit for
DEET in air.  NIOSH has not set a recommended limit for DEET in air.
WHERE CAN I GET MORE INFORMATION?
If you have any questions or concerns, please contact your community or state health or environmental
quality department, or contact ATSDR at the address and phone number below.  You may also contact
your doctor if experiencing adverse health effects or for medical concerns or questions.  ATSDR can also
provide publicly available information regarding medical specialists with expertise and experience 
recognizing, evaluating, treating, and managing patients exposed to hazardous substances.






Agency for Toxic Substances and Disease Registry

Division of Toxicology and Human Health Sciences
 






Toxicological profiles and other information are available on ATSDR’s web site:
http://www.atsdr.cdc.gov.
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2. RELEVANCE TO PUBLIC HEALTH
 
2.1  	 BACKGROUND AND ENVIRONMENTAL EXPOSURES TO DEET IN THE UNITED 
STATES 
Technical DEET is a nearly colorless liquid with a faint characteristic odor. It is mainly used as a 
commercial insect or acarid repellent.  In 1990, approximately 4 million pounds of the active ingredient
DEET was used in commercial products and the average annual domestic use of DEET has been 
estimated as ranging from 5 to 7 million pounds based on product sales.  Aquatic systems appear to be the 
main environmental sink for this chemical. DEET has been detected in sewage treatment plant effluents,
streams, surface water, and groundwater systems. The largest contribution for DEET in water systems 
comes from sewage effluents containing this chemical. Concentrations of DEET in effluents result from
washing skin and clothing where commercial products containing DEET have been applied. Albeit a 
minor contribution, human absorption of DEET after application and subsequent excretion of DEET, and 
its metabolites, also contributes to effluent concentrations. DEET-contaminated effluents may also enter
surface water and groundwater systems after passing through waste water treatment plants (WWTPs) or
domestic septic systems. Additionally, recreational activities such as swimming, via swimmers with
DEET products on their skin or clothing washing off, can contribute to DEET in water systems.
Studies have shown that DEET is not expected to bioconcentrate in aquatic systems.  DEET is expected to
be hydrolytically stable under environmental conditions.  Little degradation is expected under anaerobic
conditions; however, DEET is considered readily biodegradable in aerobic conditions and should not
persist in the environment.
See Chapter 6 for more detailed information regarding concentrations of DEET in environmental media
and its environmental fate.
The general population is exposed to DEET as a result of its use as an insect and acarid repellent intended 
for direct human application.  Insect repellent products containing DEET range in concentration from 4 to 
100%.  As of March 2017, there were 27 companies in the United States that manufactured approximately
119 consumer products containing DEET. According to the U.S. EPA, as of February 2014, there were 
123 active registrations for DEET, including co-formulations with other chemicals, formulations with 
sunscreen, and one registration for use on horses. Dermal application of repellents is the major route of
exposure.  Inhalation may be a route of exposure when aerosol formulations are used, albeit a minor route
of exposure.  Children are expected to be exposed to DEET by the same routes that affect adults.  No data
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were located regarding DEET in breast milk; therefore, an adequate determination of the importance of
this route of child exposure has not been made.  DEET absorbed through the skin, however, can transfer
through the placenta and expose the fetus.
Data from the National Health and Nutrition Examination Survey (NHANES) show that levels of DEET
in 74% of the study population were below the detection limits of 0.449 µg/L (1999–2000) and 0.1 µg/L
(2001–2002) in the urine of 4,512 members of the U.S. general population sampled during these two 
surveys.  The respective 90th and 95th percentile values were 0.11–0.13 and 0.13–0.22 μg/L.  The highest
levels were found in people 12–19 years old and in non-Hispanic whites. Levels of DEET for the survey 
years 2007–2010 were also below the detection limit (0.089 μg/L). It should be noted, that human 
monitoring data measuring the parent compound DEET does not directly correlate to initial exposure
concentrations due to the fact that the majority of absorbed DEET is metabolized. The main metabolites
of DEET in humans are 3-(diethylcarbamoyl) benzoic acid (DCBA) and N,N-diethyl-3-(hydroxymethyl)
benzamide (DHMB). Data from NHANES for the years 2007–2010 show levels of both DCBA and 
DHMB in urine higher than those reported for the parent compound, DEET, indicating the relevance of
their evaluation when assessing exposures to DEET. Details of the results can be found in Section 6.5.  
2.2  SUMMARY OF HEALTH EFFECTS 
Exposure of humans to DEET has been associated with a variety of health effects including neurological, 
respiratory, cardiovascular, gastrointestinal, dermal, and ocular. It should be noted, however, that
considering the many millions of applications of DEET per year in the United States, there have been
limited reports of serious health effects following DEET applications. A few deaths in humans have been 
associated with oral and dermal exposure to DEET, sometimes in combination with other drugs or
chemicals. This also needs to be considered in studies reporting effects other than death since 
commercial DEET products usually contain additional ingredients.  The most serious effects reported
following oral and dermal exposure to products containing DEET have been neurological effects.
Neurological signs and symptoms reported in children and adults include seizures, ataxia, restlessness,
uncontrolled limb movements, agitation, aggressive behavior, combativeness, impaired cognitive
functioning, and opisthotonos (a postural abnormality characterized by hyperextension of the back and
neck muscles, with retraction of the head, and arching forward of the trunk).  Because of the wide
spectrum of neurological effects reported, some researchers have noted that it is unlikely that they were 
due to exposure to a single agent. In a study of 242 cases in the DEET Registry, a collection of self-
reported cases spanning 6 years of DEET use in North America, there were 59 seizure cases.  At the 
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1-year follow-up of 35 of these cases, medical tests showed evidence of an underlying neurological
disorder in five of these cases, questioning the role of DEET as the sole cause of seizures in those cases.
The issue of seizures in children following exposure to DEET needs to be evaluated with caution.  In the
specific case of seizures, it should be noted that because a relatively high percentage (23–29%) of
children are exposed to DEET in the United States and because seizure disorders occur in approximately
3–5% of children from any cause, it might be possible, just by chance alone, to erroneously find an 
association.  There is no reliable information regarding doses or exposure concentrations associated with
effects.  A survey of 143 employees of the Everglades National Park, Florida who used DEET regularly
in their work, showed that more highly exposed workers (estimated >4.25 g DEET/week or about 8.7 mg 
DEET/kg/day assuming 70 kg of body weight) had a higher prevalence of dizziness, disorientation,
difficulty concentrating, and skin rashes than non-users of DEET. Because exposure was inferred from
only survey responses, a notable weakness, the findings from this report should be interpreted with 
caution. In a study of 9,086 exposures involving insect repellents containing DEET reported to Poison 
Control Centers from 1985 to 1989, it appeared that the concentration of DEET in the product used was 
not related to the severity of the symptoms following exposure. Those patients experiencing a major
effect had used products containing 11–50% DEET. The same observations were made in a later study of
20,764 exposures involving insect repellents containing DEET that were reported to poison control
centers from 1993 to 1997.
Exposure to DEET has produced skin irritation, desquamation of the skin, dermatitis, and erythema in
humans.  Cases of non-immunological and immunological contact urticaria have also been reported.
Neurological effects also have been reported in animals exposed to DEET primarily by the oral route or
by application of DEET onto the skin. Results from high dose-studies in animals support the findings in
humans exposed to high amounts of DEET.  Tremors and seizures occurred at the highest oral doses
tested: 400 mg DEET/kg/day in dogs and ≥2,000 mg DEET/kg in rats.  In rats, but not in dogs, the higher
doses also caused histological alterations in the brain. Tremors were also reported in rats exposed by 
inhalation to a high concentration of 4,100 mg/m3 DEET aerosol.  One study reported neurobehavioral
alterations in rats acutely dosed by oral gavage with lower doses of DEET (500 mg/kg) but others have
not.  Dermal application of doses of 4 mg DEET/kg/day as 10 mg/mL DEET in 70% alcohol to a 2.5-cm2 
area for 60 days affected some sensory parameters in rats and doses ≥40 mg DEET/kg/day (which the
authors considered equivalent to typical exposures of military personnel during wartime) induced 
histological alterations in various brain areas and affected cholinergic neurotransmitter systems.  It should 
be mentioned, however, that some scientists have raised concerns about possible misinterpretation of the
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histopathological findings because of artifacts resulting from inadequate handling and fixation of the
brain tissue.  The neurobehavioral alterations reported in some of these studies, however, were not
observed in a more recent similar study in rats that also applied doses of 40 mg DEET/kg/day, as
100 mg/mL DEET in 70% alcohol, to a larger 4-cm2 exposure area and shorter 30-day exposure time.  
The apparent inconsistent results between some studies need to be resolved considering the differences in
route of exposure, exposure area and exposure duration.
DEET exhibited relatively little systemic toxicity in repeated inhalation, oral and dermal exposure studies 
in animals. Daily intermittent exposure of rats to up to 1,511 mg/m3 aerosolized DEET (the highest
concentration tested) for 13 weeks did not cause morphological alterations in organs and tissues or
produce significant alterations in hematology or clinical chemistry tests. In general, alterations were seen
only at the highest oral dose tested (≥400 mg DEET/kg/day). Oral studies reported reductions in body
weight gain in rats, mice, hamsters, rabbits, and dogs.  Oral exposure to DEET also caused alterations in 
serum electrolytes in hamsters, dogs, and rabbits.  Other systemic effects induced by repeated oral
exposure to DEET include slightly decreased hemoglobin and hematocrit, increased platelets, increased
serum alkaline phosphatase, and decreased cholesterol in dogs, fatty changes in hepatocytes in rabbits, 
and increased cholesterol in rats.  In the absence of histological alterations in organs and tissues, the
toxicological significance of these findings is unclear. Following repeated dermal exposure, DEET was
not a skin sensitizer in guinea pigs or rabbits, but induced erythema and acanthosis/hyperkeratosis in rats, 
skin desquamation, hyperkeratosis and acanthosis in micropigs and rats, and skin irritation in rabbits
following repeated dermal exposure.
There are no studies of reproductive effects in humans exposed to DEET.  
DEET did not affect fertility in male or female rats in a 2-generation continuous feeding study.  DEET
also did not induce gross or microscopic alterations in the reproductive organs of male rabbits, or male or
female rats, mice, or dogs in intermediate- or chronic-duration oral studies, or in male rats in an
intermediate-duration dermal study.  DEET at ≥624 mg/kg/day, however, increased the incidence of
tubular degeneration in the testes of hamsters in a 90-day study.  
Exposure to DEET was not associated with developmental effects in two epidemiological studies.  In one
of them, pregnant women applied DEET onto themselves in the second and third trimester of pregnancy.  
The results did not show significant differences between exposed and control neonates regarding head and
arm circumference or length or in a series of neurological tests in the neonates. The other
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epidemiological study did not find significant associations between the presence of DEET in maternal
blood or cord serum and birth weight, head circumference, abdominal circumference, or birth length in 
neonates.  DEET did not induce embryotoxicity or teratogenicity in rats or rabbits at doses that caused a 
significant reduction in maternal body weight gain during gestation.  Sacrifices were conducted the last
day of gestation in these studies.  In the 2-generation continuous feeding study in rats, DEET induced 
significant reductions in weight in both male and female F1 and F2 pups during lactation.
Limited information exists regarding exposure to DEET and cancer and occupational exposure.  A case-
control study of testicular cancer and occupational exposure in Sweden reported a significant association
between exposure to insect repellents for more than 115 days and testicular cancer.  No evidence, 
however, was provided that DEET was the causative agent.  In addition, exposure was assessed by self-
recollection, which is known to be unreliable.  DEET was not carcinogenic following long-term oral
assays in rats, mice, or dogs or following long-term skin application to mice or rabbits. The EPA’s OPP 
classified DEET as a Group D substance, not classificable as a human carcinogen, based on no evidence
of mutagenicity in multiple tests, or of carcinogenicity in long-term oral ingestion studies in adult rats or
mice. DHHS and IARC have not classified DEET as to its carcinogenicity.
2.3  MINIMAL RISK LEVELS (MRLs)
Estimates of exposure levels posing minimal risk to humans (MRLs) have been established for DEET.
An MRL is defined as an estimate of daily human exposure to a substance that is likely to be without an 
appreciable risk of adverse effects (noncarcinogenic) over a specified duration of exposure. MRLs are 
derived when reliable and sufficient data exist to identify the target organ(s) of effect or the most sensitive 
health effect(s) for a specific duration within a given route of exposure. MRLs are based on
noncancerous health effects only and do not consider carcinogenic effects.  MRLs can be derived for
acute, intermediate, and chronic duration exposures for inhalation and oral routes.  Appropriate
methodology does not exist to develop MRLs for dermal exposure.
Although methods have been established to derive these levels (Barnes and Dourson 1988; EPA 1990), 
uncertainties are associated with these techniques.  Furthermore, ATSDR acknowledges additional
uncertainties inherent in the application of the procedures to derive less than lifetime MRLs.  As an
example, acute inhalation MRLs may not be protective for health effects that are delayed in development
or are acquired following repeated acute insults, such as hypersensitivity reactions, asthma, or chronic
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bronchitis.  As these kinds of health effects data become available and methods to assess levels of
significant human exposure improve, these MRLs will be revised.
Inhalation MRLs
No inhalation MRLs were derived for DEET due to insufficient data. Qualitative information regarding 
effects in humans following inhalation exposure to DEET was found in a study of 20,764 exposures
involving insect repellents containing DEET that were reported to poison control centers from 1993 to 
1997 (Bell et al. 2002).  In 520 of these cases, inhalation was identified as the leading exposure route.
Respiratory (coughing/choking, dyspnea, bronchospasm, respiratory depression, pneumonitis), 
cardiovascular (tachycardia, hypertension, hypotension), gastrointestinal (oral irritation, vomiting, 
nausea), and neurological (dizziness/vertigo, headache, drowsiness/lethargy) signs and symptoms were 
most commonly reported. About half of the subjects were reported or judged to suffer no ill effects due to 
DEET exposure.  A similar percentage of subjects were reported or judged to have a minor effect.  Four
percent experienced a moderate or greater effect or a potentially toxic exposure. Similar qualitative data 
regarding 9,086 human exposures were published earlier by Veltri et al. (1994). In 2012, there were
4,075 single cases of exposure to insect repellents with DEET reported to the American Association of
Poison Control Centers (AAPCC 2013).  Two deaths were reported in this series of cases. Most of the
other cases were in children ≤5 years of age (n=2,316, 57%) or adults ≥20 years of age (n=829, 20%), and 
the severity of health effects were primarily considered to be none (n=576, 14%) to minor (n=1,176, 
29%). No information was provided regarding the remaining 57%.  This qualitative information cannot
be used for MRL derivation.
The animal data are restricted to only a few studies, some with significant limitations. Acute-duration 
inhalation studies have been conducted in rats and mice.  Head-only exposure of rats to an aerosol of 85%
DEET for 2–6 hours induced minor changes in the lungs and trachea, but no further details were provided
(Ambrose 1959).  The actual exposure concentration that animals received was not provided in this study
and there was no indication that a control group was used.  An additional acute-duration study in rats
reported that 4-hour exposures conducted at concentrations of ≥2,300 mg/m3 DEET aerosol decreased
performance in behavioral tests conducted within 50 minutes of termination of exposure (Army 1979).  
Gross necropsy following a 14-day observation period did not show treatment-related lesions. The
limited scope of the study and the lack of histological examination of tissues, particularly the nervous
system, made this study inadequate for MRL derivation. Furthermore, the lowest concentration tested 
was considerably higher than a 4-hour LC50 of 1,369 mg/m3 reported in mice (Deb et al. 2010). In a study
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in mice, head-only exposure to a target concentration of 135 mg/m3 DEET aerosol for 4 hours increased 
respiratory frequency, but this effect was not observed at lower or higher exposure concentrations (Deb et
al. 2010).  Other respiratory parameters that were measured were not affected.  Because the actual
exposure concentrations were not specified and, according to the investigators, were 50–60% of the target
concentrations, the results of this study are unreliable.
Only a few intermediate-duration inhalation studies were available for review. In an early study by 
Ambrose (1959), exposure of rats to air saturated with vaporized DEET (approximately 71 mg/m3) 
8 hour/day, 5 days/week for 7 weeks resulted in unspecified microscopic changes in the lungs and
trachea. There was no indication that a control group was used in the study. Army (1980a) conducted 
13-week intermittent exposure studies in Sprague-Dawley rats and Beagle dogs.  In both studies, the
animals were exposed whole-body to 252, 752, or 1,511 mg/m3 aerosolized DEET.  End points examined 
in rats included body weight, gross and microscopic appearance of all major tissues and organs, 
hematology and clinical chemistry parameters, and oxygen consumption.  No significant alterations were 
reported other than the transient appearance of a red exudate around the eyes and nose of rats exposed to 
1,511 mg DEET/m3. The study in dogs tested only two animals per sex per exposure group and only
evaluated hematology and clinical chemistry parameters as well as pulmonary function (compliance and
resistance). No significant effects were reported. This information was inadequate for MRL derivation.
No chronic-duration inhalation studies in animals were located.
Oral MRLs
An acute-duration oral MRL for DEET was not derived.  No reliable estimates of doses of DEET were 
available in the numerous cases of accidental or intentional ingestion of insect repellents containing
DEET summarized in Chapter 3.  The available acute-duration database in animals is limited. It should 
be noted that in all the acute-duration studies available for review, DEET was administered by gavage.
Acute-duration studies provided information regarding lethal doses (Ambrose 1959; Carpenter et al.
1974; EPA 1998c; McCain et al. 1997; Verschoyle et al. 1992), developmental (Schoenig et al. 1994),
and neurological (Schoenig et al. 1993, 1994; Verschoyle et al. 1992) effects in rats. In the
developmental studies, the highest doses tested (750 mg/kg/day in rats and 325 mg/kg/day in rabbits)
induced maternal toxicity in the form of significantly reduced body weight gain during the entire dosing 
period in rats (gestation days [GDs] 6–15) and during GDs 6–9 in rabbits and also induced adverse 
neurological signs in the rats (hypoactivity, ataxia, decreased muscle tone), although no incidence data
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were provided (Schoenig et al. 1994). These signs were opposite to what has been reported in humans
who ingested high amounts of DEET (i.e., hyperactivity, tremors, seizures, restlessness, uncontrolled limb 
movements, agitation, and aggressive behavior) (Petrucci and Sardini 2000; Tenenbein 1987; Zadikoff
1979). The reasons for this are uncertain. No significant fetotoxicity or teratogenicity was observed in 
either species in this study, other than a 6% reduction in fetal weight in the high-dose rats that may have 
been related in part to the 35% reduction in maternal weight gain during the treatment period. A
neurological study in rats reported that a single dose of 500 mg DEET/kg (the highest dose tested)
delayed the response to a thermal stimulus and decreased vertical activity 1 hour after treatment but not at
24 hours or 14 days post-treatment (Schoenig et al. 1993). These effects were characterized in the study
as slight and questionable by the investigators (Schoenig et al. 1993).  Another neurological study
reported that single doses of ≥1,000 mg DEET/kg (approaching the lethal dose) induced clinical signs and 
histological alterations in the brain, but the exact dose level at which effects started to appear was not
totally clear (Verschoyle et al. 1992). Although it would appear that studies such as the developmental
study in rats and rabbits by Schoenig et al. (1994) or the neurotoxicity study by Schoenig et al. (1993)
described above could be considered for MRL derivation, additional information suggests that it may not
be appropriate to do so.  Regarding the former, the Reregistration Eligibility Decision (RED) for DEET
(EPA1998b) indicates that in an unpublished dose-range developmental toxicity study in rabbits
administered DEET by gavage in doses ranging from 62.5 to 1,000 mg/kg/day on GDs 6–18, deaths
occurred in groups dosed with ≥500 mg DEET/kg/day.  Necropsy of the animals that died showed
sloughing and/or ulceration of the stomach lining and suggested that the corrosive effects of DEET to the
gastric lining may have been linked to the death of the rabbits.  This effect was consistent with the report 
of significant reduction in maternal weight gain and food consumption during the dosing period in the
developmental study in rabbits (Schoenig et al. 1994), as gastric irritation induced by DEET may have
caused the animals to stop eating.  This is also consistent with the results of a 15-day study in which 
rabbits dosed by gavage with 528 mg DEET/kg/day lost approximately 1/5 of their body weight during
the study; no data regarding food consumption were provided in this study (Army 1980b).  Also, in the
52-week study in dogs (Schoenig et al. 1999), tremors were observed in some dogs before administration 
of DEET in a capsule, and because of lack of temporal relationship, were not considered to be treatment-
related.  It is possible, however, that the dogs were able to associate feeding of a capsule with gastric 
discomfort, which may have caused the tremors.  In the developmental study in rats (Schoenig et al. 
1994), high-dose animals showed a significant reduction in weight gain and food consumption during
dosing, although not as marked as the rabbits.  In that study, two rats died on day 2 of treatment, but
apparently no necropsy was conducted, so it is unknown whether gastric lesions occurred.  Long-term 
dietary studies did not report gastrointestinal alterations in rats or mice administered doses of DEET
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comparable to those given in gavage studies (400–860 mg/kg/day to rats, 1,000 mg/kg/day to mice)
(Ambrose 1959; Schoenig et al. 1999) and no other significant toxic effects were reported.  Taken 
together, this information suggests that DEET given as a bolus dose may induce stomach irritation, which
in turn may cause the animals to stop eating and, therefore, lose weight or gain less weight than untreated 
animals. This effect also suggests that decreases in body weight observed in animals following gavage 
administration of DEET may be secondary to gastric irritation and reduced food consumption and may
not be appropriate as a basis for MRL derivation.  Additionally, exposure to DEET by people living near
hazardous waste sites would likely be through drinking water rather than by ingestion of a DEET bolus, 
as occurs with gavage dosing.
Schoenig et al. (1993) reported that rats treated with a single gavage dose of 500 mg DEET/kg showed 
delayed response to a thermal stimulus and decrease vertical activity and vertical time when tested 1 hour
post-dosing. The toxicological significance of these alterations is unknown.  Furthermore, the 
investigators noted that: “The effects of the high-dose on the thermal response was weak inasmuch as the
statistically significant effect was found only in an analysis that included both males and females in a 
factorial ANOVA, but fell short of significance even for the most affected sex, the females (p<0.06) when
the two sexes were analyzed separately.” Since only vertical activity and vertical time were affected by
treatment with DEET out of multiple activity parameters measured (horizontal activity, vertical activity,
total distance travel, movement time, rest time, number of movements, vertical time, number of vertical
movements, stereotype time, number of stereotypic movements, clockwise revolutions, and 
counterclockwise revolutions), confidence in an MRL based on this endpoint would be minimal at best.
In conclusion, the available acute-duration oral database does not support derivation of an acute-duration 
oral MRL for DEET.
•	 An MRL of 1.0 mg/kg/day has been derived for intermediate-duration oral exposure (15– 
364 days) to DEET.
No relevant human data were located. Intermediate-duration oral studies provide information regarding 
systemic, neurological, reproductive, and developmental effects in various animal species, but failed to
identify a sensitive target for DEET toxicity.  The lowest lowest-observed-adverse-effect level (LOAEL)
in any study was 25 mg DEET/kg/day for hyaline nephropathy in F1 males in a 2-generation continuous
feeding study (EPA 1989). This hydrocarbon-induced nephropathy has only been demonstrated in adult
male rats and has been associated to a specific protein, α2μ-globulin, which is produced under hormonal
control by the liver (Alden 1986; Swenberg 1993).  However, the α2μ-globulin is unique to male rats and
is not present in human kidneys.  Hence, this particular nephropathy has no significance for humans and 
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would therefore be inappropriate to use for MRL derivation. Significantly higher LOAELs were reported
in other intermediate-duration oral studies. A 200-day feeding study in rats reported a no-observed-
adverse-effect level (NOAEL) of 863 mg DEET/kg/day (the highest dose tested) for organ histopathology
and a LOAEL of 863 mg/kg/day for a statistically significant reduction (11.1%) in final body weight in 
female rats; food consumption was not significantly affected in this study and no clinical signs were
observed (Ambrose 1959).  A 90-day feeding study in hamsters reported NOAELs of 940 mg
DEET/kg/day (which was also the highest dose tested) for organ histopathology (EPA 1990b).  That
study also identified a LOAEL of 624 mg DEET/kg/day for approximately 13% reduction in final body
weight in male hamsters and for histopathology of the testes, and a LOAEL of 940 mg DEET/kg/day for a 
10–16% increase in serum potassium in both male and female hamsters.  Feeding dogs with DEET
through a capsule for 52 weeks resulted in LOAELs of 400 mg DEET/kg/day for statistically significant 
hematology changes in females (reduced hemoglobin at 6 months, reduced hematocrit at 12 months, 
increased platelets at 6 and 12 months) and clinical chemistry changes in males (decreased serum alkaline 
phosphatase at 6 months, reduced cholesterol at 6 and 12 months, increased serum potassium at 6 months)
(Schoenig et al. 1999); histological examination of tissues and organs was unremarkable. The
toxicological significance of these effects is unknown, particularly since they were observed in one sex or
the other.  Terminal body weight was also reduced in dogs fed 400 mg DEET/kg/day.  Although the
extent cannot be read from a graph in the paper, the investigators noted that body weight decreased at
several time points during the study for both males and females.  Dogs in these groups consumed less 
food during the initial weeks of the study, which may have caused these animals growth to lag behind for
the rest of the study.  The authors stated that the absolute weight differences were generally small, within
a few grams, and considered that 1,000 mg/kg/day was the only dose at which body weight and food
consumption differences were toxicologically relevant. Treatment-related tremors and ataxia were also
reported in one out of eight dogs several times after dosing with 400 mg DEET/kg/day.  A 15-day gavage
study in male rabbits reported LOAELs of 528 mg DEET/kg/day (highest dose tested) for a 14% decrease 
in serum calcium and 22% body weight loss (starting weight approximately 3,500 g, terminal weight 
approximately 2,750 g) (Army 1980b).  No information was provided regarding food consumption. 
Histological examination of organs and tissues showed fatty changes in hepatocytes, but no significant
alterations in other organs or tissues. The possible role that the considerable weight loss in high-dose
rabbits in a short period of time could have had in the other effects reported was not discussed in the 
study.  A study that conducted neurological examinations of F2 rats that were exposed to DEET during
gestation, lactation, and then directly for approximately 9 months reported a transient increase in motor
activity at 500 mg DEET/kg/day during the first 5–15 minutes of testing.  No such increase was seen
during the remaining 40 minutes of the test session (Schoenig et al. 1993). The investigators considered
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this effect of minor or questionable significance based on the small magnitude of the changes and the 
transient nature (Schoenig et al. 1993).  This study also reported a reduction of approximately 14% in 
final body weight in high-dose males, but no data on food consumption were provided.  The lowest
LOAEL in the database other than the 25 mg DEET/kg/day for hyaline nephropathy mentioned above,
was 250 mg DEET/kg/day (highest dose tested) for significantly (p<0.01) reduced (11–13.3%) body
weight in F1 and F2 male and female rat pups on lactation days 14 and 21 in the 2-generation continuous
feeding study (EPA 1989). The NOAEL in the study was 100 mg DEET/kg/day. Because the effects 
showed dose-response relationships, occurred in both male and female pups, were observed in two 
generations, and may have resulted in important developmental delays, the 2-generation continuous
feeding study in rats was selected for derivation of an intermediate-duration oral MRL for DEET. A 
detailed summary of the EPA study (1989) is presented in Appendix A.
Data for body weight in F1 and F2 male and female rat pups on day 21 of lactation in the EPA study
(1989) could not be analyzed using the benchmark dose (BMD) approach for the following reason. While
the total number of F1 and F2 pups alive on lactation day 21 is provided in the EPA study (1989), the sex 
distribution is not; however, the table that shows the body weight of the F1 and F2 pups presents the body
weight broken down by sex. Without knowing the number of animals examined (n), the BMD approach 
could not be used.  Therefore, the NOAEL/LOAEL approach was used for MRL derivation. Applying an 
uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human variability) to the
NOAEL of 100 mg DEET/kg/day results in an intermediate-duration oral MRL of 1 mg/kg/day for 
DEET.
A chronic-duration oral MRL was not derived for DEET. No relevant human data were located.  Well-
conducted chronic dietary studies in rats and mice found virtually no DEET toxicity at the highest doses
tested: 400 mg DEET/kg/day for 104 weeks in rats and 1,000 mg DEET/kg/day for 78 weeks in mice
(Schoenig et al. 1999).  This study conducted gross and microscopic examination of all major organs and 
tissues and hematological tests; in addition, ophthalmologic and clinical chemistry tests were conducted
in rats. There were no treatment-related clinical signs during the studies. The only significant effects 
reported were an increase in serum cholesterol and reduced body weight in high-dose female rats and in 
high-dose mice. The reductions in body weight appeared to be associated with reduced food 
consumption, but no data were shown.  The toxicological significance of the increase in serum cholesterol
in female rats was unknown; in the same study, male dogs were dosed with 400 mg DEET/kg/day in a
capsule for 52 weeks experienced a decrease in serum cholesterol. The available chronic-duration oral
database does not support derivation of a chronic-duration oral MRL for DEET.  Long-term exposure, 
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however, does not lead to more toxic effects than those reported for intermediate-duration exposure.  The
intermediate-duration oral MRL of 1 mg/kg/day for DEET, therefore, is considered protective for 
chronic-duration exposure.
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3. HEALTH EFFECTS
3.1  INTRODUCTION 
The primary purpose of this chapter is to provide public health officials, physicians, toxicologists, and 
other interested individuals and groups with an overall perspective on the toxicology of DEET.  It
contains descriptions and evaluations of toxicological studies and epidemiological investigations and
provides conclusions, where possible, on the relevance of toxicity and toxicokinetic data to public health.
Although normal use of products containing DEET involves predominantly dermal exposure, some
inhalation and oral exposure may occur.  It is also important to note that although most human exposures
are to DEET and to other chemicals in the specific formulations, exposure to DEET is the common factor
between the studies.  
A glossary and list of acronyms, abbreviations, and symbols can be found at the end of this profile.
3.2  DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE 
To help public health professionals and others address the needs of persons living or working near
hazardous waste sites, the information in this section is organized first by route of exposure (inhalation, 
oral, and dermal) and then by health effect (e.g., death, systemic, immunological, neurological, 
reproductive, developmental, and carcinogenic effects).  These data are discussed in terms of three 
exposure periods:  acute (14 days or less), intermediate (15–364 days), and chronic (365 days or more).
Levels of significant exposure for each route and duration are presented in tables and illustrated in 
figures.  The points in the figures showing no-observed-adverse-effect levels (NOAELs) or lowest-
observed-adverse-effect levels (LOAELs) reflect the actual doses (levels of exposure) used in the studies.
LOAELs have been classified into "less serious" or "serious" effects. "Serious" effects are those that
evoke failure in a biological system and can lead to morbidity or mortality (e.g., acute respiratory distress 
or death).  "Less serious" effects are those that are not expected to cause significant dysfunction or death, 
or those whose significance to the organism is not entirely clear.  ATSDR acknowledges that a 
considerable amount of judgment may be required in establishing whether an end point should be
classified as a NOAEL, "less serious" LOAEL, or "serious" LOAEL, and that in some cases, there will be 
insufficient data to decide whether the effect is indicative of significant dysfunction.  However, the 
Agency has established guidelines and policies that are used to classify these end points.  ATSDR
   
 









    







   
   
   
 
    
   
 




    
 
  
     
   
  
 
   
    
    
     




believes that there is sufficient merit in this approach to warrant an attempt at distinguishing between 
"less serious" and "serious" effects. The distinction between "less serious" effects and "serious" effects is 
considered to be important because it helps the users of the profiles to identify levels of exposure at which
major health effects start to appear.  LOAELs or NOAELs should also help in determining whether or not
the effects vary with dose and/or duration, and place into perspective the possible significance of these
effects to human health.  
The significance of the exposure levels shown in the Levels of Significant Exposure (LSE) tables and 
figures may differ depending on the user's perspective.  Public health officials and others concerned with 
appropriate actions to take at hazardous waste sites may want information on levels of exposure 
associated with more subtle effects in humans or animals (LOAELs) or exposure levels below which no
adverse effects (NOAELs) have been observed.  Estimates of levels posing minimal risk to humans
(Minimal Risk Levels or MRLs) may be of interest to health professionals and citizens alike.
A User's Guide has been provided at the end of this profile (see Appendix B).  This guide should aid in 
the interpretation of the tables and figures for Levels of Significant Exposure and the MRLs.
3.2.1 Inhalation Exposure 
3.2.1.1  Death 
No reports of deaths in humans following inhalation exposure to DEET were located in the literature.
Without providing additional information, Army (1979) reported 4-hour LC50 values for aerosolized
DEET in male and female Sprague-Dawley rats of 6,000 and 5,860 mg/m3, respectively. Army (1980a)
reported that the LC50 for aerosolized DEET in Sprague-Dawley rats was 5,950 mg/m3. Rats were
exposed whole-body for 4 hours and were observed for 14 days.  No gross lesions were reported 
following the 14-day observation period.  In male Swiss albino mice exposed head-only for 4 hours to 
target aerosol concentrations between 35 and 2,000 mg/m3, the LC50 was 1,369 mg/m3 (Deb et al. 2010).  
All mice exposed to 2,000 mg/m3 (n=4) died after approximately 2 hours; there were no deaths at lower
concentrations.  The investigators noted that the actual exposure concentrations were 50–60% of the
theoretical concentrations with large variations.  Because they did not provide the actual exposure
concentrations, the actual LC50 might be more than twice the reported value and is unreliable.
   
 








   
 
  
     
 
         
  
 
   
       
 
    
      
     
   
      
    
   
 
       
    
 
      
  
      
     
  
  
    
 




3.2.1.2  Systemic Effects
No studies were located regarding hematological, musculoskeletal, hepatic, renal, endocrine, dermal,
ocular, or body weight effects in humans following inhalation exposure to DEET.
Respiratory Effects. In a study of 20,764 human exposures involving insect repellents containing
DEET that were reported to poison control centers from 1993 to 1997, 520 were identified as being
exposed predominantly by inhalation (Bell et al. 2002).  Of these, 70 exhibited respiratory effects that
included coughing/choking, dyspnea, bronchospasm, respiratory depression, and pneumonitis. Two of
those (a male infant and a male adult) experienced a major respiratory outcome. 
Head-only exposure of albino rats to an aerosol of 85% DEET for single periods of 2–6 hours did not
induce gross alterations in the lungs or trachea, but did induce unspecified minor microscopic changes in 
both tissues (Ambrose 1959).  There was no indication that a control group was used in this study and the
actual exposure concentrations were not provided.  Head-only exposure of male Swiss albino mice to 
target concentrations of DEET aerosol between 35 and 950 mg/m3 for 4 hours resulted in an increase in
respiratory frequency at 135 mg/m3 but not at lower or higher exposure concentrations (Deb et al. 2010).  
Other respiratory parameters that were measured including tidal volume (Vt), air flow at 0.5 Vt, time of
inspiration, and time of expiration were not affected.  Because the actual exposure concentrations were 
not specified and were 50–60% of the target concentrations, according to the investigators, the findings
from this study are unreliable.
In an intermediate-duration study, exposure of albino rats to air saturated with DEET vapor
(approximately 71 mg/m3; 1 mL of DEET was carried over 14,000 L of air) 8 hour/day, 5 days/week for
7 weeks resulted in unspecified microscopic changes in the lungs and trachea (Ambrose 1959). There
was no indication that a control group was used in the study. Whole-body intermittent exposure of male
and female Sprague-Dawley rats to up to 1,511 mg/m3 (the highest concentration tested) aerosolized
DEET for 13 weeks did not cause gross or microscopic alterations in the respiratory tract, including nares 
and nasal passages (Army 1980a). In the same study, there were no differences in measurements of
pulmonary compliance and resistance between control and exposed Beagle dogs, but there were only two 
dogs per exposure group, so the study is limited.
   
 








       






       
    
 
   
  
 
     
  
   
  
 
       
    
  
 
      
   
   
       
 
 
         
   





Cardiovascular Effects. Only 12 of the 520 human cases of exposure to DEET by inhalation and
6 cases by multiple routes studied by Bell et al. (2002) exhibited cardiovascular effects; these included 
tachycardia, hypertension, and hypotension.
In the Army (1980a) 13-week, intermittent exposure study in Sprague-Dawley rats mentioned above, 
examination of the heart and aorta did not show exposure-related gross or microscopic alterations.
Gastrointestinal Effects. In the study of Bell et al. (2002) mentioned above of the 520 human cases
reported to the AAPCC, those involving gastrointestinal effects included 130 exposed by inhalation and 
225 by multiple routes. The gastrointestinal effects included oral irritation, vomiting, and nausea.
Exposure of Sprague-Dawley rats to up to 1,511 mg/m3 aerosolized DEET for 13 weeks had no 
significant effect on the gross or microscopic morphology of the gastrointestinal tract (Army 1980a).
Hematological Effects. Hematology tests conducted in Sprague-Dawley rats and Beagle dogs 
exposed to up to 1,511 mg/m3 DEET aerosol intermittently for 13 weeks were within normal limits
(Army 1980a). Because only two dogs per sex per group were tested, the results in this species are 
unreliable. No further information was located.
Musculoskeletal Effects. Exposure of Sprague-Dawley rats to up to 1,511 mg/m3 aerosolized
DEET for 13 weeks had no significant effect on the gross or microscopic morphology of skeletal muscle,
femur, or sternum (Army 1980a).
Hepatic Effects. Intermediate-duration exposure of Sprague-Dawley rats to 253, 752, or 1,511 mg/m3 
aerosolized DEET induced a significant trend for increased relative liver weight in females after 7 weeks 
of exposure and in males and females after 13 weeks of exposure (Army 1980a).  In the absence of
morphological alterations in the liver, the increase in relative liver weight probably represents an adaptive
effect.
Renal Effects. Exposure of Sprague-Dawley rats to 253, 752, or 1,511 mg/m3 aerosolized DEET for
13 weeks resulted in a significant trend for increased relative kidneys weight in males (Army 1980a).  
Microscopic examination of the kidneys from exposed rats, however, did not reveal exposure-related
alterations. 
   
 








        
   
  
 
        
      
 
      
      
 
        
 
    
    
    
    
 
      








    
   
 
 
     




Endocrine Effects. Exposure of Sprague-Dawley rats to up to 1,511 mg/m3 aerosolized DEET for
13 weeks had no significant effect on the gross or microscopic morphology of the adrenal, pituitary, or
thyroid glands (Army 1980a).
Dermal Effects. Exposure of Sprague-Dawley rats to up to 1,511 mg/m3 DEET aerosol for 13 weeks 
had no significant effect on gross or microscopic appearance of the skin (Army 1980a).  
Ocular Effects. Exposure of Sprague-Dawley rats to up to 1,511 mg/m3 DEET aerosol for 13 weeks 
had no significant effect on gross or microscopic appearance of the eye (Army 1980a).  
Body Weight Effects. Exposure of male and female Sprague-Dawley rats to concentrations of up to 
4,100 mg/m3 DEET aerosol for 4 hours did not significantly affect body weight during a 14-day 
observation period (Army 1979). Head-only exposure of male Swiss albino mice to target concentrations
of up to 950 mg/m3 for 4 hours did not significantly affect body weight over a 14-day observation period 
(Deb et al. 2010). Exposure to Sprague-Dawley rats to up to 1,511 mg/m3 DEET aerosol for 13 weeks 
had no significant effect on body weight (Army 1980a). No further relevant information was located.
Metabolic Effects. Values for serum electrolytes and glucose were within normal ranges in male and
female Sprague-Dawley rats following intermittent exposure to up to 1,511 mg/m3 aerosolized DEET for
13 weeks (Army 1980a).
3.2.1.3  Immunological and Lymphoreticular Effects 
No studies were located regarding immunological and lymphoreticular effects in humans following
inhalation exposure to DEET.
The only information in animals is that exposure of Sprague-Dawley rats to up to 1,511 mg/m3 
aerosolized DEET for 13 weeks had no significant effect on the gross or microscopic morphology of the
spleen or thymus (Army 1980a).
The NOAEL values for immunological and lymphoreticular effects from the Army (1980a) study is
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Key to Species Frequency 
Figure (Strain) (Route) 
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histopathology of the 








1511 Army 1980a NOAEL is for 
histopathology of the 
sex organs. 
a The number corresponds to entries in Figure 3-1. 
Bd Wt = body weight; Cardio = cardiovascular; d = day(s); Endocr = endocrine; Gastro = gastrointestinal; Hemato = hematological; hr = hour(s); Immuno/Lymphoret = 
immunological/lymphoreticular; LC50 = lethal concentration, 50% kill; LOAEL = lowest-observed-adverse-effect level; Metab = metabolic; Musc/skel = musculoskeletal; NOAEL = 
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3.2.1.4  Neurological Effects 
Fifty-seven of the 520 human cases in which inhalation was the leading route of exposure in the study by
Bell et al. (2002) showed neurological effects.  The most common symptoms were dizziness/vertigo, 
headache, and drowsiness/lethargy.
The only information available in animal studies is that from an acute-duration study in Sprague-Dawley
rats (Army 1979).  After a 4-hour exposure to 0, 2,300, 2,900, or 4,100 mg/m3 DEET aerosol, the rats 
were examined for 15 common toxic neurological signs.  In addition, seven behavioral tests were
conducted within 50 minutes of termination of exposure. Toxic signs were restricted to the high-exposure
group and consisted of shaking, prostration, and loss of balance in females and shaking in males. In
general, performance in the various tests decreased as the exposure concentration increased.  The test that
seemed to show the clearest dose-response relationship and was affected at the lowest exposure 
concentration tested was the performance on a balance beam.  Gross necropsy at the end of a 14-day 
observation period did not show treatment-related lesions. In an intermediate-duration study, exposure of
Sprague-Dawley rats to up to 1,511 mg/m3 aerosolized DEET for 13 weeks did not induce gross or
microscopic alterations in the brain or spinal cord (Army 1980a).
The NOAEL values for neurological effects from the Army (1980a) study is presented in Table 3-1 and 
plotted in Figure 3-1.
3.2.1.5  Reproductive Effects
The only relevant information available is that from a 13-week inhalation study in which whole-body
exposure of male and female Sprague-Dawley rats to up to 1,511 mg/m3 aerosolized DEET for 13 weeks 
did not induce gross or microscopic alterations in the reproductive organs (Army 1980a).
The NOAEL values for reproductive effects from the Army (1980a) study is presented in Table 3-1 and 
plotted in Figure 3-1.
3.2.1.6  Developmental Effects 
No studies were located regarding developmental effects in humans or animals after inhalation exposure
to DEET.
   
 








   
 
   
 




    
    
       
   
  
   
 
  
     
  
   
  




     
     
       
     
        
     
  
   
  
    




No studies were located regarding cancer effects in humans or animals after inhalation exposure to DEET.
3.2.2 Oral Exposure
3.2.2.1  Death 
Ingestion of DEET by humans has resulted in death; however, in two out of four cases other substances 
were ingested at the same time, so deaths could not be attributed solely to DEET in these two cases.  
Tenenbein (1987) reported two cases. The first case was a 33-year-old woman who intentionally ingested
up to 50 mL of an insect repellent containing 95% DEET and 5% related toluamides along with 
presumably excessive amounts of prescription chlorpromazine hydrochloride and hydralazine
hydrochloride.  She was discovered approximately 1 hour after the ingestion and taken to a hospital where
she was comatose with a pulse of 80 beats per minute and blood pressure of 80/55 mm Hg.  After gastric
lavage and treatment with activated charcoal, she was transferred to a tertiary care facility, arrived
comatose and pulseless, was resuscitated and received aggressive care in the intensive care unit.  During
the first 24 hours, she experienced generalized seizure activity and died the second day of a massive 
generalized bowel infarction.  DEET was measured prior to death in blood (16.8 mg/dL) and postmortally
in blood and liver (11.2 and 17.7 mg/dL, respectively). The second case was a 26-year-old man who was 
found dead after ingesting up to 50 mL of an insect repellent containing 95% DEET and 5% related
toluamides following a bout of drinking.  DEET levels measured in blood, vitreous, and urine were 24, 
15, and 10 mg/dL, respectively.  Blood alcohol was 130 mg/dL and cannabinoids were present in the
urine.  The authors estimated that consumption of 50 mL of 100% DEET by an 8-year old child is
potentially lethal, if the 2.0 g/kg median lethal dose for rats reported by Ambrose (1959) is applicable to 
humans (50 mL weighs approximately 50 g based on a specific gravity of almost 1 for DEET; therefore,
50 g/25 kg body weight for an 8-year-old boy yields a lethal dose of 2 g/kg).  In their study of
9,086 exposures involving insect repellents containing DEET reported to Poison Control Centers from 
1985 to 1989, Veltri et al. (1994) reported that one 33-year-old adult male died 9 days after intentionally
ingesting 8 ounces of an insect repellent containing between 11–50% DEET.  Clinical signs included
transitory cardiorespiratory arrest shortly after poisoning followed by hyperglycemia on day 2, status 
epilepticus and disseminated intravascular coagulopathy, and ultimately cerebral edema. Recently, Wiles 
et al. (2014) described the case of a 37-year-old male who died 3 days after ingesting 6 ounces of an 
insect repellent containing 40% DEET (approximately 748 mg DEET/kg). Within minutes of ingesting
the solution, the man suffered a seizure and was transported to a community emergency department and
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3. HEALTH EFFECTS
later to a healthcare facility.  On arrival to the latter, the patient was unresponsive, had metabolic acidosis,
tachycardia and hypotension, and hypothermia.  Physical examination showed the patient to be
unresponsive, areflexic with unreactive dilated pupils, and having an altered electrocardiogram (ECG).  
Blood samples collected <1 hour after poisoning showed DEET concentrations ranging from 8.7 to 
10.2 mg/dL; urine samples contained an average of 0.64 mg DEET/dL. Over the next 3 days, the patient 
remained unresponsive.  On the 3rd day, tests revealed no cerebral blood flow, little brain electrical 
activity, cerebral edema, and transtentorial and tonsillar herniations, and the patient was declared brain
dead.
WHO identified an LD50 of 2,000 mg/kg for male rats (WHO 1987).  An early study determined oral LD50 
values of 1.8–2.7 and 1.75–1.8 mL/kg (1,793–2,689 and 1,743–1,793 mg/kg based on a specific gravity 
of 0.996 for DEET) with a central range of 1.83–2.19 mL/kg for 90% DEET in cottonseed oil in male and 
female albino rats, respectively; the observation period was 7 days (Ambrose 1959).  Clinical signs 
included hyperemia at the base of the ears, lacrimation, chromodacryorrhea, depression, prostration,
tremors, and asphyxial convulsions.  Respiratory failure usually preceded cardiac failure.  Gross 
examination showed questionable degrees of hyperemia of the gastrointestinal tract.  An oral LD50 of
3,664 mg/kg was estimated in male Sprague-Dawley rats administered technical-grade DEET in
propylene glycol (McCain et al. 1997).  Seven out of 10 rats administered 5,010 mg/kg, the highest dose
tested, died during the 14-day observation period, whereas only one rat died following administration of
2,000 mg/kg, the lowest dose tested (McCain et al. 1997).  EPA (1998c) reported that the LD50 in rats
(strain not specified) varied from 2,170 to 3,664 mg/kg.  A study that examined the effect of age on the
acute toxicity of DEET reported oral LD50 values of 3,564 and 3,429 mg/kg in adult male and female
Wistar rats, respectively (Verschoyle et al. 1992); the respective LD50 values in 11-day-old rats were 
891 and 667 mg/kg, indicating a 4–5-fold increased sensitivity in the young rats relative to the older rats.
The LC50 in rats from the Army (1980a) study is presented in Table 3-1 and plotted in Figure 3-1.
3.2.2.2  Systemic Effects
No studies were located regarding respiratory, musculoskeletal, endocrine, dermal, ocular, or body weight
effects in humans following oral exposure to DEET.
The highest NOAEL values and all LOAEL values from each reliable study for systemic effects in each
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Table 3-2 Levels of Significant Exposure to DEET - Oral	 (continued) 
a 
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750 F (hypoactivity, ataxia, 
decreased muscle tone) 
Schoenig et al. 1994 Neurological signs 




1000 (vacuolization of myelin 
sheath in cerebellum) 





250 F 750 F (6% reduced fetal weight) Schoenig et al. 1994 Weight gain 
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Key to Species Frequency 
































Chemical Form Comments 













397 F 863 F (11.1% reduced terminal 
body weight) 
Renal 25 M (hyaline nephropathy) EPA 1989 
Bd Wt 200 M 500 M (14% reduced final body 
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Table 3-2 Levels of Significant Exposure to DEET - Oral	 (continued) 
a 
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Table 3-2 Levels of Significant Exposure to DEET - Oral	 (continued) 
a 
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Schoenig et al. 1999 
Comments 
Highest dose in males 
was 100 mg/kg/day; no 
effects were reported in 
males. 
Cardio 400 F 
Gastro 400 F 
Hemato 400 F 
Musc/skel 400 F 
Hepatic 100 400 F (increased serum 
cholesterol) 
Renal 400 F 
Endocr 400 F 
Dermal 400 F 
Ocular 400 F 
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Key to Species Frequency 
Figure (Strain) (Route) 
37 Mouse 78 wk 
(CD-1) ad lib 
(F) 
Immuno/ Lymphoret 
38 Rat 104 wk 
ad lib(CD) 
(F) 
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Schoenig et al. 1999 NOAELs are for 
histopathology of 
lymphoreticular organs. 
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Table 3-2 Levels of Significant Exposure to DEET - Oral	 (continued) 
a 































Schoenig et al. 1999 NOAELs are for 
histopathology of brain 



















1000 Schoenig et al. 1999 NOAEL is for 
histopathology of 
reproductive organs. 
a The number corresponds to entries in Figure 3-2. 
b Used to derive an intermediate-duration oral minimal risk level (MRL) of 1.0 mg/kg/day for DEET; the MRL was derived by dividing the NOAEL by an uncertainty factor of 100 (10 
for animal to human extrapolation and 10 for human variability). 
ad lib = ad libitum; Bd Wt = body weight; (C) = capsule; Cardio = cardiovascular; d = day(s); Endocr = endocrine; (F) = feed; F = Female; (G) = gavage; Gastro = gastrointestinal; Gd 
= gestational day; (GO) = gavage in oil; Hemato = hematological; Immuno/Lymphoret = immunological/lymphoreticular; LD50 = lethal dose, 50% kill; LOAEL = 
lowest-observed-adverse-effect level; M = male; Metab = metabolic; mo = month(s); Musc/skel = musculoskeletal; NOAEL = no-observed-adverse-effect level; Resp = respiratory; x = 
time(s); wk = week(s) 








6r 11r 13r 
4r 





















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans





























































tolo c al We
i
mg/kg/day 
1000 18s 18s 18s 18s 18s 18s 18s15r 15r 15r 15r 15r 15r 15r 
18s 18s 
20h 20h 20h 20h 20h 20h 20h 20h 20h 20h 20h17r 
19d 19d 19d 19d 19d 19d 19d 19d 19d 19d 19d 19d15r 
18s
20h 20h 20h 
17r 





















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans
















































1000 22s 27s21r 25r 30r 
30r32s 



























 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans

















Re Ca Ga M He En Oc M Ne ReHe Re De Bo Immg/kg/day 
10000 
1000 37m 37m 37m 37m 37m 37m 37m 37m 37m 37m 39m 41m 43m 
37m 
36r 36r 36r 36r 36r 36r 36r 36r 36r 36r 36r 36r 38r 40r 42r 

















 Cancer Effect Level-Animals
 LOAEL, More Serious-Animals
LOAEL, Less Serious-Animals
NOAEL - Animals
 Cancer Effect Level-Humans






























































Figure 3-2 Levels of Significant Exposure to DEET - Oral (Continued) 
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3. HEALTH EFFECTS
Respiratory Effects. No information was located regarding respiratory effects in humans following
oral exposure to DEET. 
Several intermediate-duration (i.e., 15 days to 52 weeks) and one chronic-duration (18 months to 2 years)
oral study conducted gross and microscopic examinations of the lungs of animals (i.e., rats, mice, 
hamsters, dogs, rabbits) following oral exposure to DEET and did not find significant treatment-related
alterations.  Reported NOAELs for respiratory effects included 701 and 863 mg DEET/kg/day in male
and female albino rats, respectively, treated for 200 days (Ambrose 1959), 940 mg DEET/kg/day in male
and female Golden Syrian hamsters treated for 90 days (EPA 1990b), 400 mg DEET/kg/day in Beagle
dogs treated for 52 weeks (Schoenig et al. 1999), and 528 mg/DEET/kg/day in New Zealand White
rabbits treated for 15 days (Army 1980b).
In chronic-duration studies, the highest doses of DEET tested (100 mg/kg/day in male CD rats and 
400 mg/kg/day in female CD rats treated for 2 years; 1,000 mg/kg/day in male and female CD-1 mice 
treated for 18 months) did not induce morphological alterations in the lungs (Schoenig et al. 1999).
Cardiovascular Effects. An abnormal ECG was reported in a 19-year-old woman 1 hour after
ingesting 15–25 mL of an insect repellent containing 95% DEET (Fraser et al. 1995).  The ECG indicated
right and left atrial enlargement, diffuse ST-T abnormalities, and a normal QT interval.  Within 24 hours,
the ECG returned to baseline.  An unremarkable ECG was described in a 3-year-old girl who ingested an 
estimated 800 mg of DEET (4 mL of a 20% solution) (Petrucci and Sardini 2000). Hypotension (blood 
pressure 80/50 mm Hg) was reported in a 33-year-old woman approximately 1 hour after ingesting an 
unknown amount of an insect repellent containing 95% DEET along with presumably excessive amounts 
of prescription chlorpromazine hydrochloride and hydralazine hydrochloride (Tenenbein 1987).  The
same investigator reported hypotension in a 16-year-old girl (blood pressure 90/50 mm Hg) and in a
14-year-old girl (systolic 60 mm Hg) following ingestion of DEET.  Tachycardia, hypotension, and 
altered ECG were reported in a 37-year-old man who ingested 6 ounces of a repellent containing 40%
DEET (approximately 748 mg DEET/kg) (Wiles et al. 2014).  No further relevant information was 
located regarding cardiovascular effects in humans following oral exposure to DEET.
No treatment-related gross or microscopic alterations in the heart were reported in intermediate- and 
chronic-duration oral studies in albino or CD rats (Ambrose 1959; Schoenig et al.1999), Golden Syrian 
hamsters (EPA 1990b), beagle dogs (Schoenig et al. 1999), New Zealand White rabbits (Army 1980b), 
   
 








   
 
 





   




    
  
 
          
     
     
  
 
    
  
 
   
   
        
  
   
 






and CD-1 mice (Schoenig et al. 1999). The NOAELs were the highest doses tested and were the same as 
indicated above for Respiratory Effects. 
Gastrointestinal Effects. In a study of 20,764 human exposures involving insect repellents 
containing DEET that were reported to poison control centers from 1993 to 1997, 10,748 were identified 
as being exposed predominantly by ingestion (Bell et al. 2002).  Of these, 770 exhibited gastrointestinal
effects that included stomach irritation, vomiting, and nausea.
Albino rats treated with DEET in the diet (701 mg/kg/day in males, 863 mg/kg/day in females) for
200 days did not show treatment-related gross or microscopic alterations in the stomach or small intestine 
(Ambrose 1959).  Similar findings were reported regarding the gastrointestinal tract of Beagle dogs dosed 
with 400 mg DEET/kg/day for 52 weeks (Schoenig et al. 1999), and New Zealand White rabbits dosed 
with 528 mg DEET/kg/day for 15 days (Army 1980b).  The same was reported in CD rats dosed with 
DEET for 104 weeks (100 mg/kg/day in males, 400 mg/kg/day in females) and CD-1 mice dosed with
1,000 mg DEET/kg/day for 78 weeks (Schoenig et al. 1999).
Hematological Effects. The leukocyte count reported in a 3-year-old girl who ingested an estimated
800 mg DEET (4 mL of a 20% insect repellent solution) was within normal limits (Petrucci and Sardini
2000). No explicit statements regarding hematology tests were provided in other cases of acute 
intoxication with DEET that were reviewed.
Hematological tests conducted in Golden Syrian hamsters after 90 days of dosing with up to 940 mg
DEET/kg/day showed sporadic inconsistent changes in certain parameters without dose-response and 
were not considered treatment-related by the investigators (EPA 1990b).  A 52-week oral study in Beagle 
dogs reported that doses of 400 mg DEET/kg/day induced significant reductions in hemoglobin and 
hematocrit in males and females after 6 and 12 months of dosing and significant increases in platelets in 
females (Schoenig et al. 1999).  Hematological tests were conducted in CD rats and CD-1 mice during
chronic exposure to DEET (100 mg/kg/day in male rats; 400 mg/kg/day in female rats; 1,000 mg/kg/day
in mice) and did not show report treatment-related hematological alterations (Schoenig et al. 1999).
Musculoskeletal Effects. Skeletal muscle and bone were examined in intermediate-duration studies
in Beagle dogs (Schoenig et al. 1999) and New Zealand White rabbits (Army 1980b) and in chronic-
duration studies in CD rats and CD-1 mice (Schoenig et al. 1999).  None of these studies found treatment-
related gross or microscopic alterations in bone or muscle.  NOAELs for musculoskeletal effects were 
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400 mg/kg/day in dogs, 528 mg/kg/day in rabbits, 100 and 400 mg/kg/day in male and female rats,
respectively, and 1,000 mg/kg/day in mice.
Hepatic Effects. Of the few reported cases of ingestion of DEET by humans, only a report by 
Petrucci and Sardini (2000) explicitly indicated that liver function studies were conducted and were
unremarkable in a 3-year-old girl who ingested an estimated 800 mg DEET. No explicit statements
regarding liver function tests were provided in other cases of acute intoxication with DEET that were
reviewed.
No significant changes in clinical chemistry parameters or in gross or microscopic appearance of the liver
were reported in Golden Syrian hamsters dosed with up 940 mg DEET/kg/day for 90 days (EPA 1990b).  
In a 52-week study in male Beagle dogs treated with 400 mg DEET/kg/day, a significant increase in
serum alkaline phosphatase activity (49% at 6 months) and a significant reduction in serum cholesterol
(37% at 6 months and 35% at 12 months were observed) (Schoenig et al. 1999). No significant changes
occurred in dogs dosed with 100 mg DEET/kg/day.  Gross and microscopic examination of the dogs’
liver did not show treatment-related alterations. New Zealand White rabbits treated with 528 mg
DEET/kg/day for 15 days showed changes consisting of rare to minimal fatty change in hepatocytes
(Army 1980b).  These changes were seen primarily midzonal, but clear vacuolated hepatocytes were also
seen in central and portal areas.  Clinical chemistry tests showed significant increases in serum cholesterol
and triglycerides (about 4-fold each). The NOAEL for liver effects was 264 mg DEET/kg/day.  A
chronic-duration dietary study in CD rats also reported significant increases in serum cholesterol (2– 
4-fold) during the study in females dosed with 400 mg DEET/kg/day, but not 100 mg DEET/kg/day
(Schoenig et al. 1999).  In the chronic study there were no gross or microscopic lesions in the liver
attributable to treatment with DEET.
Renal Effects. Petrucci and Sardini (2000) mentioned that creatinine levels were within normal limits
in a 3-year-old girl who ingested an estimated 800 mg of DEET.  No further explicit information
regarding renal effects in humans following oral exposure to DEET was located.
In an early dietary study in albino rats, examination of the kidneys of the animals treated with the highest
doses (701 mg/kg/day in males and 863 mg/kg/day in females) for 200 days only showed increased
relative weight of the organs (12%) (Ambrose 1959).  There were no treatment-related gross or
microscopic alterations in the kidney that were not seen in control rats.  Interestingly, in a 2-generation 
reproductive study in Sprague-Dawley rats, hyaline nephropathy was reported in adult F1 males from all
   
 










   
         
  
     








   
 
    




    
   
 
 
   
       
     
 
        
   
  




treated groups (doses of DEET mixed in the food were 0, 25, 100, or 250 mg/kg/day) (EPA 1989).  F1 
males had been produced by F0 females that had been dosed with DEET for at least 80 days before 
mating and presumably during gestation and lactation.  F1 males were therefore exposed in utero and then
directly for at least 93 days. The kidneys from F0 males were not examined microscopically because they
did not show gross alterations (EPA 1989).  Other intermediate-duration studies did not observe adverse
kidney effects in Golden Syrian hamsters dosed with up to 940 mg DEET/kg/day for 90 days (EPA
1990b), Beagle dogs dosed with up to 400 mg DEET/kg/day for 52 weeks (Schoenig et al. 1999), or New 
Zealand White rabbits dosed with up to 528 mg DEET/kg/day for 15 days (Army 1990).
Chronic-duration studies in rats and mice did not report treatment-related kidney lesions at termination,
but did report relative high incidences of chronic progressive nephropathy in male and female CD rats and
chronic nephritis in male and female CD-1 mice, which also occurred in control groups and were 
considered unrelated to the test material (Schoenig et al. 1999).  In these studies, male and female rats 
were dosed with up to 100 and 400 mg DEET/kg/day, respectively, for 104 weeks and male and female
mice were dosed with up to 1,000 mg DEET/kg/day for 78 weeks.
Endocrine Effects. Several intermediate-duration and one chronic-duration oral study conducted 
gross and microscopic examinations of endocrine glands of animals following oral exposure to DEET and 
did not find significant treatment-related alterations.  Glands examined included the adrenals, pituitary, 
thyroid, and parathyroid.  Reported NOAELs included 701 and 863 mg DEET/kg/day in male and female
albino rats, respectively, treated for 200 days (Ambrose 1959); 940 mg DEET/kg/day in male and female
Golden Syrian hamsters treated for 90 days (EPA 1990b); 400 mg DEET/kg/day in Beagle dogs treated 
for 52 weeks (Schoenig et al. 1999); and 528 mg/DEET/kg/day in New Zealand White rabbits treated for
15 days (Army 1980b).  
In chronic-duration studies, the highest doses of DEET tested (100 mg/kg/day in CD male rats;
400 mg/kg/day in CD female rats; 1,000 mg/kg/day in male and female CD-1 mice) did not induce
morphological alterations in adrenals, thyroid, or pituitary glands (Schoenig et al. 1999).
Dermal Effects. No treatment-related skin alterations were reported in Beagle dogs dosed with up to 
400 mg DEET/kg/day for 52 weeks (Schoenig et al. 1999) or in New Zealand White rabbits dosed with 
up to 528 mg DEET/kg/day for 15 days (Army 1980b).  Similar observations were made regarding the
skin of CD-1 mice dosed with up to 1,000 mg DEET/kg/day for 78 weeks or male and female CD rats 
dosed with up to 100 or 400 mg DEET/kg/day, respectively, for 104 weeks (Schoenig et al. 1999).
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Ocular Effects. Lacrimation and chromodacryorrhea were reported in rats administered lethal doses 
of DEET by gavage (Ambrose 1959).  Three studies provided additional data regarding ocular effects in
animals exposed orally to DEET.  No significant morphological alterations were seen in the eyes of
Beagle dogs dosed with up to 400 mg DEET/kg/day for 52 weeks (Schoenig et al. 1999), New Zealand
White rabbits dosed with up to 528 mg DEET/kg/day for 15 days (Army 1980b), or male and female CD 
rats dosed with up to 100 or 400 mg DEET/kg/day, respectively, for 104 weeks (Schoenig et al. 1999).
Body Weight Effects. Several studies provide information regarding body weight effects in animals 
after oral exposure to DEET; not all of the studies, however, provided data on food consumption.  In 
general, reductions in body weight gain relative to controls were associated with reductions in food 
consumption. In acute-duration studies, Schoenig et al. (1993) reported that a single dose of up to 500 mg
DEET/kg did not affect body weight or food consumption in CD rats over a 14-day observation period.  
Administration of 750 mg DEET/kg/day to pregnant CD rats on GDs 6–15 or 325 mg DEET/kg/day to
pregnant New Zealand White rabbits on GDs 6–18, however, reduced maternal weight gain by 35 and
69%, respectively (Schoenig et al. 1994); the corresponding NOAELs were 250 and 100 mg/kg/day.  In 
both cases, food consumption was reduced.
In intermediate-duration oral studies, significant reductions in terminal body weight (≥10% differences
with controls) were seen at DEET doses of 701 mg/kg/day in albino rats (Ambrose 1959), 500 mg/kg/day 
in CD rats (Schoenig et al. 1993), 624 mg/kg/day in Golden Syrian hamsters (EPA 1990b), and 
400 mg/kg/day in Beagle dogs (Schoenig et al. 1999).  In these studies, DEET was administered via the 
food, except in dogs, which were treated with DEET in capsules.  In a 15-day study in male New Zealand
White rabbits in which DEET was administered by gavage, doses of 528 mg DEET/kg/day caused a 22%
reduction in body weight (rabbits lost weight) (Army 1980b); body weight showed a rapid and linear
decrease throughout the study with no indication of reversal.  No significant effects appeared to occur at
264 mg/kg/day, while the 132 mg/kg/day animals retained a higher portion of initial body weight
compared to controls, and by day 12, diverged positively from controls. No data on food consumption 
were provided in this study. In the 2-generation reproductive study in Sprague-Dawley rats (EPA 1989), 
decreased body weight was reported in adult F0 and F1 males and females at various time points during
the study and occurred mainly in rats in the 100 and 250 mg/kg/day dose groups.  Some of differences
with the control groups were statistically significant, but only in one case (high-dose F1 females at
18 weeks of age) was the difference with controls >10% (15.4%).  Significant decreases in food
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consumption relative to controls were also reported at various times.  Only in adult F1 high-dose females 
was reduced food consumption >10% (15 and 14% at 12 and 16 weeks of age, respectively).
In chronic-duration studies, doses of 400 mg DEET/kg/day reduced terminal body weight in female
CD rats by 10% and a similar effect was reported in CD-1 mice dosed with 1,000 mg DEET/kg/day
(Schoenig et al. 1999); the corresponding NOAELs were 100 and 500 mg/kg/day.
Metabolic Effects. Serum electrolytes within normal limits were reported in an 18-month-old child 
who had ingested an unknown, but probably small, amount of an insect repellent containing DEET the
day prior to being admitted to the hospital (Zadikoff 1979).  Petrucci and Sardini (2000) also reported 
electrolytes and glucose within normal limits in a 3-year-old girl who ingested an estimated 800 mg of
DEET. Metabolic acidosis was reported in a 37-year-old man who ingested 6 ounces of a repellent
containing 40% DEET (approximately 748 mg DEET/kg) (Wiles et al. 2014). No further relevant
information was located regarding metabolic effects in humans after oral exposure to DEET.
A few alterations in serum electrolytes were reported in studies in animals. Increases in serum potassium 
of 10 and 16% were reported in male and female Golden Syrian hamsters, respectively, following doses
of 940 mg DEET/kg/day for 90 days (EPA 1990b); no significant changes were reported at ≤624 mg
DEET/kg/day. Serum potassium was also significantly increased (23%) in male Beagle dogs after
receiving doses of 400 mg DEET/kg/day for 6 months; no significant alterations were reported in dogs
dosed with ≤100 mg DEET/kg/day or in dogs dosed with 400 mg DEET/kg/day for 12 months (Schoenig
et al. 1999).  In a study in male New Zealand White rabbits, serum calcium was significantly decreased
(14%) following dosing with 528 mg DEET/kg/day, but not 264 mg/kg/day, for 15 days (Army 1980b).  
No significant alterations in serum electrolytes or glucose were reported in a chronic-duration study in 
CD rats (Schoenig et al. 1999); the highest doses tested were 100 mg DEET/kg/day in males and 
400 mg/kg/day in females.
3.2.2.3  Immunological and Lymphoreticular Effects 
No information was located regarding immunological effects in humans following oral exposure to 
DEET.
No relevant information was located regarding effects in acute-duration studies in animals.  Intermediate-
duration studies did not find gross or microscopic lesions in lymphoreticular organs of Beagle dogs
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(Schoenig et al. 1999), albino rats (Ambrose 1959), Golden Syrian hamsters (EPA 1990b), or New 
Zealand White rabbits (Army 1980b) exposed to doses of DEET ranging from 400 to 863 mg/kg/day.  
Similar results were reported in a chronic-duration study in CD rats dosed with up to 400 mg/kg/day
DEET or CD-1mice dosed with up to 1,000 mg/kg/day DEET (Schoenig et al. 1999). None of these
studies, however, conducted tests to examine immunocompetence. 
The highest NOAEL values for effects on lymphoreticular organs in each species and duration category
are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.4  Neurological Effects 
All of the reported cases of acute oral intoxication with insect repellents containing DEET reported 
adverse neurological effects in the patients described by some as toxic encephalopathy.  Opisthotonic
episodes followed by generalized seizures with clonic movement of the facial muscles were described in a
3-year-old girl who ingested an estimated 800 mg of DEET (Petrucci and Sardini 2000). Opisthotonus is
a postural abnormality characterized by hyperextension of the back and neck muscles, with retraction of
the head, and arching forward of the trunk.  Edwards and Johnson (1987) described a similar case of a
child who developed toxic encephalopathy after ingesting an unknown amount of a product containing
10% DEET.  The five cases of oral ingestion of DEET described by Tenenbein (1987) showed 
neurological signs within several hours of ingestion of the chemical including a hypertonic condition with 
Babinski signs, tremors, seizures, opisthotonic spells, and coma.  Opisthotonic posture and bizarre 
movements were also described in a young child who ingested a small amount of an insect repellent
containing DEET (Zadikoff 1979).  Wiles et al. (2014) reported that a man suffered a seizure within 
minutes of ingesting 6 ounces of a repellent containing 40% DEET (approximately 748 mg DEET/kg)
and was unresponsive and areflexic over the next 3 days before being declared brain dead.
Oral studies in animals have examined neurobehavioral parameters as well as the gross and microscopic 
morphology of tissues of the nervous system following exposure to DEET.  An acute-duration study that
performed a functional observational battery (FOB) and a motor activity test in CD rats reported a 
decrease in vertical activity and delayed response to thermal stimuli following a single dose of
500 mg/kg, the highest dose tested; the NOAEL was 200 mg/kg (Schoenig et al. 1993).  A similar study
in Sprague-Dawley rats, however, did not report significant alterations in locomotor activity and 
thigmotaxis (response to touch) following a dose of 500 mg DEET/kg (Hoy et al. 2000a).  In a study
aimed at determining oral LD50 values for DEET in Wistar rats, no clinical signs were seen in rats treated
   
 








        
     
  
     
     
    
 
     




      
 
    
   
    






   
     
 
   
     
 
   
 




with single doses of <1,500 mg DEET/kg in arachis oil (Verschoyle et al. 1992).  Doses between
2,000 and 3,000 mg/kg, however, decreased reactivity and muscle tone.  Central nervous system
depression was occasionally interrupted by seizures; mostly qualitative data were presented in this study.  
Spikes in the electroencephalogram (EEG) arising from the auditory cortex were recorded in rats with 
implanted electrodes.  In rats given single doses of 1,000–3,000 mg DEET/kg, light microscopy showed 
histological changes in the brain consisting of vacuolization of myelin sheaths mainly in cerebellar roof
nuclei.  Axons usually appeared normal.  Also seen were single or multiple, clear cytoplasmic clefts in 
neurons diffusely distributed throughout the brain.  Rats with these lesions usually were severely 
prostrated or ataxic.  Electron microscopy showed extensive edematous swelling of the inner loop of the
myelin sheaths and splitting of the innermost myelin lamellae occurring at the intraperiod line.
In intermediate-duration studies, dietary treatment of albino rats with up to 863 mg DEET/kg/day for
200 days did not induce gross or microscopic alterations in the brain (Ambrose 1959).  A similar lack of
effects was reported in multiple tissues of the central and peripheral nervous tissue from CD rats 
following dietary doses of up to 500 mg DEET/kg/day for 9 months, but this dietary level of DEET
induced transient increases in motor activity (Schoenig et al. 1993).  Golden Syrian hamsters dosed with 
up to 940 mg DEET/kg/day for 90 days (EPA 1990b), New Zealand white rabbits dosed with up to 
528 mg DEET/kg/day for 15 days (Army 1980b), or Beagle dogs dosed with up to 400 mg DEET/kg/day
for 52 weeks (Schoenig et al. 1999) did not show gross or microscopic alterations in tissues of the 
nervous system.  In the study in dogs, doses of 400 mg DEET/kg/day induced occasional tremors in some
dogs as well as excessive salivation.
In chronic-duration studies, dietary doses of up 100 mg DEET/kg/day in male CD rats, 400 mg
DEET/kg/day in female CD rats, or 1,000 mg DEET/kg/day in CD-1 mice did not induce morphological
alterations in central or peripheral nervous tissues (Schoenig et al. 1999). 
The highest NOAEL values and all LOAEL values from each reliable study for neurological effects in
each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.5  Reproductive Effects
No information was located regarding reproductive effects in humans following oral exposure to DEET.
   
 















   
   
    
    
















     
     
   
     




Intermediate- and chronic-duration studies provide information regarding reproductive effects in animals 
after oral exposure to DEET.  In a 2-generation continuous feeding study in Sprague-Dawley rats, fertility
was not affected by treatment with up to approximately 250 mg DEET/kg/day (EPA 1989).  In addition, 
gross and microscopic examination of the reproductive organs of the F0 generation and F1 weanlings did 
not show morphological alterations.  In an earlier study, treatment of male and female albino rats with up 
to 701 or 863 mg DEET/kg/day, respectively, in the diet for 200 days did not induce gross or microscopic
changes in the reproductive organs (Ambrose 1959). A 52-week study in male and female Beagle dogs 
dosed with up to 400 mg DEET/kg/day via capsules (Schoenig et al. 1999) or a 15-day study in male New
Zealand White rabbits treated with up to 528 mg/DEET/kg/day (Army 1980b) also did not observe
morphological alterations in the animals’ reproductive organs.  A 90-day dietary study in male and female 
Golden Syrian hamsters, however, reported an increased incidence of tubular degeneration in the testes 
and accumulation of cellular debris in the lumens of the epididymides from males dosed with ≥624 mg
DEET/kg/day; the NOAEL was 305 mg DEET/kg/day (EPA 1990b).  No significant alterations were
observed in females.
Chronic-duration studies did not report gross or microscopic alteration in the reproductive organs from
male CD rats dosed with up to 100 mg DEET/kg/day, female CD rats dosed with up to 400 mg
DEET/kg/day, or male and female CD-1 mice dosed with up to 1,000 mg DEET/kg/day (Schoenig et al. 
1999).
The highest NOAEL values and all LOAEL values from each reliable study for reproductive effects in
each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.6  Developmental Effects 
No information was located regarding developmental effects in humans following oral exposure to DEET.
Limited data are available in animals. Gavage administration of 750 mg DEET/kg to pregnant CD rats on 
GDs 6–15 resulted in a 6% reduction in fetal weight measured at sacrifice on GD 21 (Schoenig et al.
1994).  The NOAEL was 250 mg DEET/kg/day (Schoenig et al. 1994). It should be noted that the
750 mg/kg/day dose level induced neurological signs in the dams during treatment as well as a significant
(35%) reduction in maternal weight gain relative to controls.  Examination of the fetuses did not show
treatment-related increases in external, visceral, or skeletal variations or malformations.  In the same 
study, gavage administration of up to 325 mg DEET/kg to pregnant New Zealand White rabbits on 
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3. HEALTH EFFECTS
GDs 6–18 did not result in embryotoxic or teratogenic effects in the offspring, despite the fact that
maternal weight gain was reduced by about 69% during treatment.
In a 2-generation continuous feeding study in Sprague-Dawley rats that included exposure for at least
80 days before mating, treatment of the F0 generation and later of the F1 generation with 250 mg
DEET/kg/day resulted in significantly reduced (>10%) F1 and F2 pup weights on lactation days 14 and 
21 (EPA 1989).  No significant differences with controls were observed at 100 mg DEET/kg/day
compared to controls.  In addition, F1 males from all treated groups (25, 100, and 250 mg/kg/day) showed 
a dose-related increased incidence of gross and microscopic lesions in the kidneys.  The lesions included 
inflammation, hyaline droplet and granular cast formation, and regeneration of tubules. The reduction in 
pup weights was used to derive an intermediate-duration oral MRL for DEET.
The highest NOAEL values and all LOAEL values from each reliable study for developmental effects in
each species and duration category are recorded in Table 3-2 and plotted in Figure 3-2.
3.2.2.7  Cancer
No studies were located regarding cancer effects in humans following oral exposure to DEET.
One publication of three studies was located that examined the potential carcinogenicity of DEET in
animals following oral exposure, and negative results were reported in the three species tested (dogs, rats,
and mice) (Schoenig et al. 1999). Male and female Beagle dogs were dosed by capsule with up to 400 mg
DEET/kg/day for 52 weeks; male CD rats were dosed with up to 100 mg/kg/day and female CD rats were 
dosed with up to 400 mg/kg/day via the diet for 104 weeks; and male and female CD-1 mice were dosed
with up to 1,000 mg/kg/day via the diet for 78 weeks.
3.2.3 Dermal Exposure 
3.2.3.1  Death 
Five deaths have been associated with dermal exposure to DEET and three of them occurred in children.  
Zadikoff (1979) reported the case of a 5-year-old girl who had been sprayed nightly for almost 3 months
with an insect repellent containing 10% DEET and subsequently developed progressively severe
headaches starting 10 days prior to hospitalization. On admission, the child was extremely agitated,
restless, and irritable with constant involuntary movements involving the head, trunk, and all limbs.  This
   
 









     
      
    
 
    
  
   
    
    
     
  
    
    
   
     
   
  
  
    
  
         
 
    
     
     
      
  
 




was interrupted periodically by short episodes of quiet, shaking, crying, and screaming.  Shortly
thereafter, she developed a generalized convulsion and for the next 24 days, she was treated with various 
combinations and doses of drugs to control the hyperactivity, which eventually become intractable even
with haloperidol treatment.  An autopsy revealed generalized edema of the brain with intense congestion
of the brain and meninges.  The second case was a 6-year-old girl who in response to repeated black fly 
bites used a spray containing 15% DEET on at least 10 occasions on extensive areas of skin and 
developed a clinical picture similar to Reye syndrome or ornithine carbamoyl transferase deficiency
(Heick et al. 1980). On the fifth day in the hospital, the child developed generalized convulsions followed
by coma, and on the seventh and eighth day, the EEG became flat and supportive therapy was 
discontinued.  Autopsy showed edematous brain.  Based on tests, it was hypothesized that the child might
have been a carrier of OCT deficiency, a potential lethal hyperammonemic condition, which may have
contributed to her death. Pronczuk de Garbino et al. (1983) briefly described the case of a 17-month-old 
girl who was admitted to the hospital with a diagnosis of acute encephalopathy of unknown origin.  
During 3 weeks prior to admission, the child had received repeated applications of a lotion containing
DEET.  The child rapidly deteriorated and died before further toxicological information could be
obtained, but DEET-induced toxicity was strongly suspected. In a study of insect repellent reports to the 
AAPCC, Bell et al. (2002) identified two deaths (a 26-year-old male and a 34-year-old female) following
dermal exposure to >50% DEET.  The male, who had applied a 52% DEET repellent liberally throughout
the day, developed dyspnea, seized, vomited, unsuccessfully underwent cardio-pulmonary resuscitation,
and was taken to the emergency department where he died within 2 hours of the initial seizure.  Of the
tissues tested, DEET levels were elevated only in the blood.  Little information was available for the 
female, but exposure duration was reported as chronic with the only effect being an adverse dermal
reaction. It should be noted that in all of these cases, excessive exposure appears to have occurred.
Limited information was located regarding lethal doses in animals exposed dermally to DEET.  Carpenter
et al. (1974) reported that the dermal LD50 in New Zealand White rabbits was 3,167 mg/kg (per 
Table 3-3).  DEET was applied to a shaved area of the skin that was covered for 24 hours; the observation
period was 14 days.  EPA (1998b) indicated that the dermal LD50 in rabbits (strain not specified) was 
4,280 mg/kg.
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Rabbit 24 hr 












Gn Pig 10 d 
1 x/d Dermal 1 
mL 
(slight erythema) 
Ambrose 1959 10% DEET was used. 
DEET was not a skin 
sensitizer. 
(albino) 
Rabbit 24 hr Dermal 4000 
mg/kg 
Ambrose 1959 Reported erythema 
was due to mechanical 
irritation. 
(albino) 
Rabbit once Ocular 0.05 
mL 




Rabbit once Ocular 10 
mg 
(moderate eye irritation) 
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(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
INTERMEDIATE EXPOSURE 
Systemic 
Rat 13 wk Resp
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EPA 1988 NOAELs are for organs 
or tissue 
histopathology. 











Lebowitz et al. 1983 Liver and kidney 
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(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Micropigs 
Pig 90 d 
5 d/wk Resp 1000 B 
mg/kg/day 
EPA 1992a NOAELs are for organ 
and tissue 
histopathology. 
Cardio 1000 B 
mg/kg/day 
Gastro 1000 B 
mg/kg/day 
Hemato 1000 B 
mg/kg/day 
Musc/skel 1000 B 
mg/kg/day 
Hepatic 1000 B 
mg/kg/day 
Renal 1000 B 
mg/kg/day 
Endocr 1000 B 
mg/kg/day 




Ocular 1000 B 
mg/kg/day 
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(Route)(Strain) System NOAEL Less Serious Serious Chemical Form Comments 
Micropigs 




Rat 13 wk 
1 x/d 






NOAELs are for organ 
and tissue 
histopathology. 















(diffuse neuronal cell 
death in brain regions) 
EPA 1992a 
Abdel-Rahman et al. 2001 





Rat 30 d 
1 x/d 40 M 
mg/kg/day 
(neuronal degeneration 
in brain; impaired 
neurobehavior) 
Abdel-Rahman et al. 2004 
(Sprague-
Dawley) 
Rat 60 d 




Abou-Donia et al. 2001a 
(Sprague-
Dawley) 
Rat 45 d 

















3.  HEALTH EFFECTS
DEET 64
















































Fediuk et al. 2010 
EPA 1992a 
EPA 1988 
Lebowitz et al. 1983 
EPA 1992a 
NOAEL is for 
histopathology of the 
brain and spinal cord. 
NOAEL is for 
neurobehavioral 
function. 
NOAEL is for 
histopathology of brain, 
spinal cord, and sciatic 
nerve. 
NOAEL is for 
histopathology of the 
reproductive organs. 
NOAEL is for testes 
histopathology and 
sperm count and 
viability. 
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Rabbit 90 wk 
2 x/wk Dermal 20 B 
mg 
Stenback 1977 
B = both; Bd Wt = body weight; d = day(s); F = Female; Gn pig = guinea pig; hr = hour(s); LD50 = lethal dose, 50% kill; LOAEL = lowest-observed-adverse-effect level; M = male; 
NOAEL = no-observed-adverse-effect level; wk = weeks(s); x = time(s) 
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3.2.3.2  Systemic Effects
No studies were located regarding body weight effects in humans following dermal exposure to DEET.
The highest NOAEL values and all LOAEL values from each reliable study for relevant effects in each
species and duration category are recorded in Table 3-3.
Respiratory Effects. The only information regarding respiratory effects in humans exposed to DEET
is that provided by a survey of 143 workers of the Everglades National Park, Florida (NIOSH 1986).  
Based on the reported use of insect repellent sprays or lotions, the workers were classified as low
exposure (n=44, non-users), medium exposure (n=55; <4.25 g DEET/week), or high exposure (n=44, 
>4.25 g DEET/week).  Concentrations of DEET in the repellents used varied from 15 to 75% in the
sprays and from 30 to 100% in the lotions. The survey found that complaints of chest pain or wheezing
were significantly elevated (p<0.05) in the high-exposure group (30%) compared to the medium- (9%) or
low-exposure (11%) groups.  It should be noted that exposure was inferred from only survey responses, a
notable weakness.  Because no actual quantification was possible, the findings from this report should be
interpreted with caution.
Application of up to 1,000 mg DEET/kg/day for 13 weeks onto the shaved back of micropigs or CD rats 
did not induce gross or microscopic alterations in the respiratory tract, although details were not reported
(EPA 1988, 1992a).
Cardiovascular Effects. Hypotension and orthostatic change in blood pressure were described in a
case of an adult woman after spraying herself with a DEET-containing insect repellent (Clem et al. 1993). 
For years she had used a product containing 14.25% DEET without adverse effects, but, that day she used 
a product with higher (but unspecified) percent of DEET and completely wetted most of her body with it.
An ECG performed on admission showed marked sinus bradycardia (44 beats/min), but a repeat ECG
performed 1 hour later showed no abnormalities. In a case report of an 18-month-old boy who was
having seizures after being applied an unknown amount of an insect repellent containing 17.6% DEET, an 
ECG performed on arrival to a medical center was within normal limits (Briassoulis et al. 2001).
Blood pressure appeared unaffected in two case reports of death from DEET overexposure, with 
respective values of 110/65 mm Hg for a 5-year-old girl (Zadikoff 1979) and 108/68 mm Hg for a 6-year-
old girl (Heick et al. 1980), but was slightly elevated at 140/86 mm Hg in a 27-year-old man who 
   
 








   
   
    
   




    
   
   
 
          
   
      
  
 
    
   
   
 
       
      
   
  
      
 







survived after significant medical treatment (Hampers et al. 1999).  Heart rate was elevated in the first
case (135/min), normal in the second (66/min), and elevated in the third (104/min). A study conducted in 
nine volunteers to determine the impact of 33% DEET lotion on various physiological measures, 
including heart rate, during exercise-heat stress reported no significant differences in heart rate between 
controls and those who applied DEET (Kenefick et al. 2011).  The investigators had hypothesized that
DEET lotion would impair measures of sweating and evaporation and thus increase strain and discomfort, 
which it did not.
Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks onto the shaved back of
micropigs or CD rats did not induce gross or microscopic alterations in the heart and aorta, although 
details were not reported (EPA 1988, 1992a).
Gastrointestinal Effects. The only relevant information with regard to gastrointestinal effects is 
from a report by Clem et al. (1993), which states that a 61-old-woman developed nausea, vomiting, and 
explosive diarrhea after spraying herself liberally with a high percentage DEET insect repellent. The
possibility that this was coincidental, however, cannot be ruled out.
Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks onto the shaved back of
micropigs or CD rats did not induce gross or microscopic alterations in the gastrointestinal tract, although 
details were not reported (EPA 1988, 1992a).
Hematological Effects. Several studies provided information regarding hematological effects 
following dermal exposure to insect repellents that contained DEET. The majority involve single case 
reports of children 6-years-old or younger that found no significant deviations from normal limits for red
and white blood cell counts (Briassoulis et al. 2001; Heick et al. 1980; Lipscomb et al. 1992; Roland et al. 
1985; Zadikoff 1979).  The one case in which leukocytosis (16,900/mm3 or 1.69x1010/L) was observed
involved an 18-months-old girl who had been sprayed daily with an insect repellent containing 20%
DEET for approximately 3 months prior to admission (Edwards and Johnson 1987).  Clem et al. (1993)
and Hampers et al. (1999) reported single cases of intoxication in adults.  Both cases had signs and 
symptoms severe enough to warrant a visit to the emergency department.  Hematological parameters were 
measured and were within normal limits.
   
 








     
    
   
 
       
      
    
 
   
  
   
 
        
  
      
          
  
   
    
     
 
 
    
    
      
    
  
   
    
    
     




Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks days onto the shaved back of
micropigs or CD rats did not induce significant alterations in hematological parameters, although details
were not reported (EPA 1988, 1992a).
Musculoskeletal Effects. In the survey of 143 employees of the Everglades National Park, Florida, 
symptoms of muscle cramping were significantly (p<0.05) increased in the medium- (24%) and high-
(25%) exposure groups compared to the low-exposure (7%) group (NIOSH 1986). 
Application of up to 1,000 mg DEET/kg/day, 5 days/weeks for 13 weeks onto the shaved back of
micropigs or CD rats did not induce gross or microscopic alterations in skeletal muscle or bone (femur), 
although details were not reported (EPA 1988, 1992a).
Hepatic Effects. Four case reports of intoxication of children following dermal exposure to insect
repellents containing DEET stated that liver function tests performed shortly after admission to an 
emergency center were within normal limits (Edwards and Johnson 1987; Lipscomb et al. 1992; Roland 
et al. 1985; Zadikoff 1979). In the case reported by Zadikoff (1979), the 5-year-old girl died 24 days after
admission. In an additional case of dermal intoxication of a 6-year-old girl who eventually died 8 days
after admission to the hospital, Heick et al. (1980) reported significantly elevated serum enzymes 
measured on the fifth day in the hospital.  Necropsy showed an enlarged liver with no other abnormalities
in appearance. Histological and ultrastructural examination of the liver suggested a nonspecific hepatic 
injury.
Liver weight was increased, but not significantly, in male Sprague-Dawley after receiving applications of
up to 1,000 mg undiluted DEET/kg/day onto the shaved dorsal skin 5 days/week for 9 weeks (Lebowitz et
al. 1983). Application of 1,000 mg DEET/kg/day (the highest dose tested) onto the shaved back of male
and female CD rats for 13 weeks induced significant increases in absolute and relative liver weight; the
same was observed in females that received doses of 300 mg DEET/kg/day (EPA 1988).  In addition, 
males from all treated groups (100, 300, and 1,000 mg DEET/kg/day) had vacuolar change in the liver
(significant only in the mid-dose group), which were considered an adaptive response; no vacuolar
changes were seen in females.  Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks
onto the shaved back of micropigs did not induce gross or microscopic alterations in the liver, nor did it
affect serum levels of transaminases, although details were not provided (EPA 1992a).
   
 








          
     
       
    
 
  
    
    
     
   
     
   
    
      
   
   
    
     
 
      
  
   
  
   
     
    
       
    
   
 
       
   




Renal Effects. Few studies reported the results of renal tests following dermal intoxication with
insect repellents containing DEET. Two case reports of children (Briassoulis et al. 2001; Roland et al. 
1985) and one case of an adult exposed to DEET (Clem et al. 1993) all reported levels of blood urea
nitrogen and creatinine within normal limits in the patients upon arrival at the emergency department.
Application of up to 1,000 mg undiluted DEET/kg/day onto the shaved back of male Sprague-Dawley rats
5 days/week for 9 weeks increased kidney weight at 36, 65, and 95 days, and the increase was significant
at 65 days (Lebowitz et al. 1983).  A study on male CD rats that received applications of 1,000 mg
undiluted DEET/kg/day, 5 days/week for 90 days with microscopic examination of the kidneys reported a 
significant increased incidence of granular casts and hyaline droplets, as well as inflammation and 
regeneration of renal tubular epithelium in treated rats compared to controls in both castrated and non-
castrated rats (EPA 1990a). The test was performed to assess whether testosterone caused greater effects
of DEET on males, but both relative kidney weights and histopathology results indicated that the renal
effects of DEET were not enhanced by this hormone.  A similar study in CD rats reported slight, but
statistically significant, increases in blood urea nitrogen in males exposed to ≥300 mg DEET/kg/day 
(EPA 1988).  In addition, gross necropsy showed enlarged kidneys in males from all exposed groups
(100, 300, and 1,000 mg DEET/kg/day), with pale and granular appearance in males exposed to
≥300 mg/kg/day.  Microscopic examination showed an increased incidence of renal lesions in all males
consisting of granular casts, inflammation, regeneration, and hyaline droplets.  High-dose females had a 
small increase in hyaline casts and inflammation, but the hyaline cast in females was, reportedly, different
from that of males (no further details were provided).  As mentioned in Chapter 2, the hydrocarbon-
induced nephropathy has only been demonstrated in adult male rats and has been linked to a specific
protein, α2μ-globulin, which is produced under hormonal control by the liver (Alden 1986; Swenberg
1993).  However, the α2μ-globulin is unique to male rats and is not present in human kidneys.  Hence, this
particular nephropathy has no significance for humans and would therefore be inappropriate to use for
evaluation of human health effects or risk assessment. Application of up to 1,000 mg DEET/kg/day,
5 days/week for 13 weeks onto the shaved back of micropigs did not induce gross or microscopic
alterations in the kidneys, nor did it affect serum creatinine levels, although details were not reported
(EPA 1992a).
Endocrine Effects. In the case report of a 5-year-old girl admitted to the emergency department after
being sprayed repeatedly with an insect repellent containing 10% DEET, Zadikoff (1979) stated that
thyroid function studies were within normal limits.  No other study provided information regarding
endocrine effects in humans following dermal exposure to DEET.
   
 









    
   
   
 
          
     
   
      




     
      
      
 
  
   
     
 
   
   
     
   
    
   
   
    
      
    




Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks onto the shaved back of
micropigs or CD rats did not induce gross or microscopic alterations in the adrenals, thyroid, parathyroid, 
or pituitary glands, although details were not provided (EPA 1988, 1992a).
Dermal Effects. A low incidence of adverse dermal effects has been reported in humans following
application of insect repellents containing DEET in the form of lotions or sprays. It should be noted, 
however, that the paucity of consumer adverse effect reports, considering the billions of product
applications that have occurred in the 60-year history of DEET usage as an active ingredient in insect and
acarid repellent, suggests that DEET is generally safe for consumer use if instructions for application are
followed.
In an early study in five volunteers (for which further information on informed consent was not provided), 
application of 1mL of a 50% solution of DEET in isopropanol to the face and 2 mL to the arms once per
day for 5 consecutive days did not cause irritation on the arms, but caused a feeling of dryness and
astringency in both face and arms (Ambrose 1959). DEET applied to the face also caused desquamation 
around the nose and some feeling of dryness and astringency.  One subject who applied undiluted DEET
to the face for 6 weeks showed desquamation around the nose after the third day; each time desquamation
appeared, applications were stopped and desquamation disappeared usually within 2 days, and then 
treatment was resumed. No other signs or symptoms were noted.
MMWR (1989) and Wantke et al. (1996) reported two cases of children who developed non-
immunological urticaria following applications of insect repellents containing DEET.  In the case 
described by Wantke et al. (1996), a 4-year-old boy with no history of prior insect repellent application 
developed urticarial and a generalized itch within minutes of applying a 25% DEET product.  Patch 
testing revealed that the boy’s skin was highly sensitive, and that his cutaneous hyperreactivity was not
specific to DEET. Wantke et al. (1996) concluded that the boy appeared to have developed non-
immunologic, chemical-induced generalized urticaria from the insect repellent. Roland et al. (1985)
reported the case of an 8-year-old girl with reportedly sensitive skin who developed a raised, 
erythematous pruritic rash on her face and extremities 2 days after applying copious amounts of Off!® to 
those skin areas for that period. On the third day that she applied Muskol®, she experienced convulsions
and seizures by the next morning, and was hospitalized.  After a 2-day stay at a hospital to treat
neurological effects, the rash faded. Results indicated this was a hypersensitivity reaction to DEET.
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A group of soldiers developed acute dermatitis 18–24 hours after applying an insect repellent containing
50% DEET before sleep to the uncovered skin of the face, neck, upper part of the trunk, and legs
(Reuveni and Yagupsky 1982). All of the subjects complained of a burning sensation and showed 
erythema of the antecubital fossa of one or both arms where applications could pool or be confined and 
macerated with sweat in the flexures. Subsequent examination showed progression of the erythema to 
hemorrhagic blister formation, and in some cases deep ulcerations in 1–2 days. Amichai et al. (1994)
reported another single case of acute dermatitis of the antecubital fossa in a soldier who developed a
burning sensation and skin eruption about 8 hours after applying an insect repellent containing 33%
DEET the previous night. The symptoms did not recur following re-exposure.  A survey of
143 employees of the Everglades National Park, Florida, who used DEET regularly in their work, showed 
that more highly exposed workers had a significantly higher (p<0.05) prevalence (27%) of skin rash and
blisters than those with medium exposure (14%) or those with low (7%) exposure (NIOSH 1986).
An acute study with occluded application of 2 or 4 mL undiluted DEET (approximately 2,000 or
4,000 mg) to the depilated torsos of albino rabbits (of which the skin was slightly abraded on half of the
animals) for 24 hours resulted in mild to moderate erythema on all animals (Ambrose 1959).  Slightly
more erythema was present on the abraded areas of skin and on the ventral compared with flanks and
dorsal surfaces.  An evaluation concluded that the greater degree of erythema observed on ventral
surfaces was due to mechanical action rather than to increased heat in that area.
Uncovered repeated application of 1 mL DEET/kg (approximately 1,000 mg/kg/day) to albino rabbits 
5 days/week for 13 weeks resulting in cutaneous irritation starting at about the third application of DEET
Ambrose 1959).  The effect was characterized by slight to moderate erythema, desquamation, and dryness
of the skin. The erythema disappeared over the weekend but not the desquamation or skin dryness.  The
skin became leathery, hard, and dry and fissures developed after the third or fourth week of treatment in 
some rabbits. Desquamation persisted and remained throughout the study. Although scarring was 
present in some rabbits, most skin alterations had disappeared three weeks after the last dose. Application
of doses of 1,000 mg neat technical DEET/kg/day to the back of male CD rats 5 days/week for 90 days 
resulted in increased incidence of erythema (EPA 1990a). A similar study in which CD rats received
applications of 100, 300, or 1,000 mg DEET/kg/day (in volumes of 0.1, 0.3, and 1.0 mL/kg) for 13 weeks
reported increased incidence of red and scabbed areas at the application site for both male and female rats 
(EPA 1988). Microscopic examination of the skin showed increased incidence of acanthosis and/or
hyperkeratosis. Application of ≥100 mg DEET/kg/day (as a mixture consisting of equal parts of
technical-grade DEET from four manufacturers) to the back of micropigs 5 days/week for 13 weeks
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resulted in skin desquamation (EPA 1992a).  Microscopic examination of two unspecified application
sites on dorsal and lateral surfaces at termination showed dose-related increased incidence of
hyperkeratosis at ≥100 mg DEET/kg/day in males and ≥300 mg DEET/kg/day in females.  Acanthosis at
application site A was observed only in males and showed a threshold response at 1,000 mg
DEET/kg/day, while at site B/C, the effect was dose-related at ≥300 mg DEET/kg/day (EPA 1992a).  
No skin lesions were reported in a chronic-duration study in male Swiss mice and in male and female 
New Zealand White rabbits that received applications of 0.02 mL of a 10, 50, or 100% solution of DEET
(2, 10, or 20 mg DEET) for 2 times/week (140 weeks in mice, 90 weeks in rabbits) (Stenback 1977).
DEET was not a skin sensitizer in guinea pigs or in rabbits (Ambrose 1959).
Ocular Effects. In the study of 20,764 human exposures involving insect repellents containing DEET
that were reported to poison control centers from 1993 to 1997, 4,422 were identified as being exposed 
predominantly by accidental contact of an insect repellent spray with the eyes (Bell et al. 2002). Six of
those (three children and three adults) experienced major ocular symptoms. Common signs and 
symptoms reported in these subjects included ocular irritation/pain and lacrimation. 
A study in CD rats applied up to 1,000 mg DEET/kg/day onto the shaved back daily for 13 weeks 
reported that ophthalmological examinations conducted at week 13 showed no compound-related effects 
(EPA 1988).  A study in albino rabbits examined the ocular effects of three different DEET preparations: 
100% undiluted (1 drop, 0.04 mg), 30% DEET in cottonseed oil (3 drops, ~0.04 mg), or a 40% emulsion
in vegetable lecithin with ethanol and water (3 drop, ~0.05 mg) (Ambrose 1959).  Two hours after
application to the conjunctival sac, there did not seem to be significant differences in the degree of eye 
injury induced by the three preparations, but it appeared that the emulsion was slightly more irritating.  
DEET induced moderate to marked edema of the nictitating membrane, lacrimation, conjunctivitis, and 
pus, which were still present 48 hours after application.  Three rabbits also showed some cloudiness.  All
treated eyes showed varying degrees of injury as revealed by fluorescein staining.  Some effects seen at
48 hours were still seen 72 hours after application, but were not as severe.  After 5 days, fluorescein
staining was negative and all eyes were considered to have a normal appearance by the investigator, 
suggesting that the eye injuries were probably not permanent. Another study in rabbits reported that 0.01 
mL of undiluted DEET (approximately 10 mg) caused moderate eye irritation, as indicated by increased
corneal thickness and fluorescein staining, swelling of the conjunctiva, corneal cloudiness, and iris
reaction (MacRae et al. 1984).  The eye returned to a normal appearance by 168 hours. Application of up 
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to 1,000 mg DEET/kg/day 5 days/week for 13 weeks onto the shaved back of micropigs did not induce
gross or microscopic alterations in the eyes, although details were not provided (EPA 1992a).
Body Weight Effects. Repeated applications of approximately 1,000 mg DEET/kg/day to a shaved
area of the skin of Sprague-Dawley rats or albino rabbits did not significantly affect body weight
(Ambrose 1959; Lebowitz et al. 1983). Similar findings were reported in male Swiss mice applied 20 mg
DEET (approximately 666–1,000 mg/kg/day assuming a body weight of 0.02–0.03 kg for the mice) for
140 weeks (Stenback 1977). Body weight was not significantly affected (<10% difference with controls)
in CD rats or micropigs that received applications of up to 1,000 mg DEET/kg/day onto the shaved back
for 13 weeks (EPA 1992a).
Metabolic Effects. Several studies of children intoxicated after skin application of insect repellents 
containing DEET reported levels of glucose and serum electrolytes within normal limits upon admission 
to emergency centers (Briassoulis et al. 2001; Edwards and Johnson 1987; Gryboski et al. 1961; Heick et
al. 1980; Roland et al. 1985; Zadikoff 1979).  Similar findings were reported by Hampers et al. (1999) in 
their description of an adult case of poisoning.  
Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks onto the shaved back of
micropigs did not induce alterations in serum electrolytes or glucose levels, although details were not
reported (EPA 1992a). Tests conducted in male and female CD rats that received applications of
1,000 mg DEET/kg/day, 5 days/week for 13 weeks showed a significant decrease in serum glucose in
males, which was considered not biologically significant by the investigators (EPA 1988).  Serum
electrolyte levels were within normal ranges in that study.
3.2.3.3  Immunological and Lymphoreticular Effects 
A few cases of contact urticaria by immunological mechanisms have been reported in humans after using 
products containing DEET. Immunological contact urticaria is a type I hypersensitivity reaction that is
mediated by antigen-specific IgE in individuals who previously have been sensitized (Shutty et al. 2013).
Maibach and Johnson (1975) reported the case of an elderly woman who discovered that she had allergic
contact dermatitis to DEET containing products after self-experimentation with insect repellents over four 
summers (applying them, observing a rash form immediately, and then noting that the rash disappeared
upon washing off the 0.1, 1, and 100% substance). Patch test application of three active ingredients of
repellents (dimethylphthalate, DEET, and butopyronoxyl), along with their inactive components, to intact 
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skin showed that DEET was the substance causing the immediate urticaria.  Application of pure samples
of DEET gave similar responses. Testing with 18 structurally-related analogs of DEET and similar
substances showed that the response depended on the nature and positions of those substances that were
substituted on the benzene ring.  It was determined that active structures required ortho, meta, or both 
positions to be fluoromethylated, inactivation occurred if the para position was so filled (as if full
activation needed access to the meta site for hydroxylation), the molecule needed a benzoyl structure, and 
the response may be mediated by histamine. Serum from the patient was injected into two volunteers 
who had an injection site response to DEET, indicating the patient’s response could be passively
transferred.  Results suggested that the mechanism of action was immunologic, and its passive 
transferability indicated a deficiency in the patient’s immune system. A similar case was reported by
Vozmediano et al. (2000) in a 16-year-old girl who historically experienced disproportional reactions to 
insect bites and developed a skin reaction accompanied by increasingly evident edema and severe pruritus
after regularly applying a lotion containing 20% DEET. The authors conducted an open skin test using
that product and 0.1%, 1% and 100% DEET.  The product and higher two concentrations resulted in a
raised area, considered to be an immunologic contact urticarial.  More recently, Shutty et al. (2013)
described the case of a 22-year-old man who developed contact urticaria immediately after application of
an insect repellent. The patient reported consistently avoiding DEET-containing products since previous 
contact with them had resulted in welts, and he had recently developed hives after contact with
individuals who had used DEET-containing repellents. Because it was unclear what ingredient produced 
the urticaria, open patch testing of the patient with DEET and picaridin (another common insect repellent)
was conducted. There were positive responses in tests areas receiving applications of 7% DEET and 7%
DEET in ethanol, but no dermal response in areas to which 5% picaridin and 5% picaridin in ethanol were
applied.
Application of up to 1,000 mg DEET/kg/day, 5 days/week for 13 weeks onto the shaved back of CD rats 
or micropigs did not induce gross or microscopic alterations in spleen, thymus, or lymph nodes, although 
details were not provided (EPA 1988, 1992a).
3.2.3.4  Neurological Effects 
There have been sporadic reports over the last several decades of adverse neurological effects in adults 
and children following dermal application of insect repellents containing DEET.  It should be noted, 
however, that in all cases, excessive amounts of the insect repellent may have been applied.  A few 
representative studies are mentioned below, and additional references can be found in review articles 
   
 








    
        
      
    
   
    
  
      
   
   
   
      
  
 
       
 
        
   
    
 
       
    
      
    
   
  
    
      
     






(Antwi et al. 2008; Bell et al. 2002; Osimitz and Murphy 1997; Qiu et al. 1998; Sudakin et al. 2003;
Veltri et al. 1994). In almost all cases, exposure involved repeated applications of an insect repellent on 
multiple days but in at least three cases, neurological effects developed after a child received a single 
application (Briassoulis et al. 2001; Lipscomb et al. 1992) and after an adult received a few applications 
in the same day (Hampers et al. 1999).  The amount applied was not known in either case, but Lipscomb 
et al. (1992) reported that the child received a virtual total body application of an insect repellent 
containing 95% DEET. Hampers et al. (1999) reported that the adult male had applied 20% DEET
sunscreen lotion early in the day and a 25% DEET spray several times later that day to his arms, neck,
and legs, resulting in the acute onset of parathesias of limbs and face, then progressive hallucinations and 
confusion, followed by combativeness.  The emergency department neurological examination identified 
tremors in all extremities and a hypertonic state.  He was unresponsive to haloperidol, diazepam, and 
phenytoin treatment, and required further medication, intubation, and mechanical ventilation.  On day 2,
he was off the ventilator, and on day 3, his mental state appeared normal, although he still had headaches.  
All effects had resolved after a week.
Neurological signs and symptoms reported in children and adults include seizures, ataxia, restlessness,
uncontrolled limb movements, agitation, aggressive behavior, combativeness, impaired cognitive
functioning, and opisthotonos (Briassoulis et al. 2001; Edwards and Johnson 1987; Gryboski et al. 1961;
Hampers et al. 1999; Heick et al. 1980; NIOSH 1986; Pronczuk de Garbino et al. 1983; Roland et al. 
1985; Snyder et al. 1986; Zadikoff 1979), or headaches that progressively worsen or are long lasting
(Hampers et al. 1999; Zadikoff 1979). Some milder symptoms included insomnia, muscle cramping, 
mood disturbances, and difficulty with starting or stopping urination (NIOSH 1986). The combination of
some of these signs and symptoms has been described as toxic encephalopathy, and Zadikoff (1979)
considered that this spectrum of symptoms could result in misdiagnosis as viral encephalitis. Five deaths 
occurred among these cases (Bell et al. 2002; Heick et al. 1980; Pronczuk de Garbino et al. 1983;
Zadikoff 1979). Osimitz and Murphy (1997) examined 14 cases that reported neurological effects
following dermal exposure to DEET and concluded that causality is difficult to establish because of
limitations in clinical details provided in the reports. The investigators noted that 8 of the 14 patients may
have had idiopathic seizures, 1 may have had an exanthematous illness and a convulsion, 3 may have had
an inflammatory process affecting the central nervous system, and 1 was heterozygous for ornithine
carbamoyl transferase deficiency, but synergisms with DEET were not excluded. There was insufficient
information on an additional patient to determine if there were alternate explanations for the patient’s 
encephalopathy.
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In a study of 20,764 human exposures involving insect repellents containing DEET that were reported to 
poison control centers from 1993 to 1997, 2,179 were identified as having been exposed predominately
by skin contact (Bell et al. 2002).  Of these, 118 exhibited minor neurologic symptoms that included 
dizziness/vertigo, headache, and drowsiness/lethargy. The severe symptoms among these cases included
tremors (15), single seizures (8), muscle weakness (10), muscle rigidity (5), peripheral neuropathy (5), 
slurred speech (3), and paralysis (1). 
In an early study in five volunteers, application of approximately 1 mL of a 50% solution of DEET in 
isopropanol to the face (i.e., enough to completely wet each area) once per day for 5 consecutive days 
induced a slight tingling sensation in all the subjects (Ambrose 1959).  No other neurological signs or
symptoms were noted.
Haley and Kurt (1997) conducted a cross-sectional survey of 249 Gulf War veterans in order to identify
risk factors of war-related syndromes.  The extent of exposure to DEET was assessed by self-estimation
of the number of times per day repellent was typically applied.  Independent risk factors were identified
by performing a series of adjusted, stepwise logistic regression analyses that required a level of
significance of p<0.005 for a variable to enter and remain in a logistic regression model. The results of
the analyses showed that the prevalence of a syndrome termed arthro-myo-neuropathy increased with the
amount of insect repellent used (p<0.005 for a univariate association and p<0.001 for trend).  This
association held true for those who used government-issued repellent (75% DEET in ethanol) (odds ratio
[OR] of 1.54; 95% confidence interval [CI] of 1.17–2.03), but not for those who reported using a 
formulation containing ≤31% DEET or one containing no DEET. While the latter gives biological 
plausibility to the results, assessing exposure by self-recollection limits the validity of the study
conclusions.
A series of animal studies have been conducted to examine the neurological effects of DEET applied to 
the skin of animals alone and in combination with other chemicals used by military personnel in the
Persian Gulf War. This section summarizes the effects of DEET alone; information regarding
interactions of DEET with other chemicals is presented in Section 3.9, Interactions with Other Chemicals.
It should be mentioned, however, that some of these studies seem to have some deficiencies in reliability, 
as explained below (Jortner 2006; Schoenig 2002).
In an intermediate-duration study, relatively low doses of 4 mg/kg/day DEET (as 10 mg/mL in 70%
alcohol) applied daily to 1 in2 of the back of the neck skin of male Sprague-Dawley rats for 60 days did
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not affect simple sensorimotor reflexes tested 30–60 days after exposure ceased, but affected some
sensory parameters such as performance on a beam, grip strength, and performance on an inclined plane 
(Abou-Donia et al. 2001a).  In addition, doses ≥4 mg DEET/kg/day decreased the permeability of the
blood brain barrier mainly in the brainstem but also in the cerebellum, doses ≥40 mg DEET/kg/day 
decreased the permeability in the midbrain, and 400 mg DEET/kg/day decreased the permeability in the
cortex.  In a companion study, similar treatment with 40 mg DEET/kg/day (only dose tested) for 45 days
was shown to significantly increase (by ~40%) acetylcholinesterase (AChE) activity in the brainstem but 
not in other brain areas and also to significantly increase (by ~20%) choline acetyltransferase (ChAT)
activity in the cortex but not in the brainstem (Abou-Donia et al. 2001b).  DEET also significantly
increased ligand binding to m2 muscarinic acetylcholine receptors in the cortex, but did not affect ligand 
binding of nicotinic receptors in the cortex. Gross and microscopic examination of the brain of the treated
rats showed neuronal degeneration principally in the motor cerebral cortex, dentate gyrus, CA1 and CA3 
subfields of the hippocampus, and the Purkinje cell layer of the cerebellum (Abdel-Rahman et al. 2001).  
In a subsequent study, the same group of investigators confirmed the findings regarding the
neurobehavioral effects and histological effects in the various brain areas (Abdel-Rahman et al. 2004).
Contrary to what was reported in a previous study (Abou-Donia et al. 2001b), however, in the more recent
study (Abdel-Rahman et al. 2004), DEET was reported to statistically significantly increase (rather than
have no effect) AChE activity in the cortex and cerebellum but not in the brainstem (which earlier was 
increased by 40%) and to have no significant effect on the ligand binding to m2 muscarinic acetylcholine 
receptors in the cortex.  No explanation was provided for these apparent discrepancies. It should also be
mentioned that Fediuk et al. (2010) applied doses of 40 mg DEET/kg/day (as 100 mL DEET in 70%
alcohol) to 4 cm2 of the shaved back of Sprague-Dawley rats for 30 days, as did Abdel-Rahman et al.
(2004) to 2.5 cm2 (dose applied in 1 mL of 70% ethanol in water) for 60 days, and reported no significant
alterations in various neurobehavioral tests that assessed arousal, locomotion, habituation, and motor
coordination.  The reason for the difference in the result between these two studies (other than the area of
skin exposed, duration of exposure, and concentration of DEET in the alcohol vehicle) is not apparent.
Regarding the histological findings in the Abdel-Rahman et al. (2001, 2004) reports, it was noted that
there may have been misinterpretation of the findings (Jortner 2006).  The main concern is that the report
of “degenerating” or “dying” neurons in this article is actually the result of poor handling and inadequate 
fixation of the brain tissue and is a “dark” neuron artifact. The presence of this artifact suggests that both
the neuron counting and the immunostaining procedures may have been compromised.  
The studies by Abou-Donia and Abou-Rahman state that the doses of DEET, pyridostigmine bromide
(PB), and permethrin used in their studies of rats were considered comparable to exposures received by
   
 








     
        
    
    
    
  
 
    
     
    
 
    
  
 





       
   
      
     
  
   
     
    
       
   
 





service members during the Persian Gulf War. The National Academy of Sciences (NAS) stated that “the
primary studies of Veterans deployed to the Gulf War compared to Veterans not deployed do not
demonstrate differences in cognitive and motor measures as determined through neurobehavioral testing.”
The NAS update committee concluded that “there is inadequate or insufficient evidence to determine if an
association exists between deployment to the Gulf War and neurocognitive and neurobehavioral
performance” (DVA 2011).
In studies in CD rats and micropigs, application of up to 1,000 mg DEET/kg/day to the shaved back 
5 days/week for 13 weeks did not induce gross or microscopic alterations in the brain, sciatic nerve, or
spinal cord, although details were not reported (EPA 1988, 1992a). 
The NOAELs and LOAELs for neurological effects from the animal studies summarized above are 
presented in Table 3-3.
3.2.3.5  Reproductive Effects
No information was located regarding reproductive effects in humans following dermal exposure to 
DEET.
Three studies were located with information regarding reproductive effects in animals following dermal
exposure to DEET.  Application of up to 1,000 mg undiluted DEET/kg/day onto the shaved dorsal skin of
male Sprague-Dawley rats for 5 days/week over a total for 9 weeks did not significantly affect sperm
count or viability, nor did it induce sperm head abnormalities (Lebowitz et al. 1983). Application of 4– 
400 mg DEET/kg/day for 60 days to 1 cm2 of skin on the necks of male Sprague-Dawley rats decreased
blood-testis barrier permeability (but not in a dose-related manner) to approximately 75% of the control
value (Abou-Donia et al. 2001).  In addition, treatment with DEET did not affect testes weight, nor did it
induce compound-related lesions in the testes. Application of up to 1,000 mg DEET/kg/day to the shaved
back of CD rats or micropigs 5 days/week for 13 weeks did not induced gross or microscopic alterations
in the reproductive organs, although details were not reported (EPA 1988, 1992a).  
The doses of 1,000 mg DEET/kg/day (the highest dose tested) in rats and pigs is listed as a NOAEL for
reproductive effects in Table 3-3.
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3.2.3.6  Developmental Effects 
Limited information is available regarding developmental effects in humans following dermal exposure to
DEET from two single cases and two cohort studies.  Schaefer and Peters (1992) reported the case of a 
34-year-old woman who had been working in Africa where she continuously applied a lotion containing
25% DEET in addition to taking prophylactic chloroquine against malaria.  Pregnancy was without
complications and she delivered a boy of normal weight at the estimated date of birth.  However, the boy
was born with antimongoloid slant of the palpebral fissures, hypertelorism, thin lips, poorly developed 
philtrum, and a broad nasal bridge.  During the first months of life, the boy developed statomotor
retardation, muscular hypotonia, central hearing loss, and strabismus.  Genetic testing did not show
inborn errors of metabolism and there was no family history of genetic disorders.  A possible role for
chloroquine was ruled out given the safety of its prophylactic use. A causal relationship with DEET was 
not established. Hall et al. (1975) described two cases of children born with cardiac anomalies leading to 
congestive heart failure and diagnosis of coarctation of the aorta.  The mothers, who were sisters, had 
used large amounts of insecticides (containing N-octyl bicycloheptene dicarboximide, piperonyl butoxide, 
allethrin, pyrethrins, and 2,2-dichlorovinyl dimethyl phosphate) and DEET in the insect repellent Off!® 
during a camping trip at about 8 weeks into their pregnancies. It is worth noting that the sisters were only
together during the camping trip, that defects in the aortic arch segment occur between gestational
weeks 6 and 10, and that there was a family history of heart problems on the father’s side of one of the
boys. In this study, the role of DEET, if any, cannot be determined.  Although Hall et al. (1975) indicated
that that multiple cases of familial coarctation are rare, others (e.g., Perera et al. 2014; Atalay and Kichilas
2011) have reported congenital aortic coarctation phenotypic malformations, and the latter reported
three such individuals in two generations of the same family.
McGready et al. (2001) studied the effects of application of 1.7 g DEET/day in the second and third
trimesters of 449 pregnant women as part of a double-blind trial of insect repellents in the prevention on 
malaria in Thailand. Controls consisted of 449 women who did not apply DEET.  Women were followed 
for the duration of their pregnancy. Newborns were assessed for head and arm circumference and length;
gestational age was assessed within 5 days of birth and neurological tests were conducted that assessed
tone, movement, behavior, and visual and auditory alertness.  Infants were followed up until 12 months of
age for growth and basic developmental milestones. DEET was not detected in 30 urine samples from
DEET-exposed women, but was detected in 4 of 50 samples of cord blood from women exposed to 
DEET.  The results of the analyses did not reveal significant differences in the outcomes measured
between offspring from exposed and non-exposed women. More recently, Barr et al. (2010) studied the
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association between exposure to various pesticides (DEET among them) in a cohort of 150 New Jersey
women and birth outcomes (birth weight, head circumference, abdominal circumference, and birth 
length).  Exposure was assessed by measuring pesticides in maternal serum prior to birth and in cord 
blood after delivery. DEET was one of the pesticides most frequently detected in maternal and cord
serum; the corresponding mean concentrations were 3.21 ng/g (range 1.82–18.84 ng/g) and 3.12 ng/ng
(range 2.06–13.07 ng/g).  The results of multivariable regression analyses carried out to minimize biases 
due to confounding factors ascertained that there was no significant association between DEET and the
birth outcomes measured. The investigators noted that since blood was collected at birth, the exposure
measured did not necessarily precede the birth outcomes measured.  Also, there was no documentation of
exposure by environmental measurements. Finally, many of the concentrations measured were near the 
limit of detection (LOD) of the analytical method.
No studies were located regarding developmental effects of DEET in animals following dermal exposure.
3.2.3.7  Cancer
Limited information exists regarding exposure to DEET and cancer in humans.  A case-control study of
testicular cancer and occupational exposures was conducted in Sweden (Hardell et al. 1998).  Exposure to 
multiple occupations and chemical agents was assessed by self-administered questionnaires. The final
analysis comprised 148 cases and 363 controls. The risk for testicular cancer among workers who used
insect repellents (most containing DEET) for <115 days was not elevated based on 15 cases (OR 1.2, 95%
CI 0.6–2.5).  The OR for those using repellents for >115 days, however, was 2.3 (95% CI 1.2–4.4), based 
on 24 cases. Little information was presented in this study regarding how potential confounders were
controlled; however, multivariate analysis found a significant interaction for those who were co-exposed 
to insect repellents and video display units (OR 2.5, CI 1.1–5.4). The investigators also noted that a 
previous study of this cohort had found an increased risk for testicular cancer associated with exposure to 
polyvinyl chloride (PVC) and that additives in PVC may also be used in the manufacture of insect
repellents. Finally, assessment of exposure by self-recollection is known to be unreliable.
Another case-control study involved 513 men with non-Hodgkin’s lymphoma (NHL) and 1,506 controls
(McDuffie et al. 2005).  The study found that simultaneous use of the pesticide mecoprop and DEET by
farmers who wore rubber gloves resulted in higher odds ratios for NHL (OR 3.86, 95% CI 1.57–9.49)
than farmers who either did not use DEET or did not use rubber gloves.  The results were explained by
DEET presumably increasing the permeability of the gloves to the phenoxyherbicide. Co-exposure to 
   
 











     
     
     
  
   
       
  
 
   
 
     
 
    
     
   
  
    
  
 
   
    
    
    
  
  
     
     
 




DEET and the herbicide dicamba also resulted in increased risk with rubber gloves (OR 2.04, CI 1.02– 
4.06) or without them (OR 1.84, CI 1.23–2.75).
Only one study was located regarding cancer in animals after dermal exposure to DEET.  In that study, 
0.02 mL of a 10, 50, or 100% solution of DEET (2, 10, or 20 mg DEET) was applied over 1 in2 of the
skin of Swiss mice (50/exposure group, 100 unexposed controls) 2 times/week for 140 weeks.  The
incidence of tumors on the application site or at any remote site compared to controls did not increase
(Stenback 1977).  Additionally, fewer DEET-exposed mice developed tumors (36–50 vs. 58% for
controls), and they had higher long-term survival rates (e.g., 12–26 vs. 6% for controls at 100 weeks).
Dosing New Zealand White rabbits (5/group) in the same manner for 90 weeks also yielded negative 
cancer results (Stenback 1977).  
3.3  GENOTOXICITY
No studies were located regarding genotoxic effects in humans exposed to DEET.
The only information regarding genotoxicity following in vivo exposure is that from a study in which
Sprague-Dawley rats were applied a single dermal dose of 400 mg DEET/kg in 70% ethanol and the urine
was collected and analyzed for the biomarker of DNA damage 8-hydroxy-2’-deoxyguanosine (Abu-Qare 
and Abou-Donia 2000).  The results showed a significant increase (p<0.05) in the levels of the biomarker
in urine over a 72-hour period after dosing.  Maximum excretion was reached 24 hours after dosing, after
which time excretion of 8-hydroxy-2’-deoxyguanosine leveled off. 
Few studies have examined the genotoxicity of DEET in in vitro assays.  Exposure of primary human 
nasal mucosal cells from the inferior and the middle turbinate to concentrations of DEET ranging from
0.5 to 1.0 mM (~0.1–0.2 µL/mL) for 60 minutes induced significant DNA damage, as quantified by the
comet assay (Tisch et al. 2002).  In another study with mammalian cells, DEET assayed to a cytotoxic 
level of ≥1.0 µL/mL for 18–20 hours did not induce unscheduled DNA synthesis in primary rat 
hepatocytes (EPA 1990c).  In yet another study in mammalian cells, incubation of Chinese hamster ovary
cells with up to 1.0 µL DEET/mL without activation (16 hours) or up to 0.5 µL DEET/mL with activation
(2 hours) did not induce chromosomal aberrations (EPA 1990c). Mutagenicity studies conducted in
prokaryotic organisms with or without metabolic activation yielded negative results (EPA 1990c; Zeiger
et al. 1992). The results of the in vitro genotoxicity studies with DEET are summarized in Table 3-4.
   
 

























    
 
  
     
     
 
    
  
 
   
  
 
   
 




Table 3-4.  Genotoxicity of DEET In Vitro
Results
With Without





Reverse mutation – – EPA 1990c
S. typhimurium TA98,
TA100, TA1535, TA1538
Reverse mutation – – Zeiger et al. 1992
Mammalian cells:
Cultured primary human 
nasal mucosal cells
DNA damage + No data Tisch et al.1992
CHO cells Chromosomal – – EPA 1990c
aberrations
Rat hepatocytes Unscheduled DNA
synthesis
No data – EPA 1990c
+ = positive results; – = negative results; DNA = deoxyribonucleic acid; CHO = Chinese hamster ovary
   
 








   
 
   
      
    
    
    
     




    
 
  
    




    
 
  
    
 
    
  
   
  
    
    
     




No data on the toxicokinetics of DEET in humans exposed via inhalation or oral routes were located in 
the literature reviewed. Similarly, there are no animal data on toxicokinetics of inhaled DEET.  Data on 
absorption of orally-administered DEET are limited to a single rat study (Schoenig et al. 1996) that 
showed rapid and nearly complete >90% absorption of DEET.  Dermal absorption of DEET has been 
extensively studied in humans, laboratory animals and in in vitro test systems.  The rate and extent of
dermal uptake are affected by species, sex, vehicle and/or formulation in which DEET is applied, dose, 
and evaporation rate; thus, estimates are highly variable.  Based on urinary excretion of radioactivity, the
available estimates of the extent of dermal 14C-DEET absorption in humans have ranged between 3.8 and
17% of the applied radioactivity (Blomquist and Thorsell 1977; Feldman and Maibach 1970; Selim et al. 
1995). 
No specific deposition site has been identified for DEET.  After oral or dermal exposure, DEET is widely
distributed.  It has been detected in the brain, liver, lung, spleen, kidney, fat, lacrimal glands, and nasal
mucosa of exposed animals.  The one study examining the potential for transplacental transfer of
14C-DEET in rabbits did not detect radioactivity in the fetuses at the end of 29 days of daily dermal
applications to the does.  After intravenous exposure of pregnant rabbits on 1 day, low levels of
radioactivity, however, were detected in the fetuses.  DEET did not bind to human serum albumin (HSA)
in in vitro tests, but did bind to bovine serum albumin (BSA).  
The primary metabolites of DEET in humans and laboratory mammals exposed via oral, dermal, or
intraperitoneal injection routes are m-(diethylaminocarbonyl) benzoic acid (DCBA) and 
m-(ethylaminocarbonyl) benzoic acid (EACB) (Sandstrom et al. 2005; Schoenig et al. 1996; Selim et al. 
1995; Taylor and Spooner 1990).  It should be noted that some older studies referred to DCBA as 
m-(diethylamino carbonyl)benzoic acid and used the acronym DACB.  Metabolism has not been 
examined in other species or after inhalation exposure.  In humans, DCBA was produced by ring methyl
oxidation via the intermediate N,N-diethyl-3-hydroxymethyl-benzamide (DHMB), primarily by
cytochrome (CYP) 1A2 and 2B6.  EACB resulted from N-dealkylation via the intermediate, N-ethyl-
m-toluamide (ET), by CYP2C19 and CYP3A4.  At low substrate concentrations, the ring methyl
oxidation pathway was expected to predominate due to higher substrate affinities of the relevant
cytochrome P-450 isozymes.  There was evidence that DEET induced CYP3A, thereby inducing its own 
metabolism (Abu-Qare and Abou-Donia 2001a; Usmani et al. 2002). Other metabolites identified in
human urine include N-ethyl-N-(1-hydroxyethyl)-3-methylbenzamide and 3-((carboxymethyl)
   
 











     
      
    
   
 
  
   
       
    
    
   
 
    
 
     
   
    
   
 
 
     
 
    
   
   
    
     





(hydroxymethyl)carbamoyl)benzoic acid (Wu et al. 1979), while m-(aminocarbonyl)benzoic acid (ACB)
and m-toluic acid were also identified in rat urine (Taylor and Spooner 1990).  
Available information from animal studies suggested that metabolism occurred rapidly and mainly in the
liver. Limited information suggested that there might be gender differences in the metabolism of DEET, 
such that males might metabolize DEET faster than females.  Females may produce more of the 
intermediate ET than DHMB at higher doses (Schoenig et al. 1996; Yeung and Taylor 1988).
DEET was rapidly cleared from the plasma after dermal exposure, with plasma elimination half-lives 
ranging from 2.5 to 9 hours in animals (Fediuk et al. 2011; Kasichayanula et al. 2007; Qiu et al. 1997a, 
1997b). The primary route of elimination after oral, dermal, or intravenous exposure was via urinary 
excretion of metabolites, although some unchanged DEET was excreted in the urine after a high-dose or
long-term exposures.  Biliary excretion of DEET or its metabolites was observed in animals.  It is not 
known whether this is a significant excretory pathway in humans.
3.4.1 Absorption 
The available literature did not include any studies of the absorption of DEET after inhalation exposure.
Data on absorption of orally-administered DEET are limited to two rat studies (Hoy et al. 2000a; 
Schoenig et al. 1996).  Schoenig et al. (1996) showed rapid and nearly complete absorption (>90%) in CD 
rats, while Hoy et al. (2000a) reported that oral administration of 200 mg DEET/kg to Sprague-Dawley
rats resulted in blood serum concentrations 30 minutes after administration that were approximately 3.5, 
8.5, and 13 ng/mL in males, pre-estrus females, and met-estrus females, respectively.  Dermal absorption
of DEET has been extensively studied in humans, laboratory animals, and in vitro test systems.  Estimates 
of the rate and extent of dermal uptake vary widely and these parameters may be affected by species 
(Moody and Nadeau 1993), sex (Snodgrass et al. 1982), vehicle and/or the formulation in which DEET is
applied (Fediuk et al. 2011; Iscan et al. 2006; Karr et al. 2012; Kasting et al. 2008; Qiu et al. 1997a, 
1997b), dose (Moody et al. 1995; Santhanam et al. 2005), and evaporation rate (Reifenrath et al. 1991;
Santhanam et al. 2005).  The sunscreen, oxybenzone, if applied after DEET application, has been shown 
to enhance the penetration of DEET across animal skin in vivo and in vitro (Chen et al. 2010; Gu et al. 
2005; Kasichayanula et al. 2007; Ross et al. 2004; Wang and Gu 2007) as has mechanical action
(Ambrose 1959).
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3.4.1.1  Inhalation Exposure 
No quantitative information on the absorption of DEET in humans or animals exposed via inhalation was
located.  Many exposures reported to poison control centers from 1993 to 1997, however, were identified 
as involving predominantly inhalation exposure and the adverse signs and symptoms exhibited by these
subjects suggest that absorption by this route may have occurred (Bell et al. 2002). Toxic effects seen in
rats and mice after acute inhalation exposure to high concentrations of DEET also provide indirect
evidence of absorption of DEET through the lungs (Ambrose 1959; Army 1979; Deb et al. 2010; EPA
1998c).
3.4.1.2  Oral Exposure
The many case reports of adverse health effects in humans following accidental or intentional ingestion of
insect repellents containing DEET mentioned in Section 3.2.2, Oral Exposure, provide evidence of
gastrointestinal absorption of this substance.
One study in CD rats examined absorption, distribution, metabolism, and elimination of radioactivity
after administration of ring-labeled 14C-DEET by gavage (Schoenig et al. 1996).  The time of peak
radioactivity in plasma was 30 minutes postdosing in males and 2 hours postdosing in females (Schoenig
et al. 1996), indicating rapid uptake.  Data from this study suggest that up to 91% of an oral dose of 100– 
500 mg DEET/kg was absorbed based on urinary recovery of radioactivity.
Hoy et al. (2000a) demonstrated oral absorption of DEET in Sprague-Dawley rats by measuring DEET in
blood serum 30 minutes after oral administration of 200 mg/kg via gavage.  The measured blood serum 
concentrations were approximately 3.5, 8.7, and 13 μg/mL in male, pre-estrus females, and met-estrus
female rats, respectively.
3.4.1.3  Dermal Exposure 
Small quantities of DEET are rapidly absorbed across human skin, based on appearance in the plasma.
Selim et al. (1995) evaluated the rate of absorption of DEET applied to the arms of volunteers.  14C-DEET
(~0.5 mg/cm2) was applied either neat or in a 15% solution in ethanol to 24 cm2 areas on the arms of six
male volunteers and left for 8 hours.  Doses of DEET in both applications were similar (~15 mg and 
37 μCi in the neat application and about 12 mg and 36 μCi in ethanol).  The peak radioactivity in plasma
occurred 6 hours after application of neat DEET and 4 hours after application of DEET in ethanol, 
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indicating that the ethanol solvent slightly enhanced absorption.  Smallwood et al. (1992) detected DEET
in serum (by high performance liquid chromatography [HPLC] analysis) within 1 hour after dermal
application of an insect repellent at estimated doses of 0.14–1.86 g.  The peak serum concentration 
typically occurred within 1–2 hours after application of the repellent (Smallwood et al. 1992).  The
authors estimated dermally applied doses ranging from 0.31 to 5.99 μg/cm2x103 and observed a
correlation (r=0.80, p=0.01) between applied dose (μg/cm2x103) and area under the serum concentration
vs. time curve (through the 6-hour measurement); in units of hour · μg/g). Feldman and Maibach (1970)
observed the maximum rate of absorption during the first 12 hours after administration of 4 μg DEET/cm2 
to the skin of volunteers, when the absorption rate was estimated as 0.773% per hour.
Estimates of the extent of DEET absorbed across the skin of humans have been made based on urinary
excretion of radioactivity; these estimates range between 3.8 to 17% of the applied radioactivity, a
primary factor for the difference may be the time that DEET was left on the skin.  Based on the 
cumulative amount of radioactivity excreted in urine collected during the 5 days after dosing in the human 
study by Selim et al. (1995), 5.6– 8.3% of the applied radioactivity was absorbed on average.  In two
experiments with the same female volunteer exposed for 8 hours to 0.12 mg/kg 14C-DEET via topical 
application, absorption was at least 3.8–5.5% of the applied radioactivity based on cumulative urinary 
excretion of radioactivity during the 48 hours following commencement of exposure (Blomquist and 
Thorsell 1977).  Feldman and Maibach (1970) reported total absorption of ~17% of a topically applied 
dose of 4 μg/cm2 (total area of 13 cm2) 14C-DEET (left untouched for 24 hours) to the forearm of
volunteers (ages and genders not reported); absorption was based on cumulative urinary excretion of
radioactivity over 5 days.
Dermal absorption of DEET in CD rats occurred rapidly, with peak blood levels occurring within 2– 
3 hours after the commencement of exposure.  A single dermal application of 100 mg/kg ring-labeled
14C-DEET (the vehicle was not reported) to the shaved backs (12.5 cm2) of fasted rats was studied.  
Radioactivity levels in blood peaked 2 hours after application in males (at 333 dpm/0.1 mL) and 3 hours
after application in females (255 dpm/0.1 mL), and persisted at a high level for the duration of the
exposure, indicating ongoing absorption from the application site (Schoenig et al. 1996).  The application 
site was covered with a glass rectangular enclosure to minimize evaporative losses.  In a study in which
evaporative losses were not prevented, a peak plasma concentration of 0.3 μg DEET/mL was reached 
90 minutes after the end of the 24-hour exposure (Fediuk et al. 2011).  Dermal absorption was rapid in
Beagle dogs; plasma concentrations of DEET in dogs exposed to two different formulations (a novel
formulation with 7.5% DEET and Off!: Skintastic II® containing 7.125% DEET) showed a similar time
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profile, with the peak concentrations of 154.3 and 196.5 ng/mL (for the two formulations) occurring at
1.25 hours postdosing (Qiu et al. 1997a, 1997b).  DEET was detected in plasma at 15 minutes
postexposure for both formulations, but the rate of absorption from the formulation with 7.5% DEET was
slower, based on the lower plasma concentration observed at that time (17.7 vs. 101 ng/mL) (Qiu et al. 
1997a).
The extent of DEET absorbed across the skin of rats has been reported to be as low as 15% and as high as 
78% due a variety of factors, including dose, vehicle and/or formulation in which DEET is applied, and 
evaporation rate.  Schoenig et al. (1996) measured radioactivity in urine collected for 7 days after a single 
dermal application of 100 mg/kg ring-labeled 14C-DEET (a vehicle was not reported) to the shaved backs 
(12.5 cm2) of fasted CD rats.  Based on the urinary radioactivity levels, approximately74–78% of the
applied dose was absorbed across rat skin (Schoenig et al. 1996). When male and female Wistar rats were 
treated topically with 50 mg/kg 14C-DEET on the shaved upper back (1.5–2 cm2 area), 52–54% of the
applied radioactivity was excreted in the urine within the first 48 hours, indicating dermal absorption of at
least 52% of the administered dose (Taylor and Spooner 1990).  Moody et al. (1995) estimated dermal
absorption of DEET by Sprague-Dawley rats to be 15.1, 26.8, and 20.3% of doses of 4.7, 6.7, and 
31.8 mg DEET/cm2 (respectively) in various formulations, based on urinary, fecal, and tissue recovery of
radioactivity, indicating a J-shaped dose-response.  
Available in vivo information on species differences in dermal uptake are limited but suggest that the
differences among laboratory animals may be small. When dermal absorption was estimated based on
cumulative urinary and fecal excretion of radioactivity over 7 days after a single dermal application of
4 μg 14C-DEET/cm2, estimates of 44, 33, 38, and 31% absorption were reported for male Sprague-Dawley
rats, female Sprague-Dawley rats, female New Zealand White rabbits, and male Beagle dogs, respectively
(Snodgrass et al. 1982).  While the species differences were small in this study, the data did suggest
gender differences, with male rats absorbing a greater percentage than females.
Fediuk et al. (2011) reported the relative bioavailability in rats of dermally-applied DEET in ethanol
(100 mg/kg) to Sprague-Dawley rats as 1.5% based on the ratio of the dermal and intravenous plasma
area under the curve values (24 hours after the end of exposure).  The study authors attributed the low
bioavailability in this study to the use of the ethanol vehicle which may have enhanced evaporation.
However, it should be noted that others have shown that 30–45% ethanolic solutions of DEET increased 
permeation of DEET into human’s skin in vitro compared to DEET alone or to 60–90% ethanolic
solutions (Stinecipher and Shah 1997).  These investigators suggested that at low ethanol concentrations,
   
 








   
     
 
 
    
     
   
     
   
  
   
   
    
  
     
   
     
      
      
 
   
     
   
     
   
    
      
 
 
   
   
     
   
DEET 88
3. HEALTH EFFECTS
extraction of skin lipids associated with alteration of polar pathways results in increased permeation of
DEET. However, higher concentrations of ethanol may extract lipids from the skin and alter the barrier
function and decrease uptake by the skin resulting in decreased permeation of DEET. 
In addition to evaporation, a variety of other factors can affect the dermal uptake of DEET. These factors 
are most notably the vehicle and/or formulation of the product containing DEET, but articles often 
provide little or no information regarding inert ingredients in the product being evaluated or any vehicle
that was used.  Qiu et al. (1997a, 1997b) evaluated the dermal bioavailability of two different DEET
formulations in Beagle dogs.  One was a novel formulation (7.5% DEET) and the second was Off!
Skintastic® containing 7.125% DEET.  Using the ratio of area under the plasma concentration-time curve 
to dose after dermal (15 mg/kg) and intravenous (2.5 mg/kg) exposures, the study authors estimated the
absolute dermal bioavailability of the two formulations to be 14% (Off! Skintastic®) and 18% (novel
formulation).  More recently, Brand et al. (2006) showed that administration of a single gavage dose of
≥4.3 g ethanol/kg to rats significantly increased skin absorption of DEET when a piece of the rat’s skin
was tested 2 hours later in an in vitro flow-through diffusion cell system. The ethanol-induced 
enhancement of DEET absorption was dose-related. A mechanism for these findings was not explored in 
the study. Their conclusion was that acute and chronic consumption of alcoholic beverages compromises 
the skin barrier and increases the dermal absorption of DEET; this enhancement remains for at least 24
hours after blood alcohol levels subside since ethanol clears from the skin more slowly than from blood.
The sunscreen, oxybenzone, has been demonstrated to enhance the dermal penetration of DEET in both 
in vivo (Kasichayanula et al. 2007; Wang and Gu 2007) and in vitro studies (Chen et al. 2010; Gu et al. 
2005; Ross et al. 2004).  Kasichayanula et al. (2007) evaluated the absorption of DEET across the shaved
skin of 3-week-old piglets.  The test materials were a commercial insect repellent containing 9% DEET
and a combined sunscreen/repellent that contained 9% DEET.  One gram of the product was applied to a
surface area of 150 cm2. Plasma samples were collected at regular intervals between 0 and 48 hours after
application for HPLC analysis. When the repellent was applied alone, the concentration of DEET in the
plasma peaked at ~28 μg/mL 2 hours after dosing, declined rapidly over the next 10 hours, and then 
declined very gradually for the subsequent 36 hours.  A similar profile was seen with the combination 
product.  The area under the curve of the plasma concentration:time plot was higher after application of
the combined repellent/sunscreen product (446.21 μg hour/mL) compared with repellent alone (286.59 μg
hour/mL), indicating enhanced absorption of DEET from the combination product. Wang and Gu (2007)
used the same experimental design as Gu et al. (2005) and had similar methodological issues.  For
example: (1) the human skin samples were prepared very aggressively with freezing, thawing, scraping,
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and cutting, but the integrity of the skin samples used for the experiments was only visual; a more
rigorous and standardized approach to evaluate the integrity of skin samples, such as 3H2O penetration 
(Santhanam et al. 2005), would have been more appropriate, and (2) it was stated that the amount of test 
sample in direct contact with the skin surface (0.64 cm2) in the diffusion cells was measured to be 0.1 g
(equivalent to approximately 100 µL/cell and 156,250 µg/cm2 skin); this appears to be an enormous dose
in comparison to human use of DEET and sunscreen products and to the in vitro study of Santhanam et al. 
(2005) in which Franz diffusion cells with DEET applied to human skin samples used doses of 5 µL/cell 
in most experiments and a maximum dose of 20 µL/cell.  
Moody and Nadeau (1993) compared the in vitro dermal permeability of 14C-DEET across skin samples 
from several animal species and humans.  Doses varied approximately 2-fold across the experiments from
12.5 to 44.7 μg/cm2; the skin thickness was the same (0.5±0.01 mm) for all samples except human
foreskin, which was 0.3 mm.  Table 3-5 shows the pharmacokinetic parameters calculated from the 
experiments.  The maximum rate of permeability was greatest across mouse skin (2.9 μg/cm2/hour) and 
lowest across guinea pig skin (0.4 μg/cm2/hour).  The maximum rate of permeability of DEET across
human skin in vitro was between 1 and 2 μg/cm2/hour (Moody and Nadeau 1993).
In vitro estimates of DEET skin permeability vary significantly depending on the vehicle in which it is
applied (Qiu et al. 1998; Moody et al. 1995; Stinecipher and Shah 1997).  Qiu et al. (1998) reported 10– 
23% reductions in the flux of DEET across the skin with the use of 20% (w/w) PEG 400, 1% (w/w)
Tween 80, or 75% (v/v) ethanol in Carbopol 940 NF and Pemulun TR-2 formulations when compared 
with a commercially-available preparation containing an equivalent concentration of DEET. In vitro
measurements of flux and permeability across human skin were higher for DEET in 30–45% ethanol
solutions compared with 75–90% ethanol solutions (Stinecipher and Shah 1997).  Similarly, in a study by
Iscan et al. (2006), in vitro skin permeation rates were shown to vary depending on the concentration of
ethanol; flux rates were 0.41, 0.14, and 0.09 mg/cm2-second at 45, 70, and 95% ethanol, respectively
(Iscan et al. 2006).
The percent of applied dose that is absorbed across human skin appears to depend on dose and integrity of
the skin samples.  Santhanam et al. (2005) evaluated in vitro permeability of DEET across human cadaver
skin at doses ranging from 0.02 to 11,000 μg/cm2. The percent penetration increased with dose up to 
680 μg/cm2 and then declined at higher doses.  Moody et al. (1995) observed lower absorption of
14C-DEET from higher doses of DEET.  Based on a methodology of recovery from receiver solution, skin 
extraction with methanol and skin digest, the authors estimated 48, 36, and 17% absorption across human 
   
 




















      
      
 
     
 
 
     
 
     
 







Table 3-5.  Species Differences in In Vitro Estimates of DEET Dermal Permeability 







receiver solution, skin 





Mouse (back) 33.3 36.2±27.5 39.0±29.0 2.9±1.81 1.4±0.45
Rat (back) 38.7 21.4±2.17 64.8±2.70 1.3±0.07 1.9±0.08
Guinea pig 12.5 10.9±1.40 38.4±4.46 0.4±0.14 1.3±0.20
(back)
Yorkshire pig 19.4 15.3±0.82 28.9±5.17 0.7±0.12 1.4±0.20
(back)
Human 44.7 27.7±4.24 28.1±4.28 2.0±0.58 0.6±0.28
(abdomen)
Human 27.9 13.1±9.58 13.8±9.59 0.98±0.91 1.6±1.73
(neonatal 
foreskin)
aTime to appearance in receiver fluid.
Source:  Moody and Nadeau (1993)
   
 









   
   
 
  








      
 
   




     
   
   
 
    
    
  
   




skin at applied doses of 16.7, 25.3, and 97.3 mg DEET/cm2, respectively, in three different commercial
preparations.  Similar experiments conducted with rat skin showed little or no difference in percent
absorption across a similar dose range and the same preparations (Moody et al. 1995).
A number of studies have examined alternative formulations of DEET intended to minimize skin
permeation and maximize the duration of insect repellent effectiveness by prolonging evaporation time.
Karr et al. (2012) showed that microencapsulation formulations resulted in lower penetration across split-
thickness human cadaver skin tested in Franz cells modified to allow controlled airflow trapping.  Kasting
et al. (2008) reported a similar observation; microencapsulation using walled polysaccharide
microcapsules diminished the dermal uptake of DEET by 25–35% (compared with an ethanol vehicle) in 
in vitro tests using human cadaver skin.  Similarly, Iscan et al. (2006) incorporated DEET into solid lipid 
particles as a colloidal solution and observed decreased permeation across human donor skin from plastic 
surgery patients when compared to free DEET in the same preparation. Wang et al. (2014) showed that
oil-in-water emulsions significantly lowered percutaneous permeation of DEET through isolated human 
skin compared to water-in-oil emulsions.  Experiments also showed that the addition of xanthan gum to 
the oil-in-water emulsion reduced the size of oil droplets containing DEET and increased penetration of
DEET through human skin.
Exposure to other compounds prior to dermal exposure to DEET may also alter skin permeability.  
Kaushik et al. (2010) observed that pretreatment of human skin in vitro with different compounds
(laurocapram, iminosulfuram, and others) could enhance or retard the rate of skin penetration depending
on the vehicle in which the pretreatment was applied.
Airflow across exposed skin affects dermal penetration of DEET by its effect on volatilization.
Santhanam et al. (2005) observed lower penetration across human skin tested in vitro under a fume hood 
with higher airflow compared with tests conducted on a laboratory workbench with lower airflow.  
Reifenrath et al. (1991) observed reduced (one-third as high) dermal penetration of 14C-DEET across 
excised pig skin in vitro when air flow was increased by 10-fold.  
   
 








    
 
      
    
  
 
   
 
  
    
  
 
       
     
    
 
    
       


















Limited data regarding distribution of DEET in humans indicate that DEET can distribute to cord blood 
following dermal exposure of pregnant women (Barr et al. 2010; McGready et al. 2001).  No data were
located regarding distribution following inhalation or oral exposure.  
Distribution data are available in animals exposed orally or dermally.  A single study of CD rats exposed
via gavage (Schoenig et al. 1996) indicated distribution to a number of organs (liver, lung, spleen, kidney, 
and fat) without identifying specific deposition sites for DEET.  Similar findings were reported after
dermal exposure to DEET in rats, rabbits, and dogs (Fediuk et al. 2010; Schoenig et al. 1996; Snodgrass
et al. 1982). An older study that used whole-body autoradiography to assess distribution after dermal
exposure to 14C-DEET reported high levels of radioactivity in the lacrimal glands and nasal mucosa of
albino mice (Blomquist and Thorsell 1977); these tissues were not assessed in other studies. When
pregnant New Zealand White rabbits were exposed topically to 14C-DEET (50, 100, or 500 mg/kg/day)
for 29 days, radioactivity was not detected in the fetuses at the end of treatment (Snodgrass et al. 1982).
After intravenous exposure, DEET undergoes extensive extravascular distribution; estimates of steady-
state volume of distribution in beagle dogs (Qiu et al. 1997b) and Sprague-Dawley rats (Fediuk et al.
2011) exceeded the total body water of these species. Some evidence for transplacental transfer of
intravenously-administered DEET was provided in studies of pregnant mice and rabbits exposed 
intravenously to 14C-DEET; radioactivity was detected at low levels in the fetuses of both species 
(Snodgrass et al. 1982; Blomquist et al. 1975).
DEET did not bind to plasma proteins in in vitro tests conducted with HSA; the fraction of unbound
DEET after a 60-minute incubation of DEET in saline with up to 10 μg/mL HSA was 95% (Abu-Qare 
and Abou-Donia 2002).  Kasting et al. (2008) measured the binding of DEET to BSA in saline using
equilibrium dialysis in side-by-side diffusion cells (one side containing BSA and one side saline only).  
Equilibrium was reached in 2–3 days, and the fraction unbound was calculated to be 0.189±0.008 
(Kasting et al. 2008).
3.4.2.1  Inhalation Exposure 
No information on the tissue distribution of DEET in humans or animals exposed via inhalation was 
located.
   
 








   
 
   
     
 
    
  





     
  
  
    
    
  
 
    
     
    
  
   
 




    
 
  
     




3.4.2.2  Oral Exposure
When CD rats were given single doses of 100 or 500 mg/kg ring-labeled 14C-DEET in corn oil via gavage
and sacrificed 7 days later for tissue analysis, total tissue residues of 14C activity ranged from 0.15 to
0.67% of administered radioactivity and the distribution of radioactivity showed highest concentrations in 
the liver, lung, spleen, kidney, and fat. The percent of administered radioactivity reaching systemic 
circulation and the tissues was much higher for animals administered 14C-DEET orally than for animals 
administered 14C-DEET dermally (Schoenig et al. 1996).
3.4.2.3  Dermal Exposure 
McGready et al. (2001) studied the distribution of 1.7 g DEET/day in the second and third trimesters of
449 pregnant women as part of a double-blind trial of insect repellents in the prevention of malaria in
Thailand.  DEET was not detected in 30 urine samples from DEET-exposed women, but was detected in 
4 of 50 samples of cord blood from women exposed to DEET.  Barr et al. (2010) assessed the distribution 
of DEET by measuring pesticides in maternal serum prior to birth and in cord blood after delivery.  DEET
was one of the pesticides most frequently detected in maternal and cord serum; the corresponding mean 
concentrations were 3.21 ng/g (range 1.82–18.84 ng/g) and 3.12 ng/ng (range 2.06–13.07 ng/g).
Schoenig et al. (1996) measured tissue concentrations of radioactivity in CD rats 7 days after a single 
dermal application of 100 mg/kg ring-labeled 14C- DEET.  Radioactivity levels were low (<0.4 ppm) in 
all tissues; apart from the carcass, the highest concentrations were in the liver (0.21 and 0.22 ppm in
males and females, respectively), kidneys (0.08 and 0.02 ppm in males and females, respectively), and 
blood (0.04 and 0.05 ppm in males and females, respectively).
Fediuk et al. (2010) detected DEET in the liver and brain of male and female Sprague-Dawley rats that
had received daily topical applications of 40 mg DEET/kg (2,500 μg/cm2 skin), either alone or in 
combination with the sunscreen, oxybenzone, for 30 days.  The median concentration in liver was
significantly higher when DEET was applied with oxybenzone (350.8 ng/g) than when applied alone
(95.9 ng/g).  In contrast, the concentrations in the brain (7.6–8.5 ng/g) were similar with both treatments
(Fediuk et al. 2010).  In a related study also conducted in rats, a single, 24-hour dermal exposure to 
100 mg DEET/kg yielded liver and kidney concentrations of 14.6 and 12.2 ng/g, respectively (Fediuk et 
al. 2011).  The study authors noted that the use of an ethanol vehicle for the latter study likely facilitated 
evaporation of DEET, decreasing the quantities that reached the liver and kidney.
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Snodgrass et al. (1982) measured the tissue distribution of 14C-DEET in small groups of Sprague-Dawley
rats (n=6/sex), New Zealand White rabbits (n=6 females), and Beagle dogs (n=3 males) 7 days after
dermal application of 4 μg/cm2, and observed the highest levels in the lung and spleen of dogs, lung of
rabbits, and liver and kidney of female rats. The levels, however, varied among individual animals;
radioactivity was not detected in these organs in some animals.  Using whole-body autoradiography, 
Blomquist and Thorsell (1977) measured the highest levels of radioactivity in the lacrimal gland, liver, 
kidney, and nasal mucosa of albino mice 2 hours after a topical application of 15 mg 14C-DEET/kg for
2 hours.  
Dermal application of 14C-DEET at doses of 50, 100, or 500 mg/kg/day to pregnant New Zealand White 
rabbits on GDs 1–29 did not result in detectable radioactivity in the fetuses at sacrifice at the end of
exposure (Snodgrass et al. 1982).
3.4.2.4  Other Routes of Exposure 
Intravenously administered DEET undergoes extensive extravascular distribution, as shown by the
volume of distribution in dogs and rats.  Qiu et al. (1997b) calculated a mean steady-state volume of 
distribution of 6.21 L/kg in Beagle dogs exposed to 2.5 or 6.0 mg DEET/kg via intravenous injection; this
volume is 10 times higher than the total body water of a lean dog (~0.6 L/kg; Davies and Morris 1993)
and demonstrates extravascular distribution.  Similarly, Fediuk et al. (2011) calculated a steady-state 
volume of distribution of 5.6 L/kg in Sprague-Dawley rats receiving intravenous injections of DEET
(2 mg/kg); this compares with a total body water of ~0.7 L/kg in rats (Davies and Morris 1993).
In albino mice exposed to 14C-DEET (0.05 µCi/g body weight) via intravenous injection and evaluated by
whole-body autoradiography, the highest concentrations of radioactivity were detected (in descending
order) in the lacrimal gland, liver, kidney, and nasal mucosa (Blomquist et al. 1975).  Radioactivity
persisted for 24 hours postdosing in the lacrimal gland, liver, nasal mucosa, urinary bladder, and intestinal
contents, but none was detected on the autoradiograms 3 days later (four days post-dosing).  When male 
albino mice were fasted for 18–24 hours prior to treatment, lower concentrations of radioactivity were
detected in the liver and kidney compared with levels in mice allowed to feed prior to exposure
(Blomquist et al. 1975). 
A similar pattern of radioactivity was seen in a pregnant albino mouse examined 20 minutes after
injection of DEET; the concentration of radioactivity in the fetus was low.  The highest concentrations in
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the fetus were in the kidney, urinary bladder, gastric mucosa, lens, and liver. Very little radioactivity was 
detected in the fetus 4 hours after exposure of the pregnant dam (Blomquist et al. 1975).  Snodgrass et al. 
(1982) observed low levels of radioactivity (about one-sixth of the corresponding maternal blood levels)
in the fetuses of New Zealand White rabbits treated with a single intravenous injection of 140.6 μg
14C-DEET on GD 15.
3.4.3 Metabolism
The major metabolic pathways for DEET are shown in Figure 3-3.  The primary metabolites of DEET in 
humans exposed dermally (Selim et al. 1995) and in rats exposed via oral, dermal, or intraperitoneal
injection routes (Schoenig et al. 1996; Taylor and Spooner 1990) are DCBA and EACB; metabolism has 
not been examined after inhalation exposure.  ET occurs in urine as the glucuronide conjugate and has
been identified in acid-hydrolyzed human (Tian and Yiin 2014; Wu et al. 1979) and rat (Taylor and
Spooner 1990) urine.  Other metabolites identified in human urine include N-ethyl-N-(1-hydroxyethyl)-
3-methylbenzamide and 3-((carboxymethyl)(hydroxymethyl)carbamoyl)benzoic acid (Wu et al. 1979), 
while ACB and m-toluic acid have also been identified in rat urine (Taylor and Spooner 1990).
DHMB is produced by oxidation of the methyl group on the benzene ring to carboxylic acid, a reaction
mediated primarily by CYPs 1A2 and 2B6 in humans (Usmani et al. 2002).  ET results from dealkylation 
of the amide group; the primary cytochrome P-450 isozymes that catalyze this reaction are CYP2C19 and 
CYP3A4 (with small contributions from CYPs 2A6 and 3A5) in humans (Usmani et al. 2002).  Other
minor metabolites have been observed after incubation of DEET with liver microsomes, including
N,N-diethyl-m-formylbenzamide and N-ethyl-m-hydroxymethylbenzamide (EHMB) (Taylor et al. 1986).
Metabolism via one or the other of these pathways will be favored in humans with higher levels of the
corresponding CYPs (Usmani et al. 2002).  At low substrate concentrations, the ring methyl oxidation 
pathway is expected to predominate due to higher substrate affinities of the relevant cytochrome P-450 
isozymes (Usmani et al. 2002).  There is evidence that DEET can induce CYPs 3A4, 2B6, 2A6, 1A1, and 
1A2 translation and transcription, thereby inducing its own metabolism (Abu-Qare and Abou-Donia
2001a; Usmani et al. 2002).
Available information suggests that metabolism occurs rapidly; metabolites were detected in the plasma 
of rats as soon as 30 minutes after a 24-hour dermal exposure (Fediuk et al. 2012).  The liver is the
primary site of metabolism (Abu-Qare and Abou-Donia 2008).  Limited in vivo and in vitro data suggest
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(DCBA) (EACB) (ACB) 
*Detected in human urine as free or conjugated metabolite 
Sources:  Constantino and Iley 1999; Schoenig et al. 1996; Selim et al. 1995; Taylor 1986; Taylor and Spooner 1990;
Usmani et al. 2002; Wu et al. 1979
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Figure 3-3.  Primary Metabolic Pathways of DEET in Rodents and Humans
   
 








   





   
 
   
 













     
    
   
  
 
    






the possibility of gender differences in metabolism of DEET (Schoenig et al. 1996; Yeung and Taylor
1988); males may metabolize DEET faster than females, and females may produce more EACB than
DCBA at higher doses.
3.4.3.1  Inhalation Exposure 
No information on the metabolism of DEET in humans or animals exposed via inhalation was located.
3.4.3.2  Oral Exposure
A single rat study provides information on metabolism of DEET after oral exposure.  Schoenig et al. 
(1996) administered 14C-DEET in corn oil via gavage to male and female CD rats and collected urine 
samples over the next 36–72 hours.  Analysis of urine samples by HPLC showed complete metabolism of
DEET at both low (100 mg/kg) and high (500 mg/kg) doses (no DEET was detected in urine).  The
majority of the excreted radioactivity (~50–60% of administered radioactivity depending on dose and 
regimen) was associated with the metabolite DCBA, which resulted from oxidation of the methyl group 
to carboxylic acid.  A second metabolite, EACB, resulting from dealkylation of the amide group, 
accounted for between 3 and 17% of the administered radioactivity (Schoenig et al. 1996).  No effort was
made to identify the minor metabolites.
3.4.3.3  Dermal Exposure 
Selim et al. (1995) analyzed the urine of human volunteers exposed to undiluted DEET or 15% DEET in
ethanol via dermal application (~0.5 mg/cm2).  Unchanged DEET was not detected in the urine.  Six
peaks were separated by HPLC; these six accounted for the majority (>60%) of urinary radioactivity after
either form of DEET was applied.  By comparing the HPLC profile from human urine with the profile
from the urine of rats treated with DEET, the authors identified two of the metabolites; 24–42% of the
urinary radioactivity consisted of DCBA, while between 7.6 and 26% consisted of EACB (a coeluting
peak prevented more precise quantification of this metabolite). 
Wu et al. (1979) identified (but did not quantify) DEET metabolites in the urine of a 30-year old, 78 kg 
male subject who applied 10.4 g of DEET in a repellent to ~75% of his body; the duration of treatment
was not specified.  Four possible metabolic pathways were identified, and five metabolites resulting from
three of the pathways were identified by electron impact ionization and chemical ionization mass
spectrometry. The metabolites were identified as: DCBA; the glucuronide conjugate of ET; N-ethyl-
   
 









    
 
    
     
   
     
    
   
    
 
 
    
    
 
    
     
   
   
     
   




    
  
   
    
   
   





acid and a small amount of DHMB was tentatively identified.
Tian and Yiin (2014) reported that application of 10 mL of a repellent containing 12% DEET to the arms
or legs of children (5–7 years old) and adults (23–25 years old) resulted in urinary excretion mainly of
DCBA and ET and a small amount of unchanged DEET over an 8-hour period after the application.  
DCBA constituted 78.2% of the total metabolites in children and 46.1% in adults.  No significant
differences regarding metabolic profile were observed between male and female subjects. Expressed as 
DEET equivalents, a greater amount of metabolites were recovered from children (1,116 µg) than from
adults (446 µg). The reason for this difference was not totally clear, but no details were provided 
regarding the exposure conditions.
The urinary metabolite profile observed in Wistar rats exposed to 100 mg DEET/kg via dermal
application was similar to that seen after oral exposure (Schoenig et al. 1996).  The major urinary
metabolites were DCBA, which represented 47–48% of the administered radioactivity, and EACB, which 
represented 3–13% of administered radioactivity.  Female rats excreted higher amounts of EACB (13%)
than males (3%).  Taylor and Spooner (1990) administered 50 mg 14C-DEET/kg by topical application to 
the backs of male and female Wistar rats.  DCBA and EACB were the primary urinary metabolites,
accounting for ~36–37% and ~11–12% of the administered radioactivity, respectively, in the first
48 hours (metabolites were quantified in two 24-hour urine samples).  Minor metabolites identified in the
rat urine were ACB and m-toluic acid; these were not quantified.  Analysis of acid-hydrolyzed urine
revealed the presence of ET; the authors suggested that it was conjugated with glucuronide in urine.  In
contrast to the results reported by Schoenig et al. (1996), Taylor and Spooner (1990) detected unchanged 
DEET in the urine, accounting for 4.7–5.5% of the applied dose in the first 48 hours after dosing.
Fediuk et al. (2012) measured the levels of DHMB and ET in the plasma of Sprague-Dawley rats as soon
as 30 minutes after the end of a 24-hour dermal treatment with 100 mg/kg (4 mg/cm2) DEET.  Plasma
was not analyzed for any other metabolites or for DEET.  The plasma concentrations of both DHMB and 
ET continued to increase for 24 hours postexposure.  At the end of the 24-hour observation period, 
concentrations of DHMB and ET were ~140 and 120 ng/mL, respectively.  In a repeated exposure
experiment conducted by the same authors, the concentrations of DHMB and ET were ~150 and 
350 ng/mL, respectively, after a 30-day repeated application of 40 mg/kg (10 mg/cm2) DEET.
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In liver samples taken at sacrifice at the end of the 24-hour exposure to 100 mg DEET/kg, the
concentrations of DHMB and ET were similar at 29±2.9 and 36±4.2 ng/g, respectively (Fediuk et al.
2012).  In contrast, after 30 days of repeated dermal dosing with 40 mg DEET/kg, the concentration of
DHMB in the liver was ~3 times higher (384.3±87.3 ng/g) than that of ET (139.6±57.1 ng/g). 
DHMB and ET were measured in urine samples taken from piglets 48 hours after dermal application of a
repellent lotion containing 9% DEET (1 g quantity) to a shaved area of 150 cm2 (Kasichayanula et al.
2005).  Urine was not analyzed for other metabolites.  The concentration of DHMB in urine was about
twice that of ET (0.99 vs. 0.55 μg/mL, respectively); no parent compound was detected.  
3.4.3.4  Other Routes of Exposure
After intraperitoneal administration of 50 mg 14C-DEET/kg, male Wistar rats excreted 55–66% of the
administered dose as DCBA in the first 24 hours after dosing; an additional 16–22% was excreted as 
EACB in the same time period (Taylor and Spooner 1990).  As with dermal exposure, two additional
urinary metabolites were identified (m-aminocarbonyl) benzoic acid and m-toluic acid; these metabolites 
were not quantified (Taylor and Spooner 1990).  Acid hydrolysis of the urine revealed ET, which was
likely present in urine as the glucuronide conjugate (Taylor and Spooner 1990).
In vitro experiments with liver microsomes show metabolism of DEET to DHMB and ET.  Based on 
studies in DEET-exposed humans and rats (Schoenig et al. 1996; Selim et al. 1995; Taylor and Spooner
1990), these compounds appear to be intermediates and/or minor in vivo metabolites of DEET.
Incubation of 1,000 nmol DEET with phenobarbital-induced male rat liver microsomes for 45 minutes
resulted in metabolism of at least 65% of the DEET (of the total 71% recovered; Taylor 1986).  The major
metabolite was DHMB (422.2 nmol), followed by ET (222.5 nmol); only 62.8 nmol of DEET was
recovered at the end of the experiments (Taylor 1986). Metabolism varied with pH.  At pH 8.6, two
minor metabolites, N,N-diethyl-m-formylbenzamide and EHMB were detected at low levels.  At pH (7.4),
metabolism of DEET was virtually abolished (<7% was metabolized).
Using baculovirus-infected insect cells expressing specific human cytochrome P-450 isozymes, Usmani et
al. (2002) demonstrated that the two primary metabolites of DEET are each produced by specific 
isozymes, with no cross-reactivity. Specifically, DHMB is formed by CYPs 1A2, 2B6, 2D6*1, and 2E1, 
while ET is formed by CYPs 2A6, 2C19, 3A4, and 3A5.  Table 3-6 shows the activity of each isozyme on 
the DEET substrate; as the table shows, CYP2E1 has relatively low activity compared with the other
   
 

















   
  
 
     
     
     
     
     
    
     
     
     











Activity at 1,000 or 3,000 μM DEET Vmax (nmol/mg CLint (10-6/nmol
CYP isoform (nmol/nmol isoform/minute) protein/minute) Km (μM) isoform/minute)
DHMB formation (ring methyl oxidation)
CYP1A2 68.94±2.64 24.5±1.2 41.0±2.0 598.7±39.6








Source: Usmani et al. (2002)
   
 













    
    
  
 




    
   
 
    
      
    
   
    
 
    
 
        
   
 
   
    
     
    




DHMB-forming isozymes.  Usmani et al. (2002) also evaluated species differences in metabolism of
DEET by human, Long-Evans rat, and CD-1 mouse microsomes in vitro; the calculated intrinsic
clearances of human and mouse microsomes were similar, while much higher clearance (>2-fold) was
calculated from data in rat microsomes (Table 3-7). 
Abu-Qare and Abou-Donia (2008) showed that DEET is primarily metabolized in the liver rather than in
plasma.  The authors incubated human plasma with DEET for 60 minutes and measured the
disappearance of DEET over time; the half-life for DEET in plasma was calculated to be 665 minutes.  In 
contrast, when DEET was incubated with human liver microsomes, the disappearance half-life was 
60 minutes. When the experiments were conducted in the presence of pyridostigmine bromide and/or
permethrin, the plasma disappearance half-life decreased by more than half (indicating accelerated
metabolism), while the liver microsome half-life increased by 2.6–5.3-fold (indicating slowed 
metabolism) (Abu-Qare and Abou-Donia 2008).  The study authors identified m-toluamide as a 
metabolite of DEET in the human liver microsomes, and reported Km and Vmax values of 62 μM and 
112 pmol/minute/mg protein, respectively, for the formation of this metabolite.  
Gender differences in the rate of DEET metabolism were demonstrated in a study by Yeung and Taylor
(1988).  When liver microsomes from male and female Wistar rats were incubated with DEET for
2 hours, microsomes from male rats metabolized DEET much faster than those from female rats, as 
measured by the disappearance of DEET from incubation solution and appearance of DHMB and ET
metabolites.  Table 3-8 compares the microsomal metabolism data for males and females.
3.4.4 Elimination and Excretion 
There are no studies of the excretion of DEET in humans or animals exposed via inhalation in the
available scientific literature.
DEET is rapidly cleared from the plasma after dermal or intravenous exposure.  Wu et al. (1979)
evaluated the metabolism of DEET in a 30-year-old, 78-kg subject who applied 10.4 g of DEET in a
repellent to ~75% of his body.  Urine was collected for 36 hours, and the rate of excretion of unchanged 
DEET via urine was estimated as 10–14% in the first hour and was reduced to 2% by the fourth hour.  
After dermal exposure, the plasma elimination half-life has been reported to be ~6–9 hours in rats (Fediuk
et al. 2011), 2.5–2.7 hours in Beagle dogs (Qiu et al. 1997a, 1997b), and 7.3 hours in piglets
   
 













   
  
 
    
    
    
    
      
   
    
    
    






Table 3-7. In vitro Liver Microsomal Metabolism Parameters of DEET
Vmax (nmol/mg CLint (10-6/mg
Species protein/minute) Km (μM) protein/minute)
DHMB formation (ring methyl oxidation)
Human 12.9±1.6 67.6±4.2 191.5±15.4
Rat 17.6±1.2 38.3±0.2 461.3±23.5
Mouse 6.8±1.4 43.4± 0.6 156.8±23.8
Mouse treated in vivo (200 mg/kg/day) 16.4±3.4 42.6±13.6 385.1±52.6
ET formation (N-deethylation)
Human 20.5±3.4 842.5±49.9 24.4±5.1
Rat 19.2±2.8 214.3±26.1 89.5±10.9
Mouse 14.5±2.9 660.6±59.5 21.7±3.9
Mouse treated in vivo (200 mg/kg/day) 22.9±2.9 630.9±128.0 38.3±5.1
Source:  Usmani et al. (2002)
   
 








    
 
 
   
   
   
   
     
















Percent metabolized at 2 hours 58±4.8a 17±1.6
Rate of DEET disappearance (minute-1) 0.0667±0.007b 0.0467±0.002
Half-life for DEET disappearance (minutes) 10±1.5b 15±1.1
Rate of DHMB appearance (minute-1) 0.0777±0.009a 0.0273±0.001
Rate of ET appearance (minute-1) 0.970±0.011a 0.346±0.002




DHMB = N,N-diethyl-m-hydroxymethylbenzamide; ET = N-ethyl-m-toluamide
 
Source:  Yeung and Taylor (1988)
 
   
 








   











   
 
   
 
    
   
   
     
    
    
 
   
 
  
    
    
    
  
   
  





(Kasichayanula et al. 2007).  After intravenous exposure, plasma elimination half-lives of 1.7 hours in 
rats (Fediuk et al. 2011) and 2.56 hours in Beagle dogs (Qiu et al. 1997a, 1997b) have been reported.
After oral, dermal, or intravenous exposure, the primary route of elimination is via urinary excretion of
metabolites (Blomquist and Thorsell 1977; Schoenig et al. 1996; Selim et al. 1995; Snodgrass et al. 
1982).  At high dermal doses and/or after long-term repeated dermal exposure, some unchanged DEET is
excreted in the urine (Smallwood et al. 1992; Taylor and Spooner 1990).  A small amount of DEET is
eliminated via the bile (Blomquist and Thorsell 1977; Moody et al. 1995; Qiu et al. 1997b; Schoenig et al. 
1996; Selim et al. 1995; Snodgrass et al. 1982). 
3.4.4.1  Inhalation Exposure 
No information on the elimination of DEET in humans or animals exposed via inhalation was located.
3.4.4.2  Oral Exposure
Available data on elimination of DEET after oral exposure is limited to a single study using gavage
administration in CD rats (Schoenig et al. 1996).  In this study, up to 91% of an administered dose of
100–500 mg DEET/kg was recovered in the urine, with 3–6% recovered in feces, within 7 days of
exposure (Schoenig et al. 1996).  The rate of urinary excretion was high in the first 12 hours, during
which ~75% of the low dose (100 mg/kg) and ~35–50% of the high dose (500 mg/kg) was excreted.  
Urinary excretion was minimal after 24 hours at both doses (Schoenig et al. 1996).
3.4.4.3  Dermal Exposure 
Urinary excretion was the primary route of elimination in volunteers exposed to 14C-DEET via dermal
application (Selim et al. 1995).  After application of ~0.5 mg DEET/cm2 (neat or as a 15% solution in
ethanol) to the arms of male volunteers, 5.6–8.3% of the administered radioactivity was excreted in the
urine, and 0.02–0.08% was excreted in feces over the first 5 days post-application.  The highest rates of
urinary excretion occurred during the first 12 hours, and cumulative excretion increased very little after
24 hours (Selim et al. 1995).  When a female volunteer was exposed for 8 hours to 0.12 mg14C-DEET/kg 
via topical application, 3.8–5.5% of the applied radioactivity was excreted via the urine during the
48 hours following commencement of exposure (Blomquist and Thorsell 1977).  The maximum rate of
excretion (~0.23% per hour) occurred ~4–6 hours after the end of exposure.  
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Smallwood et al. (1992) developed a technique to analyze DEET in urine and tested the method on eight
National Park employees who regularly used a DEET-containing insect repellent and on nine naïve 
volunteers exposed in a laboratory. The National Park employees were observed to apply sufficient
quantities of the repellent, which contained 71% DEET, to yield a daily application of approximately 1 g
of DEET. Concentrations of DEET in 24-hour urine samples collected from eight employees after the 
third day of the work week ranged from below the quantification limit of 0.18 μg/mL up to 5.69 μg/mL.  
Urinary concentrations were positively correlated (p<0.05) with estimated exposure (details not provided)
among the eight employees.  When nine volunteers without prior exposure were exposed in a laboratory
to a DEET-containing repellent at doses between 0.14 and 1.86 g DEET, however, only two of the nine
24-hour urine samples showed DEET concentrations above the quantification limit; concentrations
reported for these two volunteers ranged between 0.31 and 2.02 μg/mL; in the remaining seven
volunteers, the concentrations of DEET in urine were <0.09 μg/mL, the LOD.  
Wu et al. (1979) measured DEET in the urine of a 30-year-old, 78-kg male subject who applied 10.4 g of
DEET in a repellent to ~75% of his body.  The duration of treatment was not specified.  The rate of
excretion of unchanged DEET via urine was reported to be 10–14%/hour in the first hour and 2%/hour in 
the fourth hour.  Unchanged DEET was detected in the urine up to 18 hours after application. Because 
10.4 g is a very high dose, this may have caused saturation of metabolism pathways, which may have
contributed to the detection of unchanged DEET in the urine.  
Fediuk et al. (2011) calculated a plasma elimination half-life of ~6 hours in Sprague-Dawley rats exposed
for 24 hours to 100 mg DEET/kg in ethanol via topical treatment.  Co-treatment with oxybenzone yielded 
a 44% decrease in plasma elimination half-life (Fediuk et al. 2011).  After 30 days of topical exposure
(40 mg DEET/kg/day or 2,500 μg/cm2/day), the plasma concentration of DEET declined with an apparent
elimination half-life of 9.1 hours (Fediuk et al. 2010). DEET was still detected in the plasma 24 hours
after the last treatment.  Qiu et al. (1997a, 1997b) reported a plasma elimination half-life of 2.5–2.7 hours
in Beagle dogs exposed to two different formulations of DEET via dermal application; these values were 
similar to the plasma elimination half-life after intravenous exposure (2.56 hours).  Kasichayanula et al. 
(2007) reported a plasma elimination half-life of 7.3 hours for DEET in piglets exposed via the skin to 
either a commercial insect repellent containing 9% DEET or a sunscreen/repellent that also contained 9%
DEET (for each product, 1 g was applied to 150 cm2).  
When CD rats received a 100 mg/kg dermal application of 14C- DEET under occlusion, 74–78% of the
administered radioactivity was recovered in the urine and 4–7% was recovered in the feces (Schoenig et
   
 












     




      
   
 
 
   
  
   
    
   




    
   
    
 
    




   




al. 1996).  The rate of urinary elimination was slower than after oral exposure; only ~22–28% of the
administered radioactivity was recovered in urine samples over the first 24 hours after dermal application,
compared with up to 75% after oral dosing (Schoenig et al. 1996).  Snodgrass et al. (1982) compared the
7-day excretion profiles of male and female Sprague-Dawley rats, female New Zealand rabbits, and male 
Beagle dogs following topical application of 14C-DEET. The cumulative excretion was essentially
complete in all species by 3–4 days postdosing.  Species differences in cumulative excretion were not
apparent.
Although the group sizes were small in this study (three animals each), the excretion profiles suggested a 
sex difference in excretion by rats; males exhibited a higher percent total excretion (~44% including
urinary and fecal excretion) compared with females (~33% including urinary and fecal excretion;
Snodgrass et al. 1982).
The detection of radioactivity in feces after dermal exposure suggests that rats, rabbits, and dogs eliminate 
a small amount of DEET via enterohepatic circulation (Moody et al. 1995; Schoenig et al. 1996;
Snodgrass et al. 1982).  An older study in albino mice provided direct evidence for biliary excretion of
DEET.  Blomquist and Thorsell (1977) reported high levels of radioactivity in the bile and intestinal tract
(as well as the urine) when whole-body autoradiography of mice was performed after 2-hour dermal
exposure to 15 mg 14C-DEET/g.
3.4.4.4  Other Routes of Exposure 
Clearance of DEET from plasma is rapid after intravenous administration.  Fediuk et al. (2011) reported a
clearance rate of 67 L/hour/kg and elimination half-life of 103 minutes in Sprague-Dawley rats after
intravenous injection of 2.5 mg DEET/kg.  Qiu et al. (1997a, 1997b) reported a plasma elimination half-
life of 2.56 hours in Beagle dogs exposed intravenously to 2.5 mg DEET/kg.  Qiu et al. (1997b)
calculated the clearance of DEET in this study to be 2.66 L/hour/kg, and noted that this value exceeded
the renal blood flow rate (1.38 L/hour/kg) and thus provided evidence for intrahepatic clearance of DEET
in beagle dogs.
Snodgrass et al. (1982) observed species differences in excretion of intravenously-administered DEET,
with lower cumulative excretion (about half as much, based on visual inspection of data shown 
graphically) in male beagle dogs than male or female rats or female rabbits.
   
 












    
   
   
 
  
     
 
  
    
   
    
     
   
   
   
 
       
  
   
  
  
   
  








3.4.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models 
Physiologically based pharmacokinetic (PBPK) models use mathematical descriptions of the uptake and
disposition of chemical substances to quantitatively describe the relationships among critical biological
processes (Krishnan et al. 1994).  PBPK models are also called biologically based tissue dosimetry
models.  PBPK models are increasingly used in risk assessments, primarily to predict the concentration of
potentially toxic moieties of a chemical that will be delivered to any given target tissue following various 
combinations of route, dose level, and test species (Clewell and Andersen 1985).  Physiologically based 
pharmacodynamic (PBPD) models use mathematical descriptions of the dose-response function to 
quantitatively describe the relationship between target tissue dose and toxic end points.
PBPK/PD models refine our understanding of complex quantitative dose behaviors by helping to 
delineate and characterize the relationships between: (1) the external/exposure concentration and target
tissue dose of the toxic moiety, and (2) the target tissue dose and observed responses (Andersen and
Krishnan 1994; Andersen et al. 1987). These models are biologically and mechanistically based and can
be used to extrapolate the pharmacokinetic behavior of chemical substances from high to low dose, from
route to route, between species, and between subpopulations within a species.  The biological basis of
PBPK models results in more meaningful extrapolations than those generated with the more conventional
use of uncertainty factors.
The PBPK model for a chemical substance is developed in four interconnected steps: (1) model
representation, (2) model parameterization, (3) model simulation, and (4) model validation (Krishnan and
Andersen 1994).  In the early 1990s, validated PBPK models were developed for a number of
toxicologically important chemical substances, both volatile and nonvolatile (Krishnan and Andersen 
1994; Leung 1993).  PBPK models for a particular substance require estimates of the chemical substance-
specific physicochemical parameters, and species-specific physiological and biological parameters. The 
numerical estimates of these model parameters are incorporated within a set of differential and algebraic 
equations that describe the pharmacokinetic processes.  Solving these differential and algebraic equations 
provides the predictions of tissue dose.  Computers then provide process simulations based on these 
solutions.  
The structure and mathematical expressions used in PBPK models significantly simplify the true 
complexities of biological systems.  However, if the uptake and disposition of the chemical substance(s)
are adequately described, this simplification is desirable because data are often unavailable for many
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biological processes.  A simplified scheme reduces the magnitude of cumulative uncertainty. The 
adequacy of the model is, therefore, of great importance, and model validation is essential to the use of
PBPK models in risk assessment.
PBPK models improve the pharmacokinetic extrapolations used in risk assessments that identify the
maximal (i.e., the safe) levels for human exposure to chemical substances (Andersen and Krishnan 1994).  
PBPK models provide a scientifically sound means to predict the target tissue dose of chemicals in
humans who are exposed to environmental levels (for example, levels that might occur at hazardous waste 
sites) based on the results of studies where doses were higher or were administered in different species.
Figure 3-4 shows a conceptualized representation of a PBPK model.
If PBPK models for DEET exist, the overall results and individual models are discussed in this section in 
terms of their use in risk assessment, tissue dosimetry, and dose, route, and species extrapolations.
No PBPK modeling studies were located for DEET.
3.5  MECHANISMS OF ACTION 
3.5.1 Pharmacokinetic Mechanisms
As discussed in detail in Section 3.4 (Toxicokinetics), DEET is absorbed following oral or dermal
exposure.  No studies examining the mechanisms of DEET absorption were located in the available 
literature. The dermal absorption of DEET may be affected by species (Moody and Nadeau 1993), sex
(Snodgrass et al. 1982), vehicle and/or formulation in which DEET is applied (Fediuk et al. 2011; Iscan et
al. 2006; Karr et al. 2012; Kasting et al. 2008; Qiu et al. 1997a, 1997b), dose (Moody et al. 1995;
Santhanam et al. 2005), evaporation rate (Reifenrath et al. 1991; Santhanam et al. 2005), and coexposure
to other compounds.  In particular, the sunscreen, oxybenzone, has been shown to increase the dermal
absorption of DEET (Chen et al. 2010; Gu et al. 2005; Kasichayanula et al. 2007; Ross et al. 2004; Wang
and Gu 2007).
Available studies provide somewhat disparate findings on the plasma protein binding of DEET; Abu-Qare 
and Abou-Donia (2002) observed little or no binding to HSA, but the incubation time was short
(60 minutes).  In contrast, Kasting et al. (2008) used an equilibrium dialysis method to estimate that ~81%
of DEET is bound to BSA; equilibrium was reached at about 2–3 days of incubation, suggesting that the




















3.  HEALTH EFFECTS 
Figure 3-4. Conceptual Representation of a Physiologically Based 
Pharmacokinetic (PBPK) Model for a  
Hypothetical Chemical Substance 
Note: This is a conceptual representation of a physiologically based pharmacokinetic (PBPK) model for a 
hypothetical chemical substance.  The chemical substance is shown to be absorbed via the skin, by inhalation, or by
ingestion, metabolized in the liver, and excreted in the urine or by exhalation. 
Source: Krishnan and Andersen 1994
   
 








     
 
 
    
 
  
   
    
    
    
    
  





     
 
      
 
  
      
     
   
   
  
    
    
      
     
       




reached in days is unclear since dermally applied DEET in humans is eliminated within hours (Selim et
al. 1995). 
The role of metabolism on the toxicity of DEET is not known.  The two major pathways of DEET
metabolism (ring methyl oxidation and N-deethylation) depend on specific CYP isozymes (oxidation via
CYPs 1A2, 2B6, 2D6*1, and 2E1 and N-deethylation via CYPs 2A6, 2C19, 3A4, and 3A5); thus, the rate
of metabolism and the nature of the metabolites produced may vary among individuals due to variations
in these isozymes and their activities.  Specifically, metabolism via one or the other of these pathways 
will be favored in humans with higher levels of the corresponding CYPs (Usmani et al. 2002).  At low
substrate concentrations, the ring methyl oxidation pathway is expected to predominate due to higher
substrate affinities of the relevant cytochrome P-450 isozymes (Usmani et al. 2002).  There is evidence
that DEET can induce CYPs 3A4, 2B6, 2A6, 1A1, and 1A2 translation and transcription, thereby
inducing its own metabolism (Abu-Qare and Abou-Donia 2001a; Usmani et al. 2002).
No information was located regarding mechanisms of elimination and excretion of parent compound or
metabolites of DEET.
3.5.2 Mechanisms of Toxicity
In rare instances, DEET has been shown to induce adverse neurological effects in humans including
seizure, ataxia, restlessness, uncontrolled limb movements, agitation, aggressive behavior, combativeness,
impaired cognitive function, and opisthotonos.  Studies in animals have reproduced some of these effects
following high oral bolus exposure to DEET.  In a repeated dose dermal study in rats, doses of ≥40 mg
DEET/kg/day decreased the permeability of the blood-brain barrier (BBB) in various brain areas, but
significantly only in the brainstem (Abou-Donia et al. 2001b). Investigators in this study provided several
speculative hypotheses regarding DEET’s effects on decreasing the permeability of the BBB, including
regulation of expression of the cerebral endothelial multidrug transporter, p-glycoprotein (p-gp), which 
serves to protect the central nervous system by inducing efflux of drugs and chemicals; modulating levels 
of cyclic adenosine monophosphate (cAMP) after prolonged exposure, as high levels of cAMP have been
shown to reduce BBB permeability; causing a hypothermic response, which may be responsible for the
BBB permeability changes; and regulating the expression of proteins at tight junctions in the BBB 
resulting in reduced blood flow, and thus, reduced entry of chemicals into the brain. It should be noted 
that in this study, impaired sensory performance was reported at 4 mg DEET/kg/day, 1/10 the dose level
that affected BBB permeability, and that doses up to 400 mg DEET/kg/day did not induce observable
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clinical signs such as seizures, ataxia, or other signs.  This lack of clinical signs suggests that the altered
sensory performance may not be caused by alterations in BBB permeability and that changes of greater
magnitude in BBB permeability or recruitment of additional brain areas are necessary for overt signs such
as tremors or seizures to occur.  The results of another dermal exposure study in rats from the same group 
of investigators suggested that DEET might affect cholinergic and noradrenergic pathways innervating
brain areas involved in specific behaviors such as limb placing or beam-walking performance (Abou-
Donia et al. 2001b). In a subsequent study of repeated-dosing dermal exposure of rats, DEET was shown
to induce neuronal degeneration in the dentate gyrus, CA1 and CA3 subfields of the hippocampus, 
midbrain, brainstem, and Purkinje cell layer of the cerebellum (Abdel-Rahman et al. 2004).  Possible
mechanisms discussed by the investigators that could explain these morphological alterations included 
DEET-induced oxidative stress leading to the generation of free radicals and alterations in antioxidants,
and induction of acetylcholinesterase in various brain areas leading to neuronal damage and subsequent
apoptosis.  As noted earlier, Jortner (2006) published his concerns about the misinterpretation of the
histopathological findings reported in Abdel-Rahman et al. (2001) and other related publications.  The
main concern is that the report of “degenerating” or “dying” neurons in this article is the result of poor
handling and inadequate fixation of the brain tissue and is a “dark” neuron artifact.  The presence of this 
artifact suggests that both the neuron counting and the immunostaining procedures may have been 
compromised in the Abdel-Rahman et al. (2001) study and in subsequent studies at this laboratory.  
Studies by Chaney et al. (1999) also provide information regarding possible mechanisms of DEET
toxicity.  Treatment of mice with DEET by intraperitoneal injection resulted in seizures that could not be
prevented by pretreatment with standard anticonvulsive drugs or anticholinergic agents.  These results 
suggested that DEET-induced seizure activity is mediated by a non-cholinergic pathway.
3.5.3 Animal-to-Human Extrapolations 
Exposure of animals to DEET has resulted in effects similar to those reported in cases of intoxication in 
humans.  There does not seem to be an animal species that can be used as a preferred animal model for
studies of DEET.  
3.6  TOXICITIES MEDIATED THROUGH THE NEUROENDOCRINE AXIS
Recently, attention has focused on the potential hazardous effects of certain chemicals on the endocrine
system because of the ability of these chemicals to mimic or block endogenous hormones.  Chemicals 
with this type of activity are most commonly referred to as endocrine disruptors.  However, appropriate 
   
 








    
  
  
   
 
  
   




   
     
  
   
  
     
 
   
   
 
     
    
 
        
 
    
    
 




terminology to describe such effects remains controversial.  The terminology endocrine disruptors, 
initially used by Thomas and Colborn (1992), was also used in 1996 when Congress mandated the EPA to 
develop a screening program for “...certain substances [which] may have an effect produced by a 
naturally occurring estrogen, or other such endocrine effect[s]...”. To meet this mandate, EPA convened a 
panel called the Endocrine Disruptors Screening and Testing Advisory Committee (EDSTAC), and in 
1998, the EDSTAC completed its deliberations and made recommendations to EPA concerning endocrine
disruptors.  In 1999, the National Academy of Sciences released a report that referred to these same types 
of chemicals as hormonally active agents.  The terminology endocrine modulators has also been used to
convey the fact that effects caused by such chemicals may not necessarily be adverse.  Many scientists 
agree that chemicals with the ability to disrupt or modulate the endocrine system are a potential threat to
the health of humans, aquatic animals, and wildlife.  However, others think that endocrine-active 
chemicals do not pose a significant health risk, particularly in view of the fact that hormone mimics exist
in the natural environment.  Examples of natural hormone mimics are the isoflavinoid phytoestrogens
(Adlercreutz 1995; Livingston 1978; Mayr et al. 1992).  These chemicals are derived from plants and are
similar in structure and action to endogenous estrogen.  Although the public health significance and
descriptive terminology of substances capable of affecting the endocrine system remains controversial,
scientists agree that these chemicals may affect the synthesis, secretion, transport, binding, action, or
elimination of natural hormones in the body responsible for maintaining homeostasis, reproduction, 
development, and/or behavior (EPA 1997).  Stated differently, such compounds may cause toxicities that
are mediated through the neuroendocrine axis.  As a result, these chemicals may play a role in altering, 
for example, metabolic, sexual, immune, and neurobehavioral function.  Such chemicals are also thought
to be involved in inducing breast, testicular, and prostate cancers, as well as endometriosis (Berger 1994;
Giwercman et al. 1993; Hoel et al. 1992).
No studies were located regarding endocrine disruption in humans after exposure to DEET. Intermediate-
(Ambrose 1959; Army 1980b; Schoenig et al. 1999) and chronic-duration (Schoenig et al. 1999) oral
studies in animals that conducted gross and microscopic examination of endocrine glands found no 
evidence that DEET is an endocrine disruptor.
No in vitro studies were located regarding endocrine disruption of DEET.
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3.7  CHILDREN’S SUSCEPTIBILITY
This section discusses potential health effects from exposures during the period from conception to 
maturity at 18 years of age in humans, when most biological systems will have fully developed.  Potential
effects on offspring resulting from exposures of parental germ cells are considered, as well as any indirect 
effects on the fetus and neonate resulting from maternal exposure during gestation and lactation.  
Relevant animal and in vitro models are also discussed.
Children are not small adults.  They differ from adults in their exposures and may differ in their
susceptibility to hazardous chemicals.  Children’s unique physiology and behavior can influence the
extent of their exposure.  Exposures of children are discussed in Section 6.6, Exposures of Children.
Children sometimes differ from adults in their susceptibility to adverse health effects from exposure to
hazardous chemicals, but whether there is a difference depends on the chemical(s) (Guzelian et al. 1992;
NRC 1993).  Children may be more or less susceptible than adults to exposure-related health effects, and 
the relationship may change with developmental age (Guzelian et al. 1992; NRC 1993).  Vulnerability
often depends on developmental stage.  There are critical periods of structural and functional
development during both prenatal and postnatal life that are most sensitive to disruption from exposure to
hazardous substances.  Damage from exposure in one stage may not be evident until a later stage of
development. There are often differences in pharmacokinetics and metabolism between children and 
adults.  For example, absorption may be different in neonates because of the immaturity of their
gastrointestinal tract and their larger skin surface area in proportion to body weight (Morselli et al. 1980;
NRC 1993); the gastrointestinal absorption of lead is greatest in infants and young children (Ziegler et al.
1978).  Distribution of xenobiotics may be different; for example, infants have a larger proportion of their
bodies as extracellular water, and their brains and livers are proportionately larger (Altman and Dittmer
1974; Fomon 1966; Fomon et al. 1982; Owen and Brozek 1966; Widdowson and Dickerson 1964).  Past
literature has often described the fetus/infant as having an immature (developing) blood-brain barrier that 
is leaky and poorly intact (Costa et al. 2004).  However, current evidence suggests that the blood-brain 
barrier is anatomically and physically intact at this stage of development, and the restrictive intracellular
junctions that exist at the blood-CNS interface are fully formed, intact, and functionally effective 
(Saunders et al. 2008, 2012).
However, during development of the brain, there are differences between fetuses/infants and adults that
are toxicologically important. These differences mainly involve variations in physiological transport
   
 












   
  
     
     
 
 
     
  
    
   
 
 
   
  
   
     
   
  
     
   
    











systems that form during development (Ek et al. 2012).  These transport mechanisms (influx and efflux)
play an important role in the movement of amino acids and other vital substances across the blood-brain 
barrier in the developing brain; these transport mechanisms are far more active in the developing brain
than in the adult.  Because many drugs or potential toxins may be transported into the brain using these
same transport mechanisms—the developing brain may be rendered more vulnerable than the adult. 
Thus, concern regarding possible involvement of the blood-brain barrier with enhanced susceptibility of
the developing brain to toxins is valid.  It is important to note however, that this potential selective
vulnerability of the developing brain is associated with essential normal physiological mechanisms; and
not because of an absence or deficiency of anatomical/physical barrier mechanisms.
The presence of these unique transport systems in the developing brain of the fetus/infant is intriguing;
whether these mechanisms provide protection for the developing brain or render it more vulnerable to 
toxic injury is an important toxicological question.  Chemical exposure should be assessed on a case-by-
case basis. Research continues into the function and structure of the blood-brain barrier in early life
(Kearns et al. 2003; Saunders et al. 2012; Scheuplein et al. 2002).
Many xenobiotic metabolizing enzymes have distinctive developmental patterns. At various stages of
growth and development, levels of particular enzymes may be higher or lower than those of adults, and 
sometimes unique enzymes may exist at particular developmental stages (Komori et al. 1990; Leeder and
Kearns 1997; NRC 1993; Vieira et al. 1996).  Whether differences in xenobiotic metabolism make the 
child more or less susceptible also depends on whether the relevant enzymes are involved in activation of
the parent compound to its toxic form or in detoxification.  There may also be differences in excretion, 
particularly in newborns given their low glomerular filtration rate and not having developed efficient
tubular secretion and resorption capacities (Altman and Dittmer 1974; NRC 1993; West et al. 1948).  
Children and adults may differ in their capacity to repair damage from chemical insults.  Children also 
have a longer remaining lifetime in which to express damage from chemicals; this potential is particularly
relevant to cancer.
Certain characteristics of the developing human may increase exposure or susceptibility, whereas others 
may decrease susceptibility to the same chemical.  For example, although infants breathe more air per
kilogram of body weight than adults breathe, this difference might be somewhat counterbalanced by their
alveoli being less developed, which results in a disproportionately smaller surface area for alveolar
absorption (NRC 1993).
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As indicated throughout Section 3.2, Discussion of Health Effects by Route of Exposure, there are reports
that provide information regarding health effects in children exposed to DEET. Most of these cases 
involved oral or dermal exposure and some cases resulted in death (Heick et al. 1980; Pronczuk de
Garbino et al. 1983; Zadikoff 1979).  The most common manifestation of intoxication were neurological 
effects including agitation, hypertonia, seizures, ataxia, restlessness, and uncontrolled limb movements 
(Edwards and Johnson 1987; Gryboski et al. 1961; Heick et al. 1980; Lipscomb et al. 1992; MMWR
1989; Petrucci and Sardini 2000; Roland et al. 1985; Tenenbein 1987; Zadikoff 1979). The combination 
of some of these signs and symptoms has been described as toxic encephalopathy. The putative
association between exposure to DEET and seizures needs to be interpreted with caution since, as noted 
by Koren et al. (2003), a relatively high percentage (23–29%) of children are exposed to DEET in the
United States and seizure disorders occur in approximately 3–5% of children from any cause, making it
possible, just by chance alone, to erroneously find an association. This had been discussed earlier by
MMWR (1989), which pointed out that “since the exact circumstances under which DEET-related
neurotoxicity may occur are unclear, DEET should not be accepted as the cause of a seizure until
appropriate evaluation has reliably excluded other possible etiologies.” Also, in its Registration 
Eligibility Document for DEET, EPA (EPA 1998b) stated the following: “One possible explanation for
the seizures [reported for children] is coincidence.  Seizure coinciding with DEET is not unexpected, 
given an estimated 15,000–20,000 afebrile seizures in children (ages zero-19 years) estimated annually
and an estimated 17 million children using DEET 10 times a year.”
In the study of 9,086 human exposures involving insect repellents containing DEET reported to Poison 
Control Centers from 1985 to 1989 the majority of exposures were accidental and occurred in children
(Veltri et al. 1994).  These investigators also did not find a relationship between age and the severity of
the reaction or with gender.  They noted that “children less than six years of age were not more likely to
develop adverse effects from DEET-containing products than older children or adults and the effects that
did occur in children were not more serious” and that “exposed females were not more likely to develop
adverse effects nor were the effects more severe than in exposed males.”
An epidemiological study in which women applied DEET themselves in the second and third trimester of
pregnancy did not find significant differences between exposed and controls regarding head and arm
circumference or length or in a series of neurological tests in newborn infants (McGready et al. 2001).
Another epidemiological study did not find significant associations between DEET concentration in 
maternal blood or cord serum and birth weight, head circumference, abdominal circumference, or birth 
length in newborn infants (Barr et al. 2010).  
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Studies in rats and rabbits exposed orally to DEET during gestation did not find fetotoxicity or
teratogenicity (Schoenig et al. 1994).  In both species, exposure to the highest doses (750 mg
DEET/kg/day in rats and 325 mg DEET/kg/day in rabbits) resulted in significant reductions in maternal
weight gain during the dosing period.  In addition, rats treated with 750 mg DEET/kg/day showed a series 
of neurological signs during the dosing period including hypoactivity, ataxia, decreased muscle tone, and 
foot splay. A 2-generation reproductive study in rats reported significantly reduced body weight in F1 
and F2 male and female pups on days 14 and 21 of lactation at maternal doses of 250 mg DEET/kg/day
(EPA 1989).  
Only one study was located that showed greater susceptibility to DEET in young animals compared to 
adults (Verschoyle et al. 1992).  The study reported that the oral LD50 for DEET in 11-day-old Wistar rats
was 4–5 times lower than in adult rats.
3.8  BIOMARKERS OF EXPOSURE AND EFFECT
Biomarkers are broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility (NAS/NRC
1989).
The National Report on Human Exposure to Environmental Chemicals provides an ongoing assessment
of a generalizable sample of the exposure of the U.S. population to environmental chemicals using
biomonitoring.  This report is available at http://www.cdc.gov/exposurereport/. The biomonitoring data
for DEET from this report is discussed in Section 6.5. A biomarker of exposure is a xenobiotic substance
or its metabolite(s) or the product of an interaction between a xenobiotic agent and some target
molecule(s) or cell(s) that is measured within a compartment of an organism (NAS/NRC 1989). The
preferred biomarkers of exposure are generally the substance itself, substance-specific metabolites in
readily obtainable body fluid(s), or excreta.  However, several factors can confound the use and 
interpretation of biomarkers of exposure.  The body burden of a substance may be the result of exposures
from more than one source.  The substance being measured may be a metabolite of another xenobiotic
substance (e.g., high urinary levels of phenol can result from exposure to several different aromatic
compounds).  Depending on the properties of the substance (e.g., biologic half-life) and environmental
conditions (e.g., duration and route of exposure), the substance and all of its metabolites may have left the
body by the time samples can be taken.  It may be difficult to identify individuals exposed to hazardous
   
 








   
    
 
 
   
 
  
     
   
    
 
    
   
  
    
   
 





    
  
 
   
 
   
   
   





substances that are commonly found in body tissues and fluids (e.g., essential mineral nutrients such as
copper, zinc, and selenium).  Biomarkers of exposure to DEET are discussed in Section 3.8.1.
Biomarkers of effect are defined as any measurable biochemical, physiologic, or other alteration within an 
organism that, depending on magnitude, can be recognized as an established or potential health 
impairment or disease (NAS/NRC 1989). This definition encompasses biochemical or cellular signals of
tissue dysfunction (e.g., increased liver enzyme activity or pathologic changes in female genital epithelial
cells), as well as physiologic signs of dysfunction such as increased blood pressure or decreased lung
capacity.  Note that these markers are not often substance specific. They also may not be directly
adverse, but can indicate potential health impairment (e.g., DNA adducts).  Biomarkers of effects caused
by DEET are discussed in Section 3.8.2.
A biomarker of susceptibility is an indicator of an inherent or acquired limitation of an organism's ability
to respond to the challenge of exposure to a specific xenobiotic substance.  It can be an intrinsic genetic or
other characteristic or a preexisting disease that results in an increase in absorbed dose, a decrease in the 
biologically effective dose, or a target tissue response. If biomarkers of susceptibility exist, they are 
discussed in Section 3.10, Populations That Are Unusually Susceptible.
3.8.1 Biomarkers Used to Identify or Quantify Exposure to DEET
Measurement of DEET in urine may not be a reliable biomarker of exposure, as this compound is rapidly
metabolized after oral and dermal exposure, and the parent compound has rarely been detected in urine of
animals or humans (Selim et al. 1995; Schoenig et al. 1996; Taylor and Spooner 1990) other than for high 
doses resulting in death (Ambrose 1959). Urinary metabolites of DEET appear to be better markers of
exposure than the parent compound (Calafat et al. 2016, see below).
Smallwood et al. (1992) assessed the correlation between dermal exposure to DEET and urine and serum
levels of DEET in a group of chronically-exposed workers and in a group of naïve volunteers, observing
that neither urine nor serum levels were related to exposure estimates at low doses, but that urine samples 
may be correlated with exposure at higher doses or in individuals exposed regularly.  The authors
attributed the lack of correlation at low doses to the complex toxicokinetic behavior of DEET applied to 
the skin.  As part of an effort to develop techniques to analyze DEET in urine and serum, Smallwood et
al. (1992) tested the method on eight National Park employees who regularly used a DEET-containing
insect repellent, and nine naïve volunteers (for whom information on informed consent was not provided)
   
 










   
  
      
        
      
   
  
    
      
   
 
     
     





   
     
   
  
   
       
     




    




exposed in a laboratory.  The National Park employees were observed to apply sufficient quantities of the 
repellent, which contained 71% DEET, to yield an average daily application of approximately 1 g of
DEET.  Concentrations of DEET in spot urine samples collected from eight employees after the third day
of the work week ranged from below the quantitation limit of 0.18 μg/mL up to 5.69 μg/mL.  The authors
reported that urinary concentrations were positively correlated (r=0.7) with estimated exposure among the
eight employees; the wide range of urinary levels (0.18–5.69 μg/mL), however, appears to have no 
relationship to the single 1-g dermal dose that each individual reportedly received, suggesting that there
may have been a wide range of applied doses. When nine volunteers without prior exposure were
exposed in a laboratory to a DEET-containing repellent at doses between 0.14 and 1.86 g DEET per
volunteer, the serum of all volunteers contained detectable DEET at concentrations ranging from 0.15 to 
1.17 μg/g (Smallwood et al. 1992).  Spot urine samples from only two of the nine volunteers, however,
showed DEET concentrations above the detection limit of 0.09 μg/mL, and these subjects did not have the
highest exposures (based on flux estimates).  DEET concentrations in urine reported at various times 
(between 4 and 22 hours after application) for these two subjects ranged between 0.31 and 2.02 μg/mL
(Smallwood et al. 1992).  Dermal dose and application area were not readily correlated with spot urine or
serum levels at any time point up to 6 hours after application among the volunteers, but the areas under
the serum DEET concentration vs. time curves for the volunteers, integrated over 6 hours, were shown to 
correlate with the calculated flux of DEET across the skin (flux estimates ranged between 0.31 and 
5.99 μg-cm2x109).  
Urinary metabolites of DEET are useful biomarkers of exposure.  Kuklenyik et al. (2013) developed an 
HPLC/isotope dilution tandem mass spectrometry (MS) method to measure DEET and two of its
oxidative metabolites (DHMB and DCBA) in the urine of humans and tested the technique on 
75 anonymously collected samples from U.S. adults without known exposure.  The authors reported that
DCBA was detected most frequently and at the highest concentrations, indicating that this may be a
useful biomarker of DEET exposure (Kuklenyik et al. 2013). Because no volunteer had any known 
exposure to DEET, however, the presence of DCBA in urine may in fact be indicative of exposure to the
metabolite DCBA, perhaps in drinking water.  This theory is consistent with reports that DEET
metabolites are not effectively removed by waste water treatment facilities and may thus be available for
subsequent public exposure.
Arcury et al. (2007) analyzed the urine of children of North Carolina farmworkers for metabolites of
pesticides and reported that DEET metabolites were detected in the urine of 6 of 60 children.  The median 
concentration of DEET metabolites in urine was 0.08 μg/g creatinine.  The report did not clearly report
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the metabolites analyzed in the urine. Recently, Calafat et al. (2016) published the results of analyses of
5,348 urine samples from persons ≥6 years old in a representative sample of the U.S. general population
in the 2007–2010 NHANES.  DEET was detected in only 3% of the samples (0.08–45.1 µg/L), DCBA
was detected in approximately 84% of the samples (>0.48–30,400 µg/L), and DHMB was detected in 
approximately 15.5% of the samples (>0.09–332 µg/L).  Adjusted concentrations of DCMB were found 
to be dependent on season of the year (higher in May through September than in October through April), 
race/ethnicity highest in non-Hispanic whites, possibly reflecting different lifestyle uses), household 
income, and age. In general, children had higher adjusted concentrations of DCBA than adults, which the
investigators attributed to a higher rate of application to children by the parents than to themselves. Urine
is the normal medium for assessing human exposure to DEET, and due to the high metabolic rate of
DEET, both DCBA and DHMB are more sensitive biomarkers of exposure than DEET itself.
3.8.2 Biomarkers Used to Characterize Effects Caused by DEET
There are no specific biomarkers of effect for DEET exposure. Exposure to products containing DEET
has been associated with neurological effects such as seizures, ataxia, hypertonia, uncontrolled 
movements and agitation, as well as with skin irritation.  These and other symptoms including
hypotension, nausea and vomiting, and skin rashes can be the result of exposure to many other chemicals 
or can be caused by conditions unrelated to chemical exposures.
3.9  INTERACTIONS WITH OTHER CHEMICALS
A series of animal studies have been conducted that examined the effects of combined application of
DEET and other chemicals that were implicated in the development of neurological alterations and other
symptoms among veterans of the Persian Gulf War, termed Gulf War Syndromes or Gulf War illness.  
Some investigators (Abou-Donia et al. 1996) have proposed that the combination of chemicals, namely, 
DEET, permethrin, and pyridostigmine bromide (PB), possibly caused some of the range of symptoms
reported.  Permethrin is a type I pyrethroid insecticide that was applied to the clothing of the military
personnel.  Pyridostigmine bromide is a reversible inhibitor of AChE that was used orally.  A summary of
the findings from these studies is provided below.
A 60-day study of daily dermal applications of 4, 40, or 400 mg of 97.7% DEET/kg/day to 1 cm2 of
shaved backs of rats found decreases in permeability of the BBB [3H]hexamethomium of 78, 66, and
65%, respectively, in the brainstem, which was the most sensitive area (Abou-Donia et al. 2001a).  
Although dermally applied permethrin at doses up to 1.3 mg/kg/day had no significant effect on BBB
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permeability, DEET and permethrin in combination significantly decreased BBB permeability in the
cortex.  None of the treatments affected simple sensorimotor reflexes, but DEET alone at the lowest dose, 
4 mg/kg, and the combination with permethrin affected some sensory parameters such as performance on
a beam, grip strength, and performance on an inclined plane.  The combination of the two drugs resulted
in poorer performance in some tests, but only at the highest doses.
In a subsequent study of DEET (40 mg/kg/day dermally) that also included PB (1.3 mg/kg/day in 
drinking water) and permethrin (0.13 mg/kg/day dermally), in doses stated to be comparable to those
received by service members during the Persian Gulf War, none of the single treatments affected postural
reflexes, limb placing, or vibrissae touch (Abou-Donia et al. 2001b).  Beam walking time (but not beam
walking score) was increased over time by coexposure to DEET with PB (but not DEET with 
permethrin), and was affected most by the 3 substances in combination, but was unaffected by DEET or
permethrin alone.  Each of the 3 substances alone and in any combination reduced performance on the
incline plane and especially reduced forepaw grip strength to <10% of controls. There is no indication in 
the literature that service members comparably exposed to these substances were unable to lift items and
function on the battlefield, perhaps indicating that rats are an exquisitely sensitive species, and more 
sensitive than humans.  DEET produced occasional diarrhea, which has not been reported in other studies
conducted at higher dose levels. In general, combination with PB produced the most marked deficits.  
DEET alone increased AChE by about 40% in the brainstem but not in other brain areas.  In combination
with PB, AChE in brainstem was decreased. The three drugs together decreased AChE in brainstem and
midbrain. DEET alone caused a significant increase (about 20%) in choline acetyltransferase (ChAT, the
enzyme responsible for the synthesis of acetylcholine) activity in the cortex and a non-significant increase 
in the brainstem, the only two places measured. DEET alone and with permethrin significantly increased 
ligand binding density of m2 muscarinic acetylcholine receptors in the cortex.  DEET alone did not affect
ligand binding of nicotinic receptors in the cortex; nor did exposure to PB plus DEET only, or the three 
drugs together.
A study that conducted microscopic examination of the brain in rats exposed to the same service member
related doses of DEET, permethrin, or the combination showed that DEET alone induced neuronal
degeneration principally in the motor cerebral cortex, dentate gyrus, cornu ammonis (CA) subfields 1 and 
3 of the hippocampus, and the Purkinje cell layer of the cerebellum (Abdel-Rahman et al. 2001).  In the
cerebral cortex DEET alone generally appeared to cause more damage than permethrin alone and
degeneration appeared to occur earlier in rats treated with the combination than with either chemical
alone, but the combination did not induce enhanced neuron loss. In the dentate gyrus, there was a greater
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level of neuron loss with DEET or permethrin alone than with the combination; the authors suggested that
concurrent exposure to chemicals can decrease their absorption. As mentioned earlier, concerns have 
been expressed about the misinterpretation of the histopathological findings reported in Abdel-Rahman et
al. (2001) and other related publications. The main concern is that the report of “degenerating” or
“dying” neurons in this article is actually the result of poor handling and inadequate fixation of the brain 
tissue and is a “dark” neuron artifact. The presence of this artifact suggests that both the neuron counting
and the immunostaining procedures may have been compromised in the Abdel-Rahman et al. (2001)
study and in other studies conducted at this laboratory in this timeframe.
Yet another study that included DEET, permethrin, and malathion showed that all three chemicals alone 
altered neurobehavioral parameters (Abdel-Rahman et al. 2004).  The combination of DEET with these
other chemicals altered the effects of DEET alone.  DEET with permethrin significantly increased AChE
activity in the cortex and cerebellum, and significantly decreased AChE activity in the midbrain. Similar,
but less marked, changes were seen in the group with DEET plus malathion.  DEET plus malathion and
DEET plus permethrin significantly increased butyrylcholinesterase in plasma.  Treatment with DEET
alone or DEET combined with permethrin or malathion did not significantly affect muscarinic
acetylcholine receptor binding.  DEET alone induced neuronal degeneration in the dentate gyrus, CA1 
and CA3 subfields of the hippocampus, midbrain, brainstem, and Purkinje cell layer of the cerebellum. 
These studies used doses of DEET, PB, and permethrin at doses stated to be comparable to those received
by military personnel during the Persian Gulf War.
Similar studies in rats to those conducted by Abou-Donia and coworkers, but with DEET administered
orally once or daily over 7 days were conducted by Hoy et al. (2000a, 2000b).  In the single-dose study, 
up to 500 mg DEET/kg had no significant effect on locomotor activity except in met-estrus female rats 
for which speed was reduced at the highest dose.  Administration of DEET (100 mg/kg) and permethrin 
(15 mg/kg) significantly reduced locomotor activity in male but not female rats to 2.06 meters/min
compared to 2.24 and 2.50 meters/min achieved for each substance individually administered at twice
those doses.  Despite DEET having a greater effect on male mobility, uptake to blood serum was 2– 
3 times greater in females.  Also, the administration of PB tended to decrease oral uptake of DEET in 
female but not in male rats. In the 7-day study, administration of DEET (200 mg/kg/day) or permethrin 
(60 mg/kg/day) by gavage or PB (7.5 mg/kg/day) by intraperitoneal injection did not cause significant
alterations in locomotor activity. Administration of the combination PB/DEET (at half doses), however,
resulted in significantly lower locomotor rates, while the combination permethrin/DEET (at half doses)
significantly increased locomotor rates.  Administration of the three drugs together (at one third doses)
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caused no significant effect. The competition between drugs is consistent with the suggestion by Hoy et
al. (2000a) that PB uptake might protect rats from the effects of permethrin.
While the results summarized above suggest that the combination of PB and insect repellents may have 
synergistic neurological effects, the results of a more recent acute exposure study in humans did not
support these findings.  Roy et al. (2006) conducted a multicenter, prospective, double-blind, placebo-
controlled crossover trial, approved by human use committees at the Uniformed Services University, 
Bethesda, Maryland; Naval Health Research Center, San Diego, California, Office of the Surgeon 
General of the Army; and Navy Bureau of Medicine and Surgery. The 64 volunteers completed informed 
consent forms and were exposed to permethrin-impregnated uniforms continuously; a DEET-containing
skin cream (33% DEET) twice daily to neck, face, and legs, and oral pyridostigmine bromide (30-mg 
tablets) every 8 hours for a full day before each part was conducted. The 4-part crossover design ensured 
exposure of all participants to all treatments and placebos under both mental plus physical stress and rest
conditions.  The outcomes examined included biochemical assays and parameters of physical
performance, neurocognitive responses, and self-reported adverse effects. The results showed significant
increases in systolic blood pressure and heart rate, and increased serum levels of adrenaline,
noradrenaline, and lactate during stress sessions; however, none of these were influenced by treatment.
None of the exposure combinations significantly affected diastolic blood pressure or serum dopamine or
cortisol levels.  In addition, neurocognitive performance, as measured by the WinSCAT battery, did not
differ with exposure to treatments compared to placebos and showed a slight non-statistical improvement
with stress. Finally, self-reported effects did not differ by exposure group. Roy et al. (2006) attributed
the difference between their results and those of Abou-Donia and coworkers to the different dose levels
used and routes of administration.  Roy et al. (2006) noted that in their study, permethrin-treated uniforms
did not lead to measurable permethrin in the blood stream.
In an additional study examining the interactive effects of DEET, PB, and permethrin in animals, McCain
et al. (1997) reported that the simultaneous administration of the three chemicals to rats significantly
increased the lethality compared to expected additive values. Concurrent administration of PB and DEET
caused a significant increase in lethality compared to expected additive values.  The investigators 
suggested that possible mechanisms could involve facilitated absorption of PB in the gut by DEET or
inhibition of detoxification systems.
In studies in rats, intraperitoneal administration of 200 mg DEET/kg (at levels expected to produce 10– 
20% lethality) did not significantly alter the inhibition of cholinesterase activity in the heart (20% 
   
 








   
    
      
   
       
  
      
    
     
     
     
       
   
   
 
 
   
     
     
 
     
  
    
 
 
   
 
  
    
  






reduction), diaphragm (30% reduction), or whole blood (15% increase), whereas intraperitoneal
administration of only 1 or 3 mg PB/kg resulted in significant 80–90% reductions of cholinergic activity
in those areas (Chaney et al. 2000). Co-administration of 200 mg DEET/kg with 1 or 3 mg PB/kg, 
however, reduced ChE activity to levels achieved solely by PB, except in whole blood for which the high 
PB dose resulted in levels comparable to unexposed controls.  No dose of PB alone significantly altered
cholinesterase activity in the brain.  DEET alone slightly reduced brain ChE activity, and DEET plus the
high PB dose reached statistical significance at 40% inhibition of brain cholinesterase.  These results were
interpreted as DEET not altering the inhibition of ChE activity induced by PB in the heart, diaphragm, or
whole blood, and that DEET increased the permeability of the brain to PB rather than directly affecting 
PB-induced cholinesterase inhibition. The same group of investigators also reported that intraperitoneal
co-administration of PB and DEET to rats caused a profound and rapid decrease in heart rate that did not
occur with either chemical alone that eventually resulted in death (Chaney et al. 2002). The investigators
noted that the primary cause of death appeared to be circulatory failure and proposed the following
sequence of events: DEET may have depressed central cardiorespiratory centers and altered sympathetic 
outflow from the brain. PB aggravated DEET-induced toxicity presumably by promoting accumulation 
of acetylcholine at peripheral cholinergic receptor sites.  This accumulation at cholinergic sites resulted in 
bradycardia and further reduced cardiac output, which caused the development of progressive circulatory
shock. It is worth noting that the relevance of injection studies of DEET to safety assessment of DEET
exposure in humans is, at best, questionable.
It should also be noted that while the studies that examined the interactive action of DEET, permethrin,
and PB provide valuable information for understanding potential mechanisms that could explain some 
health outcomes manifested in the Gulf War Syndrome, it is difficult to see their relevance to civilian
exposures to DEET and other chemicals.
3.10  POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE 
A susceptible population will exhibit a different or enhanced response to DEET than will most persons
exposed to the same level of DEET in the environment.  Factors involved with increased susceptibility
may include genetic makeup, age, health and nutritional status, and exposure to other toxic substances
(e.g., cigarette smoke).  These parameters result in reduced detoxification or excretion of DEET, or
compromised function of organs affected by DEET.  Populations who are at greater risk due to their
unusually high exposure to DEET are discussed in Section 6.7, Populations with Potentially High 
Exposures.
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No populations that are unusually susceptible to adverse health effects from exposure to DEET were
identified in the literature reviewed. A study of 9,086 human exposures involving insect repellents 
containing DEET reported to Poison Control Centers from 1985 to 1989 found that children younger than 
6 years of age were not more likely to develop adverse effects from DEET-containing insect products
than older children or adults, and the effects that occurred in children were not more serious (Veltri et al.
1994).  AAPCC (2013) reported that 57%, or 2,316 case reports, of exposure to DEET were in children
≤5 years of age.  This may indicate a propensity for parents to apply DEET more liberally to protect their
youngest children from insect bites, rather than a differential susceptibility. Neurological effects, 
specifically seizures, have been reported in children and adults following oral or dermal exposure to 
products containing DEET.  Thus, the question arose as to whether subjects with known prior seizure
disorders would be more susceptible to DEET.  In a study of 296 major and moderate severity cases 
included in the DEET Registry from 1995 to 2001, people with an underlying neurological disorder or a
history of seizures prior to the first documented use of DEET were not disproportionally represented in 
the Registry (Osimitz et al. 2010).
Verschoyle et al. (1992) evaluated acute toxicity in rats and noted that neonates were significantly more 
sensitive than adult rats to DEET-induced lethality; however, no sensitivity generalizations can be made 
based on a single study, nor is it possible to make inferences about sensitivity at the lower doses to which 
humans are more likely to be exposed.
3.11  METHODS FOR REDUCING TOXIC EFFECTS
This section will describe clinical practice and research concerning methods for reducing toxic effects of
exposure to DEET.  Because some of the treatments discussed may be experimental and unproven, this 
section should not be used as a guide for treatment of exposures to DEET. When specific exposures have 
occurred, poison control centers, board certified medical toxicologists, board-certified occupational 
medicine physicians and/or other medical specialists with expertise and experience treating patients 
overexposed to DEET can be consulted for medical advice.
DEET has a low order of toxicity if used properly; however, it is prudent to avoid the overuse of DEET, 
which could result in adverse health effects (AAP 2015; Holland 2015). 
The following texts provide specific information about treatment following exposures to DEET:
   
 









          
       
     
 
              
     
 












   
 
     
    
      
      
  
    
  
 








Borron SW. 2007. Pyrethrins, repellents, and other pesticides. In: Shannon MW, Borron SW, Burns
MJ, eds. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed.
Philadelphia, PA: Saunders Elsevier, 1185-1194.
Osmundson M. 1998. Insecticides and pesticides. In: Viccellio P, ed. Emergency toxicology. 2nd ed.
Philadelphia, PA: Lippincott-Raven Publishers, 401-413.
Holland MG. 2015. Insecticides: Organochlorines, pyrethrins/pyrethroids, and insect repellents. In:
Hoffman RS, Howland MA, Lewin NA, eds.  Goldfrank's toxicologic emergencies.  10th ed.  New York, 
NY:  McGraw-Hill Education, 1435–1448.
Additional relevant information can be found in the front section of this profile under QUICK
REFERENCE FOR HEALTH CARE PROVIDERS.
3.11.1 Reducing Peak Absorption Following Exposure
The following information was extracted from the books listed above; specific chapters were written by
Borron (2007), Osmudsen (1998), and Holland (2015).  It is recommended, however, that this information 
be used along with consultation with a medical specialist with expertise and experience treating/managing
patients with DEET poisoning.
In cases of accidental dermal overexposure, skin decontamination with copious amounts of soap and 
water should be a priority to prevent further absorption. In cases of eye exposure, irrigation of the eyes 
with isotonic saline or copious amounts of room temperature water for at least 15 minutes is 
recommended.  In cases of oral ingestion, one report recommended administration of a single dose of
activated charcoal if clinically indicated (Holland 2015).  However, only one case report of treating a 
DEET-overexposed individual with activate charcoal was located (Tenenbein 1987).  Since the patient
died, the efficacy of using activated charcoal is unclear.
3.11.2 Reducing Body Burden
No information was located regarding reducing the DEET body burden following exposure to this
substance, but studies in volunteers indicate that it is rapidly cleared from the body (Selim et al. 1995; Wu 
et al. 1979).
   
 








       
 
     
      
    





   
   








     
  
 
     
 
  
       
     
     
     
 
    





3.11.3 Interfering with the Mechanism of Action for Toxic Effects
Overexposure to DEET has been associated mainly with neurological effects such as seizures and
hyperactivity, and skin effects, if exposure was dermal.  The mechanisms by which these effects occur
have not been elucidated.  Management of suspected DEET-related toxicity is essentially supportive and
aimed primarily to treat the neurological effects. Benzodiazepines may be used to treat seizures.
Refractory seizures may be treated with phenobarbital.
3.12  ADEQUACY OF THE DATABASE 
Section 104(I)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DEET is available.  Where adequate information is not
available, ATSDR, in conjunction with the National Toxicology Program (NTP), is required to assure the
initiation of a program of research designed to determine the adverse health effects (and techniques for
developing methods to determine such health effects) of DEET.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health risk assessment.  This definition should not be interpreted to 
mean that all data needs discussed in this section must be filled.  In the future, the identified data needs
will be evaluated and prioritized, and a substance-specific research agenda will be proposed.
3.12.1 Existing Information on Health Effects of DEET
The existing data on health effects of inhalation, oral, and dermal exposure of humans and animals to
DEET are summarized in Figure 3-5.  The purpose of this figure is to illustrate the existing information
concerning the health effects of DEET. Each dot in the figure indicates that one or more studies provide
information associated with that particular effect. The dot does not necessarily imply anything about the
quality of the study or studies, nor should missing information in this figure be interpreted as a “data
need”.  A data need, as defined in ATSDR’s Decision Guide for Identifying Substance-Specific Data 
Needs Related to Toxicological Profiles (Agency for Toxic Substances and Disease Registry 1989), is 
substance-specific information necessary to conduct comprehensive public health assessments.
Generally, ATSDR defines a data gap more broadly as any substance-specific information missing from
the scientific literature.
   
 



















































































































   
 









   
     
     




       
     
     
   
 
 
    
 









   
      
   
     
  
      
  
   
DEET 128
3. HEALTH EFFECTS
Most of the literature reviewed concerning the health effects of DEET in humans described case reports 
of acute dermal exposure to DEET.  There are also surveys involving great numbers of individuals from
the general population compiled from records kept in public and private poison control centers. These
individuals were exposed to products containing DEET by the inhalation, oral, or dermal route.  Also 
available are a few studies of occupational exposure and controlled dermal exposure in volunteers.  No 
reliable estimates of quantitative exposure could be obtained from case reports.
The database in animals is extensive.  As can be seen in Figure 3-5, most studies in animals have been
conducted by the oral and dermal routes of exposure.  There is more information regarding the health
effects of DEET following intermediate exposure than regarding acute or chronic exposure. There is no 
evidence suggesting that the toxicity of DEET is route-specific. The intake and uptake rates from oral
exposure, however, are faster than those by the dermal route of exposure, so greater peak concentrations 
in liver and nervous system tissues are achieved.
3.12.2 Identification of Data Needs 
Acute-Duration Exposure. Information is lacking concerning actual dermal exposures of
individuals who use DEET-containing products, and the AAPCC database only addresses the percentage 
of DEET in products for which reports are made to poison control centers.  Since environmental and 
public health agencies recommend the use of DEET to avoid insect and acarid bites, developing a 
standard for conducting dermal dosimetry and adding dose information to poison control center reports
could help improve recommendations for safely applying DEET.  
Information is available regarding the effects of acute-duration exposure in humans following inhalation 
(Bell et al. 2002), oral (Edwards and Johnson 1987; Fraser et al. 1995; Petrucci and Sardini 2000;
Tenenbein 1987; Wiles et al. 2014; Zadikoff 1979), and dermal exposure (Ambrose 1959; Briassoulis et
al. 2001; Clem et al. 1993; Edwards and Johnson 1987; Gryboski et al. 1961; Hampers et al. 1999; Heick 
et al. 1980; Lipscomb et al. 1992; Maibach and Johnson 1975; MMWR 1989; Reuveni and Yagupsky
1982; Roland et al. 1985; Shutty et al. 2013; Vozmediano et al. 2000; Wantke et al. 1996; Zadikoff 1979).  
Deaths have been reported following oral and dermal exposure to products containing DEET (Heick et al.
1980; Pronczuk de Garbino et al. 1983; Tenenbein 1987; Veltri et al. 1994; Wiles et al. 2014; Zedikoff
1979).  The main target of toxicity in humans and animals following acute, high-level exposure by any
route is the nervous system (Army 1979; Briassoulis et al. 2001; Gryboski et al. 1961; Lipscomb et al. 
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1992; Petrucci and Sardini 2000; Verschoyle et al. 1992; Zadikoff 1979). No reliable exposure
concentrations were available in surveys of people reporting to emergency departments after inhalation 
exposure to insect repellents containing DEET; therefore, no acute-duration inhalation MRL could be
derived using human data.  Very limited inhalation data in animals were located and the available studies
(Ambrose 1959; Army 1979; Deb et al. 2010) have significant limitations rendering them inadequate for
MRL derivation.  Studies that examine a comprehensive number of end points to possibly construct dose-
response relationships would seem warranted; the need to fill this data gap, however, needs to be balanced
with the fact that, assuming proper use, it is unlikely that significant inhalation of DEET will occur based 
on its estimated half-life in air of 5 hours (EPIWIN 2012), which makes persistence and long-range 
transport of DEET in air negligible. There is no information from humans who ingested DEET that is
useful for derivation of an acute-duration oral MRL for DEET. Studies in animals provided information 
regarding lethal doses (Ambrose 1959; Carpenter et al. 1974; EPA 1998c; McCain et al. 1997;
Verschoyle et al. 1992), developmental effects in rats and rabbits (Schoenig et al. 1994), and neurological
effects in rats (Schoenig et al. 1993; Verschoyle et al. 1992).  These studies did not identify a sensitive
target for DEET. Studies that provide comprehensive information regarding potential gross and 
microscopic alterations in major organs and tissues would be valuable. Based on an incomplete database,
an acute-duration oral MRL was not derived for DEET.  Case reports of people who used insect repellents 
containing DEET in the form of aerosols or lotions provide information regarding cardiovascular,
gastrointestinal, hematological, hepatic, renal, endocrine, dermal, ocular, immunological, and 
neurological effects (Amichai et al. 1994; Bell et al. 2002; Briassoulis et al. 2001; Clem et al. 1993;
Hampers et al. 1999; Heick et al. 1980; Lipscomb et al. 1992; Maibach and Johnson 1975; MMWR 1989;
Reuveni and Yagupsky 1982; Roland et al. 1985; Zadikoff 1979).  A study in volunteers provided 
information on dermal effects of DEET (Ambrose 1959).  A limited number of studies in animals
provided information on lethal doses (Carpenter et al. 1974; EPA 1998c) and on dermal and ocular effects
(Ambrose 1959; MacRae et al. 1984). Normal use of products containing DEET involves direct skin 
exposure.  Therefore, animal studies that examine a wide range of end points (systemic, immunological, 
neurological, reproductive, and developmental) and establish dose-response relationships would be
valuable.
Intermediate-Duration Exposure. There are no studies of humans exposed to DEET for
intermediate durations by the inhalation or oral routes. Two inhalation studies in animals were available 
for review.  A limited-scope study reported unspecified alterations in the lungs and trachea of rats
following a 7-week exposure period (Ambrose 1959). A 13-week study in rats examined a 
comprehensive number of end points, including organ and tissue histopathology and hematological and 
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clinical chemistry parameters and found no significant effects (Army 1980a).  In the absence of a LOAEL
being identified, an intermediate-duration inhalation MRL was not derived for DEET.  As mentioned
above, it is unlikely that humans will be exposed to significant amounts of DEET in the air; therefore, it
does not appear that additional inhalation studies are necessary at this time.  Intermediate-duration oral
studies in animals provided information on systemic (Ambrose 1959; Army 1980b; EPA 1989, 1990b;
Schoenig et al. 1993, 1999), immunological (Ambrose 1959; Army 1980b; EPA 1990b; Schoenig et al. 
1999), neurological (Ambrose 1959; Army 1980b; EPA 1990b; Schoenig et al. 1993, 1999), reproductive
(Ambrose 1959; EPA 1989), and developmental effects (EPA 1989). Although a clear target for DEET
toxicity was not apparent, a developmental study that identified the lowest LOAEL (EPA 1989) was
adequate and was used to derive an intermediate-duration oral MRL for DEET.  Additional intermediate
oral studies do not seem necessary at this time. Limited information is available regarding intermediate-
duration dermal exposure in humans.  Workers at a national park who used insect repellents or lotions 
containing DEET repeatedly during the summer season complained more often of chest pain or wheezing, 
muscle cramping, skin rashes and blisters, dizziness, disorientation, and difficulty concentrating than 
workers who used the products less often or did not use them at all (NIOSH 1986). In addition, a case
report of an 18-month-old girl who received daily applications of an insect repellent containing 20%
DEET for approximately 3 months reported hematological and neurological effects, but no evidence of
altered liver function (Edwards and Johnson 1987). Further studies of workers exposed seasonally to 
DEET would be valuable, especially if exposure can be better characterized.  Intermediate-duration 
dermal studies in animals provide information regarding systemic effects (Ambrose 1959; EPA 1988, 
1990a, 1992a; Lebowitz et al. 1983), neurological effects (Abdel-Rahman et al. 2001, 2004; Abou-Donia
et al. 2001a, 2001b), and reproductive effects (Lebowitz et al. 1983). Two of these studies (EPA
EPA1988, 1992a) conducted a comprehensive examination of the major organs and tissues from rats and 
micropigs to identify possible histological alterations; these studies also monitored hematological and 
clinical parameters. Therefore, additional intermediate-duration animal studies by the dermal route do not
seem warranted at this time. 
Chronic-Duration Exposure and Cancer. There are no studies of humans exposed chronically to 
DEET by any route with the exception of a study that monitored birth outcomes in women exposed to 
various pesticides (Barr et al. 2010) and a study of testicular cancer in Sweden (Hardell et al. 1998).  The
assumption is that in both studies, the subjects may have been exposed for extended periods of time (see 
specific sections below).  There are no chronic-duration inhalation studies in animals. Based on use
patterns and physical properties of DEET, however, chronic-inhalation exposure to DEET is not
expected; therefore, chronic-inhalation studies may not be necessary at this time. Chronic-duration oral
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studies have been conducted with DEET in rats and mice (Schoenig et al. 1999).  These studies provided
information on a comprehensive number of end points including clinical signs, gross and microscopic
appearance of tissues and organs, hematological parameters, and clinical chemistry and ophthalmology in 
rats. A chronic-duration oral MRL however, was not derived because the few alterations reported were of
questionable toxicological significance.  In addition, the available studies did not test for end points such 
as subtle neurobehavioral effects, which have been reported at relative low doses in intermediate-duration 
dermal studies in rats (Abou-Donia et al. 2001a) and in humans following seasonal used of DEET-
containing insect repellents (NIOSH 1986).  It would be useful to have this information because 
populations living near hazardous waste sites could be exposed orally via contaminated water.  Only one
chronic-duration dermal study in animals was available for review. That study examined gross lesions in 
mice and rabbits that had DEET applied onto the skin for 140 or 90 weeks, respectively, but did not
provide information regarding possible non-neoplastic changes in tissues and organs (Stenback 1977).
Based on decades of experience with humans applying DEET to the skin repeatedly and because chronic
dermal exposure is not expected except in unusual circumstances (e.g., long-term use in tropical areas 
where biting insects are active throughout the year, or in the field by military personnel), additional 
chronic-duration dermal studies do not seem necessary at this time.
Very limited information is available regarding exposure to DEET and cancer in humans.  A study of
testicular cancer and occupational exposures in Sweden found an increased risk among workers who used 
insect repellents for more than 115 days (Hardell et al. 1998). Studies of cancer need to be conducted
among groups identified as having long-term exposure to DEET, such as those involved in the 
manufacture of the chemical and those who use it for extended periods during the year, such as park
workers. DEET has been examined for carcinogenicity in oral studies in rats, mice, and dogs (Schoenig 
et al. 1999) and in dermal studies in mice and rabbits (Stenback 1977). The results were negative in all
the species tested.  Additional cancer studies in animals do not seem necessary.
Genotoxicity. There are no genotoxicity studies of humans exposed to DEET. Individuals involved 
in the manufacture and long-term use of DEET could be tested for possible genomic alterations. A single
in vivo study reported an increase in a biomarker of DNA damage in rats that had application of a single 
dermal dose of DEET (Abu-Qare and Abou-Donia 2000). Additional studies in vivo that examine 
whether DEET is a clastogenic substance would be valuable.  A limited number of studies of reverse
mutation in Salmonella gave negative results (EPA 1990c; Zeiger et al. 1992); additional studies seem
unwarranted.  Studies in mammalian cells gave mixed results.  Evidence of DNA damage was reported in
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3. HEALTH EFFECTS
cultured primary human nasal mucosal cells (Tisch et al. 2002).  It would be useful to try to replicate the
findings from Tisch et al. (2002).  
Reproductive Toxicity. No studies were located regarding reproductive effects in humans exposed
to DEET by any route.  No data on reproductive toxicity were located in animals exposed to DEET by
inhalation.  Intermediate- and chronic-duration oral studies did not find significant gross or microscopic
alterations of the reproductive organs of male and female animals (Ambrose 1959; Army 1980b; EPA
1989; Schoenig et al. 1999) except for tubular degeneration of the testes in hamsters (EPA 1990b).  
Fertility was evaluated only in a 2-generation continuous feeding study in rats and was not affected by
treatment with DEET (EPA 1989).  An intermediate-duration dermal exposure study in rats did not find 
significant histological alterations in the testes or in sperm parameters (Lebowitz et al. 1983). Two
additional intermediate-duration dermal studies did not observe morphological alterations in the
reproductive organs from rats or micropigs (EPA 1988, 1992a). Further reproductive studies are unlikely 
to provide new key information.
Developmental Toxicity. Two studies provided information regarding developmental effects in
humans following exposure to DEET (Barr et al. 2010; McGready et al. 2001).  In the latter study, 
controlled dermal exposure of pregnant women to DEET during the second and third trimesters did not
affect developmental outcomes at birth and up to 1 year of age.  Follow-up studies of these infants would
have been useful. In the Barr et al. (2010) study of the general population, there was no significant
association between levels of DEET in maternal blood and cord serum and developmental outcomes.  
Studies in rats and rabbits exposed orally to DEET during gestation showed only a slight decrease in fetal
weight in rats and no significant fetotoxicity in rabbits at dose levels that induced maternal toxicity
(Schoenig et al. 1994).  No teratogenicity was reported in either study. In a 2-generation continuous 
feeding study in rats, the only significant effect observed was a reduction in F1 and F2 pup body weight
on days 14 and 21 of lactation (EPA 1989).  Since the birth weight of pups was not significantly different 
from controls, the possibility exists that DEET was transferred to the pups via the milk or that there was
insufficient milk production by the exposed dams, or both.  Experiments could be designed to test these
hypotheses.  Cross-fostering experiments could provide information regarding the relative importance of
exposure to DEET through the placenta vs. via lactation. 
Immunotoxicity. A few studies have reported that exposure to DEET can cause contact urticaria by
immunological mechanisms in humans (Maibach and Johnson 1975; Shutty et al. 2013; Vozmediano et
al. 2000). Intermediate- and chronic-duration oral studies in animals have mainly showed that exposure
   
 








   
   
  
      
    
    
 
      
       
     
   
      
   
   
       
     
      
  
    
 
  
   
   
     
    
   
 
       
 
    
    
   
    
DEET 133
3. HEALTH EFFECTS
to DEET did not induce gross or microscopic alterations in lymphoreticular organs and tissues (Ambrose
1959; Army 1980b; EPA 1990b; Schoenig et al. 1999).  Because parameters of immunocompetence were 
affected in a study in mice administered DEET by subcutaneous injection (Keil et al. 2009), and because 
immunocompetence has been affected in animals by exposure to other chemicals at relatively low doses
(Abadin et al. 2007), it would be useful to conduct pilot studies, especially by the dermal route of
exposure, to test whether exposure to DEET can also affect immunocompetence.
Neurotoxicity. Adverse neurological effects have been reported in humans following inhalation, oral,
or dermal exposure to insect repellents containing DEET. In most cases, this has occurred following
exposure to what appears to have been excessive amounts. Signs and symptoms reported include
seizures, ataxia, restlessness, uncontrolled limb movements, agitation, aggressive behavior,
combativeness, impaired cognitive functioning, and opisthotonos (Briassoulis et al. 2001; Edwards and 
Johnson 1987; Gryboski et al. 1961; Hampers et al. 1999; Heick et al. 1980; NIOSH 1986; Petrucci and
Sardini 2000; Pronczuk de Garbino et al. 1983; Roland et al. 1985; Snyder et al. 1986; Wiles et al. 2014;
Zadikoff 1979).  Continued follow-up of the individuals with the most severe effects (i.e., seizures) would
provide valuable information regarding possible long-term effects (or lack thereof) due to acute exposure.
In a 1-year follow-up of 35 of these cases of seizures after exposure to DEET, medical tests showed
evidence of an underlying neurological disorder in 5 of these cases (Osimitz et al. 2010). Studies in
animals have reported neurobehavioral alterations (Abdel-Rahman et al. 2004; Abou-Donia et al. 2001a;
Army 1979; Schoenig et al. 1993), morphological alterations (Abdel-Rahman et al. 2001; Verschoyle et
al. 1992), and neurochemical alterations (Abou-Donia et al. 2001b).  As mentioned in Section 2.2, 
Summary of Health Effects, there are some unexplained inconsistencies between the results from some of
these studies that need to be resolved.  With regard specifically to morphological alterations, as 
mentioned earlier, findings reported by Abdel-Rahman et al. (2001, 2004) have been questioned as
possible artifacts (Jortnet 2006), so it would be useful to try to replicate their findings.  The mechanism
by which DEET (or a metabolite) induces neurological alterations has not been elucidated, so further
research in this area is needed.
Epidemiological and Human Dosimetry Studies. Most of the literature reviewed concerning the 
health effects of DEET in humans described case reports of accidental or intentional ingestion, or dermal
exposure to DEET by the general population (Barr et al. 2010; Briassoulis et al. 2001; Clem et al. 1993;
Edwards and Johnson 1987; Fraser et al. 1995; Gryboski et al. 1961; Hampers et al. 1999; Heick et al.
1980; Lipscomb et al. 1992; Maibach and Johnson 1975; MMWR 1989; Petrucci and Sardini 2000;
Pronczuk de Garbino et al. 1983; Roland et al. 1985; Shutty et al. 2013; Tenenbein 1987; Vozmediano et
   
 








       
  
    
   
   
   
     
  
   
    
    
      
   
     
 
     
 




   
   
    
 
 
       
    
    
   
    




al. 2000; Wantke et al. 1996; Wiles et al. 2014; Zadikoff 1979), and exposure of workers (NIOSH 1986),
volunteers (Ambrose 1959; McGready et al. 2001), and military personnel (Amichai et al. 1994; Haley et 
al. 1997; Reuveni and Yagupsky 1982).  Only in four of these studies was there information regarding
dose/exposure concentrations. Wiles et al. (2014) reported that a man who ingested 6 ounces of a
repellent containing 40% DEET (748 mg/DEET/kg) suffered a seizure, became unresponsive, and was
declared brain dead 3 days after poisoning.  Ambrose (1959) reported that 1–2 mL of a 50% DEET
solution applied on to the face of volunteers for 5 days caused some desquamation.  McGready et al.
(2001) reported that dermal application of 1.7 g DEET/day to women during the second and third
trimester of pregnancy did not affect developmental outcomes.  In NIOSH (1986), estimates of exposure
to >4.25 g DEET/week (based on survey recall data) were associated with chest pain or wheezing, skin 
rash and blisters, and impaired cognitive functioning.  Follow-up of individuals who have experienced the 
most severe effects (i.e., seizures) would help determine possible long-term effects of acute high
exposure. Continuous evaluation of park workers who have used insect repellents during part of the year
for several years could provide valuable information including reproductive data in both males and 
females and pregnancy outcomes in women as well as potential health effects in their offspring.
Biomarkers of Exposure and Effect.
Exposure. Further studies correlating urinary levels of DEET or its metabolites with exposure measures 
could provide valuable information to validate the use of these metrics as biomarkers of exposure to
DEET, as available studies are limited (Calafat et al. 2016).
Effect. There are no DEET-specific effects following exposure to this substance.  Neurological and 
dermal effects that have been associated with exposure to DEET can also be induced by exposure to other
chemicals or can even be caused by conditions unrelated to chemical exposures.  Any research aimed at
identifying a specific biomarker of effect for DEET would be valuable.
Absorption, Distribution, Metabolism, and Excretion. No information on the toxicokinetics of
DEET in humans or animals exposed via inhalation was available in the literature reviewed. Studies 
aimed at characterizing the behavior of DEET entering systemic circulation through the inhalation route
of exposure would be valuable, even though inhalation is an unlikely route of exposure to DEET if 
products containing DEET are used properly. Only one study (Schoenig et al. 1996) examined the
toxicokinetics of DEET after a single oral exposure in rats; studies examining other exposure regimens 
would provide useful information on the effects of exposure frequency or duration on toxicokinetics, and 
   
 








   




     
     
   
 
  
     
    
    
 
 
      
    
   
      
      
     
    
 
      
    
  
 
     
    
   
     
     
      
DEET 135
3. HEALTH EFFECTS
studies in other species would help determine whether there are species differences in toxicokinetics after
oral exposure.  The role of metabolism on the toxicity of DEET is not known; therefore, studies designed
to provide information on this issue seem warranted.
Comparative Toxicokinetics. There is suggestive evidence for species differences in the absorption,
metabolism, and/or elimination of DEET.  As only one study in rats examined toxicokinetics after oral
exposure to DEET (Schoenig et al. 1996), the lack of information on species differences in toxicokinetics
of orally-administered DEET represents an important data gap.  Additional information comparing dermal
absorption by rodents with absorption by humans under the same treatment conditions would be useful, as
cross-study comparisons are hampered by differences in exposure conditions that can markedly affect the 
rate or extent of absorption.  Likewise, there are suggestive, but not conclusive, data indicating gender
differences in metabolism and/or excretion of DEET. Further studies comparing male and female animals 
or humans are needed to provide a basis for conclusions regarding gender differences in the toxicokinetics
of DEET.  
Methods for Reducing Toxic Effects. There are no DEET-specific effects following exposure to
this chemical. Overexposure to DEET has been associated mainly with neurological effects such as 
seizures and hyperactivity, and dermatitis, if exposure was through skin contact.  The mechanisms by
which these effects occurred have not been elucidated. Management of suspected DEET-related toxicity
is essentially supportive and aimed primarily to treat the neurological effects. Publishing treatments that
have proved to be effective in randomized controlled trials in medical journals could improve and/or
prevent secondary effects and speed recovery in the most severe cases.
Children’s Susceptibility. Data needs relating to both prenatal and childhood exposures, and
developmental effects expressed either prenatally or during childhood, are discussed in detail in the
Developmental Toxicity subsection above.
Information on the effects of DEET in children is derived mainly from case reports of accidental ingestion
of insect repellents containing DEET or after receiving excessive dermal applications of the repellents.
The most common manifestation of intoxication were neurological effects including agitation, hypertonia, 
seizures, ataxia, restlessness, and uncontrolled limb movements (Edwards and Johnson 1987; Gryboski et 
al. 1961; Heick et al. 1980; Lipscomb et al. 1992; MMWR 1989; Petrucci and Sardini 2000; Roland et al. 
1985; Tenenbein 1987; Zadikoff 1979).  Evaluation of poisoning cases reported to Poison Control Centers
from 1983 to 1989 did not suggest that children are more sensitive to DEET than adults (Veltri et al.
   
 








   
    
 
      
  
 
    
  
      
     
    
   
   
  
 
    
   
    
  
 
   
    
     
       
      
    
  
     
 
   
     





1994).  Only one study in animals was located that examined the acute toxicity of DEET in relation to age
(Verschoyle et al. 1992). That study reported that neonatal rats were significantly more sensitive than
adult rats to DEET-induced lethality.  No generalization, however, can be made based on a single study, 
nor can inferences be made about sensitivity at the nonlethal dose levels to which humans are exposed.
Additional studies would be useful.
Limited information is available regarding developmental effects of DEET in humans. A study of women 
who applied a known amount of DEET onto the skin during the second and third trimesters did not affect
developmental outcomes at birth and up to 1 year after birth (McGready et al. 2001).  Follow-up studies
of these infants would have been useful. A study of the general population did not find significant 
associations between levels of DEET in maternal blood and cord serum and developmental outcomes
(Barr et al. 2010).  Conventional developmental studies in rats and rabbits did not find adverse
developmental effects in the offspring at maternal sacrifice on the last day of gestation (Schoenig et al.
1994).  In the 2-generation continuous feeding study in rats, male and female F1 and F2 pups, however,
had significantly reduced body weight on lactation days 14 and 21 (EPA 1989).  As mentioned before,
because birth weight was not affected by treatment with DEET, the reduced body weight in the pups
could have been due to reduced milk production or quality, or transfer of DEET and/or metabolites in the
milk to the pups.  Further studies regarding possible transfer of DEET and/or metabolites to the offspring
via maternal milk seem appropriate.
There are no adequate data to evaluate whether pharmacokinetics of DEET in children are different from
adults. To the extent that various cytochromes P450 that are involved in the metabolism of DEET in
humans (Usmani et al. 2002) are developmentally regulated (Tateishi et al. 1997), the metabolism of
DEET in neonates and infants, however, will likely differ from adults.  Whether this would result in
increased susceptibility of the young is not known because it is also not known whether metabolism of
DEET represents activation or detoxification. No information was located regarding levels of DEET (or 
metabolites) in human milk.  DEET, however, has been measured in cord blood (Barr et al. 2010).  
Further information on the dynamics of DEET and metabolites during pregnancy would be useful.
Biomarkers of exposure need to be further studied to better estimate human exposure at all age levels
following exposure to DEET.  There are no data on the interaction of DEET with other chemicals in
children.  The information available indicates that methods used to mitigate the effects of DEET in adults
are applicable to children.
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3. HEALTH EFFECTS
Child health data needs relating to exposure are discussed in Section 6.8.1, Identification of Data Needs:
Exposures of Children.
3.12.3 Ongoing Studies 
No relevant ongoing studies pertaining to DEET were identified in RePorter (2017).
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4. CHEMICAL AND PHYSICAL INFORMATION
4.1  CHEMICAL IDENTITY
Information regarding the chemical identity of DEET is located in Table 4-1.
DEET is the chemical, N,N-diethyl-meta-toluamide, ortho and para isomers are present at low
concentrations. DEET is an N,N-disubstituted aromatic carbonamide, which is used as an active
ingredient in insect repellents. DEET was registered for commercial use by the general public in 1957.  
In December 1980, DEET was issued a Registration Standard (PB81-207722) followed by a Data Call-In
in September 1988 requiring additional mammalian and avian toxicity data (EPA 1998c).  Technical-
grade DEET is typically formulated with carriers and solvents (such as ethanol, isopropanol, or water) for
use in commercial products.  Commercial product formulations include microencapsulated, pressurized
sprays or aerosols, impregnated materials such as towelettes and roll-ons, and ready-to-use solutions such 
as non-aerosol pump sprays, liquids, creams, lotions, and foams. Some DEET products are also 
formulated with sunscreen. (EPA 2014l, 2014m; HSDB 2001).  The DEET concentration in commercial
products varies according to country and can range from 4 to 100% (by weight) in the United States.  
Technical-grade DEET typically contains 95% meta-isomer, the most effective form of the chemical
(EPA 1998b, 1998c; O’Neil et al. 2013). The EPA does not require expiration dates to be included on the
label of DEET products manufactured in the United States (EPA 1998b).
4.2  PHYSICAL AND CHEMICAL PROPERTIES 
Information regarding the physical and chemical properties of DEET is located in Table 4-2.

































   
    
    
     
    
    
    
      
 
 




4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-1.  Chemical Identity of DEET (N,N-Diethyl-meta-Toluamide)
Characteristic Information
Chemical name N,N-Diethyl-meta-toluamide







Registered trade name(s) DEET; Delphene®; MGK ChemIDplus 2013; EPA 1998b,
diethyltoluamide; Detamide®; 1998c; HSDB 2001
Detamine; Metadelphene®; Skeeter
Skat®; Autan® (some formulations);
Amincene C 140®; Amincene C-EM®; 
Bepper-DET®; DET®; DETA®; DET-
20®; DETA-20®; Flypel®; Muscol®; 
Muskol®; Off!®; Repel®; Repper-DET®; 
Repudin-Special®; Chemform®; 
Cutter®; Old Time Woodsman® 
Chemical formula C12H17NO HSDB 2001






CAS registry 134-62-3 HSDB 2001
NIOSH RTECS No data
EPA hazardous waste No data
DOT/UN/NA/IMDG shipping UN; IMO
HSDB 1582 HSDB 2001
NCI No data
EPA Pesticide Chemical Code 080301 ChemIDplus 2013; HSDB 2001 
CAS = Chemical Abstracts Service; DOT/UN/NA/IMDG = Department of Transportation/United Nations/North 
America/International Maritime Dangerous Goods Code; EPA = Environmental Protection Agency;
HSDB = Hazardous Substances Data Bank; NCI = National Cancer Institute; NIOSH = National Institute for
Occupational Safety and Health; RTECS = Registry of Toxic Effects of Chemical Substances











    
 
   
   
   
   














   






   
   
    
    
   
   












   
   













   






      
   





4.  CHEMICAL AND PHYSICAL INFORMATION
































160°C at 19 mm Hg
111°C at 1.0 mm Hg









>1,000 mg/L at room temperature;
9,900 mg/L at 25°C
Miscible in benzene, carbon disulfide,
chloroform, ethanol, ether, and isopropanol;
soluble in hexane, acetonitrile, toluene,











0.0056 mm Hg 
0.00167 mm Hg at 25°C
0.00013 mm Hg at 25°C
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4.  CHEMICAL AND PHYSICAL INFORMATION
Table 4-2. Physical and Chemical Properties of DEET
Property Information Reference
Flammability limits No data
Explosive limits No data
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5. PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
5.1  PRODUCTION
No information is available in the TRI database on facilities that manufacture or process DEET because 
this chemical is not required to be reported under Section 313 of the Emergency Planning and Community
Right-to-Know Act (Title III of the Superfund Amendments and Reauthorization Act of 1986) (EPA
2005).
DEET was developed in 1946 by the U.S. Army and has become the world’s standard insect repellent.  
As of March 2017, there were 27 companies in the United States that manufactured approximately
119 federally active consumer products containing DEET (NPIRS 2017).  DEET is produced globally, 
with commercial production achieved via reaction of m-toluoyl chloride and diethylamine in benzene or
ether as a solvent (O’Neil et al. 2013).  Data for production volumes were not located.  DEET is
designated by the U.S. EPA as a registered “pesticide” (type of pesticide is an insect and acarid repellent).
EPA (1998b) reregistered its use in products available to the general public, except for products and
formulations that combine DEET and sunscreen, or those that are corrosive to the eye or cause corneal
involvement or irritation persisting for ≥21 days.
In the environment, Pectinophora gossypiella, commonly known as the pink bollworm, naturally
produces DEET; however, this source would not accumulate levels of environmental significance 
(Knepper 2004).
5.2  IMPORT/EXPORT
The U.S. EPA estimated that the annual U.S. production and import volumes of DEET range from
approximately 2.6 to 4.5 million pounds (EPA 2007; ILS 1999).
5.3  USE 
DEET is used globally.  The major use for DEET is as an insect and acarid repellent intended to repel, but
not kill, biting insects.  Commercial products are used in residential settings and are applied directly on 
the human body or hair and/or personal clothing, footwear, shoes, and hats while being worn, on cats, 
dogs, and horses, or on pet living and sleeping quarters (EPA 2014m).  Data from 1998 and the Centers
for Disease Control and Prevention (CDC) report there are over 225 commercial insect repellents that 
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
range in concentration from 4 to 100%; DEET use in formulations with dermal sunscreens were also
reported (Brausch and Rand 2011; CDC 2009; EPA 1998b, 1998c, 2014l).  In 1998, EPA (1998b) stated
that the reregistration eligibility decision (RED) does not include products/formulations that combine
DEET and sunscreen; however, in the EPA (2012c) environmental fate and ecological risk assessment for
registration review of DEET, 10 end-use products/formulations with sunscreen were reported.  As of
March 2017, 27 companies in the United States reported the manufacture of approximately 119 consumer
products containing DEET (NPIRS 2017). Products include lotions, creams, sticks, aerosol and non-
aerosol sprays, foams, gels, and wipes or towelettes. According to EPA, as of February 2014, there were 
123 active registrations for DEET, including co-formulations with other chemicals, formulations with 
sunscreen, and one registration for use on horses (EPA 2012c, 2014m).  Formulations may range from
4 to 95% active ingredient, and a 100% technical-grade product also exists.  Although agricultural uses 
have been reported (Aronson et al. 2012), DEET is currently registered by the EPA only as an insect and 
acarid repellent. Additional uses of DEET as a specialty solvent, surface plasticizer, pharmaceutical
dermal penetration enhancer (Windhauser 1982), and other potential applications have been reported
(Aronson et al. 2012; Carlson 2000; EPA 1998b, 1998c; Weeks et al. 2012).  The chemical properties that
enable DEET to dissolve certain plastics along with its strong smell are potential disadvantages for some 
applications (Wang et al. 2013). 
Wang et al. (2013) evaluated DEET against other repellents for effectiveness against bed bugs moving
into an area in which a CO2 cue was present.  Bed bugs are currently of international concern following a 
population rebound after the termination of DDT use.  Filter papers in petri dishes were treated with a
repellent over half of the surface and with the vehicle on the other half, entirely bathed in CO2. After nine
males and six large nymphs (immature bedbugs) were released at the center, the portion avoiding the 
repellent side was recorded over time.  Complete effectiveness for 24 hours was found for 5% DEET as
well as for two naturally occurring repellents (3-methyl-5-hexyl-2-cyclohexanone [isolongifolenone] or
propyl dihydrojasmonate [isolongifolanone]).  A minimum of 10% DEET was required to repel at least
93% of bed bugs for 9 hours, and 25% DEET was effective for 14 days. Two other substances were 
ineffective (7% picaridin repellent or 0.5% permethrin insecticide). Current production volumes for
DEET were not available in the EPA Inventory Update Reporting Database or the Chemical Data 
Reporting Database.  According to 1990 data, the EPA Registration Eligibility Decision document for
DEET reported annual use of approximately 4 million pounds (active ingredient) and about 30% of the
U.S. population used DEET annually as an insect and acarid repellent (EPA 1998b, 1998c, 2014l).  
Approximately 19% of households used it on household members, and about 4% of households that had 
cats and/or dogs applied DEET to pets. The average annual domestic use of DEET has been estimated as 
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5.  PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL
approximately 5–7 million pounds based on product sales (EPA 2004).  According to the California
Environmental Protection Agency, approximately 577,874 pounds (active ingredient) of DEET were sold 
in California alone in 2008 (Aronson et al. 2012).
Since 1998, in Germany, DEET has been replaced by 1-piperidine carboxylic acid 2-(2-hydroxy-
ethyl)-1-methylpropylester (Bayrepel) in some products (Knepper 2004).
5.4  DISPOSAL
According to the Material Safety Data Sheet for one DEET product, the disposal method noted that waste 
must be disposed of in accordance with federal, state, and local environmental control regulations; the
container must not be reused; it may be placed in the trash for disposal; absorbents should be disposed of
in the trash (Sawyer 2010).  It is assumed that most products containing DEET are discarded into landfills 
following their disposal in common household waste.  Large spillages of DEET should be
decontaminated by rinsing with a 5% solution of sodium hydroxide (WHO 1987).
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6. POTENTIAL FOR HUMAN EXPOSURE
6.1  OVERVIEW
DEET was previously identified in at least 2 of the 1,832 hazardous waste sites across the United States (a 
refining operation in Friendswood, Texas and a municipal landfill in Bennington, Vermont) that have
been proposed for inclusion on the EPA National Priorities List (NPL) (ATSDR 2015).  The
concentrations of DEET found at these two NPL sites were not considered a health concern (ATSDR
2015).  Figure 6-1 shows the states with DEET-contaminated NPL sites, and the frequency or number of
occurrences of these sites in each state.  However, recent NPL site information indicates that DEET is no
longer identified as an existing contaminant at any of the 1,832 hazardous waste sites across the United
States that are listed as of that date on the NPL (EPA 2017a, 2017b).  The EPA Superfund program is a
dynamic system that continually evaluates sites across the United States for inclusion and deletion from
the NPL; therefore, the exact number of hazardous waste sites may vary with time. The site in Texas is 
no longer on the NPL (EPA 2014g) and the site narrative for the Vermont site does not identify DEET as
a major contaminant (EPA 2014h).  However, the number of sites evaluated for DEET is not known.  
DEET enters the environment via direct and indirect sources through its use as a commercial product.
DEET is an insect and acarid repellent intended for indoor and outdoor residential human use.  Water is
the most common environmental medium in which DEET has been detected.  DEET has been detected in 
surface water, groundwater, and drinking water.  DEET enters aquatic systems as a result of common
human activities, such as showering or bathing and laundering of clothes after products containing DEET
have been applied.  DEET is expected to be moderately mobile and has the potential to leach into 
groundwater.  It is not expected to undergo hydrolysis in aquatic environments, and biodegradation under
anaerobic conditions is negligible.  However, DEET is considered inherently and readily biodegradable
(Weeks et al. 2012) and is not considered a persistent or bioaccumulative substance.
The most important route of exposure to the general population is through dermal contact via intentional 
application to the skin of consumer products containing DEET.  Dermal application of DEET can result in 
absorption through the skin.  Exposure via inhalation, ocular and oral routes may be possible; however, 
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Figure 6-1. Frequency of NPL Sites with DEET Contamination
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Occupational exposure may occur via dermal contact and inhalation where DEET is manufactured or
used.  DEET has been monitored in human urine and blood samples.
6.2  RELEASES TO THE ENVIRONMENT
The Toxics Release Inventory (TRI) data should be used with caution because only certain types of
facilities are required to report (EPA 2005).  This is not an exhaustive list.  Manufacturing and processing
facilities are required to report information to the TRI only if they employ 10 or more full-time
employees; if their facility is included in Standard Industrial Classification (SIC) Codes 10 (except 1011, 
1081, and 1094), 12 (except 1241), 20–39, 4911 (limited to facilities that combust coal and/or oil for the
purpose of generating electricity for distribution in commerce), 4931 (limited to facilities that combust
coal and/or oil for the purpose of generating electricity for distribution in commerce), 4939 (limited to 
facilities that combust coal and/or oil for the purpose of generating electricity for distribution in
commerce), 4953 (limited to facilities regulated under RCRA Subtitle C, 42 U.S.C. section 6921 et seq.), 
5169, 5171, and 7389 (limited S.C. section 6921 et seq.), 5169, 5171, and 7389 (limited to facilities
primarily engaged in solvents recovery services on a contract or fee basis); and if their facility produces, 
imports, or processes ≥25,000 pounds of any TRI chemical or otherwise uses >10,000 pounds of a TRI
chemical in a calendar year (EPA 2005).
DEET may be released to the environment directly or indirectly through its use in commercial products. 
There are no natural sources of DEET known to be environmentally significant. 
6.2.1 Air
There is no information on releases of DEET to the atmosphere from manufacturing and processing
facilities because these releases are not required to be reported (EPA 2005).
DEET is released into the atmosphere solely by human activities associated with its production and use as 
an insect and acarid repellent.  DEET can enter the air during spray application onto skin or clothing. It
has been reported that evaporation from human skin is 9.6% in 1 hour (Spencer et al. 1979). Cheng et al.
(2006) surmised that the presence of DEET in air of the Lower Fraser Valley of Canada was primarily
due to its widespread use by the Canadian population during the summer.  Levels in the urban forest
showed a diurnal change (3.03 ng/m3 during the day and 1.25 ng/m3 at night), while those near highly
visited Golden Ear Provincial Park were higher (11.1–11.4 ng/m3 in the day and up to 37.1 ng/m3 at night 
when insect density may have been greatest). The lowest levels measured (0.53–0.78 ng/m3) were at a 










   
  
 
     
 
    
    
 
   
    
   
   
   
  
    
      
  
   
     
 
   
 
 
    
 
    
    
 
   
       




6.  POTENTIAL FOR HUMAN EXPOSURE
remote location and were considered to be the ambient background for the area resulting from spraying
livestock in that rural area.
6.2.2 Water
There is no information on releases of DEET to the water from manufacturing and processing facilities
because these releases are not required to be reported (EPA 2005).
DEET is frequently detected in the aquatic environment (Knepper 2004; Kolpin et al. 2002; Sandstrom et
al. 2005).  DEET can enter surface waters directly due to recreational activities such as swimming, via
swimmers with DEET products on their skin or clothing, or indirectly from overspray during application.  
Because of its limited absorption through human skin, the majority of applied DEET is washed off the
skin (Selim et al. 1995).  DEET is released into water systems through routine human activities such as 
showering and bathing of individuals who have recently applied DEET products.  DEET applied to 
clothing may end up in waste water treatment plants (WWTPs) or may be released with gray water after
the clothes are laundered and enter the environment after passing through the WWTPs or domestic septic
systems.  Additionally, sewage effluent may contain DEET and DEET metabolites due to human 
absorption and excretion (Aronson et al. 2012; Costanzo et al. 2007).  Monitoring data indicate that the
highest concentration of DEET in aquatic environments correlates with its increased application during
the summer months (Knepper 2004; Sandstrom et al. 2005) and late winter (Sandstrom et al. 2005).  
DEET can enter groundwater from contaminated surface waters or leachate from landfills (Cordy et al.
2004).  
6.2.3 Soil 
There is no information on releases of DEET to the soil from manufacturing and processing facilities 
because these releases are not required to be reported (EPA 2005).
DEET may be released to soil as a result of overspray during application as a repellent or irrigation of
soils with reclaimed water in which DEET is present. DEET may also be released to soil when it is 
disposed of in landfills or from accidental spills of products or wastes containing DEET during overland 
transportation.
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6.3  ENVIRONMENTAL FATE
The environmental fate of DEET, which includes the transport, partitioning, and transformation of this
substance, is controlled by various physicochemical properties, degradation, and other loss processes.
According to European Union (EU) regulatory criteria and the overall data presented below, DEET is
unlikely to bioaccumulate and is not expected to be highly persistent in the environment (Aronson 2012;
Weeks et al. 2012). 
6.3.1 Transport and Partitioning 
Based on its vapor pressure of 5.6x10-3 mm Hg at 20°C, DEET will exist solely as a vapor if released to
the atmosphere.  Vapor-phase DEET is expected to degrade in the atmosphere via reaction with
photochemically-produced hydroxyl radicals, with an estimated half-life of 5 hours (EPIWIN 2012).  
Therefore, persistence and long-range transport of DEET in air is not expected.
Monitoring data indicate water as the major environmental sink for DEET.  If released to water, DEET is 
not expected to accumulate in aquatic organisms.  Experimental bioconcentration factors (BCFs) of 0.8– 
2.4 L/kg at 0.5 mg/L and <2.4 at 0.05 mg/L measured in carp indicate that the potential for
bioconcentration in aquatic organisms is low (CITI 1992; Weeks et al. 2012).  Volatilization of DEET
from water surfaces is not expected to be an important fate process based on its estimated Henry’s Law
constant of 4.5x10-8 atm-m3/mole (EPIWIN 2012).
DEET is expected to have low adsorption to soils and sediment; therefore, leaching into groundwater is
possible and removal by sludge adsorption in sewage treatment plants is incomplete.  Experimental soil 
sorption Koc factors have been reported as 43.3 L/kg resulting from a high-performance liquid 
chromatography (HPLC) estimation and 47–126 L/kg from an Organization for Economic Co-operation 
(OECD) guideline method (Adsorption-Desorption Using a Batch Equilibrium Method) using five soils
(ECHA 2010; Weeks et al. 2012).  Secondarily-treated effluent from a municipal waste treatment plant 
containing DEET was applied to a 2.4-m soil column packed with Mohall-Laveen sandy loam soil over
23 days in a study assessing the potential for compounds to persist and possibly enter groundwater upon 
recharge.  DEET was detected in the column inflow at the beginning and the end of the experiment at
concentrations of 1.4 and 1.6 µg/L, respectively.  DEET was finally detected in the drainage samples at
the end of the experiment at a concentration of 2.3 µg/L (Cordy et al. 2004).  
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6.3.2 Transformation and Degradation
DEET can partition into various environmental compartments and is subject to abiotic and biotic
degradation processes. 
6.3.2.1  Air
The major removal process for DEET in the atmosphere is photooxidation via reaction with hydroxyl
radicals. The estimated half-life for this reaction is 5 hours, based on an estimated rate constant of
2.5x10-11 cm3/molecule-second at 25°C (EPIWIN 2012).  Direct photolysis in the ambient atmosphere is
not expected to be an important fate process because DEET does not absorb light at environmentally
relevant wavelengths (EPA 2014m; Weeks et al. 2012).
6.3.2.2  Water
DEET is considered to be hydrolytically stable; results from guideline studies however, indicate that
DEET will be biodegradable under environmental conditions and should not be persistent in the
environment.
Using the Japanese Ministry of International Trade and Industry (MITI) test based on OECD Guideline
301C, DEET, at 100 mg/L, achieved 0% of its theoretical biochemical oxygen demand (BOD) after
4 weeks using a sewage inoculum maintained under aerobic conditions and was not considered readily
biodegradable (CITI 1992).  DEET was degraded 48.6% after 28 days using the closed bottle (OECD
Guideline 301D) test and it was concluded that DEET was probably inherently biodegradable but did not
meet the criteria to be classified as readily biodegradable (Weeks et al. 2012).  In another guideline study, 
DEET achieved 83.8% of its theoretical CO2 evolution after a 28-day incubation period using the
modified Sturm (OECD Guideline 301B) test and was considered readily biodegradable (Weeks et al.
2012).  The discrepancies in results could be attributed to the toxic effects of DEET on microbial
populations at high concentrations, such as those used in OECD Guideline 301C.  Testing indicated that
DEET only caused minor inhibitory effects on microbial activity and was not typically a concern at
environmentally relevant concentrations (ECHA 2010; Weeks et al. 2012). 
Hydrolysis in water is not expected to be an important fate process.  Results from two studies following
OECD Guideline 111, EPA Method 835.2110, and EC C.7 demonstrate that DEET is hydrolytically










   
   
   
       
 





      
 
  
    
 
   
 
    
  
  
   
   
 
 
   
 
  




6.  POTENTIAL FOR HUMAN EXPOSURE
stable at 50°C and pH 4, 7, and 9 (EPA 1998b, 1998c, 2002; Weeks et al. 2012).  The UV/visible
absorption spectrum for a 10 ppm DEET solution in methanol of 200–225 nm (EPA 2014m) suggests that
this chemical does not absorb at wavelengths >290 nm and therefore would not be expected to undergo 
direct photolysis in sunlight. Direct photolysis in sterile water did not contribute to decomposition in a
simulation experiment by Calza et al. (2011) and in a 7-day experiment using distilled water and a xenon 
arc light (Weeks et al. 2012).  Indirect photolysis in river water, however, resulted in degradation.  
Photocatalytic degradation experiments in river water under illumination and in the dark resulted in half-
lives of 5 and 15 days, respectively (Calza et al. 2011).  The main transformation products identified were
N,N-diethyl-3-hydroxymethyl-benzamide, N,N-diethyl-m-benzamide, N-ethyl-m-formylbenzamide, and 
N-ethyl-m-toluenamide (Calza et al. 2011).  Confirmed DEET microbial degradates that have been 
reported include 3-methylbenzoate (which further degrades to 3-methylcatechol), N,N-diethyl-
m-toluamide-N-oxide, and N-ethyl-m-toluamide (which further degrades to N-ethyl-m-toluamide-
N-oxide) (Aronson et al. 2012).  Of the degradation products detected in the river water study, it was
noted that several resulted from biotic processes, while others were formed from indirect photolysis.  
Indirect photolysis in sunlit surface waters and biotic degradation under aerobic conditions are the most
important removal processes for DEET (Calza et al. 2011).  Biotic degradation processes produce 
products via monohydroxylation (or N-oxidation), N-dealkylation, and demethylation on the benzene ring
(Calza et al. 2011; Rivera-Cancel et al. 2007; Seo et al. 2005).
Anaerobic biodegradation of DEET using aquifer slurries obtained from the Norman municipal landfill in 
Oklahoma was shown to be negligible.  Measured DEET concentrations at 0, 1, 8, and 11 months of
incubation were 171, 194, 198, and 199 μM, respectively, in aquifer slurries from a sulfate reducing site.  
DEET did not biodegrade in an aquifer slurry from a methanogenic site; at 0, 1, 8, and 11 months of
incubation, concentrations of DEET were 194, 192, 190, and 199 μM, respectively (Kuhn and Sulflita
1989).  
6.3.2.3  Sediment and Soil
No biodegradation studies in soil samples were located; OECD guideline studies and aquifer studies,
however, suggest that DEET is biodegradable under aerobic conditions, but biodegrades slowly under
anaerobic conditions (Kuhn and Sulflita 1989; Weeks et al. 2012).  
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6.3.2.4  Other Media
Results from pure culture studies have demonstrated the ability of Pseudomonas putida DTB to 
metabolize DEET by hydrolyzing the amide bond resulting in two degradation products, 
3-methylbenzoate and diethylamine (Rivera-Cancel et al. 2007).  3-Methylbenzoate has been shown to be
readily biodegradable, and predictive methods have suggested that other DEET metabolites are not 
expected to persist in the environment (Aronson et al. 2012).  An additional study on the metabolism of
DEET by soil fungi (Cunninghamella elegans) identified three metabolites:  N,N-diethyl-m-toluamide-
N-oxide, N-ethyl-m-toluamide-N-oxide, and N-ethyl-m-toluamide (Seo et al. 2005).  It should be noted 
that these studies were not with mixed microbial populations typically found in natural systems and 
should therefore not be considered definitively representative of the biodegradation of DEET in the
environment.
DEET removal from WWTPs varies depending on the specific conditions of each site.  Aronson et al. 
(2012) summarized several studies in which removal from WWTPs ranged from 10 to 99%.  Removal
from trickling filter treatment plants was generally lower than activated sludge plants.  Knepper (2004)
observed that elimination rates in WWTPs varied with influent concentration levels of DEET.
Elimination rates were negligible in winter and spring months and increased in late summer up to 90%
when concentration levels of DEET peak.
The removal of DEET from drinking water and waste water treatment plants located in South Korea was
assessed by Kim et al. (2007). Various removal systems including membrane bioreactors, reverse 
osmosis, nanofiltration, and ultraviolet (UV) irradiation were analyzed.  Minimal removal was reported
with membrane systems; the other systems, however, removed DEET to concentrations <1 ng/L (initial
concentrations averaged 18 ng/L).  Utilizing granulated activated carbon was the most efficient removal
system for drinking waters.
6.4  LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT
Reliable evaluation of the potential for human exposure to DEET depends in part on the reliability of
supporting analytical data from environmental samples and biological specimens.  Concentrations of
DEET in unpolluted atmospheres and in pristine surface waters are often so low as to be near the limits of
current analytical methods.  In reviewing data on DEET levels monitored or estimated in the
environment, it should also be noted that the amount of chemical identified analytically is not necessarily
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equivalent to the amount that is bioavailable. The analytical methods available for monitoring DEET in a 
variety of environmental media are detailed in Chapter 7.
Care should be taken when assessing analytical results for which a limit of detection (LOD) or similar
sensitivity value is not provided for the substance of interest, as well as the study reports not having
detected that substance; failing to detect a substance does not mean that it is not present.
6.4.1 Air
DEET was detected in an air quality study of <2.5 μm aerosol samples performed in Canada from
August 1 to 30, 2001.  Samples were taken both at daytime and nighttime at five locations:  Golden Ears 
Park (in a forested area), Cassiar Tunnel, Slocan Park (low-density urban surrounding), Langley Lochiel
(a rural environment), and an elevated Sumas Eagle Ridge (forest/urban area).  DEET concentrations 
ranged from 0.95 to 15.4 ng/m3 (Cheng et al. 2006). 
DEET was detected, but not quantified, in the atmosphere of Rome, Italy in the winter and summer of
2009 (Balducci et al. 2012).
6.4.2 Water
DEET has been detected in streams, surface water and groundwater systems, and sewage treatment plant
effluents throughout the United States (Glassmeyer et al. 2005; Kolpin et al. 2002; Sandstrom et al. 
2005).  A summary of published studies by Brausch and Rand (2011) reported measured concentrations
for DEET in 188 surface waters samples throughout the United States ranging from 13 to 660 ng/L
(0.013–0.66 µg/L), with a median value of 55 ng/L (0.055 µg/L).  A review by Costanzo et al. (2007)
reported that DEET has been detected and reported in worldwide water samples, such as drinking water,
streams, marine waters, groundwater, and treated effluent at concentrations of 40–3,000 ng/L (0.04– 
3.0 µg/L) and has also been detected in coastal waterways in Australia at concentrations of 8–1,500 ng/L
(0.008–1.5 µg/L).  DEET was detected in 8 of 50 groundwater samples from unconfined (<30 m) and 
confined (up to 500 m) aquifers in Tokyo taken between October and November 2007 (Kuroda et al. 
2012).  The arithmetic mean limit of quantification (LOQ) for the study was reported as 20.8 ng/L
(0.0208 µg/L).  The concentrations in these groundwater samples were lower on average, yet were 
comparable to sewage influent concentrations of DEET (503 ng/L [0.503 µg/L]) measured in the WWTPs
of Tokyo in a previous study (Kuroda et al. 2012).  DEET was detected in 83.5% of groundwater samples 












   
  
    
  
     
   
  
   
    
 
 
    
   
 
  
     
     
 
 













6.  POTENTIAL FOR HUMAN EXPOSURE
(n=164) obtained from 23 European countries at an average concentration of 9 ng/L (0.009 µg/L) (Loos et
al. 2010).  Knepper (2004) investigated WWTP samples from June 1998 until October 2002 in 
Wiesbaden, Germany.  During the winter and spring months of 1999, influent and effluent concentrations
were comparable, yielding concentrations as high as to 0.6 µg/L.  Summer influent concentrations in 1999 
increased to 3 µg/L; effluent concentrations increased to 1–1.5 µg/L.  Influent concentrations in 
November 1999 decreased from the summer month concentrations to 0.26–0.49 µg/L (Knepper 2004).  
Effluents from 90 WWTPs across Europe were sampled in 2010.  Out of 156 chemicals targeted for
analysis, DEET was one of the highest concentration chemicals found at levels up to 15.8 µg/L, with an 
average detection of 678 ng/L (0.678 µg/L); LOQ=1 ng/L (0.001 µg/L) (Loos et al. 2013a).  DEET was
detected in influent samples from three WWTPs serving large metropolitan areas of the United States at
levels of 54–500 ng/L (0.054–0.5 µg/L) and in effluent samples at 100–260 ng/L (0.1–0.26 µg/L)
(Trenholm et al. 2008).  
Guardiola et al. (1989) identified DEET in groundwater samples from wells, which had been closed for
several years due to pollution, in the Besos river basin (northeastern Spain) at concentrations up to 
34 ng/L (0.034 µg/L).  In a United States Geological Survey (USGS) study, samples were taken on 
September 6, 2000 from five multilevel monitoring wells near the Norman Landfill in Oklahoma, with
reported concentrations of DEET ranging from <800 to 1,300 ng/L (<0.8–1.3 µg/L); the detection limit 
was 40 ng/L (0.04 µg/L). Well depths ranging from 3.26 to 6.29 m and their distances from the landfill
were from 1 to 574 m (Barnes et al. 2004).  DEET has been detected in surface water samples in
numerous studies at concentrations of 2–2,100 ng/L (0.002–2.1 µg/L) (Dougherty et al. 2010).  DEET
was detected in water samples at 3 of 11 sites sampled in September and April near Liberty Bay,
Washington.  It was detected in one surface water sample and two groundwater samples at concentrations
of 2.3–3.3 ng/L (0.0023–0.0033 µg/L).  Two of the sites were also tested with polar organic chemical
integrative samplers (POCIS) put in place for 62 days from January to March 2007 and again for 61 days
from July to September 2007; DEET was detected at site 1 at 2.1–3.4 ng/POCIS (detection limit 
1.0 ng/POCIS) and at site 2 at 3.0–6.3 ng/POCIS (Dougherty et al. 2010). 
DEET was detected, but not quantified, in leachate samples of three domestic and industrial waste 
landfills (Eggen at al. 2010).  These sites operated between 1973 and 1989 (this site also accepted 
separated residual domestic waste from 1985 through 2010 when the paper was written), 1974 and 2006, 
and 1972 and 2002.
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In a USGS survey during 1999 and 2000, 139 streams from 30 states were sampled.  DEET was reported 
in 74.1% of the samples analyzed at a median concentration of 60 ng/L (0.06 µg/L) and a maximum
concentration of 1,100 ng/L (1.1 µg/L) (Kolpin et al. 2002).  In the 2000 USGS survey, DEET was
detected in 73.2% of 56 stream samples at a median concentration of 0.05 µg/L and a maximum
concentration of 1.13 µg/L.  The analytical method used methylene chloride liquid-liquid extraction 
(LLE) of whole water followed by capillary-column gas chromatography/mass spectrometry (GC/MS)
operated in selected-ion monitoring mode, and achieved a detection level of 0.02 µg/L, if retention time
and ionic abundance criteria were met; otherwise, the reporting limit was 0.08 µg/L (Sandstrom 2005).  
Site selection focused on urban and agricultural areas, during various seasons, at locations where there
was the possibility of waste water contamination, via human, industrial, and agricultural sources, entering
the streams.  Levels were highest near urban areas and during summer and late winter.  An attempt was
made to re-analyze these samples for DEET metabolites; however, none of the chemicals could be 
detected in the samples.  Limitations were noted and more accurate methods for their determination need 
further consideration (Sandstrom et al. 2005).  In 2001, Kolpin et al. (2004) detected DEET in water
samples collected from 23 stream locations situated upstream and downstream of 10 cities in Iowa.  
Stream samples were taken during high, normal, and low flow conditions.  DEET was detected in the
23 normal-flow samples with a frequency of 4.3% and a maximum concentration of 62 ng/L (0.062 µg/L)
and in the 30 low-flow samples with a frequency of 6.7% and a maximum concentration of 130 ng/L
(0.13 µg/L).  DEET was not detected in any of the 23 high-flow samples.  DEET was detected in 43% of
samples collected in March, April, and August of 2004 from 18 streams in north-central and northwestern 
Arkansas.  Concentrations in the water samples were below the detection limit (0.5 µg/L) and were
estimated as 18–83 ng/L (0.018–0.083 µg/L) (Haggard et al. 2006).  Water samples collected from the
main-stem Mississippi River during 1987 through 1992 contained DEET at concentrations of 8–110 ng/L
(0.008–0.11 µg/L) (Goolsby and Pereira 1996).  In 1989, DEET was detected in five of eight surface
water samples taken at various locations along the Rhine River in The Netherlands at concentrations of
21–46 ng/L (0.021–0.046 µg/L) (Hendriks et al. 1994).  DEET was detected in 12 of 15 sampling sites
along the northern River in Germany between June 24 and July 7, 1998 at concentrations of 0.11– 
1.09 ng/L (0.00011–0.00109 µg/L) (Weigel et al. 2002).  Po River water samples collected in July 2008 
were analyzed for DEET and its degradation products. Fifteen transformation products were identified in 
the water samples.  DEET was detected in seven of the eight samples at concentrations of 0.6– 
155.55 ng/L (0.0006–0.156 µg/L).  The detection limit was 0.5 ng/L (0.0005 µg/L) (Calza et al. 2011).  
Freshwater streams were monitored in Hessisches Ried region, Germany from September 2003 to 
September 2006 (Quednow and Puttmann 2009); 330 samples were collected on 13 different occasions at
26 locations.  The mean concentration of DEET detected was 245 ng/L (0.245 µg/L), with the highest
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concentration (1.3 µg/L) occurring in June 2004.  Overall, mean concentrations were higher in the
summer months than during the other seasons.
Water samples taken from 0.5 m below the water surface of the Zhujiang and Shijing Rivers were
collected in July and August 2011 (Yang et al. 2013). Concentrations of DEET were below the LOQ in 
three samples; however, concentrations ranged from 0.2 to 107 ng/L (0.0002–0.107 µg/L) in all other
samples (n=24). The higher levels of DEET at some of the sites were attributed to its use as a pesticide in
those areas.  Water samples (n=10) taken from 0.5 m below the water surface of the Beijiang River were 
also collected in July and August 2011; concentrations of DEET were 3–47 ng/L (0.003–0.047 µg/L
[ppb]).
Around Norway in 2002, DEET was detected in 12 seawater samples, into which sewage treatment plant
effluents and non-treated sewage are discharged, at concentrations of 0.4–13 ng/L (0.0004–0.013 µg/L)
(Weigel et al. 2004).  Marine samples taken in February, May, and September 2011 and March 2012 from
the northern Adriatic Sea approximately 50 cm below the surface contained DEET at concentrations of
0.349, 1.255, 4.995, and 0.460 ng/L, respectively (0.000349, 0.001255, 0.004995, and 0.00046 µg/L); the
average LOQ was reported as 0.213 ng/L (0.000213 µg/L [ppb]) (Loos et al. 2013b).  
Between November and December 2001, water samples were collected at several sites within a U.S.
drinking water treatment facility in a heavily populated, urbanized drainage basin.  DEET was detected in 
3 of the 12 stream and raw water samples (25% frequency of detection).  The highest concentration of
DEET in samples of finished water was 0.066 µg/L (ppb) (reporting level 0.5 µg/L) (Stackelberg et al.
2004).  DEET was not detected in 15 finished drinking water samples from four water filtration plants in 
San Diego County, California; the sample dates were between August 2001 and June 2002.  DEET was, 
however, detected in 1 of 13 source water samples for four water filtration plants in San Diego County, 
California at a mean concentration of 0.131 µg/L (ppb); sample dates were August 2001 to November
2002 (Loraine and Pettigrove 2006).  DEET was detected in two of six water samples from a waste water
reclamation plant in San Diego County, California at a mean concentration of 1.31 µg/L; sample dates
were September 2001 to June 2002 (Loraine and Pettigrove 2006).  In samples taken during 2006 and 
2007 from drinking water treatment plants across the United States, DEET was detected in the source 
water at 6 of 19 plants at a maximum concentration of 110 ng/L (0.11 µg/L) and a median concentration 
of 85 ng/L (0.085 µg/L) and in the finished water at 6 of 18 plants at a maximum concentration of
93 ng/L (0.093 µg/L) and a median concentration of 63 ng/L (0.063 µg/L [ppb]) (Benotti et al. 2009).  In 
New York between May 2003 and January 2005, effluent concentrations, ranging from 0.3 to 15 µg/L
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(ppb), from WWTPs indicated that removal rates were minimal (Phillips et al. 2005).  Effluent 
concentrations in Las Vegas, Nevada in June 2005 and January 2006 were on average between 0.123 and 
0.188 µg/L [ppb]) (Snyder 2005).
DEET was detected in water samples taken from two locations on Assunpink Creek in Trenton, New
Jersey.  At the first collection site downstream from a WWTP effluent discharge, DEET was detected at
levels of 51–99 ng/L (0.051–0.099 µg/L).  At the second site, 2 miles further downstream, DEET was
detected at 45–340 ng/L (0.045–0.34 µg/L) (Alvarez et al. (2005).  DEET was analyzed for in 10 WWTP-
influenced sites around the United States.  Samples were taken upstream from the plant, from the effluent, 
and two samples were taken at varying distances downstream.  DEET was reported in 70% of the
samples, with a median concentration of 0.097 µg/L and a maximum concentration of 2.1 µg/L; the
reporting level was 0.5 µg/L (Glassmeyer et al. 2005).  In July 2006, DEET was detected at
concentrations of 0.09, 0.02, 0.04, and 0.065 µg/L (median detection level of 0.005 µg/L) in samples from
sites on Wascana Creek, Saskatchewan, Canada.  Samples were collected 31.8 km upstream from Regina,
a sewage treatment plant, and 9.3, 59.8, and 104.8 km downstream from the sewage treatment plant, 
respectively. DEET was also detected at the same sampling sites in May 2007 (Waiser et al. 2011).
During October 2006–November 2007, Foster (2007) tested WWTPs in San Marcos, Texas and found 
that DEET was one of the most frequently detected compounds.  The treatment plant uses activated
sludge, granular activated carbon filtration, and ultraviolet disinfection.  There was no detection of DEET
30 yards upstream from the effluent discharge.  DEET was detected at a mean concentration of 1.7 µg/L
(ppb) in 100% of the influent samples; DEET was detected at a mean concentration of 0.023 µg/L in 33%
of the effluent samples and 0.009 µg/L (ppb) in 33% of the samples 30 yards downstream from the
effluent discharge (detection limit=14.5 ng/L).
Through 1998 and 1999, DEET was detected in the effluents of 11 out of 19 WWTPs located in 
Switzerland at concentrations under the detection limit up to 1.3 µg/L (ppb) (Gerecke et al. 2002).  Kim et
al. (2007) reported a mean concentration of 0.0247 µg/L (ppb) for DEET in seven WWTPs located in 
South Korea. These plants receive about 85% domestic waste and use mainly activated sludge treatment
methods. 
In northeastern Kansas, Lee and Rasmussen (2006) detected median levels of DEET at 1.4 and <0.5 µg/L
in the effluent of three trickling filter WWTPs and four activated sludge WWTPs (MRL 0.5 µg/L).  In
southeastern Miami, an activated sludge WWTP produced median effluent concentrations of
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6.  POTENTIAL FOR HUMAN EXPOSURE
approximately 0.20 µg/L (ppb) (method detection limit=0.14 µg/L) during spring and summer months of
March and July 2004 (Lietz and Meyer 2006).
In 1984 and 1991, Eckel et al. (1993) detected, but did not quantify DEET in the leachate from Hipps
Road Landfill, Jacksonville, Florida, a site that received waste in 1968 and 1969.  In May 1990, DEET
was detected, but not quantified, in three municipal landfill leachate samples in Gryta, Vasteras, Sweden
(Oman and Hynning 1993).
DEET was detected in marine coastal areas along the Florida Keys following an underwater music 
festival in which human recreational activities occurred in and around the water.  Samples were taken
before, during, and after the festival.  DEET concentrations ranged from not detected to 17 ng/L
(0.017 µg/L) (Chaudhary et al. 2005).  DEET was detected in coastal waters of Norway at levels of 4.2– 
240.8 ng/L (0.0042–0.2408 µg/L) (Langford et al. 2008).  
Aronson et al. (2012) reported a study in which DEET produced mean concentrations ranging from 2.6 to 
4.3 µg/L (ppb) in confined animal-feeding operation waste waters in Nebraska, while feed lot lagoons in 
Minnesota had concentrations under the method reporting level of 0.5µg/L (ppb) (Lee et al. 2004).  
Additionally, these authors compiled concentrations of DEET measured in published studies from 1996 to 
2010 found in influent and effluent waste waters, and published studies from 1994 to 2010 of surface
waters in and outside of the United States. Kim et al. (2007) studied rivers receiving WWTP effluents 
and found DEET in seven out of eight samples with a mean concentration of 0.022 µg/L (ppb) (method 
detection limit=1 ng/L). 
DEET was detected in 98% of reclaimed water samples (n=55) collected from sprinkler systems used for
daily irrigation in Florida.  The water had received primary and secondary treatments not designed to 
remove micronutrients.  One sample reached the maximum concentration of approximately 14,000 ng/L
(14 µg/L), while the rest were <1.5 µg/L (Wang and Gardinali 2013). 
6.4.3 Sediment and Soil
No data were located on the environmental levels of DEET in sediment or soil.
6.4.4 Other Environmental Media 
No data were located on the levels of DEET in other environmental media.
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6.5  GENERAL POPULATION AND OCCUPATIONAL EXPOSURE
Exposure of the general population to DEET is expected to be relatively high based on its use as an insect
and acarid repellent.  Consumer products containing DEET are intended for direct application onto skin 
and/ or clothing while being worn.  Products such as wrist bands or nets may also be impregnated with 
DEET.  The general population is exposed to DEET via dermal contact after direct application of DEET
insect repellents.
The Fourth National Report on Human Exposure to Environmental Chemicals (CDC 2009, 2017) 
includes results from the assessment of DEET levels in the National Health and Nutrition Examination 
Survey (NHANES) for urine samples from 4,512 members of the U.S. general population surveyed 
during the years 1999–2000 and 2001–2002.  As shown in Table 6-1 and 6-2, the average for DEET was 
below the detection limit (0.449 µg/L) for the survey years 1999–2000 in each selected percentile.  For
the survey years 2001–2002, the total geometric mean, and the 50th and 75th percentiles were also below
the detection limit (0.1 µg/L).  The 90th and 95th percentiles were just above the LOD and reported DEET
concentrations were 0.11 and 0.18 µg/L (Table 6-1), respectively, and the creatinine corrected values
were 0.27 and 0.41 µg/g creatinine, respectively (Table 6-2). For the survey years 2007–2008 and 2009– 
2010, the average for DEET was again below the detection limit (0.089 µg/L) in each selected percentile.
Because DEET undergoes oxidative metabolism in humans, more sensitive biomarkers for assessing
DEET exposure are the metabolites DCBA and DHMB (Calafat et al. 2016), which are included in the
updated tables, January 2017 of the Fourth National Report on Human Exposure to Environmental
Chemicals (CDC 2017). As shown in Tables 6-3 and 6-5, for the survey years 2007–2008, the total
geometric mean for DCBA was 3.50 µg/L, while that for DHMB was not determinable, and the respective
90th and 95th percentiles were 33.9 and 79.2 µg/L for DCBA and 0.229 and 0.780 µg/L for DHMB. For
the survey years 2009–2010, the total geometric mean for DCBA was 4.54 µg/L, while that for DHMB
was not determinable, and the respective 90th and 95th percentiles were 51.9 and 165 µg/L for DCBA and 
0.455 and 1.34 µg/L for DHMB. In Tables 6-4 and 6-6, for the survey years 2007–2008, the total
geometric mean for DCBA was 3.60 µg/g creatinine, while that for DHMB was not determinable, and the
respective 90th and 95th percentiles were 27.3 and 70.8 µg/g creatinine for DCBA and 0.331 and 
0.628 µg/g creatinine for DHMB. For the survey years 2009–2010, the total geometric mean for DCBA
was 4.74 µg/g creatinine, while that for DHMB was not determinable, and the respective 90th and 
95th percentiles were 44.6 and 131 µg/g creatinine for DCBA and 0.449 and 1.13 µg/g creatinine for
DHMB.
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Table 6-1.  Geometric Mean and Selected Percentiles of Urine Concentrations of DEET (in µg/L) for the
 




Geometric Selected percentiles (95% CI)
Survey years
mean 
(95% CI) 50th 75th 90th 95th 
Sample 
size
Total 1999–2000b *d <LODf <LOD <LOD <LOD 1,977
2001–2002b *d <LOD <LOD 0.11 (0.10–0.14) 0.18 (0.14–0.22) 2,535
2007–2008c *e <LOD <LOD <LOD <LOD 2,565
2009–2010c *e <LOD <LOD <LOD <LOD 2,744
Age group
6–11 years 1999–2000 * <LOD <LOD <LOD <LOD 480
2001–2002 * <LOD <LOD 0.13 (0.10–0.18) 0.21 (0.12–0.56) 580
2007–2008 * <LOD <LOD <LOD <LOD 380
2009–2010 * <LOD <LOD <LOD <LOD 386
12–19 years 1999–2000 * <LOD <LOD <LOD <LOD 672
2001–2002 * <LOD <LOD 0.13 (0.11–0.16) 0.22 (0.13–0.52) 829
2007–2008 * <LOD <LOD <LOD <LOD 386
2009–2010 * <LOD <LOD <LOD <LOD 400
20–59 years 1999–2000 * <LOD <LOD <LOD <LOD 825
2001–2002 * <LOD <LOD 0.11 (<LOD–0.13) 0.17 (0.13–0.21) 1,126
2007–2008 * <LOD <LOD <LOD <LOD 1,169
2009–2010 * <LOD <LOD <LOD <LOD 1,307
≥60 years 2007–2008 * <LOD <LOD <LOD <LOD 630
2009–2010 * <LOD <LOD <LOD <LOD 651
Gender
Males 1999–2000 * <LOD <LOD <LOD <LOD 964
2001–2002 * <LOD <LOD 0.11 (0.10–0.15) 0.18 (0.13–0.25) 1,191
2007–2008 * <LOD <LOD <LOD <LOD 1,286
2009–2010 * <LOD <LOD <LOD <LOD 1,343
Females 1999–2000 * <LOD <LOD <LOD <LOD 1,013
2001–2002 * <LOD <LOD 0.11 (0.10–0.13) 0.17 (0.13–0.21) 1,344
2007–2008 * <LOD <LOD <LOD <LOD 1,279
2009–2010 * <LOD <LOD <LOD <LOD 1,401
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Table 6-1.  Geometric Mean and Selected Percentiles of Urine Concentrations of DEET (in µg/L) for the
 







(95% CI) 50th 
Selected percentiles (95% CI)






































































aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
 








dNot calculated; the proportion of results below limit of detection (LOD) was too high to provide a valid result.  The LODs for survey years 1999–2000 and 2001–
 
2002 were 0.449 and 0.1 µg/L, respectively.
 
eNot calculated; the proportion of results below LOD was too high to provide a valid result. The LOD for survey years 2007–2008 and 2009–2010 was 0.089 µg/L.
 
f<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
CI = confidence interval
























































































































































        

























































6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Geometric Mean and Selected Percentiles of Urine Concentrations of DEET (Creatinine Corrected)
(µg/g creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey
(NHANES) 1999–2002, 2007–2010a 
Geometric Selected percentiles (95% CI)
Survey years
mean 
(95% CI) 50th 75th 90th 95th 
Sample 
size
Total 1999–2000b *d <LODf <LOD <LOD <LOD 1,977
2001–2002b *d <LOD <LOD 0.27 (0.24–0.30) 0.41 (0.35–0.50) 2,534
2007–2008c *e <LOD <LOD <LOD <LOD 2,563
2009–2010c *e <LOD <LOD <LOD <LOD 2,744
Age group
6–11 years 1999–2000 * <LOD <LOD <LOD <LOD 480
2001–2002 * <LOD <LOD 0.33 (0.23–0.63) 0.64 (0.28–1.93) 580
2007–2008 * <LOD <LOD <LOD <LOD 380
2009–2010 * <LOD <LOD <LOD <LOD 386
12–19 years 1999–2000 * <LOD <LOD <LOD <LOD 672
2001–2002 * <LOD <LOD 0.19 (0.15–0.24) 0.25 (0.19–0.49) 828
2007–2008 * <LOD <LOD <LOD <LOD 384
2009–2010 * <LOD <LOD <LOD <LOD 400
20–59 years 1999–2000 * <LOD <LOD <LOD <LOD 825
2001–2002 * <LOD <LOD 0.27 (<LOD–0.32) 0.41 (0.37–0.50) 1,126
2007–2008 * <LOD <LOD <LOD <LOD 1,169
2009–2010 * <LOD <LOD <LOD <LOD 1,307
≥60 years 2007–2008 * <LOD <LOD <LOD <LOD 630
2009–2010 * <LOD <LOD <LOD <LOD 651
Gender
Males 1999–2000 * <LOD <LOD <LOD <LOD 964
2001–2002 * <LOD <LOD 0.20 (0.17–0.25) 0.32 (0.25–0.44) 1,191
2007–2008 * <LOD <LOD <LOD <LOD 1,285
2009–2010 * <LOD <LOD <LOD <LOD 1,343
Females 1999–2000 * <LOD <LOD <LOD <LOD 1,013
2001–2002 * <LOD <LOD 0.33 (0.29–0.37) 0.50 (0.41–0.58) 1,343
2007–2008 * <LOD <LOD <LOD <LOD 1,278
2009–2010 * <LOD <LOD <LOD <LOD 1,401



















        
        























































































   
 
 
      
 
    
  





6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-2.  Geometric Mean and Selected Percentiles of Urine Concentrations of DEET (Creatinine Corrected)
(µg/g creatinine) for the U.S. Population from the National Health and Nutrition Examination Survey




(95% CI) 50th 
Selected percentiles (95% CI)






































































aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
 








dNot calculated; the proportion of results below limit of detection (LOD) was too high to provide a valid result. The LODs (not corrected for creatinine) for survey
 
years 1999–2000 and 2001–2002 were 0.449 and 0.1 µg/L, respectively.
 
eNot calculated; the proportion of results below LOD was too high to provide a valid result. The LOD (not corrected for creatinine) for survey years 2007–2008
 
and 2009–2010 was 0.089 µg/L.

f<LOD means less than the limit of detection for urine samples; not corrected for creatinine.
 
CI = confidence interval
































































































        





























6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-3.  Geometric Mean and Selected Percentiles of Urine Concentrations of 3-(Diethylcarbamoyl) Benzoic 
Acid (DCBA) (µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey
(NHANES) 2007–2010a 
Selected percentiles (95% CI)Geometric Sample 































































































































        
        













































   
 







6.  POTENTIAL FOR HUMAN EXPOSURE
Table 6-3.  Geometric Mean and Selected Percentiles of Urine Concentrations of 3-(Diethylcarbamoyl) Benzoic 




mean (95% CI) 50th 
Selected percentiles (95% CI)




Mexican Americans 2007–2008 3.70 (2.57–5.33) 3.26 (1.87–5.17) 9.63 (5.93–17.6) 28.0 (14.7–69.1) 69.1 (27.5–133) 490
2009–2010 2.63 (1.61–4.28) 2.03 (.932–4.71) 7.35 (4.22–14.5) 23.1 (12.5–48.2) 48.9 (26.0–94.3) 599
Non-Hispanic blacks 2007–2008 4.36 (3.18–5.96) 3.54 (2.24–6.04) 10.3 (6.78–17.4) 31.9 (19.3–51.6) 62.4 (40.4–103) 562
2009–2010 3.91 (2.85–5.35) 3.22 (2.24–4.75) 9.53 (5.88–14.4) 23.4 (18.0–33.4) 38.4 (29.1–60.5) 497
Non-Hispanic whites 2007–2008 3.47 (2.35–5.14) 2.22 (1.65–3.19) 9.12 (4.82–17.0) 36.5 (17.7–82.0) 86.9 (32.9–356) 1,064
2009–2010 5.48 (3.83–7.84) 4.31 (2.64–6.25) 17.7 (10.5–28.4) 67.9 (32.6–195) 200 (63.8–832) 1,199
aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
measurements.  The most up-to-date data for environmental chemicals and reference ranges in the U.S. general population are available at the National Report
website: https://www.cdc.gov/exposurereport/. 
The limits of detection for survey years 2007–2008 and 2009–2010 were 0.93 and 0.475 µg/L, respectively.
CI = confidence interval
Source:  CDC 2017
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Table 6-4.  Geometric Mean and Selected Percentiles of Urine Concentrations of 3-(Diethylcarbamoyl) Benzoic 

Acid (DCBA) (Creatinine Corrected) (µg/g creatinine) for the U.S. Population from the National Health and
 
Nutrition Examination Survey (NHANES) 2007–2010a
 
Selected percentiles (95% CI)Geometric Sample 
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Table 6-4.  Geometric Mean and Selected Percentiles of Urine Concentrations of 3-(Diethylcarbamoyl) Benzoic 

Acid (DCBA) (Creatinine Corrected) (µg/g creatinine) for the U.S. Population from the National Health and
 




mean (95% CI) 50th 
Selected percentiles (95% CI)




Mexican Americans 2007–2008 3.79 (2.57–5.58) 3.60 (1.99–5.96) 9.91 (6.55–16.9) 27.8 (15.0–60.6) 60.6 (24.4–107) 490
2009–2010 2.74 (1.75–4.28) 2.03 (1.12–5.18) 7.57 (3.92–14.0) 23.3 (13.6–31.8) 37.4 (23.6–90.5) 599
Non-Hispanic blacks 2007–2008 3.33 (2.46–4.49) 2.74 (1.91–3.76) 7.07 (4.88–11.9) 22.5 (12.6–45.1) 53.9 (28.7–103) 561
2009–2010 2.98 (2.26–3.94) 2.41 (1.70–3.37) 6.73 (4.34–9.46) 16.5 (13.0–20.4) 30.6 (19.4–51.1) 497
Non-Hispanic whites 2007–2008 3.78 (2.69–5.32) 2.82 (2.05–4.02) 8.70 (5.23–14.9) 30.7 (16.7–57.2) 76.9 (26.7–432) 1,064
2009–2010 5.97 (4.13–8.64) 4.41 (2.61–7.43) 17.4 (10.7–26.7) 61.1 (29.0–189) 189 (56.4–849) 1,199
aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
measurements.  The most up-to-date data for environmental chemicals and reference ranges in the U.S. general population are available at the National Report
website: https://www.cdc.gov/exposurereport/. 
The limit of detection (not corrected for creatinine) for survey years 2007–2008 and 2009–2010 were 0.93 and 0.475 µg/L, respectively.
CI = confidence interval
Source:  CDC 2017
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Table 6-5.  Geometric Mean and Selected Percentiles of Urine Concentrations of N,N-Diethyl-3-(Hydroxymethyl) 
Benzamide (DHMB) (µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey
(NHANES) 2007–2010a 
Geometric Selected percentiles (95% CI)
Survey years
mean (95%

















2007–2008 * <LOD <LOD 0.275 (0.168–0.433) 0.640 (0.264–2.64) 380
2009–2010 * <LOD <LOD 0.655 (<LOD–2.93) 2.82 (0.205–24.6) 385
2007–2008 * <LOD <LOD 0.356 (<LOD–0.879) 0.665 (0.165–8.14) 386
2009–2010 * <LOD <LOD 0.472 (<LOD–1.59) 1.20 (0.201–4.11) 398
2007–2008 * <LOD <LOD 0.188 (<LOD–0.413) 0.767 (0.335–1.30) 1,167
2009–2010 * <LOD <LOD 0.498 (0.172–0.956) 1.34 (0.729–2.29) 1,304
2007–2008 * <LOD <LOD 0.256 (<LOD–0.787) 0.787 (0.194–1.81) 629
2009–2010 * <LOD <LOD 0.257 (0.106–0.512) 0.840 (0.521–2.46) 649
2007–2008 * <LOD <LOD 0.325 (0.091–0.909) 1.05 (0.249–4.86) 1,283
2009–2010 * <LOD <LOD 0.744 (0.323–1.43) 1.81 (0.946–3.94) 1,339
2007–2008 * <LOD <LOD 0.165 (<LOD–0.326) 0.512 (0.256–0.968) 1,279
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Table 6-5.  Geometric Mean and Selected Percentiles of Urine Concentrations of N,N-Diethyl-3-(Hydroxymethyl) 
Benzamide (DHMB) (µg/L) for the U.S. Population from the National Health and Nutrition Examination Survey
(NHANES) 2007–2010a 
Geometric Selected percentiles (95% CI)
mean (95% Sample 
Survey years CI) 50th 75th 90th 95th size
Race/ethnicity
Mexican Americans 2007–2008 * <LOD <LOD 0.216 (0.092–0.509) 0.509 (0.207–0.989) 499
2009–2010 * <LOD <LOD 0.228 (<LOD–0.504) 0.507 (0.223–0.866) 598
Non-Hispanic blacks 2007–2008 * <LOD <LOD 0.310 (0.091–0.470) 0.640 (0.378–1.29) 567
2009–2010 * <LOD <LOD 0.135 (<LOD–0.292) 0.449 (0.212–0.884) 503
Non-Hispanic whites 2007–2008 * <LOD <LOD 0.255 (<LOD–0.861) 0.884 (0.225–4.84) 1,071
2009–2010 * <LOD <LOD 0.644 (0.182–1.34) 1.89 (0.770–5.34) 1,195
aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
 




bNot calculated; the proportion of results below limit of detection (LOD) was too high to provide a valid result.  The LOD for survey years 2007–2008 and 2009–
 
2010 was 0.083 µg/L.
 
c<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
CI = confidence interval
Source:  CDC 2017
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Table 6-6.  Geometric Mean and Selected Percentiles of Urine Concentrations of N,N-Diethyl-3-(Hydroxymethyl) 
Benzamide (DHMB) (Creatinine Corrected) (µg/g creatinine) for the U.S. Population from the National Health 
and Nutrition Examination Survey (NHANES) 2007–2010a 
Geometric Selected percentiles (95% CI)
mean Sample 
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Table 6-6.  Geometric Mean and Selected Percentiles of Urine Concentrations of N,N-Diethyl-3-(Hydroxymethyl) 
Benzamide (DHMB) (Creatinine Corrected) (µg/g creatinine) for the U.S. Population from the National Health 
and Nutrition Examination Survey (NHANES) 2007–2010a 
Geometric Selected percentiles (95% CI)
mean Sample 
Survey years (95% CI) 50th 75th 90th 95th size
Race/ethnicity
Mexican Americans 2007–2008 * <LOD <LOD 0.315 (0.203–0.446) 0.467 (0.337–0.720) 498
2009–2010 * <LOD <LOD 0.297 (<LOD–0.401) 0.415 (0.299–0.718) 598
Non-Hispanic blacks 2007–2008 * <LOD <LOD 0.234 (0.175–0.411) 0.487 (0.315–1.05) 566
2009–2010 * <LOD <LOD 0.221 (<LOD–0.262) 0.362 (0.246–0.648) 503
Non-Hispanic whites 2007–2008 * <LOD <LOD 0.343 (<LOD–0.583) 0.826 (0.349–2.99) 1,071
2009–2010 * <LOD <LOD 0.531 (0.305–1.36) 1.59 (0.524–5.83) 1,195
aData in this table come from the National Report on Human Exposure to Environmental Chemicals and Update Tables, which is continuously updated with new
 




bNot calculated; the proportion of results below limit of detection (LOD) was too high to provide a valid result.  The LOD (not corrected for creatinine) for survey
 
years 2007–2008 and 2009–2010 was 0.083 µg/L.
 
c<LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
 
CI = confidence interval
Source:  CDC 2017
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6.  POTENTIAL FOR HUMAN EXPOSURE
Records of human exposure to DEET and/or DEET and other products were compiled from centers
reporting to the Toxic Exposure Surveillance System from 1993 to 1997 (Bell et al. 2002). There were
20,764 exposure cases identified.  Cases involving infants, children, and teenagers accounted for 18.6, 
64.5, and 3.1% respectively.  Of all the exposures, 89.2% occurred at the subject’s home due to misuse of
the product.  There were 20,346 cases that involved products intended for human use, while 418 of the
cases involved DEET-containing veterinary products.  Ingestion accounted for 51.8% of the exposure
incidents.  Ocular, dermal, and multiple route exposures accounted for 21.3, 10.5, and 13.4% respectively.  
Of all the cases, 6,267 involved products containing <11% DEET, 9,003 involved products containing
between 11 and 50% DEET, and 2,111 involved products containing >50% DEET; 3,293 of the cases
reported unknown concentrations of DEET.  A similar study conducted between 1985 and 1989 evaluated 
9,086 human exposures of any product containing DEET reported to Poison Control Centers (Veltri et al. 
1994). Most of the exposures occurred between May and September when DEET use is at its highest.
Close to two-thirds of the incidents resulted in minor symptoms or did not have any adverse effects. 
Forty-nine percent of the exposures were due to ingestion, 32% resulted from ocular exposure, 12% were
reported from multiple exposure routes, 4.2% from dermal exposure, and 2% via inhalation.  More than 
65% of exposure cases involved children 2–5 years of age.  In a more recent report (from the 2012 
Annual Report of the American Association of Poison Control Centers’ National Poison Data System
[NPDS] 30th Annual Report) (AAPCC 2013), it is stated that there were 4,158 cases in which DEET was
mentioned and 4,075 cases that involved solely DEET exposure.  There were 3,759 cases reported as 
unintentional.  The majority of the cases (2,316 cases) involved children ≤5 years old.  The outcome of all
the exposure incidents were typically minor (1,176 cases) or none at all (576 cases).  Moderate (83 cases), 
major (3 cases), and deadly (2 cases) outcomes were rarely observed.  Of the exposures reported, 88% did 
not produce symptoms that required treatment in a health care facility (Veltri et al. 1994).
Wu et al. (1979) found DEET in the urine sample of a 30-year-old male who applied a commercial
product containing DEET 18 hours after exposure.  Eight hours after application, the DEET concentration 
in the blood was reported at 0.3 mg%.  It was concluded that DEET was absorbed through the skin and 
about 10–14% was excreted unchanged.  Urinary metabolites such as N-ethyl-m-toluamide and 
m-carboxyl-N,N-diethylbenzoylamide were identified, but not quantified, in the study. In 1991, average
exposure estimates were derived for DEET based on one application/day to typical amounts used per
application (see Table 6-7).  Daily exposure values determined were 12.10, 9.68, 21.05, and 
37.63 mg/kg/day for adult males, adult females, children ages 13–17 years old, and children ≤12 years
old, respectively.  These values may underestimate actual exposure levels in some users as it is possible 
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6.  POTENTIAL FOR HUMAN EXPOSURE
assessments considering scenarios of individual adults who applied either a spray or aerosol product have 
been done following Standard Operating Procedures for Residential Pesticide Assessment developed by
EPA’s Health Effects Division (EPA 2012c). Individuals weighing 80 kg and applying spray or aerosol
products with 98% active ingredient (a.i.) were reported to be treating themselves with 9,453 and 
16,771 mg a.i./day, respectively (Table 6-7). 
A survey by the DEET Joint Venture reported on the use of products containing DEET as an active 
ingredient: 37% of the U.S. population is expected to use insect repellents and 60% of this usage occurs
in June and July. During these 2 months, repellents were used on an average of 7.5 and 5.6 days by adults
and children, respectively (EPA 2002). The yearly averages for numbers of days in which insect
repellents were used by the general population and children were 12.5 and 9.3 days, respectively (EPA
2002). It was estimated that either 5.9 g (aerosol), 1.0 g (lotion), or 2.3 g (pump spray) are applied as a 
single application either directly to skin or clothing (EPA 2002).
DEET was detected in urine samples from eight national park employees who applied approximately 1 g 
of lotion containing 71% DEET daily to their skin and clothes for 1 week.  The DEET concentration in 
the urine collected mid-week ranged from <180 to 5,960 µg/L.  In a laboratory study, two of nine male
volunteers ages 18–34 years, who applied a DEET-containing lotion, had quantifiable levels in their
urine.  Levels for the subject with higher readings were 2,020, 900, and 1,050 µg/L respectively at 4, 
12.5, and 22.0 hours after application. The urine concentration of the second subject with quantifiable 
concentrations at the last time point reported was 3-fold less at 310 µg/L.  The remaining seven 
volunteers had levels <90 µg/L (LOD=90 µg/L); below the limit of quantification (LOQ=180 µg/L) of
DEET in their urine. The highest concentration quantified was 2,020 µg/L at 4 hours after application 
and the lowest concentration was 310 µg/L at 22 hours after application.  Blood samples from the nine
volunteers had concentrations of DEET <LOQ to 1.17 µg/g (the LOQ for serum samples was 0.18 µg/g)
(Smallwood et al. 1992).
Although exposure from contaminated drinking water is minimal compared to that of exposure via dermal
application, DEET has been found at trace levels in water intended for human consumption (Benotti et al.
2009; Calza et al. 2011; Kim et al. 2007).
Two prenatal urine samples, the first at ~13 weeks of gestation and the second at ~26 weeks of gestation,
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Amount of DEET per
Category of exposure application (mg) Body weight (kg) Daily exposure (mg/kg/day)
Adult male 952.25 78.70 12.10
Adult female 649.31 67.10 9.68
Child, 13–17 years old 1,065.24 50.60 21.05
Child, ≤12 years old 940.83 25.00 37.63
Sources:  EPA 1998b, 1998c
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0.98 0.62 0.75 280 3.7 0.25 118 9,453
Aerosol spray,
adult human





cExposure estimated by multiplying the values in first six columns.

dIndividual exposure estimated by multiplying estimated body weight (e.g., 80 kg) by exposure (mg a.i./kg/day).
 
Source: EPA 2012c
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during 1999–2000.  The LOD of the analytical method was reported as 0.1 µg/L.  For the first and second 
samples, the maximum levels detected were 1.9 and 0.3 µg/L, the 95th percentile levels were 0.1 µg/L and
<LOD, and detection frequencies were 5.6 and 1.9%, respectively (Castorina et al. 2010).  The maximum 
concentrations were higher than the 95th percentile values reported during the latest monitoring period 
(2009–2010) by CDC (2017) in Table 6-1.
Cheng et al. (2006) reported finding DEET in air of the Lower Fraser Valley of Canada due to its
widespread use during summer.  The lowest levels measured (0.53–0.78 mg/m3) at a remote location and
were considered to be the ambient background for the area resulting from spraying livestock in that rural
area.  Higher levels in the urban forest were 3.03 ng/m3 during the day and 1.25 ng/m3 at night.  The
highest levels were in nearby Golden Ear Provincial Park, measuring 11.1–11.4 ng/m3 in the day and up 
to 37.1 ng/m3 at night when insect density and DEET use may have been greatest.
6.6  EXPOSURES OF CHILDREN 
This section focuses on exposures from conception to maturity at 18 years in humans.  Differences from
adults in susceptibility to hazardous substances are discussed in Section 3.7, Children’s Susceptibility.
Children are not small adults.  A child’s exposure may differ from an adult’s exposure in many ways.  
Children drink more fluids, eat more food, breathe more air per kilogram of body weight, and have a
larger skin surface in proportion to their body volume than adults.  A child’s diet often differs from that of 
adults.  The developing human’s source of nutrition changes with age: from placental nourishment to 
breast milk or formula to the diet of older children who eat more of certain types of foods than adults.  A
child’s behavior and lifestyle also influence exposure.  Children crawl on the floor, put things in their
mouths, sometimes eat inappropriate things (such as dirt or paint chips), and may spend more time
outdoors.  Children also are generally closer to the ground and have not yet developed the adult capacity
to judge and take actions to avoid hazards (NRC 1993).
Data regarding the exposure of children to DEET indicate that dermal exposure from direct application of
consumer products containing DEET is the most likely route.  Inhalation is possible during aerosol
product application, albeit a minor concern for exposure; additionally, hand-to-mouth behavior may result
in oral exposure.  Application of sunscreens containing DEET may result in unintentional overexposure to
children if the sunscreen is applied repeatedly throughout the day as many consumer sunscreen products
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children ≤5 years of age.  This may indicate a propensity for parents to apply DEET more liberally to 
protect their young children from insect bites, rather than a differential susceptibility. A recent interim
review of DEET by the EPA, under the Registration Review Program, states that DEET is approved for
use on children with no age restriction or percentage of DEET in the product; however, DEET should not
be applied by children under 10 and application should follow the guidelines stated on specific product
labels (EPA 2014i). In addition, the AAP recommends that repellents used on children should not contain 
more than 30% DEET and that no repellents should be used on infants below the age of 2 months (AAP
2015).  The CDC concurs with this use profile as adjusted by AAP (CDC 2015).  
Daily exposure estimates for DEET, assuming one application per day and standard body weights, were
calculated as 21.05 mg/kg/day for children 13–17 years old, and 37.63 mg/kg/day for children ≤12 years
old, in comparison to estimates of 93.68 mg/kg/day for adult females, and 12.10 mg/kg/day for adult
males.  These values may underestimate actual exposure due to individual consumer use patterns and do
not include exposure via inhalation or oral routes, although these are judged to be minor (EPA 1998b,
1998c). 
Menon and Brown (2005) documented patterns of children’s exposure to DEET products as a result of
their direct use as insect repellents.  Between 31 and 65% of the subjects did not follow recommended
procedures described in Chapter 1 of this document for the proper use of the products with respect to 
children, resulting in conditions that could lead to unnecessary overexposure.  For example, when 
applying DEET to the facial area, first apply to your hands and then rub the product onto your face.  
Avoid direct spraying to the face as this could cause the product to get into your eyes, mouth, or lungs.  
And, be sure to take off DEET products before going to bed (by showering or using a wash cloth) to
avoid overexposure.  Do not apply to children’s hands, and do not allow children to handle products
containing DEET since this can increase internal exposure through hand-to-mouth activities typical of
some children.
DEET exposure may occur during pregnancy.  Schaefer and Peters (1992) reported a case in which a 
pregnant woman living in Africa applied a lotion with 25% DEET to her arms and legs once or twice a
day during pregnancy.  Bradman et al. (2003) did not detect DEET in amniotic fluid samples (15– 
18 weeks of gestation) from 100 women in California (LOD =0.4 µg/L).  However, a study conducted 
from July 2003 to May 2004 of 150 women detected DEET in maternal serum samples at 1.82 to 
18.84 ng/g and in corresponding cord serum at 2.06–13.07 ng/g (Barr et al. 2010).  DEET was the most
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150 women in New Jersey at concentrations of 1.819–18.844 and 2.060–13.671 pg/mL, respectively
(LOD=0.01 pg/mL) (Yan et al. 2009).
In 2004, Arcury et al. (2007) evaluated urine samples from 60 farm children (1–6 years old) in eastern
North Carolina. Ten percent of the children had detectable levels of the metabolite for DEET
(LOD=0.1 ng/mL) in their urine. 
6.7  POPULATIONS WITH POTENTIALLY HIGH EXPOSURES 
Workers in industries that manufacture and formulate DEET and DEET-containing products are likely to 
be at higher risk than the general population for DEET exposure. People who work or recreate outdoors
(e.g., park rangers, hikers, hunters, campers) are more likely to be exposed to higher levels of DEET
through the use of products containing this substance as opposed to people who work and recreate indoors
(i.e., city dwellers) (Smallwood et al. 1992).  Consumers who use commercial products containing DEET
regularly, as a preventative measure for warding off insect bites, are exposed to higher levels of DEET
than the general population who do not directly use DEET products. Children have the potential to be
overexposed through misuse of the product (Bell et al. 2002).
6.8  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DEET is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research 
designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of DEET.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment.  This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
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6.8.1 Identification of Data Needs 
Physical and Chemical Properties. The physical chemical properties of DEET are summarized in
Chapter 4 (HSDB 2001; O’Neil et al. 2013; Weeks et al. 2012).  No data needs are identified.
Production, Import/Export, Use, Release, and Disposal. No information is available in the
TRI database on facilities that manufacture or process 2-hexanone because this chemical is not required to
be reported under Section 313 of the Emergency Planning and Community Right-to-Know Act (Title III 
of the Superfund Amendments and Reauthorization Act of 1986) (EPA 2005).
Environmental Fate. Transport, partitioning, and bioconcentration data are available for DEET.  The
fate of DEET in WWTPs has been summarized (ECHA 2010; Weeks et al. 2012).  Biodegradation in 
aquifer slurries and standard tests are available; however, no studies were located that assess 
biodegradation in soils.
Bioavailability from Environmental Media. No data were identified that assess the bioavailability
of DEET from environmental media such as soil and foods.
Food Chain Bioaccumulation. Studies are available that indicate that DEET does not
bioconcentrate in aquatic organisms and is not expected to bioaccumulate in the food chain (CITI 1992).  
No data needs are identified.
Exposure Levels in Environmental Media. Reliable monitoring data for the levels of DEET in
contaminated media at hazardous waste sites are needed so that the information obtained on levels of
DEET in the environment can be used in combination with the known body burden of DEET to assess the
potential risk of adverse health effects in populations living in the vicinity of hazardous waste sites.
Monitoring data are available for DEET in air (Balducci 2012; Cheng et al. 2006) and water (Brausch and 
Rand 2011; Glassmeyer et al. 2005; Kolpin et al. 2002; Sandstrom et al. 2005).  No monitoring data were
located for DEET in soil and sediment. 
Exposure Levels in Humans.  Exposure levels of DEET in human biological samples are available 
(CDC 2009; Wu et al. 1979).  Continued biological monitoring of human serum and urine samples is
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population.  This information is necessary for assessing the need to conduct health studies on these
populations.
Exposures of Children. Children are exposed to DEET by the same routes that affect adults 
(primarily dermal exposure).  Continued monitoring of children’s exposure to DEET is considered a data
need.  Child health data needs relating to susceptibility are discussed in Section 3.12.2, Identification of
Data Needs: Children’s Susceptibility.
Exposure Registries. The information amassed in the National Exposure Registry facilitates the 
epidemiological research needed to assess adverse health outcomes that may be related to exposure to this 
substance; however, no exposure registries for DEET were located.  DEET is not currently one of the
compounds for which a sub-registry has been established in the National Exposure Registry.  DEET will
be considered in the future when chemical selection is made for sub-registries to be established.
6.8.2 Ongoing Studies 
No ongoing environmental fate studies for DEET were identified using the NIH RePORTER version 
6.1.0 or the Defense Technical Information Center (DTIC) online database.  
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7. ANALYTICAL METHODS
The purpose of this chapter is to describe the analytical methods that are available for detecting,
measuring, and/or monitoring DEET, its metabolites, and other biomarkers of exposure and effect to 
DEET. The intent is not to provide an exhaustive list of analytical methods.  Rather, the intention is to
identify well-established methods that are used as the standard methods of analysis.  Many of the
analytical methods used for environmental samples are the methods approved by federal agencies and
organizations such as EPA and the National Institute for Occupational Safety and Health (NIOSH).  Other
methods presented in this chapter are those that are approved by groups such as the Association of
Official Analytical Chemists (AOAC) and the American Public Health Association (APHA).
Additionally, analytical methods are included that modify previously used methods to obtain lower
detection limits and/or to improve accuracy and precision.
7.1  BIOLOGICAL MATERIALS
DEET is used globally as a commercial insect repellent, which results in the direct exposure of humans.  
Studies have shown that DEET is absorbed and most is metabolized before excretion.  Analytical methods
for the determination of DEET and its metabolites in biological materials and environmental media (e.g., 
waste water samples) may be used to verify that exposure and absorption has occurred.
Dermal absorption of DEET following applications of various DEET products has been reported between 
5.6 and 16.7% of the amount applied (Blomquist and Thorsell 1977; Feldman and Maibach 1970; Selim
et al. 1995). The majority of dermally absorbed DEET is metabolized and excreted in human urine
(Selim et al. 1995). The main human urinary metabolites of DEET are DCBA and EACB. Additional
metabolites may include ET, DHMB, m-toluic acid, and ACB. Additional information and standards
relating to metabolites of DEET would prove useful for better analytical analysis of both biological and
environmental samples.
Several methods have been validated for the analysis of DEET in biological samples. The principal
method used for the detection of DEET and/or its metabolites in biological samples is high performance
liquid chromatography (HPLC) and GC coupled with MS.  Sample preparation is typically performed 
using solid-phase extraction (SPE) and/or LLE with organic solvents such as methanol, methylene 
chloride, and acetonitrile. Those methods are generally suitable for the analysis of DEET by itself or
simultaneously with other similar substances (e.g., repellents and pesticides).
   
 













   
  
   
 
  
   
  
   
    
      
   
   
  
    
   
 
   
 
   
      
    
   
 
    
   
    





Identification of DEET and DEET metabolites in human urine has been performed using GC glass
capillary columns and MS elucidations with both electron impact (EI) and chemical ionization-methane 
(MCI) mass spectra.  Failure to control food and beverage intake, including caffeine, and the presence of
plasticizers complicated the evaluation (Wu et al. 1979).  A method for the rapid quantification of DEET
in human urine using HPLC and a triple-quadrupole tandem MS using an atmospheric pressure chemical
ionization application has been published (Olsson et al. 2004).  Sample preparation involves enzyme
hydrolysis, SPE, and concentration, and throughput is ~50 samples/day.
Qiu and Jun (1996) have used SPE and reverse-phase liquid chromatography (LC) with UV detection at
220 nm for the quantification of DEET in both dog and human plasma.  Extraction was achieved with 
reverse-phase C8 (yielding faster throughput) or C18 SPE cartridges using acetonitrile-ammonium acetate 
solutions as wash and elution solvent systems as well as for the mobile phase for the chromatography.  
This method had an overall absolute recovery of 97.7%, with a range of recovery, dependent on DEET
concentration, of 96.9–100.2%, accuracy range of 1.5–5.1%, precision of 2.6–11.1%, and an LOQ of
15 ng/mL.  Abu-Qare and Abou-Donia (2001c) have developed an analytical method using HPLC with 
reverse-phase C18 columns and UV detection, with a reported LOD of 50 ng/mL and LOQ of 50– 
100 ng/mL, for the simultaneous quantitative and qualitative detection of DEET and its metabolites, in rat
plasma and urine that could be used in the monitoring of human plasma and urine.  Barr et al. (2002) have
developed a sensitive analytical method for quantifying serum and plasma concentrations of DEET in
human blood, reporting an LOD of 10 pg/g.  The method employs SPE using an OASIS cartridge with a 
mixed polarity phase followed by isotopic dilution GC-high resolution (HR)-MS for analysis.
Smallwood et al. (1992) demonstrated that DEET can be detected in both serum and urine after dermal
exposure to DEET by HPLC. DEET quickly metabolizes in the body; therefore, urine concentrations of
DEET specifically are not the most accurate reflection of dermal exposure concentrations. Kuklenyik et
al. (2013) have successfully developed a rapid HPLC-MS/MS method to measure concentrations of
DEET in addition to two of its oxidative metabolites, DHMB and DCBA, in human urine.  Because
DEET, DHMB, and DCBA undergo metabolism to form conjugates, they must be hydrolyzed in order to 
evaluate total concentrations. Enzymatic hydrolysis of the urine sample is achieved via previously
described methods (Olsson et al. 2004) using β-glucuronidase/sulfatase. Separation is done on a reverse-
phase analytical column and detection is achieved via atmospheric pressure chemical ionization in
positive ion mode.  Detection limits for these three chemicals are reported to be between 0.1 and 
1.0 ng/mL.  
   
 









   
  
    
    
   








      
 
   
   
    
  








       
   





Evaluation of fetal exposure is a key concern that was addressed by Bradman et al. (2003).  Amniotic
fluid was evaluated using an MS analytical method previously intended for detection of DEET in urine.  
The LOD for urine was reported as 0.1 µg/L, with 98% recovery, and the LOD for amniotic fluid was
reported as 0.40 µg/L, with 100% recovery.  Although DEET was not detected in the amniotic samples
evaluated in the study, it was noted that the analytical method for measuring DEET in urine is transferable
to amniotic fluids with little modification.
It has been reported that high-level exposure to DEET in combination with other chemicals may increase 
adverse effects (Abu-Qare and Abou-Donia 2001b, 2001c; Abou-Donia et al. 2001a; Kuklenyik et al. 
2013). Cherstniakova et al. (2006) developed rapid and sensitive methods for simultaneous determination 
of DEET and permethrin, and DEET and pyridostigmine bromide, in human plasma using GC-MS and 
HPLC, respectively.  Abu-Qare et al. (2001) found that urinary excretion of 3-nitrotyrosine (a biomarker
of oxidative stress) in rats increased when an oral dose of pyridostigmine bromide and a dermal dose of
DEET were administered alone and in combination. Due to the possibility of the combined exposure
scenarios, the method developed by Abu-Qare and Abou-Donia (2001b) using reverse-phase HPLC and 
UV detection, mentioned above, was developed for the simultaneous determination of diazinon, 
permethrin, DEET, and their metabolites in rat plasma and urine using solid-phase extraction of DEET
and its metabolites.  HPLC methods for the separation and quantification of chlorpyrifos, pyridostigmine
bromide, N,N-diethyl-m-toluamide, and their metabolites in rat plasma and urine had detection limits
ranging from 20 and 150 ng/mL (Abu-Qare and Abou-Donia 2001c).  HPLC methods for the
simultaneous determination of malathion, permethrin, DEET, and their metabolites in rat plasma and 
urine have been developed (Abu-Qare and Abou-Donia 2001d). 
Analytical methods for the determination of DEET in biological materials and fluids are summarized in 
Table 7-1.
7.2  ENVIRONMENTAL SAMPLES 
Analysis of environmental samples is similar to or the same as that of biological samples. The primary
methods of analyzing for DEET in water samples involve SPE or LLE followed by GC, HPLC, and MS.  
Those methods are generally suitable for the analysis of DEET by itself or simultaneously with other
similar substances (e.g., repellents and pesticides).
   
 












       
 







    
 





   
 




















































Table 7-1. Analytical Methods for Determining DEET and Transformation 





Sample matrix Preparation method method limit recovery Reference
Human blood	 Blood containing heparin
centrifuged and plasma collected;
serum samples denatured with 
ammonium sulfate and 
centrifuged; SPE with OASIS
cartridges.
Human serum	 LLE with MTBE or SPE
Human urine 	 Urine: extraction with diethyl
and serum	 ether; evaporation and dilution 
with methanol
Serum:  centrifuge and mix with 
20% saline; SPE with C18 Sep-
Pak Vac cartridges; wash with 
water; elute with methanol;
evaporate
Human urine	 Hydrolysis with β-glucuronidase,
SPE OASIS cartridge; LLE;
evaporate; 50 samples/day
throughput
Human urine 	 Urine samples in sodium
(DEET and 	 carbonate extracted with DCM/ 
selected	 ethyl alcohol and centrifuged;
metabolites)	 aqueous-phase pH adjusted and 
re-extracted; organic phase dried,
evaporated, and reconstituted in 
methanol
Human urine 	 Hydrolysis with β-glucuronidase/ 
(DEET and 	 sulfatase in 0.1 M sodium acetate 
selected	 buffer; mixed, incubated at 37°C
metabolites)	 for 17 hours, then vortex mixed
Human tissue	 Minced tissue homogenized with 
water; HCl added and filtered;
filtrate pH adjusted; hexane
added and centrifuged; direct













10 pg/g 43	 Barr et al.
2002
Not reported >90	 Cherstniakova 
et al. 2006
0.09 μg/mL 90–91 (urine) Smallwood et
(urine; 92–100 al. 1992
serum) (serum)





Not reported Not reported	 Wu et al. 1979






Not reported 45–60 Crowley et al. 
1986
   
 











       
 





















   
 
 











    
      
    
     




Table 7-1. Analytical Methods for Determining DEET and Transformation 





Sample matrix Preparation method method limit recovery Reference










Acidify with 1 N acetic acid; vortex HPLC 50 ng/mL 78.4–89.1 Abu-Qare and 
and centrifuge samples; SPE with (DEET, Abou-Donia 
C18 Sep-Pak Vac cartridges; wash urine) 2001c
with water; elute with methanol 72.8–84.2 
and acetonitrile (DEET,
plasma)
Acidify with 1 N acetic acid; vortex HPLC 20 ng/mL 83 Abu-Qare and 
and centrifuge samples; SPE with Abou-Donia 
C18 Sep-Pak Vac cartridges wash 2001b
with water; elute with methanol
and acetonitrile
Vortex sample; SPE with C18 HPLC-UV 15 ng/mL 96.9–100.2 Qiu and Jun
cartridges; wash and elute with (LOQ) based on 1996
acetonitrile and ammonium DEET
acetate concentration
APCI = atmospheric pressure chemical ionization; DHMB = N,N-diethyl-3-(hydroxymethyl)benzamide;
 
DCBA = m-diethylcarbonyl) benzoic acid; DCM = methylene chloride; GC = gas chromatography; HCl = hydrogen
 
chloride; HPLC = high-performance liquid chromatography; LLE = liquid-liquid extraction; LOQ = limit of quantification;
 
MS = mass spectrometry; MS/MS = isotope dilution tandem mass spectrometry; MTBE = methyl-tert-butyl ether;
 
SD = standard deviation; SPE = solid-phase extraction; UV = ultraviolet
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7. ANALYTICAL METHODS
Cheng et al. (2006) used an accelerated solvent extractor with dichloromethane and methanol followed by
separation using a silica gel chromatography column, followed by GC/MS to analyze aerosol samples.
He and Lee (1997) developed a method for combining capillary electrophoresis (CE) with field-amplified 
concentration (FAC) and SPE for rapid concentration, separation, and quantification of DEET and five
organonitrogen pesticides in water samples.  However, the method recovery for DEET was less than half
that for the pesticides (5–50 ppb was recovered 40.5–37.8%) and the reason was not discovered.  Knepper
(2004) employed solid-phase enrichment of DEET in surface waters and WWTP effluents on a capillary
column followed by quantification using GC/MS in single ion monitoring mode.  LOQs for surface water
and WWTP effluent were 0.03 and 0.1 µg/L, respectively.  Sandstrom et al. (2005) analyzed whole
surface water for DEET and a range of other substances using methylene chloride LLE followed by
GC/MS operated in selected-ion monitoring mode.  They achieved a detection level of 0.02 µg/L for
DEET, if retention time and ionic abundance criteria were met; otherwise, the reporting limit was 
0.08 µg/L.  Surface water samples may be analyzed using SPE followed by ultrahigh pressure LC-MS.
Loos et al. (2013b) developed a method employing these analytical techniques using a hybrid triple-
quadrupole linear ion trap instrument.  Wang and Gardinali (2013) reported the successful use of an SPE-
HPLC-atmospheric pressure photoionization (APPI)-MS/MS method for the detection and quantification 
of DEET in filtered water.
Methods for analyzing DEET in soils were not readily available.
An analytical method for determination of DEET in soda water was reported by Chandramouli et al. 
(2004); however, analytical procedures for food were not located.
Details of commonly used analytical methods for several types of environmental samples are presented in
Table 7-2.
7.3  ADEQUACY OF THE DATABASE 
Section 104(i)(5) of CERCLA, as amended, directs the Administrator of ATSDR (in consultation with the
Administrator of EPA and agencies and programs of the Public Health Service) to assess whether
adequate information on the health effects of DEET is available.  Where adequate information is not
available, ATSDR, in conjunction with NTP, is required to assure the initiation of a program of research
   
 












       
 
    









   
 
 





















































   
 









Table 7-2. Analytical Methods for Determining DEET and Transformation 

Products in Environmental Samples
 
Sample 
Sample Analytical detection Percent
matrixa Preparation method method limit recovery Reference
Air Collection with quartz filters GC with mass No data 58 Cheng et al.
followed by extraction with selective 2006
DCM/methanol (3:1 v/v) detector
Waste water SPE; elution with 10/90 (v/v) GC-MS/MS 0.1 ng/L 70–111 Trenholm et
influent and methanol/MTBE followed by al. 2008
effluent DCM
Waste water Sample extraction with 15% GC-FID No data No data EPA 1983
DCM in hexane followed by
concentration
Filtered Field sample filtration using GC/MS 0.14 μg/L 100 Zaugg et al.
waste water glass-filter fibers and SPE; (9% RSD) 2002
and natural elution of dry SPE cartridges
water with dichloromethane and 
samples diethyl ether followed by
evaporation
Whole water CLLE with DCM Capillary- 0.12 μg/L Ground- USGS-06.pdf
column GC/MS water 98.57;
surface water
71.31





Drinking Grab samples from tap; SPE GC-MS full 0.019 μg/L 97.9– EPA 2012b
water (Oasis HLB or Empore SDVB scan, SIM or (Oasis); 106 (finished 
sorbent); elution with organic SIS mode 0.0042 μg/L drinking 
solvent, dried over column of (Empore) water from








Surface LLE with DCM GC/MS SIM 20 ng/L 74±10 Sandstrom et
water mode al. 2005
Surface SPE; elution with methanol UHPLC- 0.213 ng/L Not reported Loos et al.
water, and evaporation MS/MS (LOQ) 2013b
marine water
   
 











       
 
    



























     
 
 
     
 
    
   





Table 7-2. Analytical Methods for Determining DEET and Transformation 

Products in Environmental Samples
 
Sample 








Air Collection with quartz filters










Extracted with DCM (water) or
heptane (soda); dried with 
sodium sulfate; nonane added 
as keeper solvent; samples
evaporated down to nonane 
GC-HRMS Not reported Not reported Chandramouli
et al. 2004
amount
Seawater Extraction using a polymeric
sorbent; elution with ethyl
acetate followed by n-hexane/ 
ethyl acetate; rotary
evaporation; iso-octane added 
as a keeper




Samples prepared in ethyl
acetate




CLLE = continuous liquid-liquid extraction; DCM = methylene chloride; GC = gas chromatography; FID = flame 
ionization detector; HLB = hydrophilic-lipophilic-balanced; HRMS = high-resolution mass spectrometry; LOQ = limit 
of quantification; MS = mass spectrometry; MS/MS = tandem mass spectrometry; MTBE = methyl-tert butyl ether; 
RSD = relative standard deviation; SDBV = styrene divinylbenzene; SIM = selected ion monitoring; SIS = selected 
ion storage; SPE = solid-phase extraction; UHPLC = ultra-high performance liquid chromatography; UV = ultraviolet
absorbance detection
   
 












   
 
   
 
    
 
     
 
  
   
  
   
  
      
   
   




     
   
   
    
 
 






designed to determine the health effects (and techniques for developing methods to determine such health 
effects) of DEET.
The following categories of possible data needs have been identified by a joint team of scientists from
ATSDR, NTP, and EPA.  They are defined as substance-specific informational needs that if met would 
reduce the uncertainties of human health assessment. This definition should not be interpreted to mean 
that all data needs discussed in this section must be filled.  In the future, the identified data needs will be 
evaluated and prioritized, and a substance-specific research agenda will be proposed.
7.3.1 Identification of Data Needs 
Methods for Determining Biomarkers of Exposure and Effect.
Exposure.  Methods for the detection of DEET in human urine (Olsson et al. 2004; Smallwood et al. 
1992; Wu et al. 1979) and serum (Cherstniakova et al. 2006; Smallwood et al. 1992) are available. These 
methods are sensitive and detect levels of DEET at background levels in the population, levels at which
biological effects may occur.  No data needs are identified for DEET-specific analytical methods.  DEET
rapidly metabolizes after absorption, however, suggesting that DEET concentrations in urine may not be 
the best biomarker. The Fourth National Report on Human Exposure to Environmental Chemicals (CDC
2017) includes results from the assessment of DEET levels and its metabolites, DHMB and DCBA, in 
NHANES for urine samples. An analytical method for detecting the main DEET metabolites, DHMB and 
DCBA, in urine has been validated by Kuklenyik et al. (2013). This area may be a potential focus for
further investigation. 
Methods for Determining Parent Compounds and Degradation Products in Environmental
Media. Analytical methods are available to measure levels of DEET in air (Cheng et al. 2006) and
water media (including waste water) (Trenholm et al. 2008; Weeks et al. 2012; Weigel et al. 2002; Zaugg
et al. 2002).  Studies describing methods for identifying DEET in soil or sediment samples would be
useful; however, it is likely that liquid extraction of DEET from solid media followed by standard 
analytical methods described above for biological or environmental samples would be effective.
7.3.2 Ongoing Studies 
No ongoing analytical studies for DEET were identified using the NIH RePORTER version 6.1.0 or the
DTIC online database.  
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8. REGULATIONS, ADVISORIES, AND GUIDELINES
 
MRLs are substance-specific estimates that are intended to serve as screening levels. They are used by
ATSDR health assessors and other responders to identify contaminants and potential health effects that
may be of concern at hazardous waste sites.
ATSDR derived an intermediate-duration oral MRL of 1.0 mg/kg/day for DEET based on a NOAEL of
100 mg DEET/kg/day for developmental effects in rats (EPA 1989).  The MRL was derived by dividing
the NOAEL by an uncertainty factor of 100 (10 for animal to human extrapolation and 10 for human 
variability).
The International Agency for Research on Cancer (IARC) has not classified DEET as to its 
carcinogenicity (IARC 2013). The World Health Organization (WHO) has not established any air quality
or drinking water guidelines for DEET (WHO 2010, 2011).
The Occupational Safety and Health Administration (OSHA) has not established any enforceable
standards for DEET (OSHA 2013b) nor has the National Institute for Occupational Safety and Health 
(NIOSH) or the American Conference of Governmental Industrial Hygienists (ACGIH) recommended a 
threshold limit value for DEET (ACGIH 2013; NIOSH 2012).
The American Industrial Hygiene Association (AIHA) and the Department of Energy (DOE) have not
established any values for responding to potential releases of airborne DEET for use in community
emergency planning (AIHA 2013, DOE 2012).
The Department of Health and Human Services (NTP 2016) has not classified DEET as a carcinogen.
The EPA’s OPP (EPA 2007) classified DEET as a Group D substance, not classifiable as a human
carcinogen, based on no evidence of mutagenicity in multiple tests, or of carcinogenicity in long-term oral
ingestion studies in adult rats or mice. EPA’s OPP (EPA2007) has not derived inhalation or oral toxicity
values for DEET.  
EPA has classified DEET as an inert pesticide ingredient in pesticide products that are approved for
nonfood human and veterinary use only (EPA 2014c).
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
The international and national regulations, advisories, and guidelines regarding DEET in air, water, and 
other media are summarized in Table 8-1.  
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8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to DEET
Agency Description Information Reference
INTERNATIONAL
Guidelines:
IARC Carcinogenicity classification No data IARC 2013
WHO Air quality guidelines No data WHO 2010




ACGIH TLV-TWA No data ACGIH 2013
AIHA ERPGs No data AIHA 2013
DOE PACs No data DOE 2012
EPA AEGLs No data EPA 2013a
Second AEGL chemical priority list No data EPA 2014a
Hazardous air pollutant No data EPA 2014b
42 USC 7412
NAAQS No data EPA 2014e
NIOSH REL No data NIOSH 2014
IDLH No data
OSHA PEL (8-hour TWA) for general industry No data OSHA 2013b
29 CFR 1910.1000, Table Z-1
Highly hazardous chemicals No data OSHA 2013a
29 CFR 1910.119, Appendix A
b. Water
EPA Designated as hazardous substances in No data EPA 2013b
accordance with Section 311(b)(2)(A) of the 40 CFR 116.4
Clean Water Act
Drinking water contaminant candidate list No data EPA 2009a
74 FR 51850
Drinking water standards and health No data EPA 2012a
advisories
National primary drinking water standards No data EPA 2009b
National recommended water quality No data EPA 2014f
criteria
Reportable quantities of hazardous No data EPA 2013d
substances designated pursuant to 40 CFR 117.3
Section 311 of the Clean Water Act
c. Food
FDA EAFUSa No data FDA 2014










      
 
    
    
    
     
     
    
    
      
   
   
 
  
     









   
 
  
    
 
  
   
 
   
    
 
   
 
      
       
     
 




     
     
      
       
        
         
       
     
     
     
         
      




8.  REGULATIONS, ADVISORIES, AND GUIDELINES
Table 8-1. Regulations, Advisories, and Guidelines Applicable to DEET
Agency Description Information Reference
NATIONAL (cont.)
d. Other
ACGIH Carcinogenicity classification No data ACGIH 2013
EPA Carcinogenicity classification Group Db EPA 2007
RfC Not available
RfD Not available
Identification and listing of hazardous waste No data EPA 2013c
40 CFR 261, Appendix VIII
Inert pesticide ingredients in pesticide Yes EPA 2014c
products approved for nonfood use only
Master Testing List No data EPA 2014d
RCRA waste minimization PBT priority No data EPA 1998a
chemical list 63 FR 60332
Standards for owners and operators of No data EPA 2013e
hazardous waste TSD facilities; 40 CFR 264; Appendix IX
groundwater monitoring list
Superfund, emergency planning, and 
community right-to-know
Designated CERCLA hazardous No data EPA 2013f, 40 CFR 302.4 
substance and reportable quantity
Effective date of toxic chemical release No data EPA 2013h, 40 CFR 372.65
reporting
Extremely hazardous substances and its No data EPA 2013g, 40 CFR 355,
threshold planning quantity Appendix A
TSCA chemical lists and reporting periods No data EPA 2013i, 40 CFR 712.30
TSCA health and safety data reporting No data EPA 2013j, 40 CFR 716.120
NTP Carcinogenicity classification No data NTP 2016
aThe EAFUS list of substances contains ingredients added directly to food that FDA has either approved as food 

additives or listed or affirmed as GRAS.
 
bNot classifiable as a human carcinogen.
 
ACGIH = American Conference of Governmental Industrial Hygienists; AEGL = acute exposure guideline levels;
 
AIHA = American Industrial Hygiene Association; CERCLA = Comprehensive Environmental Response,
 
Compensation, and Liability Act; CFR = Code of Federal Regulations; DOE = Department of Energy;
 
EAFUS = Everything Added to Food in the United States; EPA = Environmental Protection Agency;
 
ERPG = emergency response planning guidelines; FDA = Food and Drug Administration; FR = Federal Register;
 
GRAS = generally recognized as safe; IARC = International Agency for Research on Cancer; IDLH = immediately
 
dangerous to life or health; NAAQS = National Ambient Air Quality Standards; NIOSH = National Institute for
 
Occupational Safety and Health; NTP = National Toxicology Program; OSHA = Occupational Safety and Health 

Administration; PAC = protective action criteria; PBT = persistent, bioaccumulative, and toxic; PEL = permissible 

exposure limit; RCRA = Resource Conservation and Recovery Act; REL = recommended exposure limit;
 
RfC = inhalation reference concentration; RfD = oral reference dose; TLV = threshold limit values; TSCA = Toxic
 
Substances Control Act; TSD = treatment, storage, and disposal; TWA = time-weighted average; USC = United 

States Code; WHO = World Health Organization
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10.  GLOSSARY
Absorption—The taking up of liquids by solids, or of gases by solids or liquids.
Acute Exposure—Exposure to a chemical for a duration of 14 days or less, as specified in the
Toxicological Profiles.
Adsorption—The adhesion in an extremely thin layer of molecules (as of gases, solutes, or liquids) to the 
surfaces of solid bodies or liquids with which they are in contact.
Adsorption Coefficient (Koc)—The ratio of the amount of a chemical adsorbed per unit weight of
organic carbon in the soil or sediment to the concentration of the chemical in solution at equilibrium.
Adsorption Ratio (Kd)—The amount of a chemical adsorbed by sediment or soil (i.e., the solid phase)
divided by the amount of chemical in the solution phase, which is in equilibrium with the solid phase, at a
fixed solid/solution ratio.  It is generally expressed in micrograms of chemical sorbed per gram of soil or
sediment.
Benchmark Dose (BMD)—Usually defined as the lower confidence limit on the dose that produces a
specified magnitude of changes in a specified adverse response.  For example, a BMD10 would be the
dose at the 95% lower confidence limit on a 10% response, and the benchmark response (BMR) would be
10%.  The BMD is determined by modeling the dose response curve in the region of the dose response
relationship where biologically observable data are feasible.
Benchmark Dose Model—A statistical dose-response model applied to either experimental toxicological
or epidemiological data to calculate a BMD.
Bioconcentration Factor (BCF)—The quotient of the concentration of a chemical in aquatic organisms
at a specific time or during a discrete time period of exposure divided by the concentration in the
surrounding water at the same time or during the same period.
Biomarkers—Broadly defined as indicators signaling events in biologic systems or samples. They have 
been classified as markers of exposure, markers of effect, and markers of susceptibility.
Cancer Effect Level (CEL)—The lowest dose of chemical in a study, or group of studies, that produces
significant increases in the incidence of cancer (or tumors) between the exposed population and its
appropriate control.
Carcinogen—A chemical capable of inducing cancer.
Case-Control Study— A type of epidemiological study that examines the relationship between a 
particular outcome (disease or condition) and a variety of potential causative agents (such as toxic 
chemicals).  In a case-control study, a group of people with a specified and well-defined outcome is 
identified and compared to a similar group of people without the outcome.
Case Report—Describes a single individual with a particular disease or exposure.  These may suggest
some potential topics for scientific research, but are not actual research studies.
Case Series—Describes the experience of a small number of individuals with the same disease or
exposure. These may suggest potential topics for scientific research, but are not actual research studies.













   
 
 
      




   





   













    





   
   
   
 
    
  
 
       
   
 
 





Ceiling Value—A concentration that must not be exceeded. 
Chronic Exposure—Exposure to a chemical for 365 days or more, as specified in the Toxicological
Profiles.
Cohort Study—A type of epidemiological study of a specific group or groups of people who have had a
common insult (e.g., exposure to an agent suspected of causing disease or a common disease) and are
followed forward from exposure to outcome.  At least one exposed group is compared to one unexposed 
group.
Cross-sectional Study—A type of epidemiological study of a group or groups of people that examines
the relationship between exposure and outcome to a chemical or to chemicals at one point in time.
Data Needs—Substance-specific informational needs that, if met, would reduce the uncertainties of
human health risk assessment.
Developmental Toxicity—The occurrence of adverse effects on the developing organism that may result
from exposure to a chemical prior to conception (either parent), during prenatal development, or
postnatally to the time of sexual maturation.  Adverse developmental effects may be detected at any point
in the life span of the organism.
Dose-Response Relationship—The quantitative relationship between the amount of exposure to a
toxicant and the incidence of the adverse effects.
Embryotoxicity and Fetotoxicity—Any toxic effect on the conceptus as a result of prenatal exposure to
a chemical; the distinguishing feature between the two terms is the stage of development during which the
insult occurs.  The terms, as used here, include malformations and variations, altered growth, and in utero
death.
Environmental Protection Agency (EPA) Health Advisory—An estimate of acceptable drinking water 
levels for a chemical substance based on health effects information.  A health advisory is not a legally
enforceable federal standard, but serves as technical guidance to assist federal, state, and local officials.
Epidemiology—Refers to the investigation of factors that determine the frequency and distribution of
disease or other health-related conditions within a defined human population during a specified period.  
Genotoxicity—A specific adverse effect on the genome of living cells that, upon the duplication of
affected cells, can be expressed as a mutagenic, clastogenic, or carcinogenic event because of specific 
alteration of the molecular structure of the genome.
Half-life—A measure of rate for the time required to eliminate one half of a quantity of a chemical from
the body or environmental media.
Immediately Dangerous to Life or Health (IDLH)—A condition that poses a threat of life or health, or
conditions that pose an immediate threat of severe exposure to contaminants that are likely to have 
adverse cumulative or delayed effects on health.  
Immunologic Toxicity—The occurrence of adverse effects on the immune system that may result from
exposure to environmental agents such as chemicals.












   
     
 
 
   
 
 




      
 
 
    
  
 
    
  
 
     
 
 
    















   
   









Immunological Effects—Functional changes in the immune response.
Incidence—The ratio of new cases of individuals in a population who develop a specified condition to 
the total number of individuals in that population who could have developed that condition in a specified 
time period. 
Intermediate Exposure—Exposure to a chemical for a duration of 15–364 days, as specified in the 
Toxicological Profiles.
In Vitro—Isolated from the living organism and artificially maintained, as in a test tube.
In Vivo—Occurring within the living organism.
Lethal Concentration(LO) (LCLO)—The lowest concentration of a chemical in air that has been reported
to have caused death in humans or animals.
Lethal Concentration(50) (LC50)—A calculated concentration of a chemical in air to which exposure for
a specific length of time is expected to cause death in 50% of a defined experimental animal population.
Lethal Dose(LO) (LDLo)—The lowest dose of a chemical introduced by a route other than inhalation that
has been reported to have caused death in humans or animals.
Lethal Dose(50) (LD50)—The dose of a chemical that has been calculated to cause death in 50% of a 
defined experimental animal population.
Lethal Time(50) (LT50)—A calculated period of time within which a specific concentration of a chemical
is expected to cause death in 50% of a defined experimental animal population.
Lowest-Observed-Adverse-Effect Level (LOAEL)—The lowest exposure level of chemical in a study,
or group of studies, that produces statistically or biologically significant increases in frequency or severity 
of adverse effects between the exposed population and its appropriate control.
Lymphoreticular Effects—Represent morphological effects involving lymphatic tissues such as the 
lymph nodes, spleen, and thymus.
Malformations—Permanent structural changes that may adversely affect survival, development, or
function.
Minimal Risk Level (MRL)—An estimate of daily human exposure to a hazardous substance that is 
likely to be without an appreciable risk of adverse noncancer health effects over a specified route and 
duration of exposure.
Modifying Factor (MF)—A value (greater than zero) that is applied to the derivation of a Minimal Risk
Level (MRL) to reflect additional concerns about the database that are not covered by the uncertainty
factors.  The default value for a MF is 1.
Morbidity—State of being diseased; morbidity rate is the incidence or prevalence of disease in a specific 
population.
Mortality—Death; mortality rate is a measure of the number of deaths in a population during a specified 
interval of time.












   
 
   
  
 
   
 
 
   
   







   
     






   
  
 
   
       
 
     







    
 
 
     
   





Mutagen—A substance that causes mutations.  A mutation is a change in the DNA sequence of a cell’s 
DNA.  Mutations can lead to birth defects, miscarriages, or cancer.
Necropsy—The gross examination of the organs and tissues of a dead body to determine the cause of
death or pathological conditions.
Neurotoxicity—The occurrence of adverse effects on the nervous system following exposure to a 
hazardous substance.
No-Observed-Adverse-Effect Level (NOAEL)—The dose of a chemical at which there were no
statistically or biologically significant increases in frequency or severity of adverse effects seen between
the exposed population and its appropriate control.  Effects may be produced at this dose, but they are not
considered to be adverse.
Octanol-Water Partition Coefficient (Kow)—The equilibrium ratio of the concentrations of a chemical
in n-octanol and water, in dilute solution.
Odds Ratio (OR)—A means of measuring the association between an exposure (such as toxic substances 
and a disease or condition) that represents the best estimate of relative risk (risk as a ratio of the incidence
among subjects exposed to a particular risk factor divided by the incidence among subjects who were not
exposed to the risk factor).  An OR of greater than 1 is considered to indicate greater risk of disease in the 
exposed group compared to the unexposed group.
Organophosphate or Organophosphorus Compound—A phosphorus-containing organic compound 
and especially a pesticide that acts by inhibiting cholinesterase.
Permissible Exposure Limit (PEL)—An Occupational Safety and Health Administration (OSHA)
regulatory limit on the amount or concentration of a substance not to be exceeded in workplace air
averaged over any 8-hour work shift of a 40-hour workweek.
Pesticide—General classification of chemicals specifically developed and produced for use in the control
of agricultural and public health pests (insects or other organisms harmful to cultivated plants or animals).
Pharmacokinetics—The dynamic behavior of a material in the body, used to predict the fate
(disposition) of an exogenous substance in an organism.  Utilizing computational techniques, it provides
the means of studying the absorption, distribution, metabolism, and excretion of chemicals by the body.
Pharmacokinetic Model—A set of equations that can be used to describe the time course of a parent
chemical or metabolite in an animal system.  There are two types of pharmacokinetic models:  data-based
and physiologically-based.  A data-based model divides the animal system into a series of compartments,
which, in general, do not represent real, identifiable anatomic regions of the body, whereas the
physiologically-based model compartments represent real anatomic regions of the body.
Physiologically Based Pharmacodynamic (PBPD) Model—A type of physiologically based dose-
response model that quantitatively describes the relationship between target tissue dose and toxic end
points.  These models advance the importance of physiologically based models in that they clearly
describe the biological effect (response) produced by the system following exposure to an exogenous
substance. 
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10.  GLOSSARY
Physiologically Based Pharmacokinetic (PBPK) Model—Comprised of a series of compartments
representing organs or tissue groups with realistic weights and blood flows. These models require a
variety of physiological information: tissue volumes, blood flow rates to tissues, cardiac output, alveolar
ventilation rates, and possibly membrane permeabilities.  The models also utilize biochemical
information, such as blood:air partition coefficients, and metabolic parameters.  PBPK models are also
called biologically based tissue dosimetry models.
Prevalence—The number of cases of a disease or condition in a population at one point in time. 
Prospective Study—A type of cohort study in which the pertinent observations are made on events
occurring after the start of the study.  A group is followed over time.
q1*—The upper-bound estimate of the low-dose slope of the dose-response curve as determined by the
multistage procedure.  The q1* can be used to calculate an estimate of carcinogenic potency, the 
incremental excess cancer risk per unit of exposure (usually μg/L for water, mg/kg/day for food, and 
μg/m3 for air).
Recommended Exposure Limit (REL)—A National Institute for Occupational Safety and Health
(NIOSH) time-weighted average (TWA) concentration for up to a 10-hour workday during a 40-hour
workweek.
Reference Concentration (RfC)—An estimate (with uncertainty spanning perhaps an order of
magnitude) of a continuous inhalation exposure to the human population (including sensitive subgroups)
that is likely to be without an appreciable risk of deleterious noncancer health effects during a lifetime.
The inhalation reference concentration is for continuous inhalation exposures and is appropriately
expressed in units of mg/m3 or ppm.
Reference Dose (RfD)—An estimate (with uncertainty spanning perhaps an order of magnitude) of the
daily exposure of the human population to a potential hazard that is likely to be without risk of deleterious
effects during a lifetime.  The RfD is operationally derived from the no-observed-adverse-effect level
(NOAEL, from animal and human studies) by a consistent application of uncertainty factors that reflect
various types of data used to estimate RfDs and an additional modifying factor, which is based on a
professional judgment of the entire database on the chemical. The RfDs are not applicable to
nonthreshold effects such as cancer.
Reportable Quantity (RQ)—The quantity of a hazardous substance that is considered reportable under
the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA).  Reportable
quantities are (1) 1 pound or greater or (2) for selected substances, an amount established by regulation 
either under CERCLA or under Section 311 of the Clean Water Act.  Quantities are measured over a 
24-hour period.
Reproductive Toxicity—The occurrence of adverse effects on the reproductive system that may result
from exposure to a hazardous substance. The toxicity may be directed to the reproductive organs and/or
the related endocrine system.  The manifestation of such toxicity may be noted as alterations in sexual
behavior, fertility, pregnancy outcomes, or modifications in other functions that are dependent on the
integrity of this system.
Retrospective Study—A type of cohort study based on a group of persons known to have been exposed 
at some time in the past.  Data are collected from routinely recorded events, up to the time the study is
undertaken.  Retrospective studies are limited to causal factors that can be ascertained from existing
records and/or examining survivors of the cohort.
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10.  GLOSSARY
Risk—The possibility or chance that some adverse effect will result from a given exposure to a hazardous 
substance.
Risk Factor—An aspect of personal behavior or lifestyle, an environmental exposure, existing health 
condition, or an inborn or inherited characteristic that is associated with an increased occurrence of
disease or other health-related event or condition.
Risk Ratio—The ratio of the risk among persons with specific risk factors compared to the risk among
persons without risk factors.  A risk ratio greater than 1 indicates greater risk of disease in the exposed
group compared to the unexposed group.
Short-Term Exposure Limit (STEL)—A STEL is a 15-minute TWA exposure that should not be
exceeded at any time during a workday.  
Standardized Mortality Ratio (SMR)—A ratio of the observed number of deaths and the expected 
number of deaths in a specific standard population.
Target Organ Toxicity—This term covers a broad range of adverse effects on target organs or
physiological systems (e.g., renal, cardiovascular) extending from those arising through a single limited 
exposure to those assumed over a lifetime of exposure to a chemical.
Teratogen—A chemical that causes structural defects that affect the development of an organism.
Threshold Limit Value (TLV)—An American Conference of Governmental Industrial Hygienists 
(ACGIH) concentration of a substance to which it is believed that nearly all workers may be repeatedly
exposed, day after day, for a working lifetime without adverse effect. The TLV may be expressed as a 
Time Weighted Average (TLV-TWA), as a Short-Term Exposure Limit (TLV-STEL), or as a ceiling
limit (TLV-C).
Time-Weighted Average (TWA)—An average exposure within a given time period.  
Toxic Dose(50) (TD50)—A calculated dose of a chemical, introduced by a route other than inhalation, 
which is expected to cause a specific toxic effect in 50% of a defined experimental animal population.
Toxicokinetic—The absorption, distribution, and elimination of toxic compounds in the living organism.
Uncertainty Factor (UF)—A factor used in operationally deriving the Minimal Risk Level (MRL) or
Reference Dose (RfD) or Reference Concentration (RfC) from experimental data.  UFs are intended to 
account for (1) the variation in sensitivity among the members of the human population, (2) the
uncertainty in extrapolating animal data to the case of human, (3) the uncertainty in extrapolating from
data obtained in a study that is of less than lifetime exposure, and (4) the uncertainty in using lowest-
observed-adverse-effect level (LOAEL) data rather than no-observed-adverse-effect level (NOAEL) data.
A default for each individual UF is 10; if complete certainty in data exists, a value of 1 can be used;
however, a reduced UF of 3 may be used on a case-by-case basis, 3 being the approximate logarithmic
average of 10 and 1.
Xenobiotic—Any substance that is foreign to the biological system.














    
  
 
    
   
 
  
   
    
   
     
    
    
  
  
   
 
 
   
     
   
   
 
    
  
   
  
 
     
  
DEET A-1
APPENDIX A.  ATSDR MINIMAL RISK LEVELS AND WORKSHEETS
The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) [42 U.S.C. 
9601 et seq.], as amended by the Superfund Amendments and Reauthorization Act (SARA) [Pub. L. 99– 
499], requires that the Agency for Toxic Substances and Disease Registry (ATSDR) develop jointly with
the U.S. Environmental Protection Agency (EPA), in order of priority, a list of hazardous substances most
commonly found at facilities on the CERCLA National Priorities List (NPL); prepare toxicological 
profiles for each substance included on the priority list of hazardous substances; and assure the initiation 
of a research program to fill identified data needs associated with the substances.
The toxicological profiles include an examination, summary, and interpretation of available toxicological
information and epidemiologic evaluations of a hazardous substance.  During the development of
toxicological profiles, Minimal Risk Levels (MRLs) are derived when reliable and sufficient data exist to
identify the target organ(s) of effect or the most sensitive health effect(s) for a specific duration for a 
given route of exposure.  An MRL is an estimate of the daily human exposure to a hazardous substance
that is likely to be without appreciable risk of adverse noncancer health effects over a specified route and
duration of exposure.  MRLs are based on noncancer health effects only and are not based on a
consideration of cancer effects. These substance-specific estimates, which are intended to serve as 
screening levels, are used by ATSDR health assessors to identify contaminants and potential health
effects that may be of concern at hazardous waste sites.  It is important to note that MRLs are not
intended to define clean-up or action levels.
MRLs are derived for hazardous substances using the no-observed-adverse-effect level/uncertainty factor
approach. They are below levels that might cause adverse health effects in the people most sensitive to 
such chemical-induced effects. MRLs are derived for acute (1–14 days), intermediate (15–364 days), and 
chronic (365 days and longer) durations and for the oral and inhalation routes of exposure.  Currently, 
MRLs for the dermal route of exposure are not derived because ATSDR has not yet identified a method
suitable for this route of exposure.  MRLs are generally based on the most sensitive substance-induced
endpoint considered to be of relevance to humans.  Serious health effects (such as irreparable damage to
the liver or kidneys, or birth defects) are not used as a basis for establishing MRLs.  Exposure to a level
above the MRL does not mean that adverse health effects will occur.
MRLs are intended only to serve as a screening tool to help public health professionals decide where to 
look more closely.  They may also be viewed as a mechanism to identify those hazardous waste sites that










    
  
   
  
   
   
  
    
    
 
   
   
    
   







are not expected to cause adverse health effects.  Most MRLs contain a degree of uncertainty because of
the lack of precise toxicological information on the people who might be most sensitive (e.g., infants,
elderly, nutritionally or immunologically compromised) to the effects of hazardous substances.  ATSDR
uses a conservative (i.e., protective) approach to address this uncertainty consistent with the public health 
principle of prevention.  Although human data are preferred, MRLs often must be based on animal studies
because relevant human studies are lacking. In the absence of evidence to the contrary, ATSDR assumes 
that humans are more sensitive to the effects of hazardous substance than animals and that certain persons 
may be particularly sensitive. Thus, the resulting MRL may be as much as 100-fold below levels that 
have been shown to be nontoxic in laboratory animals.
Proposed MRLs undergo a rigorous review process:  Health Effects/MRL Workgroup reviews within the
Division of Toxicology and Human Health Sciences, expert panel peer reviews, and agency-wide MRL
Workgroup reviews, with participation from other federal agencies and comments from the public.  They
are subject to change as new information becomes available concomitant with updating the toxicological
profiles. Thus, MRLs in the most recent toxicological profiles supersede previously published levels.  
For additional information regarding MRLs, please contact the Division of Toxicology and Human 
Health Sciences, Agency for Toxic Substances and Disease Registry, 1600 Clifton Road NE, Mailstop
F-57, Atlanta, Georgia 30329-4027.
 





















     
 
   
     
    
 
  
    
    
    
     
      
   
  
    
 








    
    
    
  
        
 
     
   
  









Route: [ ] Inhalation   [X] Oral
Duration: [ ] Acute   [X] Intermediate   [ ] Chronic
Graph Key: 35
Species: Rats
Minimal Risk Level: 1.0 [X] mg/kg/day  [ ] ppm
Reference: EPA.  1989.  [EPA memorandum 007645 from Whang Phang, Subject: Review of a two-
generation reproduction on DEET, dated 13 December 1989]. Washington, DC: U.S. Environmental
Protection Agency. http://www.epa.gov/pesticides/chem_search/cleared_reviews/csr_PC-080301_13-
Dec-89_032.pdf. April 24, 2014.
Experimental design: Groups of Sprague-Dawley rats (28/sex/group) were fed diets containing 0, 500, 
2,000, or 5,000 ppm DEET for at least 80 days before mating (EPA 1989).  Using the standard 
conversion, 20 ppm=1 mg/kg/day (EPA 1998b), the diet provided doses of approximately 0, 25, 100, or
250 mg DEET/kg/day.  Parental F0 animals were allowed to produce only one litter. Animals remained
on the test diets during mating, gestation, and lactation. After weaning of F1 rats, 28 males and 
28 females were randomly chosen to serve as parents for the F2 generation.  F1 rats were mated after at
least 93 days on the test diet.  After weaning, 10 pups/sex/groups were subjected to gross necropsy.  
F0 females were killed after the selection of F1 parents.  F1 females were sacrificed after weaning of their
litters. The following parameters were used to assess toxicity:  twice daily observations for deaths and
clinical signs, body weight, and food consumption (not measured during the mating periods).  
Additionally, gross necropsy and histological examination of the ovaries, prostate, seminal vesicles, testes 
with epididymides, uterus, vagina, and all gross lesions were conducted in all parental rats and
10 weanlings/sex/group in the control and high-dose groups.  Parameters used to assess developmental
toxicity in the F1 and F2 litters included number of live and stillborn pups, external anomalies, sex and 
body weight grouped by sex on lactation days 0, 4, 7, and 14, sex and individual body weights (only
group weights reported) on lactation day 21, viability, and behavioral abnormalities at least twice daily
during lactation.  
Effects noted in study and corresponding doses: There were no chemical-related deaths during the study.  
Hair loss appeared to be more prominent in high-dose F0 and F1 females than in other groups. Body 
weights of parental rats were lower in some of the mid- and high-dose groups at some points in the study,
but the difference with controls was generally <10%. Changes in food consumption tended to parallel the
changes in body weight and were generally <10% different than controls.  F1 males showed mottled 
kidneys with incidences of 0/23, 2/23 (9%), 6/23 (26%), and 8/23 (35%) of the males (control and 
increasing dose groups).  Microscopy revealed inflammation, hyaline droplet and granular cast formation, 
and regeneration of tubules. No explicit information was provided in the review regarding the other
organs examined. The only significant reproductive/developmental effects reported were decreased F2
pup viability in the low- and high-dose groups on postnatal day 4 and reduced male and female F1 and F2 
pup weights in the high-dose group on lactation days 14 and 21 (Table A-1).













     
     
     
     







   






   
    
   
  
   





    
 
   
    
     
     
  
 
    
    
    












Doses (mg/kg/day) 0 25 100 250
F1 males 46.2±6.50a 46.8±5.06 45.7±4.53 40.1±4.22b 
F1 females 44.1±4.64 44.6±4.44 44.2±4.51 39.1±4.60b 
F2 males 50.4±4.31 49.4±6.07 47.9±4.02 44.5±3.93b 
F2 females 47.3±4.52 47.6±5.35 44.1±7.50 42.3±3.23b 
aMean±standard deviation.
bp<0.01.
Source:  EPA (1989)
Dose and end point used for MRL derivation: NOAEL of 100 mg/kg/day (LOAEL of 250 mg/kg/day for 
reduced body weight in F1 and F2 male and female pups on lactation day 21).
[X] NOAEL   [ ] LOAEL
Uncertainty Factors used in MRL derivation:
[ ] 10 for use of a LOAEL
[X]  10 for extrapolation from animals to humans
[X]  10 for human variability
Was a conversion factor used from ppm in food or water to a mg/body weight dose? Yes,
20 ppm=1 mg/kg/day was used as done in EPA (1998b).
If an inhalation study in animals, list conversion factors used in determining human equivalent dose: Not
applicable.
Was a conversion used from intermittent to continuous exposure? No.
Other additional studies or pertinent information that lend support to this MRL: The intermediate-
duration oral database showed relatively little toxicity for DEET. Most effects reported were of
questionable toxicological significance except for the developmental effects that were used for MRL
derivation. The fact that the reduction in body weight occurred in both male and female pups from both 
the F1 and F2 generations, provides strength to the MRL.  
Intermediate-duration oral MRL is protective for chronic-duration exposure.  The available chronic-
duration oral database does not support derivation of a chronic-duration oral MRL for DEET. Long-term 
exposure, however, does not lead to more toxic effects than those reported for intermediate-duration 
exposure, so the intermediate-duration oral MRL of 1 mg/kg/day for DEET is protective for chronic-
duration exposure.
Agency Contacts (Chemical Managers): Sam Keith
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APPENDIX B.  USER'S GUIDE
Chapter 1
Public Health Statement
This chapter of the profile is a health effects summary written in non-technical language. Its intended
audience is the general public, especially people living in the vicinity of a hazardous waste site or
chemical release.  If the Public Health Statement were removed from the rest of the document, it would
still communicate to the lay public essential information about the chemical.
The major headings in the Public Health Statement are useful to find specific topics of concern. The 
topics are written in a question and answer format. The answer to each question includes a sentence that
will direct the reader to chapters in the profile that will provide more information on the given topic.
Chapter 2
Relevance to Public Health
This chapter provides a health effects summary based on evaluations of existing toxicologic,
epidemiologic, and toxicokinetic information.  This summary is designed to present interpretive, weight-
of-evidence discussions for human health end points by addressing the following questions:
1.	 What effects are known to occur in humans?
2.	 What effects observed in animals are likely to be of concern to humans?
3.	 What exposure conditions are likely to be of concern to humans, especially around hazardous
waste sites?
The chapter covers end points in the same order that they appear within the Discussion of Health Effects
by Route of Exposure section, by route (inhalation, oral, and dermal) and within route by effect.  Human 
data are presented first, then animal data.  Both are organized by duration (acute, intermediate, chronic).  
In vitro data and data from parenteral routes (intramuscular, intravenous, subcutaneous, etc.) are also 
considered in this chapter.
The carcinogenic potential of the profiled substance is qualitatively evaluated, when appropriate, using
existing toxicokinetic, genotoxic, and carcinogenic data.  ATSDR does not currently assess cancer
potency or perform cancer risk assessments. Minimal Risk Levels (MRLs) for noncancer end points (if
derived) and the end points from which they were derived are indicated and discussed.
Limitations to existing scientific literature that prevent a satisfactory evaluation of the relevance to public
health are identified in the Chapter 3 Data Needs section.
Interpretation of Minimal Risk Levels
Where sufficient toxicologic information is available, ATSDR has derived MRLs for inhalation and oral
routes of entry at each duration of exposure (acute, intermediate, and chronic). These MRLs are not
meant to support regulatory action, but to acquaint health professionals with exposure levels at which 
adverse health effects are not expected to occur in humans.










    
    
   
 
 
    
     
     
 
 
   
    
     
 
  
    
  
  
    
    
    
    
  
 
   
    









   
     
  
    
  
   




   





MRLs should help physicians and public health officials determine the safety of a community living near
a hazardous substance emission, given the concentration of a contaminant in air or the estimated daily
dose in water. MRLs are based largely on toxicological studies in animals and on reports of human 
occupational exposure.
MRL users should be familiar with the toxicologic information on which the number is based.  Chapter 2, 
"Relevance to Public Health," contains basic information known about the substance.  Other sections such 
as Chapter 3 Section 3.9, "Interactions with Other Substances,” and Section 3.10, "Populations that are
Unusually Susceptible" provide important supplemental information.
MRL users should also understand the MRL derivation methodology.  MRLs are derived using a
modified version of the risk assessment methodology that the Environmental Protection Agency (EPA)
provides (Barnes and Dourson 1988) to determine reference doses (RfDs) for lifetime exposure.  
To derive an MRL, ATSDR generally selects the most sensitive end point which, in its best judgement, 
represents the most sensitive human health effect for a given exposure route and duration.  ATSDR
cannot make this judgement or derive an MRL unless information (quantitative or qualitative) is available 
for all potential systemic, neurological, and developmental effects.  If this information and reliable
quantitative data on the chosen end point are available, ATSDR derives an MRL using the most sensitive 
species (when information from multiple species is available) with the highest no-observed-adverse-effect
level (NOAEL) that does not exceed any adverse effect levels.  When a NOAEL is not available, a 
lowest-observed-adverse-effect level (LOAEL) can be used to derive an MRL, and an uncertainty factor
(UF) of 10 must be employed.  Additional uncertainty factors of 10 must be used both for human 
variability to protect sensitive subpopulations (people who are most susceptible to the health effects 
caused by the substance) and for interspecies variability (extrapolation from animals to humans).  In 
deriving an MRL, these individual uncertainty factors are multiplied together.  The product is then 
divided into the inhalation concentration or oral dosage selected from the study. Uncertainty factors used




Tables and Figures for Levels of Significant Exposure (LSE)
Tables and figures are used to summarize health effects and illustrate graphically levels of exposure 
associated with those effects. These levels cover health effects observed at increasing dose 
concentrations and durations, differences in response by species, MRLs to humans for noncancer end
points, and EPA's estimated range associated with an upper- bound individual lifetime cancer risk of 1 in 
10,000 to 1 in 10,000,000.  Use the LSE tables and figures for a quick review of the health effects and to 
locate data for a specific exposure scenario.  The LSE tables and figures should always be used in
conjunction with the text. All entries in these tables and figures represent studies that provide reliable,
quantitative estimates of NOAELs, LOAELs, or Cancer Effect Levels (CELs).
The legends presented below demonstrate the application of these tables and figures.  Representative 
examples of LSE Table 3-1 and Figure 3-1 are shown.  The numbers in the left column of the legends
correspond to the numbers in the example table and figure.














     
    
  
   
   
 
 
      




   
  
      
   
 
 











   
    
   
  
    
 
 
    
 




    






See Sample LSE Table 3-1 (page B-6)
(1)	 Route of Exposure.  One of the first considerations when reviewing the toxicity of a substance 
using these tables and figures should be the relevant and appropriate route of exposure. Typically
when sufficient data exist, three LSE tables and two LSE figures are presented in the document.  
The three LSE tables present data on the three principal routes of exposure, i.e., inhalation, oral, 
and dermal (LSE Tables 3-1, 3-2, and 3-3, respectively).  LSE figures are limited to the inhalation
(LSE Figure 3-1) and oral (LSE Figure 3-2) routes.  Not all substances will have data on each
route of exposure and will not, therefore, have all five of the tables and figures.
(2)	 Exposure Period. Three exposure periods—acute (less than 15 days), intermediate (15– 
364 days), and chronic (365 days or more)—are presented within each relevant route of exposure.
In this example, an inhalation study of intermediate exposure duration is reported.  For quick
reference to health effects occurring from a known length of exposure, locate the applicable 
exposure period within the LSE table and figure.
(3)	 Health Effect. The major categories of health effects included in LSE tables and figures include 
death, systemic, immunological, neurological, developmental, reproductive, and cancer. 
NOAELs and LOAELs can be reported in the tables and figures for all effects but cancer.
Systemic effects are further defined in the "System" column of the LSE table (see key number
18).
(4)	 Key to Figure. Each key number in the LSE table links study information to one or more data
points using the same key number in the corresponding LSE figure.  In this example, the study
represented by key number 18 has been used to derive a NOAEL and a Less Serious LOAEL
(also see the two "18r" data points in sample Figure 3-1).
(5)	 Species. The test species, whether animal or human, are identified in this column.  Chapter 2,
"Relevance to Public Health," covers the relevance of animal data to human toxicity and
Section 3.4, "Toxicokinetics," contains any available information on comparative toxicokinetics.  
Although NOAELs and LOAELs are species specific, the levels are extrapolated to equivalent
human doses to derive an MRL.
(6)	 Exposure Frequency/Duration. The duration of the study and the weekly and daily exposure
regimens are provided in this column.  This permits comparison of NOAELs and LOAELs from
different studies.  In this case (key number 18), rats were exposed to “Chemical x” via inhalation
for 6 hours/day, 5 days/week, for 13 weeks.  For a more complete review of the dosing regimen,
refer to the appropriate sections of the text or the original reference paper (i.e., Nitschke et al.
1981).
(7)	 System.  This column further defines the systemic effects. These systems include respiratory,
cardiovascular, gastrointestinal, hematological, musculoskeletal, hepatic, renal, and
dermal/ocular. "Other" refers to any systemic effect (e.g., a decrease in body weight) not covered
in these systems.  In the example of key number 18, one systemic effect (respiratory) was 
investigated.
(8)	 NOAEL.  A NOAEL is the highest exposure level at which no adverse effects were seen in the 
organ system studied.  Key number 18 reports a NOAEL of 3 ppm for the respiratory system, 
which was used to derive an intermediate exposure, inhalation MRL of 0.005 ppm (see 
footnote "b").











    
       
  
    
     
    
 
 
    
 
    













   
 
 
      
  
 
   
      
 
   
  




      
      
    
 
     





(9)	 LOAEL.  A LOAEL is the lowest dose used in the study that caused an adverse health effect.
LOAELs have been classified into "Less Serious" and "Serious" effects. These distinctions help
readers identify the levels of exposure at which adverse health effects first appear and the 
gradation of effects with increasing dose.  A brief description of the specific end point used to 
quantify the adverse effect accompanies the LOAEL. The respiratory effect reported in key
number 18 (hyperplasia) is a Less Serious LOAEL of 10 ppm.  MRLs are not derived from
Serious LOAELs.
(10)	 Reference. The complete reference citation is given in Chapter 9 of the profile.
(11)	 CEL.  A CEL is the lowest exposure level associated with the onset of carcinogenesis in
experimental or epidemiologic studies.  CELs are always considered serious effects. The LSE
tables and figures do not contain NOAELs for cancer, but the text may report doses not causing
measurable cancer increases.
(12)	 Footnotes.  Explanations of abbreviations or reference notes for data in the LSE tables are found 
in the footnotes.  Footnote "b" indicates that the NOAEL of 3 ppm in key number 18 was used to 
derive an MRL of 0.005 ppm.
LEGEND
See Sample Figure 3-1 (page B-7)
LSE figures graphically illustrate the data presented in the corresponding LSE tables.  Figures help the
reader quickly compare health effects according to exposure concentrations for particular exposure
periods.
(13)	 Exposure Period. The same exposure periods appear as in the LSE table.  In this example, health
effects observed within the acute and intermediate exposure periods are illustrated.
(14)	 Health Effect. These are the categories of health effects for which reliable quantitative data 
exists. The same health effects appear in the LSE table.
(15)	 Levels of Exposure.  Concentrations or doses for each health effect in the LSE tables are 
graphically displayed in the LSE figures.  Exposure concentration or dose is measured on the log 
scale "y" axis.  Inhalation exposure is reported in mg/m3 or ppm and oral exposure is reported in 
mg/kg/day.
(16)	 NOAEL. In this example, the open circle designated 18r identifies a NOAEL critical end point in 
the rat upon which an intermediate inhalation exposure MRL is based.  The key number 18 
corresponds to the entry in the LSE table.  The dashed descending arrow indicates the
extrapolation from the exposure level of 3 ppm (see entry 18 in the table) to the MRL of
0.005 ppm (see footnote "b" in the LSE table).
(17)	 CEL. Key number 38m is one of three studies for which CELs were derived.  The diamond 
symbol refers to a CEL for the test species-mouse.  The number 38 corresponds to the entry in the
LSE table.










    
    
   
 
 
     
DEET	 B-5
APPENDIX B
(18)	 Estimated Upper-Bound Human Cancer Risk Levels. This is the range associated with the upper-
bound for lifetime cancer risk of 1 in 10,000 to 1 in 10,000,000.  These risk levels are derived 
from the EPA's Human Health Assessment Group's upper-bound estimates of the slope of the
cancer dose response curve at low dose levels (q1*).






         
 













    
    











































































































































1 →	 Table 3-1.  Levels of Significant Exposure to [Chemical x] – Inhalation
LOAEL (effect)Exposure 
Less serious Serious (ppm)Key to 	 frequency/ NOAEL



































10	 (CEL, lung tumors,
nasal tumors)




Nitschke et al. 1981
Wong et al. 1982
NTP 1982
NTP 1982
12 →	 a The number corresponds to entries in Figure 3-1.
b Used to derive an intermediate inhalation Minimal Risk Level (MRL) of 5x10-3 ppm; dose adjusted for intermittent exposure and divided 
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DEET C-1
APPENDIX C. ACRONYMS, ABBREVIATIONS, AND SYMBOLS
ACGIH American Conference of Governmental Industrial Hygienists
ACOEM American College of Occupational and Environmental Medicine
ADI acceptable daily intake
ADME absorption, distribution, metabolism, and excretion
AED atomic emission detection
AFID alkali flame ionization detector
AFOSH Air Force Office of Safety and Health
ALT alanine aminotransferase
AML acute myeloid leukemia
AOAC Association of Official Analytical Chemists
AOEC Association of Occupational and Environmental Clinics
AP alkaline phosphatase
APHA American Public Health Association
AST aspartate aminotransferase
atm atmosphere
ATSDR Agency for Toxic Substances and Disease Registry
AWQC Ambient Water Quality Criteria
BAT best available technology
BCF bioconcentration factor
BEI Biological Exposure Index
BMD/C benchmark dose or benchmark concentration
BMDX dose that produces a X% change in response rate of an adverse effect
BMDLX 95% lower confidence limit on the BMDX 
BMDS Benchmark Dose Software
BMR benchmark response
BSC Board of Scientific Counselors
C centigrade
CAA Clean Air Act
CAG Cancer Assessment Group of the U.S. Environmental Protection Agency
CAS Chemical Abstract Services
CDC Centers for Disease Control and Prevention
CEL cancer effect level
CELDS Computer-Environmental Legislative Data System
CERCLA Comprehensive Environmental Response, Compensation, and Liability Act
CFR Code of Federal Regulations
Ci curie
CI confidence interval
CLP Contract Laboratory Program
cm centimeter
CML chronic myeloid leukemia
CPSC Consumer Products Safety Commission
CWA Clean Water Act
DHEW Department of Health, Education, and Welfare
DHHS Department of Health and Human Services
DNA deoxyribonucleic acid
DOD Department of Defense
DOE Department of Energy
DOL Department of Labor
DOT Department of Transportation










   
           





   
  
  



























   
  
   





   
  
  
   
  
   
DEET C-2
APPENDIX C
DOT/UN/ Department of Transportation/United Nations/
NA/IMDG North America/Intergovernmental Maritime Dangerous Goods Code
DWEL drinking water exposure level
ECD electron capture detection
ECG/EKG electrocardiogram
EEG electroencephalogram
EEGL Emergency Exposure Guidance Level
EPA Environmental Protection Agency
F Fahrenheit
F1 first-filial generation
FAO Food and Agricultural Organization of the United Nations
FDA Food and Drug Administration
FEMA Federal Emergency Management Agency
FIFRA Federal Insecticide, Fungicide, and Rodenticide Act
FPD flame photometric detection
fpm feet per minute
FR Federal Register




GLC gas liquid chromatography
GPC gel permeation chromatography
HPLC high-performance liquid chromatography
HRGC high resolution gas chromatography
HSDB Hazardous Substance Data Bank
IARC International Agency for Research on Cancer
IDLH immediately dangerous to life and health
ILO International Labor Organization
IRIS Integrated Risk Information System
Kd adsorption ratio
kg kilogram
kkg kilokilogram; 1 kilokilogram is equivalent to 1,000 kilograms and 1 metric ton
Koc organic carbon partition coefficient
Kow octanol-water partition coefficient
L liter
LC liquid chromatography
LC50 lethal concentration, 50% kill
LCLo lethal concentration, low
LD50 lethal dose, 50% kill




LSE Levels of Significant Exposure
LT50 lethal time, 50% kill
m meter
MA trans,trans-muconic acid
MAL maximum allowable level
mCi millicurie
MCL maximum contaminant level
























   
   
  







   
  














   





    
  
   
   
   
DEET C-3
APPENDIX C
MCLG maximum contaminant level goal
MF modifying factor




mmHg millimeters of mercury
mmol millimole
mppcf millions of particles per cubic foot
MRL Minimal Risk Level
MS mass spectrometry
mt metric ton
NAAQS National Ambient Air Quality Standard
NAS National Academy of Science
NATICH National Air Toxics Information Clearinghouse
NATO North Atlantic Treaty Organization
NCE normochromatic erythrocytes
NCEH National Center for Environmental Health
NCI National Cancer Institute
ND not detected
NFPA National Fire Protection Association
ng nanogram
NHANES National Health and Nutrition Examination Survey
NIEHS National Institute of Environmental Health Sciences
NIOSH National Institute for Occupational Safety and Health
NIOSHTIC NIOSH's Computerized Information Retrieval System




NOES National Occupational Exposure Survey
NOHS National Occupational Hazard Survey
NPD nitrogen phosphorus detection
NPDES National Pollutant Discharge Elimination System
NPL National Priorities List
NR not reported
NRC National Research Council
NS not specified
NSPS New Source Performance Standards
NTIS National Technical Information Service
NTP National Toxicology Program
ODW Office of Drinking Water, EPA
OERR Office of Emergency and Remedial Response, EPA
OHM/TADS Oil and Hazardous Materials/Technical Assistance Data System
OPP Office of Pesticide Programs, EPA
OPPT Office of Pollution Prevention and Toxics, EPA
OPPTS Office of Prevention, Pesticides and Toxic Substances, EPA
OR odds ratio
OSHA Occupational Safety and Health Administration
OSW Office of Solid Waste, EPA
OTS Office of Toxic Substances












   













   
  
   





   
  
  
   
  











   
  
  










OW Office of Water
OWRS Office of Water Regulations and Standards, EPA
PAH polycyclic aromatic hydrocarbon
PBPD physiologically based pharmacodynamic
PBPK physiologically based pharmacokinetic 
PCE polychromatic erythrocytes
PEL permissible exposure limit
PEL-C permissible exposure limit-ceiling value
pg picogram
PHS Public Health Service
PID photo ionization detector
pmol picomole
PMR proportionate mortality ratio
ppb parts per billion
ppm parts per million
ppt parts per trillion
PSNS pretreatment standards for new sources
RBC red blood cell
REL recommended exposure level/limit
REL-C recommended exposure level-ceiling value
RfC reference concentration (inhalation)
RfD reference dose (oral)
RNA ribonucleic acid
RQ reportable quantity
RTECS Registry of Toxic Effects of Chemical Substances
SARA Superfund Amendments and Reauthorization Act
SCE sister chromatid exchange
SGOT serum glutamic oxaloacetic transaminase (same as aspartate aminotransferase or AST)
SGPT serum glutamic pyruvic transaminase (same as alanine aminotransferase or ALT)
SIC standard industrial classification
SIM selected ion monitoring
SMCL secondary maximum contaminant level
SMR standardized mortality ratio
SNARL suggested no adverse response level
SPEGL Short-Term Public Emergency Guidance Level
STEL short term exposure limit
STORET Storage and Retrieval
TD50 toxic dose, 50% specific toxic effect
TLV threshold limit value
TLV-C threshold limit value-ceiling value
TOC total organic carbon
TPQ threshold planning quantity
TRI Toxics Release Inventory




USDA United States Department of Agriculture
USGS United States Geological Survey
VOC volatile organic compound
WBC white blood cell














   
  
  
















WHO World Health Organization
> greater than
≥ greater than or equal to
= equal to
< less than








q1* cancer slope factor
– negative
+ positive
(+) weakly positive result
(–) weakly negative result
